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Chapter 1 General Introduction 
 
The paragraphs that follow provide an introduction to this thesis which is about a global 
approach to studying disease occurrence and drug effects in children.  
 
Diseases in children: burden and characteristics on a global scale 
Usually, children are healthy when they are born. In the first 6-12 months of life, they are 
protected against infections mainly by maternal antibodies acquired during pregnancy1-4. 
Although they ultimately develop their own immunity, this takes time. Meanwhile, they get 
exposed to various environmental pathogens and therefore can become infected. Newborns 
and older children can also experience diseases and injuries resulting from genetic or 
multifactorial causes5-8. Some childhood infections are common, transient and recurrent i.e. 
acute otitis media (AOM). On the other end of the spectrum of recurrent diseases there may be 
rare conditions i.e. acute pyelonephritis (APN)9 10.  Other infections are highly contagious but 
seldom recur i.e. measles11. Non-infectious, multifactorial diseases that affect children may be 
chronic and differ in frequency: asthma is common and chronic unlike type 1 diabetes (DM) 
which is also chronic but less common12,13. Complications may occur, including death and 
disability.  
According to findings from a study that was conducted in 188 countries14, the leading causes of 
death (globally) among children aged <5 years in 2013 were lower respiratory tract infections 
(LRTIs), preterm birth complications, neonatal encephalopathy following birth trauma and 
asphyxia, malaria, and diarrheal diseases. Altogether, these causes accounted for 3.4 million 
deaths (54% of all deaths) in this age group. Preterm birth complications and congenital 
anomalies were the leading causes of death among countries in North America, Australasia, 
Europe, East Asia, and most countries in Latin America and the Caribbean. LRTIs, malaria, and 
diarrheal diseases were the leading causes of death in sub-Saharan African countries. Lower 
respiratory tract infections were also the leading cause for some countries in Asia. Neonatal 
encephalopathy was the most common cause of death in some South Asian countries.  
    
Among children aged 5-9 years, the most common cause of death in 2013 was diarrheal 
disease, followed by LRTIs, road injuries, intestinal infectious diseases (mainly typhoid and 
paratyphoid), and malaria. Altogether, these causes accounted for 181 000 deaths (39% of all 
deaths) in this age group. Road injuries were the leading cause of death for countries in North 
America, Latin America and the Caribbean, and Australasia, while drowning was the most 
common cause of death in most countries in Eastern Europe, East Asia, and Southeast Asia. 
Intestinal infectious diseases and LRTIs were the leading causes for countries in South Asia, 
while diarrheal diseases, HIV/AIDS, and malaria were the leading causes for countries in sub-
Saharan Africa.  
Among children aged 10-19 years, the leading causes of death in 2013 were road injuries, 
HIV/AIDS, self-harm, drowning, and intestinal infectious diseases; accounting for 34% of all 
deaths in this age group. Injury-related deaths were the leading causes in most countries 
except for those in sub-Saharan Africa, where HIV/AIDS was the leading cause of death. Self-
harm was the most common cause of death for some parts of Asia and Eastern Europe. 
Regarding disability, iron deficiency anemia was the most common cause of years lived with 
disability (YLDs) among children and adolescents.  Fifty countries with the largest child and 
adolescent population contributed to 86% of global iron deficiency anemia cases with India, 
China and Nigeria being the top three countries. Skin diseases and depression were the second 
and third leading causes of YLDs. 
Drugs for children: Inadequate evidence supporting safe and effective use, and 
legislations aimed at generating better evidence  
 
Many childhood diseases can be  treated using (essential) medicines. Following the thalidomide 
scandal15; regulations were introduced that require evaluation of quality, benefits and risks of 
medicines, prior to marketing. In the past, children were often excluded from randomized 
clinical trials (RCTs) because of ethical considerations leading to a high rate of unlicensed or 
off-label use of drugs in pediatrics. Unlicensed drug use is the use of medications that are not 
approved for use by the relevant national authority while off-label use means the use of 
pharmaceutical drugs outside the product license for an unapproved indication, an unapproved 
age group, unapproved dosage, or unapproved form of administration16,17. In an overview of 
    
different studies Conroy et. al (1999) reported unlicensed or off-label drug use to be as high as 
90%18. In Australia, 47% of prescriptions in the neonatal intensive care unit was off-label, while 
in France, 42% prevalence was reported. Radley et al (2006) reported that 21% prescriptions 
were off-label while Shah et al (2007) reported that 78.9% of discharged children were taking 
at least one off-label drug19,20. In a survey conducted in the pediatric wards of five European 
countries, Conroy et al (2000) reported that 67% of admitted children received drugs 
prescribed either unlicensed or used in an off-label manner21. Analgesics and bronchodilators 
were most commonly prescribed off-label. In three of the five countries, off-label drug use most 
often pertained to dose and frequency accounting for more than half of off-label use. Almost 
half (46%) of all prescriptions (2262) were either unlicensed or off-label. According to 
Pandolfini et al (2005), out of 30 studies conducted between 1985 to 2004, off-label and 
unlicensed prescription rates ranged from 11% to 80% with higher rates found in younger 
patients than older ones22. 
The importance of pediatric drugs as a global health issue was recognized in the World Health 
Assembly resolution WHA60.20 “Better medicines for children” 
(http://www.who.int/gb/ebwha/pdf_files/WHA60/A60_R20-en) in 200723. The increased 
awareness of the need for improved drugs for children has led to legislation in the US and 
Europe, and aimed at facilitating the development of drugs for children specifically. In the US 
the legislation include the Food and Drug Administration Modernization Act (1997), Best 
Pharmaceuticals for Children Act (BPCA) (2002), Pediatric Research Equity Act (PREA) (2003) 
and the Food and Drug Administration Amendments Act (FDAAA) (2007)24-27. In Europe 
pediatric drugs has been an area of focus in: European Medicines Agency (EMA) Round Table of 
experts (1997), Note for Guidance on the Clinical Investigation of Medicinal products in Children 
(1999), Council of the Ministers of Health Resolution (2000), Regulation no. 141/2000 (2000) 
and Directive EC/2001/20 (2000). Finally, the European regulation on Medicinal products for 
pediatrics, which was introduced in January 2007, represented a major breakthrough in 
pediatric drug development28,29. 
Currently, both the US Federal Drug Administration (FDA) and EMA require that each drug in 
development that may be used in children should be investigated specifically in children. The 
    
procedures  include waivers for diseases that affect only adults or deferrals if studies in children 
are not appropriate or would lead to unnecessary delay in the authorization of drugs for adults. 
Both the FDA and EMA can offer extended patent protection to marketing authorization holders 
who have tested new drugs in children and meet other criteria. In addition, in Europe, the 
‘Paediatric Use Marketing Authorization’ (PUMA), provides a specific marketing authorization 
and 10 years of data protection for off-patent drugs when MA holders test such drugs in 
children specifically. The importance of supporting the development of orphan drugs (those that 
can only ever be used in a small population of patients) is underlined by both EMA and the FDA. 
The FDA ruled that children constitute a medically plausible subset of patient population to be 
granted an orphan designation. In Europe, a Pediatric Orphan indication grants 12 instead of 10 
years market exclusivity.  
For these regulations it is important that estimates of disease occurrence in children are 
provided in the pediatric investigation plans (PIPs). A PIP should not only include identifying 
information about the drug to be developed but also information about the proposed indication 
in children including details of the potential therapeutic benefit of the drug in relation to unmet 
needs30. Valid estimates of disease occurrence in children are required. 
Available data demonstrate that up till now, both the FDA and EMA programs have been 
successful in meeting their stated goals. According to  a report to the US Congress in July 2016, 
implementation of the BPCA and PREA have resulted in more than 600 pediatric labelling 
changes31. Based on a five-year evaluation (August 2007-December 2012), the EMA and its 
PDCO approved more than 600 PIPs with 30% including neonates. There were 221 labelling 
changes pertaining to safety and efficacy in children and 89 additions of dosing information 
about children (a direct consequence of studies from PIPs)32. Out of 152 authorizations that 
were granted, 31 (34%) included a pediatric indication with 10 linked to a PIP. Some PIPs were 
completed but the information did not support the use of the drugs in children. However, this 
information can be included in the product label, indicating that the PIP process can lead to 
decisions not to use medicines in children.  
Despite the achievements, major concerns about insufficient capacity for pediatric drug 
research (especially  pharmacoepidemiology), and the scarcity of human (including trained 
    
pediatric investigators) and economic resources were discovered33. The increase in research 
activity has highlighted the complexity of conducting drug research in children. Even if enough 
pediatric clinical trials are conducted, RCTs may be inadequate to answer some questions 
regarding drug effects in children. Typically, RCTs include few (and carefully selected) persons 
who are followed up for short periods. Therefore, when approved drugs are administered to 
heterogeneous populations during routine clinical practice, the drugs may not be as effective. 
Due to small sample size especially in studies including neonates and infants, RCTs are not well 
suited to studying effects of rare exposures and/or outcomes. Because of short follow-up, long-
term effects of drug use cannot be investigated. Yet long-term drug effects especially safety 
issues have become an important issue, as evidenced by the public workshop organized by the 
US FDA in April 2016, aimed at stimulating discussion among stakeholders34.  
Pharmacoepidemiological studies exhibit characteristics that can help to overcome the 
aforementioned challenges. Drug prescription and health outcomes data (pertaining to the 
general population including children) from routine healthcare can generate enough sample size 
for studies, even of rare exposures and outcomes. By linking databases while maintaining 
anonymity, studies of neonates and infants, investigating rare exposures and/or outcomes in 
particular can be conducted. However, pharmacoepidemiological methods that are well suited 
to children specifically are lacking.  
 
Data sources for studying disease occurrence and effects of drugs in children: 
focusing on the WHO 
 
Being the United Nations’ organ that is concerned with maintaining public health globally, the 
WHO invests considerable effort and resources to study disease occurrence and the effects of 
drugs in the general population, including children. The WHO utilizes data from vital 
registrations and verbal autopsy to measure the occurrence of diseases that result in death. 
Vital registration data implies data pertaining to live births, deaths, fetal deaths, marriages and 
divorces35. In developed countries where there are good civil registration systems, vital 
statistics are easily available and therefore a good source for assessing cause of death. 
Complete or incomplete death registration systems provide information about cause of death 
    
for almost all high income countries, as well as many countries in Eastern Europe, Central Asia, 
Latin America and the Caribbean36,37. Although to a much less extent, such information is also 
available in other regions. In contrast, many low-and-middle-income (LMIC) countries lack well 
developed record-keeping systems, many deaths are undocumented and therefore, verbal 
autopsy (VA) is a good method for assessing cause of death38-40. VA is a method of gathering 
health information about a deceased individual to determine his or her cause of death and has 
been widely used in children40. Health information and a description of events prior to death are 
acquired from conversations or interviews with a person or persons familiar with the deceased. 
To assign a probable cause of death, health professionals or computer algorithms then analyze 
the information. In order to estimate the occurrence of non-fatal diseases or injuries, the WHO 
and other stakeholders commonly conduct surveys to collect the required data36. 
Regarding drug effects, the WHO focuses on monitoring the safety of medicines. The WHO 
Collaborating Center for International Drug Monitoring (Uppsala, Sweden) monitors the safety 
of medicines that are used globally. Usually, countries submit individual case safety reports 
(ICSRs) into a global database called VigiBase41. As at December 2015, 122 WHO member 
countries had submitted about 11 million ICSRs to VigiBase, with about 1 million coming from 
LMICs. From 2017, VigiBase will receive ICSRs transferred by the EMA on a daily basis41. The 
data submitted to VigiBase is usually routinely screened for new-suspected adverse drug 
reactions. While methods for screening of data pertaining to adults have been extensively 
researched, the same cannot be said of children. 
The efforts of the WHO can be complemented by using active surveillance. Electronic health 
records (EHR), including medical and claims data, contain vast amounts of information 
pertaining to diagnosis, referrals, laboratory tests and results as well as drug prescriptions. 
Such data can be used for population-based studies of disease occurrence and drug effects 
including both safety and effectiveness. Data pertaining to children specifically (especially 
underrepresented age categories like neonates) are not readily available especially for studies 
of rare diseases, drugs and outcomes. Such data should be identified and characterized. 
Researchers that can analyze pediatric data specifically, to generate pediatric-specific evidence 
are required.  
    
Aims and outline of this thesis 
The Global Research in Pediatrics (GRIP) (http://www.grip-
network.org/index.php/cms/en/home) was set up to provide a progressive and durable 
integration of the research capacity of the major European (and other) countries and the US. 
To achieve this objective, various required approaches were identified. First, implementing 
pediatric studies requires well–trained researchers, investigators and other experts in number 
and capacity that do not currently exist. Therefore providing a joint clinical pharmacology 
training programme was outlined as the main objective of GRIP. 
Secondly, GRIP was set up to promote sharing of best practices in research, including 
methodologies and research tools that can be used globally. Central to this is the evaluation of 
methodologies and research tools that meet the needs of researchers and patients. Therefore 
GRIP was aimed at focusing on knowledge translation, exploitation and mobilization. Attaining 
these objectives require close collaboration between pediatric health professionals, academics 
and representatives of the pharmaceutical industries, ethics bodies and regulatory authorities. 
Thirdly, GRIP was aimed at building upon existing European and US excellence and therefore 
included partners with direct and strong links in training and pediatric research networks. 
Therefore GRIP mobilized 17 partners from Europe, the National Institutes of Child Health and 
Development-National Institutes of Health (NICHD-NIH) representing a network of US 
institutions and the FDA, the National Center for Child Health and Development (NCCHD) in 
Japan, the Hospital for Sick Children in Toronto, Canada, and the WHO. Ultimately, a total of 
more than 1000 institutions worldwide, linked to the aforementioned partners and their 
affiliates and networks were identified. 
As specific objectives, GRIP aimed to: increase the number of internationally trained pediatric 
clinical pharmacologists, researchers and formulation scientists; develop an integrated 
electronic infrastructure for epidemiological, pharmacovigilance and post marketing research; 
develop pediatric research tools to facilitate interoperability in pediatric research thereby 
improving efficiency in clinical research and enabling comparison of study results; develop and 
evaluate models for information sharing for Human Research Subject Protection among ethics 
committees and Institutional Review Boards to facilitate review and support consistency in 
    
review practice; explore and validate the use of new protocol designs, procedures and 
methodologies for clinical trials in children; create and maintain an international platform to 
share knowledge and educate professionals on pediatric drug formulation to support clinical 
trials worldwide; set up an international initiative for implementation of clinical trials in 
neonates; create a durable collaboration between participating partners and expand network 
activities to other countries and settings including LMICs; and base dissemination and 
implementation of GRIP outputs on well-planned activities relating to knowledge translation, 
exploitation and mobilization.  
 The work resulting in this thesis was conducted as part of the second specific objective of GRIP 
i.e. develop an integrated electronic infrastructure for epidemiological, pharmacovigilance and 
post marketing research. In defining this objective, GRIP aimed to exploit the information that 
is compiled in real life, and captured in spontaneous reporting and EHR databases. By applying 
pharmacoepidemiological methods, disease occurrence can be estimated from EHR data. Also, 
drug and vaccine utilization, safety of drug and vaccine use in pediatrics, and effectiveness of 
drugs can be evaluated. To allow the combination of large-scale research databases from 
various countries in the European Union (EU) and the US, a common data model was planned 
with mapping of diagnosis and drug terminologies. Also, GRIP planned to create thesauri for 
disease coding systems used throughout the world, and define procedures for data mining and 
data pooling. Further, GRIP planned to develop common methodologies for: measuring disease 
incidence and prevalence; assessing drug utilization; performing drug safety signal detection; 
and evaluating drug safety and effectiveness. 
In chapter 1, we provide a general introduction to the thesis, highlighting: the difficulties 
associated with accurately measuring occurrence of disease, the lack of evidence regarding safe 
and effective use of drugs, the attempts that have been made to generate better evidence of 
drug use and persisting problems. 
    
Table 1: Overview of topics that are described in this thesis 
Chapter  Research topic Design Setting/Data 
source(s) 
Countries (number 
and/or specific 
countries) 
Exposure(s) Outcome(s) 
2.1 Impact of different assumptions on 
estimates of disease in children: A 
retrospective cohort study 
Cohort study IPCI 1 (Netherlands) NA AOM, APN, Asthma, 
Type 1 DM 
       
3.1 Pediatric Drug Safety Signal Detection: A 
new Drug-Event Reference Set for 
Performance Testing of Data-Mining 
Methods and Systems 
Review eMC, Dailymed, 
Micromedex, peer-
reviewed literature 
(medline and 
embase) 
NA Drugs (16)  16 
       
3.2 Drug safety monitoring in children: 
Performance of signal detection 
algorithms and impact of age stratification 
Spontaneous 
reporting analyses 
FAERS 1 (USA) Drugs (16) 16 
       
4.1 Pharmacoepidemiological safety studies in 
children: a systematic review 
Review Medline and embase 28  Drugs and vaccines 
(291) 
212 
       
4.2 Quality of published pediatric 
pharmacoepidemiological safety studies: 
Implications for evidence-based drug 
prescribing in pediatrics 
Review Medline and embase 24 NA NA 
       
5.1 Comparing drug effectiveness in children: 
a systematic review 
Review  Medline and embase 33 NA NA 
       
5.2 Comparing drug effectiveness in children 
using propensity scores based on different 
durations of patient history: A 
retrospective cohort study 
Cohort study IPCI 1 (Netherlands) Drug (ICS+LABA, 
fixed) 
asthma exacerbation 
 
 
       
    
6.1 Reference set for performance testing of 
pediatric vaccine safety signal detection 
methods and systems 
Review Medline, embase and 
cochrane 
NA Vaccines (13) 14 
       
6.2 Current needs in pediatric 
pharmacoepidemiology 
Survey ISPE members USA, Canada, The 
Netherlands, Taiwan 
NA NA 
IPCI - Integrated Primary Care Information; NA – Not applicable; AOM – Acute Otitis media; APN - Acute Pyelonephritis; DM - Diabetes mellitus; Emc - Electronic Medicnes Compendium; FAERS – 
US FDA Adverse Event Reporting System; ICS+LABA – Inhalational Corticosteroids and Long-acting Beta-2-agonists 
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In chapter 2, we investigate the impact of the peculiar characteristics of diseases affecting children on 
accurate measurement of their incidence and prevalence by testing different assumptions.  
 
In chapter 3, we test different methods for detecting safety signals resulting from the use of drugs. 
According to the Council for International Organizations of Medical Sciences (CIOMS)42; a signal can be 
defined as ‘information that arises from one or multiple sources (including observations or experiments), 
which suggests a new, potentially causal association, or a new aspect of a known association between an 
intervention (i.e. administration of a medicine) and an event or set of related events, either adverse or 
beneficial, that is judged to be of sufficient likelihood to justify verificatory action.’ We explain the need 
for creating a pediatric-specific reference set of drug-adverse event combinations. Also, we describe how 
we used this reference set for testing the performance of published signal detection algorithms (SDAs) 
when these SDAs are applied to pediatric data specifically.  
 
In chapter 4, we describe published pharmacoepidemiological safety studies that included children with 
the aim of identifying gaps in study conduct and reporting of published results. Also, we evaluated the 
quality of the studies with the aim to identify study characteristics related to the quality. Consequently, 
critical appraisal of published studies may become easier for clinicians and other persons with limited 
knowledge of epidemiology.  
 
In chapter 5, we investigate the methods that have been applied to conduct comparative 
(pharmacoepidemiological) drug effectiveness studies in children, aiming to identify areas that can be 
improved upon. Also, we test the impact of propensity scores adjustment to control confounding by 
indication, a common type of confounding in comparative drug effectiveness studies. As an example, we 
investigate the effectiveness of asthma treatment in children on the prevention of asthma exacerbations. 
Asthma was chosen as it is a common and chronic condition in children.  
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In chapter 6, we present other issues that are also important for a complete understanding of the 
problems we highlighted in the introduction of this thesis. We emphasize the need to monitor vaccine 
safety in children since they represent the drugs that are most frequently used in children worldwide. 
Monitoring of vaccine safety requires the creation of a specific adverse event reference set. Also, we 
present results of a survey that was conducted to identify the most pressing needs in the field of pediatric 
pharmacoepidemiology.  
In chapter 7, the main findings of the thesis are summarized and discussed. 
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Chapter 2 Estimating the occurrence of childhood diseases 
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Chapter 2.1 Impact of different assumptions on estimates of pediatric disease 
occurrence from health care data: A retrospective cohort study 
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Abstract 
Purpose: Pediatric-specific drug legislations have been introduced and require estimates of disease 
incidence in children to support the pediatric investigation plans. Automated population-based electronic 
healthcare records (EHR) provide a potential data source but methods for calculation of disease 
occurrence have not been specified for children. We aimed to understand the impact of assumptions 
regarding duration of disease episode and length of run-in period on incidence estimates from EHRs. 
Methods: Children aged 0-17 years (5-17 years for asthma) registered in the Integrated Primary Care 
Information (IPCI) database between 2002 and 2014, were studied. We tested impact of assumptions on 
incidence estimates. These were firstly, maximum duration of disease episode (namely 0, 14, 30, 60 and 
90 days) for recurrent diseases (acute otitis media (AOM) (common) and acute pyelonephritis (APN) 
(rare)). Secondly we tested the impact of database run-in period when applied to chronic diseases: 
asthma (common) and type 1 diabetes (DM) (rare). We calculated incidence rate ratios (IRR) with 95% 
confidence intervals (CI) and stratified by age using 1-year categories. 
Results: In the IPCI database, 503,495 children were registered during the study period.  The incidence 
of AOM was highest in < 2 year old children. Using 30 days episode length as reference, the rate 
increased with 8% if the duration was 14 days and it decreased with 8% when it was extended to 60 
days. Episode duration had no impact on the rate of APN (rare disease). Lack of a naïve period (to 
exclude prevalent cases) as compared to a 24 months naïve period overestimated the incidence rate for 
asthma as well as for DM by a factor of two.  
Conclusions: Use of electronic health care records of which IPCI is a representative example, allows for 
estimation of disease incidence but the assumptions on episode length and run-in period impact on the 
incidence estimates, and this differs for common/rare recurrent and chronic diseases. We recommend 
that disease incidence estimation for children based on dynamic electronic health care databases carefully 
explore assumptions around episode length and naïve period. 
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Introduction 
Globally, legislations have been introduced to stimulate development of drugs for children 
specifically26,43,44. Regulatory authorities now require pharmaceutical companies to include pediatric 
investigation plans (PIPs) when submitting proposals for drug development in adults. PIPs may be waived 
if the target indication affects only adults. For PIPs that are considered for approval, the potential 
therapeutic benefits for children should be explained in the document. Such explanation may include data 
regarding the background occurrence  of the indication in the pediatric population30.  
Population based electronic health care records  (EHR) provide an excellent  datasource for calculation of 
disease occurrence45, however there are specific methodological challenges that should be considered 
based on the fact that these data are not collected for research but for every day care.  
Firstly since EHR were introduced only in the last decades, software systems may change, and patients 
may also move between physicians/health care plans. Therefore the data often captures only a specific 
(limited) part of an individual’s life-time. In order to distinguish incident from prevalent disease, 
researchers usually apply a look-back (run-in) period which is often arbitrarily chosen and the impact of 
the choice is not investigated or reported46. In addition, parents visit a physician usually at the start of 
the disease of their child but not anymore once the condition is over, which hampers calculation of the 
duration of transient diseases. 
Secondly, the characteristics of childhood diseases present additional challenges, children suffer mostly 
from common transient infection related disease such as acute otitis media (AOM). On the other end of 
the spectrum of recurrent diseases there may be rare conditions such as acute pyelonephritis (APN)9 10. 
Diseases that affect children may also be chronic and differ in frequency: asthma is common and chronic 
unlike type 1 diabetes (DM) which is also chronic but less common12,13. It would be important to 
understand the impact of different assumptions on estimation of disease occurrence.  
As part of the Global Research in Paediatrics - Network of Excellence (http://www.grip-network.org/), we 
aimed to understand how different assumptions regarding duration of a disease episode (for transient 
and recurrent diseases) and run-in period (for chronic diseases) may impact incidence and prevalence 
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estimates. As examples, we investigated AOM and APN (both transient and recurrent), and asthma and 
type 1 diabetes (both chronic conditions). 
Methods 
Setting 
This retrospective cohort study was performed using the Integrated Primary Care Information (IPCI) 
database as an example for other electronic health care databases. IPCI is a longitudinal, observational, 
primary care database with records of approximately 1,500,000 patients from about 450 general 
practitioners in the Netherlands. The records comprise information on patient demographics, symptoms 
and diagnoses, referrals, laboratory test and results, drug prescriptions, hospitalizations and discharge 
letters. Details of the data source have been published elsewhere47. Diagnoses are coded according to 
the International Classification for Primary Care (ICPC)48. Drug names are coded following the World 
Health Organization-Anatomic Therapeutic Chemical (WHO-ATC) classification system. The database has 
been proven to be valid for conducting pharmacoepidemiological studies49. The study and the access to 
the database were approved by the IPCI governance board (number 05/2015)  
Study population 
All children aged 0-17 years that were registered for at least one day between January 1 2002 and 
December 31 2014 could be included in the study. For the investigation of asthma, the minimum age for 
inclusion was 5 years since the diagnosis of asthma in children under 5 years old is prone to 
misclassification due to the high incidence of viral infections associated with wheezing50,51. Patients 
entered the study population at the latest of the following dates: start of the study period, date of birth 
or date of registration in IPCI, age of 5 years (asthma only). Exit from the study population occurred at 
the earliest of the following events: leaving the GP practice, death, subject turned 18 years old or end of 
the study period. Since some chronic diseases require run-in periods to exclude prevalent cases, start of 
follow-up was dependent on the length of the run-in period, which was added to the criteria listed above. 
 
Outcome definition and identification 
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Four outcomes of interest were studied based on different frequencies (common or rare) and durations 
(transient or chronic). The outcomes were identified based on diagnosis and prescription codes. See 
appendix 1.  
Acute otitis media (AOM) is a transient disease, the systemic and local features of AOM usually resolve 
within 24-72 hours52,53. One patient can experience more than one episode of AOM54. Children with AOM 
were identified through a search on the International Classification of Primary Care (ICPC) AOM disease 
code H74.  
Acute pyelonephritis (APN) is also a transient disease. According to the Dutch classification, ICPC disease 
code U70 implies that APN was diagnosed by urine testing55. APN may be recurrent 56  
Asthma is a chronic and rather common condition in children13. Cases were identified by combining the 
ICPC disease code (R96) with at least 2 prescriptions for asthma medication (ATC code R03) in the year 
following the initial diagnosis13,57.  
Type 1 diabetes (DM) is a chronic and rare disease in children. Cases were identified by combining ICPC 
disease code (T90) and at least 1 prescription for insulin (A10A) in the year following the initial 
diagnosis58.  
Statistical analyses 
Overall and age-specific incidence rates (IR) were calculated by dividing the events/outcomes by the total 
number of person-years (PY) accumulated in the study population. The IR was expressed per 100,000 
PY. Age stratification was done in 1-year categories. For the transient outcomes (AOM and APN), 
recurrent episodes were considered as new events based on a duration of episodes of 0,14,30,60 and 90 
days. Person-time was not censored at diagnosis. For the chronic outcomes, person-time was censored at 
the date of first diagnosis. The run-in period was altered from 24 to 12 and 6 months to assess the 
impact on the incidence rate. Further, the impact of not applying a run-in period was tested. The 95% 
confidence intervals (CI) around the incidence rates were estimated based on the negative binomial 
distribution59. For the transient outcomes (AOM and APN), age-specific incidence rate ratios (IRR) were 
calculated by comparing the IRs based on clinically plausible episode durations - 14 days vs 30 days. For 
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the chronic outcomes (asthma and DM), age-specific IRRs were calculated by dividing the IR resulting 
from not applying run-in vs 24 months’ run-in.  
Point prevalence was calculated on July 1 2010 by dividing the number of children with the outcome on 
that date by the total number of children in the study population on that date. 95% CIs were calculated 
based on the Wilson score interval 60. To calculate the age-specific prevalence rate ratio (PRR) for the 
transient outcomes (AOM and APN), we assumed an event to be new if it occurred ≥30 days after the 
preceding event and we divided the resulting point prevalence by the estimate that was based on 14 
days duration. Regarding the chronic outcomes (asthma and DM), age-specific PRRs were calculated by 
dividing the point prevalence resulting from 24 months’ run-in vs no run-in. The 95% CIs around the 
IRRs and PRRs were calculated following the negative binomial distribution 61. 
Analyses were conducted using a custom built Java application called Jerboa Reloaded (Erasmus 
University Medical Center, Rotterdam), and IBM SPSS Statistics for windows version 21.0, Armonk, NY: 
IBM Corp. 
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Results 
To investigate AOM and APN, the study population comprised 503,495 children. For asthma (studied in 
children 5 years or older) and DM we studied  304856 and 405600 children respectively; the total PYs of 
follow-up were 710,980 PY and 1,042,067 PY . Figure 1 shows the distribution of age (at start of follow-
up (no run in)) and duration of follow-up of the population base, without censoring.     
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Note: Run-in was not applied and subjects were not censored 
Figure 1: Median follow-up time according to the age categories of the studied 
populations
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Recurrent diseases and impact of episode duration  
Based on the assumptions that a new event can only re-occur 0, ≥14, ≥30, ≥60, or ≥90 days after the 
preceding event, overall IRs for AOM decreased from 8.2, 7.1, 6.6, 6.2 to  5.9 per 100 PY respectively 
(table 1). The estimates resulting from the shortest assumed duration were the highest, decreasing with 
increasing length of an episode in all age categories (figure 2). Incidence was highest in the youngest 
children although this did not affect the impact of episode duration on the IRR: comparing 14 vs 30 days: 
IRR=1.10 (95% CI: 1.08; 1.12) for subjects aged <1 year and 1.09 (95% CI: 1.07; 1.11) for subjects 
aged 1-2 years; overall IRR= 1.08 (95% CI: 1.07; 1.09). The incidence rates for APN were much lower 
than for AOM. Assuming 0, ≥14, ≥30, ≥60 or ≥90 days between new events, the overall IRs reduced 
relatively little from 31.1, 29.6, 28.9, 27.9 to  27.0 per 100,000 PY, respectively. The age-specific IRRs to 
test assumptions on duration of episodes comparing 14 vs 30 days were all around  1, showing no age 
specific effect modification of the impact of episode duration.  
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Table 1: Total number of studied children, total person-years (PY) of follow-up, total number of incident events (transient and recurrent 
outcomes) or cases (chronic outcomes),  and  overall incidence rates according to the investigated outcomes  
Outcome Assumption a Total number of 
subjects b 
 
Total person-
years (PY) 
Total number of 
events/cases 
Incidence rate 
(per 100,000 
PY)  
Acute otitis media 0 days 503,495 1,781,625 146,391 8,216.7 
 ≥14 days 503,495 1,761,172 124,749 7,083.3 
 ≥30 days 503,495 1,752,235 115,107 6,564.0 
 ≥60 days 503,495 1,746,245 107,860 6,176.7 
 ≥90 days 503,495 1,742,821 103,089 5,915.1 
      
Acute 
pyelonephritis 
0 days 503,495 1,734,774 540 31.1 
 ≥14 days 503,495 1,734,750 513 29.6 
 ≥30 days 503,495 1,734,740 502 28.9 
 ≥60 days 503,495 1,734,724 484 27.9 
 ≥90 days 503,495 1,734,713 468 27.0 
      
Asthmab No run-in 304,856 710,980 4,238 596.1 
 6-months run-in 304,856 710,980 3,385 476.1 
 12 months run-in 304,856 710,980 2,786 391.9 
 24 months run-in 304,856 710,980 1,881 264.6 
      
Type 1 diabetes No run-in 405,600 1,042,067 256 24.6 
 6-months run-in 405,600 1,042,067 212 20.3 
 12 months run-in 405,600 1,042,067 172 16.5 
 24 months run-in 405,600 1,042,067 115 11.0 
a For the transient outcomes, this refers to the time between new episodes;  for the chronic outcomes, it refers to the length of the run-in period; b For asthma and type 1 diabetes, 
subjects that had a minimum 24 months’run-in were studied to know the impact of decreasing the run-in period on the incidence rate  
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Note: The confidence intervals for the point prevalence of Acute pyelonephritis are not presented because they are too wide 
Figure 2: Incidence rate, Incidence rate ratio, point prevalence and prevalence rate ratio for 
the transient outcomes 
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The impact of episode duration length had quite an opposite effect on the point prevalence with 
increasing duration of episodes the point prevalence increased.  The overall PRR that compared an 
episode duration of 30 days to 14 days duration for AOM was 1.92 (95% CI: 1.73; 2.12), which was 
higher than for APN: 1.50 (95% CI: 0.25; 8.98). In APN the impact was less pronounced due to a very 
low prevalence overall.   
 
Chronic diseases and impact of run-in period  
By applying a 0, 6, 12, or 24 months’ naïve period, overall IRs for asthma (age 5-17 years) lowered from 
5.96, 4.76, 3.92 to 2.65 per 1,000 PY respectively. The impact of a 0 vs 24 months’ run-in was a more 
than two fold increase in incidence rate across all ages (figure 3), IRR overall=2.25 (95%CI: 2.13; 2.38). 
By applying a 0, 6, 12, or 24 months’ naïve period, overall IRs for DM were 2.46, 2.03, 1.65 and 1.10 per 
10,000 PY respectively.  Again, the highest IRs were observed when no run-in was applied and they were 
lowest with 24-months’ run-in. The impact of applying 0 vs 24 months’ run-in leads to a twofold increase 
in incidence rate in most age categories, IRR overall=2.22 (95%CI: 1.79; 2.77). 
The impact of an increase in the run-in period, during which prevalent cases would be identified and 
excluded, was a lowering of the rate of asthma as well as DM. The impact of applying a 24 months’ run-
in vs no run-in on the age specific point prevalence rate was negligible for both asthma (overall PRR: 
1.10 (95% CI: 1.06; 1.14)) as well as DM (overall PRR: 0.82 (95% CI: 0.64; 1.04)). 
The results are summarized in figure 4. 
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Figure 3: Incidence rate, Incidence rate ratio, point prevalence and prevalence rate ratio for 
the chronic outcome
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Outcome 
Chronic 
Testing assumptions regarding duration of an 
episode 
Testing assumptions regarding length of 
the run-in period 
Transient/  
recurrent 
Common 
outcome 
Rare 
outcome 
Common 
outcome 
Rare 
outcome 
Do the assumptions 
impact the incidence or 
prevalence? 
Do the assumptions 
impact the incidence or 
prevalence? 
Do the assumptions 
impact the incidence or 
prevalence? 
Do the assumptions 
impact the incidence or 
prevalence? 
NO YES - INCIDENCE YES - INCIDENCE YES - BOTH 
Figure 4: Summary of the impact of assumptions on the investigated outcomes 
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Discussion 
This study showed that incidence and point prevalence of disease in childhood can be estimated well 
using a population-based dynamic electronic health care record database. The lack of complete follow-up 
from birth till 17 years of age, and the fact that only the visit for a disease and not the ending of a 
disease is  recorded in the electronic medical record has an impact on disease occurrence estimation. 
Usually epidemiologists apply assumptions to deal with these limitations, such as ‘assuming a standard 
disease episode duration’ and use of a run-in period prior to start of follow-up that can be used to 
exclude prevalent disease. In this paper we wanted to investigate the impact of these assumptions on the 
different occurrence measures in children, and we witnessed relatively great impact. General rules can be 
obtained from this exercise: for common recurrent diseases the impact of the choice of episode duration 
is relatively high, assuming longer disease episodes leads to lower incidence. The impact of a change in 
episode duration on the incidence is negligible in a rare recurrent disease. This is understandable since 
the probability of having another event of a rare disease is low and this will not likely occur close 
together. The impact of an increasing episode duration on the prevalence of a common recurrent disease 
is opposite, with increasing duration the point prevalence increases. The impact is negligible on the point 
prevalence for a rare recurrent disease.  We recommend that studies aiming to estimate incidence and 
prevalence of common recurrent diseases better explore the impact of the episode length since the true 
length cannot be observed in medical record databases. Patients do not return to tell the general 
practitioner (GP) that disease is cured. For rare diseases the impact of different episode durations may be 
ignored both for incidence and prevalence estimations.  For chronic diseases, varying the run-in impacts 
the incidence with negligible impact on the prevalence. We recommend that studies investigating chronic 
diseases apply the longest possible run-in to avoid misclassifying prevalent cases as incident.  
Regarding AOM, there was no difference in incidence when we compared two clinically plausible episode 
durations: 14 versus 30 days; 30 days has been applied in a previous study9. Based on the natural history 
of AOM, the actual duration of an episode is not clear62. Therefore we also compared the incidence rates 
(results not presented) we derived from the shortest (0 days) versus longest (90 days) assumptions, the 
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estimates were significantly different. When we performed the same comparisons for APN, the result was 
not significant, further confirming that the episode duration is important for estimating the occurrence of 
only the common outcomes. We observed that assuming episode duration of 30 vs 14 days significantly 
impacted the prevalence of AOM. We recommend further research to know the most appropriate 
assumptions to apply when estimating the occurrence of AOM and other common and recurrent 
childhood diseases. Prevalence might be a good measure. 
Regarding both asthma and DM, increasing the run-in period considerably decreased the incidence. This 
finding is important given that people can be observed for only a part of their lifetime; despite conducting 
the current study over a 12-year calendar period, the median duration of follow-up for the studied 
population was 1500 days, showing the incomplete follow-up (figure 1). Therefore we recommend that 
the longest feasible run-in period be applied when estimating the incidence of chronic diseases.  
This study has strengths and limitations. As strengths, we tested assumptions that are plausible from 
both an epidemiological and clinical point of view and we demonstrated the ability to estimate the impact 
of different assumptions.Limitations are the fact that we looked only at 4 different conditions and try to 
draw general conclusions. We do feel however that the conclusions hold, but cannot provide thresholds 
when something is considered rare or common. This will be a continuum, with the specific  
demonstrators we try to show that assumptions should be considered and the impact may be 
considerable. A second limitation is that we applied the assumption to one database only, a highly 
dynamic general practitioners’ database. The impact of the episode length is generalizable across all 
databases, but the impact of the run in period may be less pronounced in more stable regional or 
national databases where persons are registered from birth. 
Conclusions 
Population based electronic health care records provide a rich and readily available source of data for 
estimation of disease occurrence in children which can be used in pediatric investigation plans. Trial 
planning as well as potential market implications usually require estimates of occurrence in children. 
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Assumptions on the episode length and run in period may impact a lot on the absolute measures of 
occurrence and should be explored, especially in more common childhood diseases.  
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Appendix 1: Characteristics and event (transient and recurrent outcomes) or case (chronic outcomes) definitions for the 
investigated outcomes  
 
Outcome Duration Frequency Prevalence/Incidence 
in general population  
Clinical definition Case definition  Alternative 
assumptions  
Acute otitis 
media:  
Transient Common 107 episodes/1000 PY63 ‘Acute otitis media is 
understood to be an 
inflammation of the 
middle ear with a 
maximum duration of 
three weeks. Acute 
otitis media is 
generally associated 
with earache, 
symptoms of general 
illness, fever and 
sometimes purulent 
discharge (otorrhoea), 
and is characterised 
by a bulging tympanic 
membrane with 
change in colour (red 
or opaque)’  64 the 
systemic and local 
features of AOM 
usually resolve within 
24-72 hours 52,53. 
 
ICPC code H71 54  Varying the time 
between new  events a 
0 days 
≥14 days  
≥30 days 
≥60 days and 
≥90 days  
 
Acute 
pyelonephritis  
Transient  Rare 15.7/100000 persons65 Symptoms of Urinary 
Tract Infection (UTI) 
in children may 
include fever, 
vomiting, screaming, 
anorexia, and 
irritability. Acute 
pyelonephritis is a 
component of UTI 55  
 
ICPC code U70b AND 
prescription of any 
antibiotic (J01) on the 
same date of diagnosisc 
55  
 
Varying the time 
between new events b 
0 days 
≥14 days  
≥30 days 
≥60 days  
≥90 days  
 
 
Asthma Chronic Common 6.7/1000 PY13 Asthma is a syndrome 
with a highly variable 
clinical spectrum, 
characterised by 
airway inflammation 66 
ICPC code R96 AND at 
least two prescriptions 
for asthma medications 
(R03) in the first year 
following the initial 
diagnosis 13. 
 
Varying the run-in 
periodd 
No run-in (prevalent 
cases included) 
6 months 
12 months 
24 months 
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Type 1 diabetes Chronic  Rare 23.2/100000 children 12 ‘Type 1 diabetes is an 
autoimmune –
mediated disease 
associated with 
several complications 
and decrease in 
quality of life’ 67 
ICPC code T90 AND at 
least one prescription of 
insulin (A10A) in the 
first year following the 
initial diagnosis 58. 
Varying the run-in 
periodd 
No run-in (prevalent 
cases included) 
6 months 
12 months 
24 months 
a For ‘0 days’, this implies that every record is considered as a new episode and for the other assumptions, all records within the stated time window (<14 , <30 , <60, and <90 days) 
are considered as the same episode. 
b According to the Dutch classification, ICPC code U70 implies that APN was diagnosed by urine testing 55  
c In the Netherlands, physicians are encouraged to administer antibiotics for every case of AP because of the risk of renal scarring. 
d This applies only to prevalence calculation; run in period will not be applied to patients with age< run-in period
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Chapter 3 Detecting drug safety signals 
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Chapter 3.1 Pediatric Drug Safety Signal Detection: A new Drug-Event Reference Set 
for Performance Testing of Data-Mining Methods and Systems 
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Abstract 
Background: Better evidence regarding drug safety in the pediatric population might be generated from 
existing data sources like spontaneous reporting systems and electronic health care records. The Global 
Research in Paediatrics (GRiP) – Network of Excellence aims to develop pediatric-specific methods that 
can be applied to these data sources. A reference set of positive and negative drug-event associations is 
required. 
Objective: To develop a pediatric-specific reference set of positive and negative drug-event associations. 
Methods: Considering user patterns and expert opinion, sixteen drugs that are used in individuals aged 
0-18 years were selected; and evaluated against sixteen events, regarded as important safety outcomes. 
A cross-table of unique drug-event pairs was created. Each pair was classified as potential positive or 
negative control based on information from the drug’s Summary of Product Characteristics and 
Micromedex. If both information sources consistently listed the event as adverse event, the combination 
was reviewed as potential positive control. If both did not, it was evaluated as potential negative control. 
Further evaluation was based on published literature. 
Results: Some selected drugs are ibuprofen, flucloxacillin, domperidone, methylphenidate, montelukast, 
quinine, and cyproterone/ethinylestradiol. Some selected events are bullous eruption, aplastic anemia, 
ventricular arrhythmia, sudden death, acute kidney injury, psychosis and seizure. Altogether, 256 unique 
combinations were reviewed, yielding 37 positive (17 with evidence in children and 20 with evidence in 
adults only) and 90 negative control pairs, the remainder being unclassifiable.  
Conclusion: We propose a drug-event reference set that can be used to compare different signal 
detection methods in the pediatric population.  
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Introduction 
In the last 50 years, drug safety monitoring has developed rapidly in terms of increasing interest, 
broadening capacity, innovation of methods and availability of data 68-70. This evolution has focused more 
on the adult population than the pediatric age group (individuals aged 0 -18 years). However, drug safety 
monitoring in pediatrics is of particular importance, because we continue to observe that many drugs are 
prescribed unlicensed and there is lack of adequate information on safety issues affecting this age group. 
This is of particular concern as the impact of adverse events during growth and maturation may be more 
serious and longer term as compared to adults 17,71-74. 
Globally, specific regulations are being implemented to generate better evidence on safety and efficacy in 
the pediatric population but mostly by clinical trials 24,75. Although useful for efficacy, such trials are 
usually too small and with too short follow-up to yield adequate information on rare adverse drug 
reactions (ADR) and long-term safety 76. Therefore, other and preferably existing data sources should be 
utilized to provide information on safety of drugs in pediatrics 77. Existing sources with lots of data 
comprise spontaneous reporting systems (SRS) and electronic health care record (EHR) databases.  
Although analysis of spontaneous reports is currently the most commonly used method for identifying 
safety signals, specific approaches to surveillance of the pediatric population are limited. The Council for 
International Organizations of Medical Sciences (CIOMS) Working Group VIII recently advocated for an 
increased pediatric focus in signal detection 42. CIOMS also suggested methods to control for confounding 
in vaccines safety assessment, an issue specific to the pediatric population, and de Bie et. al proposed 
further refinement of these methods 78.  
Safety signal detection using SRS databases may be complemented by mining longitudinal data in EHRs 
as described by the European Adverse Drug Reaction (EU-ADR) project - ‘Exploring and Understanding 
Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge’ and the 
‘Observational Medical Outcomes Partnership’ (OMOP) project 79-81. Although newly developed methods 
i.e. Longitudinal Gamma Poisson Shrinker (LGPS) show promising results on pediatric data 82, more 
extensive and systematic testing is needed. 
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The Global Research in Paediatrics (GRiP) - Network of excellence (http://www.grip-network.org/) was 
set up with the general objective of facilitating the development, and safe use of medicines in the 
pediatric population; a specific objective being to apply innovative approaches, standardized 
methodologies, as well as better utilization of existing healthcare and spontaneous reporting databases. 
GRiP aims to tailor existing signal detection methods to pediatric safety data. Comparison of the 
performance of existing methods within and across SRS and EHR databases is the first step in defining 
suitable methods to be implemented. For this purpose, creation of a reference set comprising pediatric 
drug-event pairs serving as positive and negative control, is required to calculate baseline performance 
statistics. Coloma et al. recently described the methodology for creating a reference set used to test 
methods in the EU-ADR project 83. Similarly, Ryan et. al. established a reference set for testing methods 
in the OMOP project 84. However, both were not specific to the pediatric population and comprise many 
drugs infrequently prescribed within this age group, and events that rarely (or never) affect them. 
In this paper we describe how we created a proposed reference set for comparing the performance of 
different methods in detecting drug safety signals in the pediatric population. This may be used for 
spontaneous reporting databases as well as electronic health care record databases  
Methods 
 
The first step in creating the reference set was to select a list of eligible drugs to be utilized. Based on 
four criteria, four (primary) lists of drugs were created:  we compiled drugs that are frequently prescribed 
in pediatrics (including off-label use), on outpatient basis in high income countries (as per papers and 
reports of use) 85,86; to allow for inpatient databases to be  assessed, we included drugs that are 
administered to hospitalized persons aged 0-18 years (or administered by specialists) 86; to allow for  
databases from low-and-middle-income countries (LMICs) to be assessed,  we included drugs that are 
used in such countries (as per World Health Organization – WHO list of essential medicines for 
children)87; and to allow for testing signal detection performance by different  age groups, we included 
drugs that are used in specific pediatric age groups (for example - adolescents) 86.  
    
46 | P a g e  
 
To obtain a final drug list, a stepwise procedure was implemented. First, if 2 or more drugs (5th level 
chemical substances, World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) 
Classification System) belonged to the same class (‘WHO-ATC, 4th level’), and were listed in an equal 
number of primary lists (>1), we preferentially selected only the drug that had the oldest initial marketing 
authorization worldwide. This was done to have most evidence available. For example, doxycycline 
(WHO-ATC code J01AA02) would be selected instead of minocycline (WHO-ATC code J01AA08) because 
although they both belong to the same class - ‘WHO-ATC, 4th level’ (tetracyclines), doxycycline was first 
marketed in 1967 88, and minocycline in 1972 89. Secondly, we preferentially selected drugs that appeared 
in most of the lists, for example a drug appearing on 3 of 4 primary lists would be retained instead of 
another drug appearing on only 2 lists. The final list comprised more than 30 drugs which was beyond 
our capacity and resources and was reduced to 16 for pragmatic reasons. 
Events were chosen (independent of the drugs) with the aim of generating a set which may be used for 
methods’ development on spontaneous reporting as well as electronic health care records. Both rare and 
common events were included to allow for investigation of effect modification. Starting with common 
adverse events observed in pediatrics as reported by Star et al. 201190, we selected only events that 
were deemed serious (as per WHO definition-91); and  specific (to avoid misclassification). For example 
aplastic anemia was selected rather than anemia; as the former connotes a more serious and specific 
medical condition. Some events (i.e. psychosis and seizure) were included by consensus in the research 
team because they were considered relevant for the pediatric population from a pharmacovigilance and 
public health point of view. Fifteen drugs and events were considered as the minimum required for 
generating enough positive and negative associations. Finally, the total number of drugs and events was 
set at 16 for pragmatic reasons.  
Four researchers -MS, IW, JB and GWJ- with a range of expertise spanning pediatrics,  pharmacology, 
and pharmacoepidemiology,  determined the final list of selected drugs and events. MS and IW are 
pharmacists/pharmacoepidemiologists; JB is a pediatrician; while GWJ is a pediatrician/clinical 
pharmacologist/pharmacoepidemiologist.  
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All events of interest were defined using standard resources (i.e. medical textbooks, uptodate.com and 
scientific societies such as CIOMS) to increase the likelihood of comprehensive literature searches.  The 
final reference set was generated by cross tabulating the final lists of drugs and events which led to a 
matrix of 256 unique drug-event pairs. In order to classify each unique drug-event pair as a ‘positive’, 
‘negative’ or ‘unclassifiable’ association, evidence was reviewed in 2 sequential steps:  
Review of Summary of Product Characteristics (SPC) and Micromedex 
First, 2 researchers (OO and CF) with expertise in general medicine, pharmacy and 
pharmacoepidemiology reviewed each drug’s SPC to ascertain that a specific event (for example aplastic 
anemia) was listed as a possible adverse event under the appropriate section(s): ‘Undesirable effects’ 
(section 4.8) and/or ‘Special warnings and precautions for use’ (section 4.4) from the electronic Medicines 
Compendium (eMC) 92. DailyMed (the ‘Contraindications, Warnings, Precautions’ and/or ‘Adverse 
Reactions’ section(s)) was consulted only if a drug was not listed in eMC 93. The eMC contains >9000, up-
to-date, freely accessible documents containing information about medicines licensed for use in the 
United Kingdom (UK). Prior to publishing, these documents are usually checked and approved by either 
the UK Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency 
(EMA). DailyMed, published by the National Library of Medicine (NLM) in the US, contains up-to-date 
information about drugs licensed for use in the US. Both eMC and DailyMed are freely accessible online.  
Secondly, OO and CF reviewed Micromedex to check if the event was listed under the section: ‘Adverse 
Reactions’ within the Drugdex component. Micromedex is an online drug information system that contains 
referenced information from various sources needed for clinical decision-making including adverse effects 
of drugs (http://www.micromedex.com/).  
After reviewing the SPC and Micromedex, drug-event pairs were classified as: (1) ‘potential positive 
control’ (event was mentioned in both SPC and Micromedex); or (2) ‘potential negative control’ (event 
was mentioned in neither SPC nor Micromedex); or (3) unclassifiable (discordant information between 
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SPC and Micromedex). ‘Potential positive control’ and ‘potential negative control’ pairs were retained and 
the relationship of each drug-event pair was further evaluated using published literature (figure 1). 
 
 
 
 
Fig. 1 Procedure adopted for the construction of the reference set (adapted from Coloma et al. 2013). 
SPC Summary of Product Characteristics, # drug-event pairs 
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Review of published literature  
For each drug-event pair that was classified as a ‘potential negative control’, a systematic literature 
search was conducted in Embase.com and Medline (via OvidSP). The sensitive search algorithm applied 
to both title and abstract, comprised controlled vocabulary plus free text for each of 2 concepts: event of 
interest and drug.  
For each ‘potential positive control’, the search algorithm was more specific (to avoid large numbers 
of papers) than for the potential negative controls and included only controlled vocabulary for the drug 
name. However, the event was searched by using both controlled vocabulary and free text. In addition, 
controlled vocabulary was included for the concept: ‘general adverse drug reaction’, this was done to 
increase the probability of retrieving only those articles where adverse event and drug co-occurred in the 
context of drug safety 83.  
For potential negative and positive control pairs we only considered articles published in English. 
Publications could be biological and/or epidemiological studies. Epidemiological studies could be case 
reports, observational studies (i.e. cohort, case-control), reviews, meta-analysis and clinical trials. As 
examples, the search strings for the negative control sudden death-cyproterone/ethinylestradiol, and 
positive control sudden death-clarithromycin are presented in appendix 1. 
One of 5 researchers (OO, CF, FF, MC, and YH) reviewed retrieved publications pertaining to a unique 
drug-event pair. All 5 researchers have received medical, biological and/or pharmacology training. Based 
on data extracted from relevant publications, unique drug-event pairs were classified according to the 
criteria outlined in table 1. For example, a pair was assigned as level I evidence if there was evidence 
from at least one randomized controlled trial or meta-analysis, while ‘positive control – grade 1’ (PC1) 
meant that in addition, there was ‘proven biological mechanism for causal association’. Level V evidence 
- (not mentioned in SPC/Micromedex) AND (published evidence against causal association; OR no 
published evidence supporting causal association) - qualified a specific drug-event pair as a negative 
control, while ‘negative control – grade 1’ (NC1) meant that in addition, there was ‘proven biological 
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mechanism against causal association’. ‘Proven biological mechanism’ meant that there was at least 1 
publication providing relevant biological evidence regarding a unique drug-event pair. Two researchers - 
MS and FK (a pediatrician, clinical pharmacologist and pharmacoepidemiologist) - reviewed all 
associations that were classified as positive or negative control.  
Whereas confirmation of negative control pairs required lack of association for either adults or the 
pediatric age group, positive control pairs were specifically assessed for availability of evidence pertaining 
to persons aged 0-18years. However, such evidence was not mandatory for classification as positive 
control, due to the acknowledged lack of pediatric-specific studies 94. Those with lack of evidence in 
pediatrics are listed separately. 
To further illustrate the process of reviewing the published literature, 126 unique references were 
retrieved following database search for articles supporting the potential positive control sudden death-
clarithromycin. Of these, 103 articles were excluded following title/abstract screening; while 13 articles 
were excluded following full-text screening. Full text copies of 6 articles could not be obtained. Finally, 4 
articles-1 clinical trial, 2 case control studies and 1 case report-presented sufficient evidence to support 
the association. 
 
    
51 | P a g e  
 
Table 1: Evaluation and grading of unique drug-event pairs based on SPC/Micromedex and literature evidence 
Classification Level of evidence Description 
Biological 
mechanism Description Grade 
Positive 
Control (PC) I 
(Included in SPC/Micromedex ) AND (Evidence from at 
least one randomized controlled trial or meta-analysis) 
Proven for causal 
association 
Evidence from at least 
one publication 
explaining mechanistic 
pathway 
PC1 
Plausible for causal 
association No published evidence PC2 
 II 
(Included in SPC/Micromedex) AND (Evidence from at 
least one observational study [e.g. cohort, case-control, 
case-crossover, self-controlled case series] OR review of 
spontaneous reports OR systematic review OR [at least 
three published case reports from different sources and 
concerning different patients with causality evaluation 
of definite or probable]) 
Proven for causal 
association 
Evidence from at least 
one publication 
explaining mechanistic 
pathway 
PC1 
Plausible for causal 
association No published evidence PC2 
 
Indeterminate 
III 
(Included in SPC/Micromedex) AND (Evidence from less 
than three published case reports and no further 
substantiation in the literature) 
   
IV Included in SPC/Micromedex BUT no published case reports or studies    
 
Negative 
Control (NC) V 
(Not mentioned in SPC/Micromedex) AND (published 
evidence against causal association OR no published 
evidence supporting causal association)  
Proven against 
causal association 
Evidence from at least 
one publication 
explaining mechanistic 
pathway 
NC1 
Plausible against 
causal association No published evidence NC2 
SPC - summary of product characteristics 
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Results  
As presented in table 2, 16 drugs (unique WHO-ATC codes, 5th level chemical substance) were selected 
for the reference set. They comprise 8 anti-infectives: flucloxacillin, clarithromycin, doxycycline, lopinavir 
(which is always administered in fixed-dose combination with ritonavir), isoniazid, praziquantel, 
mebendazole and quinine. The remaining are respiratory drugs (fluticasone, administered as inhalant, 
and montelukast), gastrointestinal drugs (loperamide and domperidone), antipyretic/analgesic 
(ibuprofen), a drug for attention-deficit hyperactivity disorder (methylphenidate), anti-acne (isotretinoin), 
and a hormonal oral contraceptive (cyproterone/ethinylestradiol).  
We selected 16 events for the reference set. They are bullous eruption (comprising fixed drug eruption 
[FDE], erythema multiforme [EM], Stevens-Johnson syndrome [SJS] and toxic epidermal necrolysis 
[TEN]), aplastic anemia, agranulocytosis, thrombocytopenia, psychosis, suicide, ventricular arrhythmia, 
sudden death, QT prolongation, venous thromboembolism, anaphylaxis, seizure, acute kidney injury, 
acute liver injury, sepsis and sudden infant death syndrome (SIDS) (table 2). Medical definitions for all 
the events and their proposed (unvalidated) MedDRA codes are presented in appendix 2.  
From the total number of combinations (256), we discontinued assessment of 34 unclassifiable drug-
event pairs since we found discrepant information between the SPC and Micromedex. For the remaining 
222 pairs the literature search generated 17,685 hits. Based on review of these hits 127 pairs were 
confirmed as ‘positive control’ (37 pairs) or ‘negative control’ (90 pairs) (tables 2 and 3); for 95 
‘unclassifiable’ pairs there was discrepant information between the published literature on one hand, and 
the SPC and Micromedex on the other hand.  
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Table 2: Classification of each drug-event pair as positive control or negative control 
 Abbreviations: Vent.- ventricular; SIDS - Sudden Infant Death Syndrome; Eth.est.- Ethinylestradiol;  
 Selected Adverse Events 
Bullous 
eruption 
Aplastic 
anemia 
Agranulo
-cytosis 
Thrombo-
cytopenia 
Psycho- 
Sis 
Sui-
cide 
Vent. 
arrhyth-
mia 
Sudden 
death 
QT 
prolon- 
gation 
Venous 
thrombo-
embolism 
Anaphy- 
laxis Seizure 
Acute 
kidney 
injury 
Acute 
liver 
injury 
Sepsis SIDS 
Se
le
ct
ed
 D
ru
gs
 
flucloxa- 
cillin                               
 
clarithro-
mycin                               
 
doxycy- 
cline                               
 
lopina- 
vir                               
 
isonia- 
zid                               
 
prazi- 
quantel                               
 
meben- 
dazole                               
 
quinine                                
 
flutica- 
sone                               
 
monte- 
lukast                               
 
isotreti- 
noin                               
 
lopera- 
mide                               
 
dompe- 
ridone                               
 
methyl- 
phenidate                               
 
ibupro- 
fen                               
 
cyproteron
e/eth.est.                               
 
 Positive control 
 Negative control 
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Table 3: Level of epidemiological and biological evidence; population in which association 
was found (adults, ‘children’a or both) and grading of positive drug-event associations.  
 
Event 
Positive associations 
 
ATC code 
 
Drug name 
 
Level of 
epidemiological 
evidenceb 
 
Population 
 (A / B / C)c 
 
Biological 
evidence 
(Pr/Pl) d 
 
Grade 
Bullous eruptione 
J01FA09 clarithromycin II B Pl PC2 
 
J01CF05 doxicycline II B Pl PC2 
 J04AC01 isoniazid II B Pl PC2 
 P01BC01 quinine II A Pl PC2 
 
M01AE01 iIbuprofen II B Pl PC2 
Aplastic anemia 
P01BC01 quinine II A Pr PC1 
Agranulocytosis 
P02CA01 mebendazole II A Pl PC2 
 P01BC01 quinine II A Pr PC1 
Thrombocytopenia J01FA09 clarithromycin II C Pl PC2 
 
J01CF05 doxicycline I A Pl PC2 
 
P01BC01 quinine II A Pr PC1 
 
M01AE01 ibuprofen I A Pl PC2 
Psychosis J01FA09 clarithromycin II A Pl PC2 
 J04AC01 isoniazid II A Pl PC2 
 
R03DC03 montelukast II C Pl PC2 
 
D10BA01 isotretinoin II B Pr PC1 
 
N06BA04 methylphenidate I C Pr PC1 
Suicide R03DC03 montelukast II C Pl PC2 
 D10BA01 isotretinoin II B Pr PC1 
Ventricular 
arrhythmia J01FA09 clarithromycin II A Pl PC2 
 P01BC01 quinine II A Pl PC2 
 
A03FA03 domperidone II A Pr PC1 
Sudden death 
J01FA09 clarithromycin I A Pl PC2 
 
A03FA03 domperidone II A Pr PC1 
QT prolongation 
J01FA09 clarithromycin II A Pr PC1 
 P01BC01 quinine I B Pr PC1 
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Anaphylaxis 
M01AE01 ibuprofen II B Pr PC1 
Seizure J04AC01 isoniazid II B Pr PC1 
Acute kidney injury P01BC01 quinine II A Pl PC2 
 
M01AE01 ibuprofen II B Pr PC1 
Acute liver injury 
J01CF05 flucloxacillin II A Pl PC2 
 
J01FA09 clarithromycin II B Pl PC2 
 J05AE06 lopinavir I A Pl PC2 
 J04AC01 isoniazid I B Pl PC2 
 
P02CA01 mebendazole I B Pl PC2 
 
P01BC01 quinine II A Pl PC2 
 
M01AE01 ibuprofen II A Pl PC2 
ATC Anatomical Therapeutic Chemical, Pr proven biological evidence, Pl plausible biological evidence, PC positive control 
 
a In this context, ‘Children’ refers to individuals aged 0-18 years 
 
b Epidemiological evidence levels I and II are defined in Table 1 
 
c Population in which epidemiological evidence was found: A-adults; B-both adults and ‘children’; C-‘children’. 
 
d As defined in table 1 
 
 e Bullous eruption includes: fixed drug eruption, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis  
 
In confirming the 37 positive control pairs, evidence was used from 171 relevant publications, comprising 
14 biological studies, 10 clinical trials, 23 observational studies, 34 reviews, and 90 case reports/series. 
The association between quinine and thrombocytopenia had the highest number of supporting 
publications i.e. 20 (out of 171): eight publications pertained to biological evidence while 12 reported on 
epidemiologic evidence. Table 4 shows how the positive associations: quinine-thrombocytopenia and 
clarithromycin-sudden death were established. For the complete evaluation of all positive drug-event 
associations, please refer to appendix 3. 
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Table 4: Examples of evaluation of a positive drug-event association: 1) quinine-thrombocytopenia and 2) clarithromycin-
sudden death  
ATC Code Drug Name Event Type Labelled as AE in SPC(Yes/No) Type/No. of Supporting Literature Citations 
P01BC01 Quinine Thrombocytopenia Yes 
*eMC (Special warnings and 
precautions for use; Undesirable 
effects) 
 
#Micromedex (Summary): Blackbox 
warning;(Contraindications/Warni
ngs→Contraindications; 
precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 20 
Biological studies = 8 
Review of biological studies = 4 
Systematic review = 1 
Case series = 1 
Case reports = 4 
Review of Spontaneous reports = 2 
     
J01FA09 Clarithromycin Sudden death Yes 
*eMC (Undesirable effects) 
# Micromedex (Summary): 
(Contraindications/Warnings→ 
precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 4 
Clinical trial = 1 
Case-control = 2 
Case report = 1 
ATC Anatomical Therapeutic Chemical, AE Adverse effect, SPC Summary of Product Characteristics, eMC  Electronic Medicines Compendium; * https://www.medicines.org.uk/emc/; # 
http://micromedex.com/ 
    
57 | P a g e  
 
As presented in table 3, we generated 37 positive associations; of these, level I evidence was available 
for only 8 (22%) and 13 (35%) were supported by both biological and epidemiological evidence. Only 4 
associations (clarithromycin-thrombocytopenia, montelukast-psychosis, montelukast-suicide AND 
methylphenidate-psychosis) were supported by evidence generated exclusively from the pediatric age 
group, while 13 associations were supported by evidence from both adults and the pediatric population. 
Overall, 17 (46%) of all positive associations were based on evidence from the pediatric population. 
Twenty associations were supported by evidence from only adults.  
In appendix 4, we compare the reference set we have created with the reference sets that were 
created within EU-ADR and OMOP. Out of the 16 drugs that were selected for GRiP, 4 were also included 
in EU-ADR and/or OMOP: fluticasone, ibuprofen, isoniazid and mebendazole. Ibuprofen was classified to 
be a positive control for acute kidney injury (AKI) in each of the 3 reference sets; while the same drug 
was classified to be associated with acute liver injury (ALI) only within GRiP and EU-ADR. Isoniazid was 
classified as positive control for ALI, both in GRiP and OMOP. OMOP nor EU-ADR labelled mebendazole 
with AKI, nor fluticasone with ALI. 
    
58 | P a g e  
 
Discussion 
We describe a pediatric focused reference set of drug-event associations that may be used for 
testing the performance of different signal detection methods and databases. To our 
knowledge, this is the first structured approach to creating a reference set that is specific to 
pediatric safety outcomes. This approach yielded 37 positive and 90 negative drug-event 
associations, 17 positive associations were supported by evidence in children, and 20 were 
based on adult information only.  
Projects such as OMOP and EU-ADR have also created reference sets, but none of them was 
targeted to pediatrics, in addition the construct of these reference sets was different 83,95-97. In 
the current project, drugs and events were selected independently, unlike EU-ADR and OMOP 
83,84. In addition the EU-ADR network restricted the list of drugs based on the amount of drug 
exposure that would be required to identify associations with selected adverse events at pre-
specified relative risk (RR) values. This was done so that such drug-event associations could 
actually be identified if indeed they occurred within the network. Similar calculations were not 
done for the current project although most of the selected drugs are frequently administered in 
the pediatric population (based on reported evidence in the literature). Further, the reference 
set resulting from the current project will be applied to SRS databases (in addition to EHRs) and 
therefore should preferably be unbiased to one or the other.  
The GRiP reference set focused on diversity of drugs and events which may allow us to stratify 
by outpatient/inpatient care, frequent and rare events. Sets with drugs for inpatient use may 
favour performance of data mining on SRS databases, while sets utilizing drugs prescribed for 
outpatient treatments may favour mining performance on EHR databases 98. In order to have 
enough power for both, we focused on drugs with longer license status.  
In selecting adverse events, we considered both frequent and rare events. Thus, the resulting 
reference set can be tested in a wide variety of databases with unique adverse event profiles, 
such as spontaneous reporting systems, hospital based and general practice health care 
databases. Previous reference sets focused mostly on rare and well known drug-induced events 
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which may favour SRS 83. Such events may be reported more often than common, multifactorial 
events because they are easier to identify as being caused by drugs. Given that the composition 
of the lists of drugs and adverse events to be tested may have an extensive impact on 
performance assessment 99, we tried to ensure that the criteria and data sources that were 
utilized to create the reference set were independent of the data on which they will eventually 
be tested.   
We conducted extensive reviews to list evidence for both positive and negative controls. Fewer 
publications were retrieved for the potential positive control pairs (7745 hits), compared to the 
potential negative control pairs (9940 hits), possibly because the search algorithm for the 
former was more specific. However, this was considered necessary to increase the probability of 
retrieving relevant publications (i.e. publications that reported on adverse event and drug in the 
context of drug safety), an approach similar to that adopted by the EU-ADR project83.  
To validate potential negative controls, terms that were related to the actual event term were 
considered. For example suicide-isoniazid was initially classified as potential negative control 
because suicide was not mentioned (in relation to isoniazid), both in SPC (DailyMed) and 
Micromedex. However a case report described the occurrence of suicide attempt following 
ingestion of isoniazid100. Therefore this association could not be confirmed as negative control. 
Whereas the negative drug-event associations required lack of association for adults or the 
pediatric population, the positive drug-event associations were specifically (or primarily) 
assessed for availability of evidence pertaining to the pediatric age group. However, due to the 
general lack of pediatric pharmacoepidemiological data only 4 associations (clarithromycin-
thrombocytopenia, montelukast-psychosis, montelukast-suicide AND methylphenidate-
psychosis) were supported by evidence generated exclusively from this age group: a case-
control study for clarithromycin-thrombocytopenia 101; case reports (more than 3) for 
montelukast-psychosis 102; review of spontaneous reports for montelukast-suicide 103; and 
clinical trial as well as case series for methylphenidate-psychosis104. The scarcity and quality of 
pediatric-specific data further highlight the difficulties in generating safety evidence in the 
pediatric population, thereby underlining the importance of developing a tool to define 
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appropriate signal detection methods in this population.  We recommend that the 20 positive 
associations that come from adult evidence only, be treated separately in the performance 
testing in pediatric data.  
We chose to classify all pairs with inconsistent evidence as unclassifiable, to avoid 
misclassification. We searched for biological (in addition to epidemiological) evidence to further 
strenghthen retrieved evidence for positive controls. However we were able to find such 
evidence for only 13 out of 37 positive associations: quinine-aplastic anemia105; quinine-
agranulocytosis106; quinine-thrombocytopenia107; isotretinoin-psychosis108,109; methylphenidate-
psychosis 110,111; isotretinion-suicide108,109; domperidone-ventricular arrhythmia112; 
domperidone-sudden death113; clarithromycin-QT prolongation114; quinine-QT 
prolongation115,116; ibuprofen-anaphylaxis117; isoniazid-seizure118; and ibuprofen-acute kidney 
injury119. Of these, quinine-thrombocytopenia had the highest number of supporting 
publications i.e. 8 regarding biological evidence (besides 12 others pertaining to epidemiological 
evidence). This is possibly because quinine has been in use for a long time, both as over-the-
counter (OTC) and prescription drug120; therefore its safety profile has been well investigated. 
Otherwise, the limited biological evidence for most of the other positive associations may reflect 
the current gap of knowledge and understanding of adverse drug reactions.  
Comparing our reference set to others, we found little overlap in the choice of drugs, possibly 
because we aimed to be pediatric-specific in our selection while also including drugs used in 
specific sub-populations (i.e. adolescents) and context (LMICs). Out of 16 drugs considered in 
GRiP, only 4 were considered also in EU-ADR and/or OMOP: isoniazid, ibuprofen, mebendazole 
and fluticasone. Perhaps this, as well as differences in adverse event selection explains the few 
similarities we found across the 3 reference sets. Nevertheless, ibuprofen was found to be 
associated with acute kidney injury in all the sets.  
There are several limitations in the use of a reference set and the creation of it. Some potential 
positive associations that are well known (i.e. domperidone-QT prolongation and 
cyproterone/ethinylestradiol-venous thromboembolism both of which have been well 
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investigated) could not be validated. The search query we used to retrieve the publications may 
have been too specific. For other unconfirmed potential positive control pairs, events mentioned 
in the SPC and Micromedex may have been reported through means other than peer-reviewed 
literature (for example US Federal Drug Administration - FDA - reports). 
Time is an important limiting aspect in building a reference set, both for the positive as well as 
negative controls. We labelled drug-event associations as negative if there is lack of evidence, 
which in itself is something that may rapidly change over time, checking of the absence of 
evidence should always be done prior to using the reference set.  For the positive controls it is 
important to know at which point in time the association was ‘known’ as this may lead to 
changes in reporting behaviour to spontaneous reporting databases and to changes in clinical 
care. Those changes may have an impact on the ability to detect associations (e.g. in 
spontaneous reporting databases it may increase the association whereas it may decrease in 
electronic health care databases) 121-123. Time stamping of the ‘known’ associations would be 
important. This was however impossible for this reference set since we chose drugs that are 
available for a long time and have been registered nationally. Inclusion of information in an SPC 
may vary from country to country. We recommend investigators that will use this set, to assess 
in their reality when associations were ‘known’ in order to evaluate the impact of that on 
performance.   
In order to use the reference set, the events need to be translated into codes. This is an 
important step and may impact on the performance testing. In appendix 2 we have provided 
initial MedDRA codes as most of the events have SMQs. These codes should be reviewed and 
the impact of choices should be carefully evaluated, they may differ between spontaneous 
reporting databases and electronic health care records. Within the GRiP project we aim to 
perform this work for MeDDRA, ICD-9, 10, READ and ICPC and a full code list with the impact 
of choice on performance will become available later.  
Conclusion 
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We have generated a pediatric focused reference set that can be applied for testing 
performance of methods and databases for drug safety signal detection in the pediatric 
population. This reference set may be viewed as dynamic. The status of drug-event 
associations may change over time, particularly as more evidence derived specifically from the 
pediatric population becomes available in the future. Therefore periodic review and checking 
against the local situation is advisable. 
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Appendix 1: Medline search algorithms for sudden death- cyproterone/ethinyl estradiol (negative control) and sudden death-clarithromycin (positive 
control)  
Association Concept Algorithm 
sudden death- cyproterone/ethinyl estradiol sudden death (exp Death, Sudden/ OR (((sudden* OR unexpect* 
OR instant*) adj3 (death OR dead OR died OR 
dying)) OR mors subita).ab,ti.) 
  AND 
 cyproterone/ ethinylestradiol (Estradiol/aa and Cyproterone Acetate/) or 
((cyproterone acetate adj3 (ethinyl estradiol or 
ethinyloestradiol)) or co cyprindiol or cocyprindiol 
or climen or diane or dianette).ab,ti. 
   
sudden death- clarithromycin sudden death (exp Death, Sudden/ OR (((sudden* OR unexpect* 
OR instant*) adj3 (death OR dead OR died OR 
dying)) OR mors subita).ab,ti.) 
  AND 
 general adverse drug reaction drug toxicity/ 
  AND 
 clarithromycin clarithromycin/ 
Note: For each association, the search results were limited to articles published in English 
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Appendix 2: Medical definitions of selected adverse events; and corresponding proposed but unvalidated Medical Definition for Regulatory 
Activities (MedDRA) codes (SMQ-standardized MedDRA query; PT-preferred term; LT-lower level term; HT-high level term; HG- high level 
group term; OL-noncurrent lower level term) 
S/N Event Medical (case) definition References MedDRA codes 
1 bullous 
eruptions 
 
fixed drug eruption 
These are reactions characterized by: 
(1) One or more sharply demarcated, 
erythematous lesions, sometimes 
leading to a blister.  
(2) Hyperpigmentation which often results 
after resolution of the acute 
inflammation.  
(3) With rechallenge, the lesion recurs in 
the same (i.e., fixed) location.  
(4) Lesions often involve the lips, hands, 
legs, face, genitalia, and oral mucosa 
and cause a burning sensation.  
(5) Most patients have multiple lesions. 
 
See references for further details 
(1) Shinkai K, Roujeau J, Stern RS, Wintroub BU. 
Chapter 55. Cutaneous Drug Reactions. In: Longo 
DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, 
Loscalzo J, eds. Harrison's Principles of Internal 
Medicine. 18th ed. New York: McGraw-Hill; 2012. 
http://www.accessmedicine.com/content.aspx?a
ID=9098524. Accessed October 1, 2012 
(2) Stern RS, Shear NH. Cutaneous reactions to drugs 
and biological modifiers. In: Cutaneous Medicine 
and Surgery, Arndt KA, LeBoit PE, Robinson JK, 
Wintroub BU (Eds), WB Saunders, Philadelphia 
1996. Vol 1, p.412. 
(3) Yawalkar N. Drug-induced exanthems. 
Toxicology. 2005;209:131–134. doi: 
10.1016/j.tox.2004.12.023 
(LT/10016740), (LT/10048796) 
  erythema multiforme 
Characteristics include: 
(1) Acute self-limited, usually mild and 
often relapsing muco-cutaneous 
syndrome. 
(2) Usually benign but with frequent 
recurrences 
(3) The skin lesions are usually target-
shaped plaques with or without central 
blisters, predominant on the face and 
extremities. 
sub-types (1) Erythema multiforme minor: Skin 
lesions without involvement of mucous 
membranes (2) Erythema multiforme major: Skin 
(1) Roujeau J. Chapter 39. Erythema Multiforme. In: 
Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, 
Leffell DJ, Dallas NA, eds. Fitzpatrick's 
Dermatology in General Medicine. 8th ed. New 
York: McGraw-Hill; 2012. 
http://www.accessmedicine.com/content.aspx?aI
D=56032944. Accessed October 2, 2012. 
 
(LT/10015217), (LT/10015218),(LT/10015221), 
(LT/10015222), (LT/10015223), (LT/10015223), 
(LT/10015224), (LT/10033726), (LT/10033730), 
(LT/10037876), (LT/10040843), (LT/10044259), 
(LT/10057783), (LT/10057866), (LT/10057970), 
(LT/10057971), (LT/10068560), (PT/10015218), 
(PT/10037876), (PT/10057970) 
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lesions with involvement of mucous 
membranes (3) Mucosal erythema multiforme (Fuchs 
syndrome, ectodermosis 
pluriorificialis): Mucous membrane 
lesions without cutaneous 
involvement 
 
See references for further details 
  epidermal necrolysis (Stevens-Johnsons 
Syndrome and toxic epidermal necrolysis) 
Characteristics include: 
(1) They are “rare and life-threatening, 
mainly drug induced”. 
(2) There is “widespread apoptosis of 
keratinocytes provoked by the 
activation of a cell-mediated cytotoxic 
reaction and amplified by cytokines, 
mainly granulysin” 
(3) “Confluent purpuric and erythematous 
macules evolving to flaccid blisters and 
epidermal detachment predominating 
on the trunk and upper limbs and 
associated with mucous membrane 
involvement”. 
(4) Pathologic analysis shows full-
thickness necrosis of epidermis 
associated with mild mononuclear cell 
infiltrate 
See references for further details 
(1) Valeyrie-Allanore L, Roujeau J. Chapter 40. 
Epidermal Necrolysis (Stevens–Johnson 
Syndrome and Toxic Epidermal Necrolysis). In: 
Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, 
Leffell DJ, Dallas NA, eds. Fitzpatrick's 
Dermatology in General Medicine. 8th ed. New 
York: McGraw-Hill; 2012. 
http://www.accessmedicine.com/content.aspx
?aID=56033128. Accessed October 2, 2012. 
 
(LT/10006561), (LT/10015156), (LT/10015209), 
(LT/10015210), (LT/10015211), (LT/10015219), 
(LT/10015220), (LT/10015222), (LT/10028077), 
(LT/10030068), (LT/10030081), (LT/10042029), 
(LT/10042030), (LT/10042033), (LT/10042849), 
(LT/10047376), (OL/10042032), (PT/10030081), 
(PT/10042033), (LT/10014986), (LT/10025166), 
(LT/10025167), (LT/10025168), (LT/10028848), 
(LT/10028849), (LT/10043221), (LT/10044223), 
(OL/10025165), (OL/10042821), (OL/10044222), 
(PT/10044223) 
 
S/N Event Medical (case) definition References MedDRA codes 
2 aplastic 
anemia 
Aplastic anemia is characterized by the 
suppression of all bone marrow lines – erythroid, 
granulocytic and megakaryocytic ultimately 
(1) Primack BA, Mahaniah KJ. Chapter 31. Anemia. 
In: South-Paul JE, Matheny SC, Lewis EL, eds. 
CURRENT Diagnosis & Treatment in Family 
(LT/10049494), (LT/10002037),(LT/10002038), 
(LT/10002061), (LT/10002274), (LT/10002274), 
(LT/10002275), (LT/10002294), (LT/10002962), 
    
66 | P a g e  
 
leading to pancytopenia 
Characteristics 
(1) Pancytopenia 
(2) Hypocellular bone marrow 
(3) Normal hematopoetic cells 
 
 
See references for further details 
 
 
Medicine. 3rd ed. New York: McGraw-Hill; 2011. 
http://www.accessmedicine.com/content.aspx?a
ID=8153552. Accessed October 2, 2012 
(2) Neal S. Young; Acquired Aplastic Anemia. Annals 
of Internal Medicine. 2002 Apr;136(7):534-546 
(3) Guinan EC. Diagnosis and management of 
aplastic anemia. Hematology Am Soc Hematol 
Educ Program. 2011;2011:76–81 
(LT/10002967), (LT/10002968), (LT/10002969), 
(LT/10002970), (LT/10002971), (LT/10003506), 
(LT/10004738), (LT/10005980), (LT/10005984), 
(LT/10005986), (LT/10005987), (LT/10010776), 
(LT/10010777), (LT/10012381), (LT/10020954), 
(LT/10021069), (LT/10021074), (LT/10021075), 
(LT/10021077), (LT/10026846), (LT/10026848), 
(LT/10026853), (LT/10033661), (LT/10036699), 
(LT/10048580), (LT/10051779), (LT/10053138), 
(LT/10053213), (LT/10053504), (LT/10054329), 
(LT/10054361), (LT/10054580), (LT/10057528), 
(LT/10064566), (LT/10065553), (LT/10068061), 
(LT/10068063), (LT/10071576), (LT/10071584), 
(PT/10002967), (PT/10003506), (PT/10004738), 
(PT/10021074), (PT/10033661), (PT/10051779), 
(PT/10053138), (PT/10053213), (PT/10053504), 
(PT/10057528), (PT/10065553), (PT/10071576) 
 
S/N Event Medical (case) definition References MedDRA codes 
3 Agranuloc
ytosis 
agranulocytosis means the absence of 
granulocytes (i.e. Absolute Neutrophil count  of 
zero). 
However,  “agranulocytosis or acute 
neutropenia currently refers to a profound 
decrease or an absolute lack of circulating 
granulocytes, classically resulting in a neutrophil 
count of <0.5 × 10^9/l” 
In the majority of patients, the neutrophil count 
is < 0.1 × 10^9/l 
 
See references for further details 
(1) Andres E., Zimmer J., Mecili M., Weitten T., Alt 
M., Maloisel F. Clinical presentation and 
management of drug-induced agranulocytosis. 
Expert Rev. Hematol. 2011; 4 (2): 143- 151 
(2) Frank Andersohn, Christine Konzen, Edeltraut 
Garbe; Systematic Review: Agranulocytosis 
Induced by Nonchemotherapy Drugs. Annals of 
Internal Medicine. 2007 May;146(9):657-665 
(LT/10001507), (LT/10003506), (LT/10004738), 
(LT/10005984), (LT/10018687), (LT/10029366), 
(LT/10029369), (LT/10029382), (LT/10050443), 
(LT/10051645), (LT/10057528), (LT/10066542), 
(PT/10001507), (PT/10003506),(PT/10004738), 
(PT/10018687), (PT/10029366),(PT/10050443), 
(PT/10051645), (PT/10057528), (SMQ/20000023) 
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S/N Event Medical (case) definition References MedDRA codes 
4 Thrombocytopenia Thrombocytopenia can be defined as follows: 
(1) Level 1 of diagnostic certainty 
(confirmed TP):   
Platelet count less than 150×109 L−1  
AND  
confirmed by blood smear 
examination OR the presence of 
clinical signs and symptoms of 
spontaneous bleeding. 
 
(2) Level 2 of diagnostic certainty 
(unconfirmed TP): Platelet count less 
than 150×109 L−1 
 
Drug-induced thrombocytopenia (DITP) should 
be suspected in a patient who presents with 
new onset of thrombocytopenia without an 
obvious cause other than drug ingestion. A 
patient with recurrent episodes of acute 
thrombocytopenia should be suspected of 
having a drug-induced etiology. A detailed 
history, including all of the medications being 
taken by the patient, is essential. This should 
include all prescribed drugs, over-the-counter 
medications, herbal preparations, folk 
remedies, quinine-containing beverages, and 
recent vaccinations. 
 
See references for further details 
(1) Wise RP, Bonhoeffer J, Beeler J, et 
al. Thrombocytopenia: Case 
definition and guidelines for 
collection, analysis, and 
presentation of immunization safety 
data. Vaccine 2007; 25: 5717–5724 
 
(2) Royer, D. J., George, J. N. and 
Terrell, D. R. (2010), 
Thrombocytopenia as an adverse 
effect of complementary and 
alternative medicines, herbal 
remedies, nutritional supplements, 
foods, and beverages. European 
Journal of Haematology, 84: 421–
429 
 
(HG/10035534), (HT/10035533), (HT/10043555), 
(LT/10012530), (LT/10024922), (LT/10035524), 
(LT/10035526), (LT/10035527), (LT/10035528), 
(LT/10035529), (LT/10035531), (LT/10035532), 
(LT/10035540), (LT/10035545), (LT/10036735), 
(LT/10037557), (LT/10037561), (LT/10038213), 
(LT/10039884), (LT/10043545), (LT/10043546), 
(LT/10043552), (LT/10043553), (LT/10043554), 
(LT/10043556), (LT/10043557), (LT/10043558), 
(LT/10043559), (LT/10043560), (LT/10043561), 
(LT/10043569), (LT/10044394), (LT/10048672), 
(LT/10050245), (LT/10051057), (LT/10051601), 
(LT/10058336), (LT/10062506), (LT/10063129), 
(LT/10066667), (LT/10070664), (LT/10072326), 
(LT/10072332), (MTH_SMQ/20000031), (OL/10013258), 
(OL/10043551), (PT/10035526), (PT/10035528), 
(PT/10035531), (PT/10035532), (PT/10035540), 
(PT/10037557), (PT/10043554), (PT/10043557), 
(PT/10043561), (PT/10050245), (PT/10062506), 
(PT/10070664), (PT/10072326), (SMQ/20000031) 
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S/N Event Medical (case) definition References MedDRA codes 
5 psychosis ‘psychosis is a disturbance in the perception of 
reality, evidenced by hallucinations, delusions, 
or thought disorganization. Psychotic states 
are periods of high risk for agitation, 
aggression, impulsivity, and other forms of 
behavioral dysfunction’ 
 
‘hallucinations are false sensory perceptions 
occurring in any of the five sensory modalities. 
Auditory hallucinations are the most common, 
followed by visual, tactile, olfactory, and 
gustatory’ 
 
‘delusions are false beliefs that are firmly held 
despite obvious evidence to the contrary, and 
not typical of the patient's culture, faith, or 
family. Persecutory, grandiose, religious, 
somatic, and other delusions are all common 
and cut across diagnostic boundaries’ 
 
‘thought disorganization - disruption of the 
logical process of thought may be represented 
by loose associations, nonsensical speech, or 
bizarre behavior. These symptoms are typically 
accompanied by a high level of functional 
impairment and high risk for agitated and 
aggressive behavior’ 
See references for further details 
(1) Shelton RC. Chapter 17. Other 
Psychotic Disorders. In: Ebert MH, 
Loosen PT, Nurcombe B, Leckman 
JF, eds. CURRENT Diagnosis & 
Treatment: Psychiatry. 2nd ed. New 
York: McGraw-Hill; 2008. 
http://www.accessmedicine.com/c
ontent.aspx?aID=3284695. 
Accessed October 2, 2012. 
(2) UpToDate. Overview of psychosis. 
2013  [cited 2014 19th June]; 
Available from: 
http://www.uptodate.com/content
s/overview-of-
psychosis?source=search_result&se
arch=overview+of+psychosis&select
edTitle=1~150. 
(HT/10004938), (HT/10006360), (HT/10012259), 
(LT/10000958), (LT/10001022), (LT/10001443), 
(LT/10001444), (LT/10001445), (LT/10001449), 
(LT/10001450), (LT/10001451), (LT/10004908), 
(LT/10004935), (LT/10008522), (LT/10008524), 
(LT/10009080), (LT/10011717), (LT/10012239), 
(LT/10012240), (LT/10012241), (LT/10012242), 
(LT/10012243), (LT/10012244), (LT/10012245), 
(LT/10012246), (LT/10012247), (LT/10012247), 
(LT/10012248), (LT/10012257), (LT/10012260), 
(LT/10012261), (LT/10012262), (LT/10012287), 
(LT/10012393), (LT/10012408), (LT/10013143), 
(LT/10013144), (LT/10013145), (LT/10013708), 
(LT/10013741), (LT/10013758), (LT/10013759), 
(LT/10013761), (LT/10015134), (LT/10015626), 
(LT/10016894), (LT/10018669), (LT/10018671), 
(LT/10019379), (LT/10021031), (LT/10021166), 
(LT/10021720), (LT/10023164), (LT/10026754), 
(LT/10026755), (LT/10026756), (LT/10026757), 
(LT/10026758), (LT/10026780), (LT/10026781), 
(LT/10026784), (LT/10026785), (LT/10026786), 
(LT/10026787), (LT/10026789), (LT/10026790), 
(LT/10026791), (LT/10027740), (LT/10027945), 
(LT/10033864), (LT/10033867), (LT/10033870), 
(LT/10034702), (LT/10037200), (LT/10037234), 
(LT/10037235), (LT/10037237), (LT/10037238), 
(LT/10037239), (LT/10037240), (LT/10037241), 
(LT/10037242), (LT/10037243), (LT/10037245), 
(LT/10037248), (LT/10037250), (LT/10037253), 
(LT/10037953), (LT/10037954), (LT/10039612), 
(LT/10039613), (LT/10039621), (LT/10039622), 
(LT/10039635), (LT/10039987), (LT/10040534), 
(LT/10040535), (LT/10041317), (LT/10041317), 
(LT/10044395), (LT/10045620), (LT/10045654), 
(LT/10045655), (LT/10045656), (LT/10045855), 
(LT/10045856), (LT/10046122), (LT/10046160), 
(LT/10048343), (LT/10053415), (LT/10053632), 
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(LT/10056309), (LT/10056326), (LT/10057667), 
(LT/10059232), (LT/10059419), (LT/10061040), 
(LT/10061920), (LT/10062645), (LT/10063033), 
(LT/10065617), (LT/10066731), (LT/10068305), 
(LT/10070669), (LT/10072389), (LT/10072392), 
(OL/10001437), (OL/10001448), (OL/10004918), 
(OL/10013739), (OL/10025459), (OL/10025460), 
(OL/10026788), (OL/10031481), (OL/10031518), 
(OL/10031602), (OL/10031619), (OL/10032253), 
(OL/10032711), (OL/10032712), (OL/10032889), 
(OL/10033866), (OL/10037221), (PT/10001022), 
(PT/10001443), (PT/10008522), (PT/10012239), 
(PT/10012241), (PT/10012244), (PT/10012245), 
(PT/10015134), (PT/10018671), (PT/10023164), 
(PT/10033864), (PT/10034702), (PT/10039621), 
(PT/10039987), (PT/10040535), (PT/10041317), 
(PT/10041317), (PT/10053632), (PT/10056326), 
(PT/10057667), (PT/10059232), (PT/10061040), 
(PT/10061920), (PT/10062645), (PT/10063033), 
(PT/10065617), (PT/10070669), (SMQ/20000117) 
 
S/N Event Medical (case) definition References MedDRA codes 
6 suicide Two concepts will be considered: 
(1) completed suicide 
(2) suicide attempt 
completed suicide 
Death caused by self-directed injurious 
behavior with any intent to die as a result of 
the behavior. 
suicide attempt 
A non-fatal self-directed potentially injurious 
behavior with any intent to die as a result of 
the behavior.  A suicide attempt may or may 
not result in injury. 
 
(1) Crosby AE, Ortega L, Melanson C. 
Self-directed Violence Surveillance: 
Uniform Definitions and 
Recommended Data Elements, 
Version 1.0. Atlanta (GA): Centers 
for Disease Control and Prevention, 
National Center for Injury 
Prevention and Control; 2011 
 
(LT/10000394), (LT/10003728), (LT/10010144), 
(LT/10013738), (LT/10033298), (LT/10033927), 
(LT/10036001), (LT/10042462), (LT/10042463), 
(LT/10042464), (LT/10042465), (LT/10042466), 
(LT/10067875), (OL/10057354), (PT/10010144), 
(PT/10042464), (SMQ/20000035), (SMQ/20000037) 
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See references for further details 
 
S/N Event Medical (case) definition References MedDRA codes 
7 ventricular arrhythmia Three concepts will be considered: (1) Ventricular Tachycardia (2) Ventricular Fibrillation (3) Bradycardia 
 
ventricular tachycardia 
This can be defined on the basis of heart 
rate and ECG findings.  
On the basis of heart rate: 
• >180 beats/minute (regular) in 
infants and young children 
• > 120 beats/minute (regular) in 
older children/adolescents 
(indicate tachycardia generally) 
On the basis of ECG, the following 
features apply: 
• Ventricular rate is >120 beats per 
minute and regular 
• P waves are often not 
identifiable, may have AV 
dissociation, or may have 
retrograde depolarization 
• QRS is typically wide (>0.09 sec) 
• T waves are often opposite in 
polarity from the QRS complex 
ventricular fibrillation (VF) 
It is characterized by rapid, chaotic, and 
asynchronous contraction of the left 
ventricle. The surface electrogram of VF 
reveals a rapid, irregular, dysmorphic 
pattern with no clearly defined QRS 
complex.  
(1) UpToDate. Causes of wide QRS 
complex tachycardia in children. 
2014  [cited 2014 19th June]; 
Available from: 
http://www.uptodate.com/content
s/causes-of-wide-qrs-complex-
tachycardia-in-
children?source=machineLearning&
search=causes+of+wide+qrs+tachyc
ardia+in+children&selectedTitle=1~
150&sectionRank=1&anchor=H3#H
3. 
(2) Rho RW, Page RL. Chapter 42. 
Ventricular Arrhythmias. In: Fuster 
V, Walsh RA, Harrington RA, eds. 
Hurst's The Heart. 13th ed. New 
York: McGraw-Hill; 2011. 
http://www.accessmedicine.com/c
ontent.aspx?aID=7814365. 
Accessed October 4, 2012 
(3) Michaelson M, Engle MA. 
Congenital complete heart block: 
An international study of the 
natural history. In: Cardiovascular 
Clinics, Brest AN, Engle MA (Eds), FA 
Davis, Philadelphia 1972. p.85 
(4) Kugler JD. Sinus node dysfunction. 
In: Pediatric Arrhythmias: 
Electrophysiology and Pacing, 
Gillette PC, Garson AG Jr (Eds), WB 
Saunders, Philadelphia 1990. p.250. 
 
(LT/10003131), (LT/10003132), (LT/10016571), 
(LT/10016573), (LT/10034048), (LT/10034049), 
(LT/10034050), (LT/10043082), (LT/10047281), 
(LT/10047282), (LT/10047290), (LT/10047292), 
(LT/10047293), (LT/10049447), (LT/10051363), 
(LT/10060730), (LT/10066663), (LT/10066685), 
(LT/10066686), (LT/10073034), (OL/10047395), 
(PT/10047281), (PT/10047290), (PT/10049447) 
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bradycardia 
Normally, the value for average heart rates 
varies with age. Younger patients usually 
have higher heart rates which decrease to 
adult values by the late teenage years.  
Bradycardia can be established by either 
using 12-lead electrocardiogram (ECG) or 
by 24-hour ambulatory monitoring. 
On the basis of 12-lead electrocardiogram 
(ECG): 
• Newborn to 3 years:  < 100 
beats/minute 
• 3 - 9 years: < 60 beats/ minute 
• 9 – 16 years: < 50 beats per 
minute 
On the basis of 24-hour ambulatory 
monitoring: 
• Newborns – 2 years: < 60 
beats/minute while asleep and < 
80 beats/ minute while awake 
• 2 – 6  years: < 60 beats per 
minute 
• 6 – 11 years: < 45 beats/ minute 
• > 11 years (adolescents): < 40 
beats/minute 
• > 11 years who are well-trained 
athletes: < 30 beats per minute 
N.B The 24-hour ambulatory guidelines 
vary from the ECG guidelines as they 
include the slower heart rates that occur 
normally at rest and sleep 
See references for further details 
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S/N Event Medical (case) definition References MedDRA codes 
8 sudden death  Two concepts will be considered: 
(1) Sudden death 
(2) Sudden cardiac death 
 
Sudden death 
Two definitions will be considered for 
sudden death: 
(1) Unwitnessed death occurring 
within 24hrs of being seen alive 
and functioning normally. 
(2) Natural, unexpected death within 
1 hour of the onset of symptoms.  
Four temporal elements have to 
be considered in the use of this 
definition:  prodromes, onset of 
the terminal event, cardiac 
arrest, and biological death. The 
1-hour definition refers to the 
period between onset of the 
terminal event, that is, acute 
changes in cardiovascular status, 
and cardiac arrest. The biological 
legal death can occur days or 
weeks after the cardiac arrest, as 
patients can survive with 
irreversible brain damage and life 
support 
 
Sudden cardiac death (SCD) 
Sudden cardiac death (SCD) is said to have 
occurred when there is sudden cessation 
of cardiac activity so that the victim 
becomes unresponsive, with no normal 
breathing and no signs of circulation, 
thereby leading to death (if corrective 
measures are not taken rapidly)  
 
(1) C. van der Werf, I. van Langen, A.A. 
Wilde. Sudden death in the young: 
what do we know about it and how 
to prevent? Circ Arrhythm 
Electrophysiol, 3 (2010), pp. 96–104 
 
(2) UpToDate. Overview of sudden 
cardiac arrest and sudden cardiac 
death. 2013  [cited 2014 19th June]; 
Available from: 
http://www.uptodate.com/content
s/overview-of-sudden-cardiac-
arrest-and-sudden-cardiac-
death?source=search_result&searc
h=overview+of+sudden+cardiac+arr
est+and+sudden+cardiac+death&se
lectedTitle=1~150. 
(HT/10011907), (LT/10042434), (LT/10042435), 
(LT/10042436), (LT/10042437), (LT/10046269), 
(LT/10049418), (LT/10052810), (LT/10063894), 
(LT/10063895), (LT/10069409), (OL/10011915), 
(OL/10011938), (PT/10042434), (PT/10049418), 
(PT/10063894) 
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Cardiac arrest should be used to signify an 
event as described above, that is reversed, 
usually by CPR and/or defibrillation or 
cardioversion, or cardiac pacing.  
 
Sudden cardiac death should not be used 
to describe events that are not fatal." 
 
See references for further details 
 
S/N Event Medical (case) definition References MedDRA codes 
9 QT prolongation.  Torsades de pointes (TdP)  will be included 
in this definition 
 
QT prolongation 
It refers to prolongation of heart rate-
corrected QT (QTc) interval from a 12-lead 
electrocardiogram (ECG).  
For children aged 1 – 15 years, prolonged 
QTc is defined as:  
• > 460 milliseconds 
 
Bazett formula (QTc=QT/RR0.5) is most 
often used for heart rate correction 
 
Long QT syndrome (LQTS) 
This is characterized by prolonged QT with 
clinical manifestations/sequelae like 
palpitations, syncope, seizures, and sudden 
cardiac death (SCD). 
 
Torsades de pointes (TdP) 
Torsades de pointes (TdP) is a form of 
polymorphic ventricular tachycardia (VT) 
that occurs in the setting of acquired or 
(1) ICH Topic E 14 The Clinical 
Evaluation of QT/QTc Interval 
Prolongation and Proarrhythmic 
Potential for Non Antiarrhythmic 
Drugs; CPMP/986/96. The 
assessment of the potential for QT 
interval prolongation by non-
cardiovascular medicinal products. 
London: Committee for proprietary 
medicinal products. 1997 
(2) UpToDate. Definition of normal, 
borderline, and prolonged corrected 
QT interval (QTc) in seconds 
according to age and gender.  [cited 
2012 18th October]; Available from: 
http://www.uptodate.com/content
s/image?imageKey=CARD/78934&t
opicKey=CARD%2F1053&source=pr
eview&rank=undefined. 
(3) El-Sherif N, Turitto G. Torsade de 
pointes. Curr Opin Cardiol 
2003;18(1):6–13 
(4) Passman R, Kadish A. Polymorphic 
ventricular tachycardia, long Q-T 
(LT/10014383), (LT/10014387), (LT/10024802), 
(LT/10024803), (LT/10036887), (LT/10037094), 
(LT/10037700), (LT/10037703), (LT/10037705), 
(LT/10044066), (LT/10044067), (LT/10053604), 
(LT/10053698), (LT/10054581), (PT/10014387), 
(PT/10024803), (PT/10044066), (SMQ/20000001) 
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congenital QT interval prolongation. It is 
usually found on ECG. 
 
Polymorphic VT is defined as a ventricular 
rhythm faster than 100 beats per min with 
frequent variations of the QRS axis, 
morphology, or both. In the specific case of 
TdP, these variations take the form of a 
progressive, sinusoidal, cyclic alteration of 
the QRS axis. The peaks of the QRS 
complexes appear to "twist" around the 
isoelectric line of the recording; hence the 
name torsades de pointes or "twisting of 
the points." 
 
See references for further details 
syndrome, and torsades de pointes. 
Med Clin North Am. 2001;85: 321–
341. 
 
S/N Event Medical (case) definition References MedDRA codes 
10 venous thromboembolism Two manifestations of venous 
thromboembolism will be considered: (1) Deep venous thrombosis (DVT) (2) Pulmonary thromboembolism 
(PE) 
deep venous thrombosis (DVT) 
This is characterized by: 
• Leg pain  
• Inguinal or abdominal pain  
• Swelling, and reddish or purple 
discoloration of the legs 
• Palpable cord (reflecting a 
thrombosed vein), 
• Ipsilateral edema  
• Warmth, and/or superficial 
venous dilation 
• “Positive” result on compression 
(1) UpToDate. Pathogenesis and 
clinical manifestations of venous 
thrombosis and thromboembolism 
in infants and children. 2013  [cited 
2014 19th June]; Available from: 
http://www.uptodate.com/content
s/pathogenesis-and-clinical-
manifestations-of-venous-
thrombosis-and-thromboembolism-
in-infants-and-
children?source=search_result&sea
rch=pathogenesis+and+clinical+ma
nifestation+of+thrombosis+and+thr
omboembolism+in+children&select
edTitle=1~150. 
(2) Lensing AWA, Prandoni P, Prins HR, 
Büller HR. Deep-vein thrombosis. 
(HT/10037379), (HT/10037379), (HT/10047197), 
(LT/10000853), (LT/10012098), (LT/10012107), 
(LT/10013877), (LT/10013879), (LT/10014521), 
(LT/10014537), (LT/10034272), (LT/10037377), 
(LT/10037380), (LT/10037436), (LT/10038547), 
(LT/10043566), (LT/10043567), (LT/10043578), 
(LT/10043630), (LT/10043642), (LT/10047251), 
(LT/10047252), (LT/10049915), (LT/10049916), 
(LT/10049917), (LT/10049918), (LT/10050071), 
(LT/10051055), (LT/10054751), (LT/10056966), 
(LT/10064602), (LT/10065052), (LT/10066529), 
(LT/10066738), (LT/10066899), (LT/10073531), 
(OL/10014511), (OL/10034191), (OL/10037378), 
(PT/10034272), (PT/10037377), (PT/10038547), 
(PT/10051055), (PT/10064602) 
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ultrasonography  
• “Positive” result on impedance 
plethysmography  
• “Positive” result on contrast 
venography (reference test). 
pulmonary thromboembolism (PE) 
This is characterized by: 
• Pleuritic chest pain 
• Tachypnea 
• Cough  
• Tachycardia  
• Acute dyspnea 
• Sudden collapse 
• Leukocytosis 
• Increased erythrocyte 
sedimentation rate (ESR) 
• Elevated serum LDH or AST 
(SGOT) with a normal serum 
bilirubin 
• Arterial blood gases: hypoxemia, 
hypocapnia, and respiratory 
alkalosis 
 
See references for further details 
Lancet. 1999;353:479-485. 
(3) Hirsh J, Hull RD, Raskob GE. Clinical 
features and diagnosis of venous 
thrombosis. J Am Coll Cardiol 
1986;8:114B-27B 
(4) Wells PS, Hirsh J, Anderson DR, et 
al.  Accuracy of clinical assessment 
of deep-vein thrombosis . Lancet . 
1995;;345:1326-1330. 
(5) Kahn SR, Joseph L, Abenhaim L, 
Leclerc JR. Clinical prediction of 
deep vein thrombosis in patients 
with leg symptoms. Thromb 
Haemost. 1999;81:353-7 
(6) Donnelly R, Emslie-Smith AM, 
Gardner ID, Morris AD. ABC of 
arterial and venous disease. Non-
invasive methods of arterial and 
venous assessment. Br Med J 
2000;320:698–701. 
(7) Hull R, Taylor DW, Hirsh J, Sackett 
DL, Powers P, Turpie AGG, Walker 
ID: Impedance plethysmography: 
The relationship between venous 
filling and sensitivity and specificity 
for proximal vein thrombosis. 
Circulation 58:898, 1978 
(8) Hull R, Hirsh J, Sackett DL, Taylor 
DW, Carter C, Turpie AG, Powers P, 
Gent M: Clinical validity of a 
negative venogram in patients with 
clinically suspected venous 
thrombosis. Circulation. 1981; 
64(3):622. 
(9) Lensing AW, Büller HR, Prandoni P, 
Batchelor D, Molenaar AH, Cogo A, 
Vigo M, Huisman PM, ten Cate JW. 
Contrast venography, the gold 
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standard for the diagnosis of deep-
vein thrombosis: improvement in 
observer agreement. Thromb 
Haemost. 1992;67(1):8. 
(10) Buck JR, Connors RH, Coon WW, 
Weintraub WH, Wesley JR, Coran 
AG. Pulmonary embolism in 
children. J Pediatr Surg. 
1981;16(3):385. 
(11) Byard RW, Cutz E. Sudden and 
unexpected death in infancy and 
childhood due to pulmonary 
thromboembolism. An autopsy 
study. Arch Pathol Lab Med. 
1990;114(2):142. 
(12)Matthew DJ, Levin M. Pulmonary 
thromboembolism in children. 
Intensive Care Med. 
1986;12(6):404. 
 
S/N Event Case definition References MedDRA codes 
11 anaphylaxis See Brighton Collaboration case 
definition 
(1) Anaphylaxis: case definition and guidelines for data 
collection, analysis, and presentation of immunization 
safety data. 
(2) Rüggeberg JU, Gold MS, Bayas JM, Blum MD, 
Bonhoeffer J, Friedlander S, de Souza Brito G, 
Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-
Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, 
Simpson N; Brighton Collaboration Anaphylaxis 
Working Group. 
(3) Vaccine. 2007 Aug 1;25(31):5675-84. Epub 2007 Mar 
12.  
 
(SMQ/20000071) 
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S/N Event Medical (case) definition References MedDRA codes 
12 seizure This is defined in 3 levels with respect to diagnostic 
certainty. All levels are acceptable. 
Level 1 of diagnostic certainty  (1) witnessed sudden loss of consciousness AND (2) generalized, tonic, clonic, tonic–clonic, or or 
atonic motor manifestations. 
Level 2 of diagnostic certainty 
history of unconsciousness AND (1) generalized,  tonic, clonic, tonic–clonic, or 
atonic motor manifestations. 
Level 3 of diagnostic certainty 
(1) history of unconsciousness AND 
(2) other generalized motor manifestations 
 
See references for further details 
(1) Bonhoeffer J, Menkes J, Gold MS, de Souza-
Brito G, Fisher M, et al. (2004) Generalized 
convulsive seizure as an adverse event 
following immunization: case definition and 
guidelines for data collection, analysis, and 
presentation. Vaccine 22 (5–6): 557–562 
 
(SMQ/20000212) 
 
S/N Event Medical (case) definition References MedDRA codes 
13 acute 
kidney 
injury 
(AKI) 
‘acute kidney injury (AKI) is defined as a 
decrease in glomerular filtration rate (GFR), 
which traditionally is manifested by an elevated 
or a rise in serum creatinine. However, serum 
creatinine is often a delayed and imprecise test 
as it reflects GFR in individuals at steady state 
with stable kidney function, and does not 
accurately estimate the GFR in a patient whose 
renal function is changing’ 
(1) Nephrology TA. The American Society of Nephrology 
Renal Research Report. J Am Soc Nephrol. 
2005;16:1886–1903 
(2) Devarajan P. Update on mechanisms of ischemic acute 
kidney injury. J Am Soc Nephrol 2006; 17: 1503–1520 
(3) Devarajan P. Emerging urinary biomarkers in the 
diagnosis of acute kidney injury. Expert Opin Med Diagn. 
2008;2:387–398 
(4) Zappitelli M. Epidemiology and diagnosis of acute kidney 
(HT/10038443), (LT/10000821), (LT/10000952), 
(LT/10001041), (LT/10001049), (LT/10001051), 
(LT/10001099), (LT/10005481), (LT/10005483), 
(LT/10009254), (LT/10009255), (LT/10011361), 
(LT/10011363), (LT/10011372), (LT/10011373), 
(LT/10011375), (LT/10016150), (LT/10021678), 
(LT/10022436), (LT/10022865), (LT/10022870), 
(LT/10022872), (LT/10023414), (LT/10023419), 
(LT/10024963), (LT/10028864), (LT/10028865), 
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‘The term AKI has largely replaced acute renal 
failure (ARF) as it more clearly defines renal 
dysfunction as a continuum rather than a 
discrete finding of failed kidney function’ 
 
pediatric AKI presents as a wide range of clinical 
manifestations from a minimal elevation in 
serum creatinine to anuric renal failure, arises 
from multiple causes, and occurs in a variety of 
clinical settings. Below are the normal range of 
values of serum creatinine for different pediatric 
age groups: 
• Newborn – 0.3 to 1.0 mg/dL (27 to 88 
micromol/L) 
• Infant – 0.2 to 0.4 mg/dL (18 to 35 
micromol/L) 
• Child – 0.3 to 0.7 mg/dL (27 to 62 
micromol/L) 
• Adolescent – 0.5 to 1.0 mg/dL (44 to 88 
micromol/L) 
 
See references for further details 
 
injury. Semin Nephrol 28: 436–446, 2008 
(5) Andreoli SP: Acute kidney injury in children. Pediatr 
Nephrol 2009; 24:253–263 
(6) Askenazi D. Evaluation and Management of Critically Ill 
Children with Acute Kidney Injury. Curr Opin Pediatr. 
2011 April ; 23(2): 201–207. 
doi:10.1097/MOP.0b013e328342ff37. 
(7) Devarajan P (2011) Biomarkers for the early detection of 
acute kidney injury. Curr Opin Pediatr 23: 194–200. 
10.1097/MOP.0b013e328343f4dd [doi] 
(8) The Harriet Lane Handbook, 19th ed, Tschudy KM, 
Arcara KM (Eds), Mosby, St. Louis 2012. p.642. 
 
(LT/10028876), (LT/10029162), (LT/10033695), 
(LT/10033699), (LT/10033711), (LT/10035276), 
(LT/10035278), (LT/10037825), (LT/10038422), 
(LT/10038436), (LT/10038437), (LT/10038438), 
(LT/10038439), (LT/10038440), (LT/10038441), 
(LT/10038479), (LT/10038491), (LT/10038493), 
(LT/10038494), (LT/10038526), (LT/10038541), 
(LT/10040233), (LT/10055003), (LT/10056221), 
(LT/10061436), (LT/10068447), (LT/10068736), 
(LT/10069339), (OL/10001047), (OL/10001048), 
(OL/10001048), (OL/10001050), (PT/10005481), 
(PT/10005483), (PT/10011372), (PT/10022870), 
(PT/10038422), (PT/10038436), (PT/10038491), 
(PT/10055003), (PT/10068447), (SMQ/20000003) 
 
S/N Event Medical (case) definition References MedDRA codes 
14 acute liver 
injury (ALI) 
Only potential cases of drug-induced liver injury (DILI) are of 
interest; an important requirement will be the availability or 
otherwise of histological data. The following manifestations will be 
considered: 
- Hepatic necrosis 
- Liver cirrhosis 
- Other cases of DILI in which there is no histological data 
available 
 
(1) Bénichou C. 1990 Criteria of 
drug-induced liver disorders. 
Report of an international 
consensus meeting. J Hepatol. 
11:272–276 
(2) UpToDate. Drug-induced liver 
injury. 2014  [cited 2014 19th 
June]; Available from: 
http://www.uptodate.com/c
(HT/10019669), (HT/10019833), (LT/10001544), 
(LT/10001547), (LT/10001548), (LT/10001550), 
(LT/10001551), (LT/10001669), (LT/10001675), 
(LT/10001677), (LT/10001679), (LT/10001771), 
(LT/10001845), (LT/10004659), (LT/10004660), 
(LT/10004685), (LT/10004697), (LT/10005308), 
(LT/10005313), (LT/10008639), (LT/10008641), 
(LT/10009210), (LT/10009211), (LT/10009213), 
(LT/10009214), (LT/10010689), (LT/10010690), 
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(A) On the basis of availability of histological data: 
(1) hepatic necrosis: characterized by 
- Death of hepatic parenchyma: single cell 
(necrobiosis), or multicell in piecemeal, focal, 
periacinar, midzonal, periportal or paracentral 
locations.  
- Massive necrosis:  refers to events in individual acini 
in which all hepatocytes are dead. 
 
(2) liver cirrhosis: Features include 
- Necrosis of liver cells, slowly progressive over a long 
period and ultimately causing chronic liver failure 
and death 
- Fibrosis, involving both central veins and portal areas 
- Regenerative nodules, the result of hyperplasia of 
surviving liver cells 
- Distortion of normal hepatic lobular architecture 
- Diffuse involvement of the whole liver 
Note:  A regenerative nodule is an abnormal mass of liver cells 
without a normal cord pattern or central venule and surrounded 
completely by fibrosis 
 
(B) In the absence of histological data, only liver tests (NOT 
liver function tests) can be used in diagnosis as follows: 
(1) liver injury:  
- Increase of over 2N (2 times N; where N is the upper 
limit of normal range) in Alanine Aminotransferase 
(ALT) or Conjugated Bilirubin (CB)  
OR 
-  A combined increase in Aspartate Aminotransferase 
(AST), Alkaline Phosphatase (AP) and Total Bilirubin 
(TB), provided one of them is above 2N  
 
Various forms of drug-induced liver injury 
 
- hepatocellular: increase of over 2N in ALT alone, or R≥5 
[where R (ratio) is the serum activity of ALT/serum activity 
of AP. Each activity is measured as a multiple of N. Both 
ontents/drug-induced-liver-
injury?source=search_result&
search=drugs+and+the+liver+
patterns+of+druinduced+liver
+injury&selectedTitle=6~150. 
(3) Chandrasoma P., Taylor C.R. 
(1998). Chapter 43. The Liver: 
II. Toxic & Metabolic 
Diseases; Neoplasms. In P. 
Chandrasoma, C.R. Taylor 
(Eds), Concise Pathology, 3e. 
Retrieved September 18, 
2012 from 
http://www.accessmedicine.c
om/content.aspx?aID=18981
6. 
 
(LT/10011853), (LT/10013705), (LT/10013762), 
(LT/10018455), (LT/10018457), (LT/10018644), 
(LT/10019641), (LT/10019642), (LT/10019648), 
(LT/10019649), (LT/10019684), (LT/10019684), 
(LT/10019692), (LT/10019693), (LT/10019693), 
(LT/10019710), (LT/10019754), (LT/10019766) , 
(LT/10019796), (LT/10019831), (LT/10019832), 
(LT/10019834), (LT/10019835), (LT/10019837), 
(LT/10022224), (LT/10022227), (LT/10024665), 
(LT/10024666), (LT/10024667), (LT/10024668), 
(LT/10024701), (LT/10028859), (LT/10028867), 
(LT/10034513), (LT/10034927), (LT/10040133), 
(LT/10040275), (LT/10040526), (LT/10044345), 
(LT/10045974), (LT/10049199), (LT/10049228), 
(LT/10050279), (LT/10056502), (LT/10056806), 
(LT/10058473), (LT/10059570), (LT/10059571), 
(LT/10066503), (LT/10066756), (LT/10066756), 
(LT/10066758), (LT/10067125), (LT/10067718), 
(LT/10067969), (LT/10067969), (LT/10067970), 
(LT/10067971), (LT/10070815), (LT/10071561), 
(LT/10072032), (LT/10072268), (LT/10072734), 
(LT/10072937), (OL/10000670), (OL/10001673), 
(OL/10001678),(OL/10003695), (OL/10004708), 
(OL/10009209),(OL/10018456), (OL/10018643), 
(OL/10032161),(OL/10039482), (OL/10040274), 
(PT/10001547),(PT/10001551), (PT/10004659), 
(PT/10004685), (PT/10019641), (PT/10019692), 
(PT/10019754), (PT/10019834), (PT/10019837), 
(PT/10059570), (PT/10059571), (PT/10066758), 
(PT/10067125), (PT/10067718), (PT/10067969), 
(PT/10067969), (PT/10070815), (PT/10072268), 
(SMQ/20000013) 
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should have been measured together at the time of 
recognition of liver injury].  
 
- cholestatic: Liver injury is designated cholestatic when 
there is  increase of over 2N in AP alone, or R≤2 
 
- mixed: occurs when there is a combination of the 
following: increase in  ALT (over 2N) and AP as well as 
2<R<5. R ismost useful in patients with jaundice and may 
vary during the course of liver injury. 
 
S/N Event Medical (case) definition References MedDRA codes 
15 sepsis ‘Sepsis refers to Systemic Inflammatory Response 
Syndrome (SIRS) in the presence of or as a result of 
suspected or proven infection’ 
 
‘Systemic Inflammatory Response Syndrome (SIRS) is a 
widespread inflammatory response that may or may not 
be associated with infection. The presence of two or 
more of the following criteria (one of which must be 
abnormal temperature or leukocyte count) defines 
SIRS’: 
 
• Core temperature (measured by rectal, 
bladder, oral, or central probe) of >38.5ºC or 
<36ºC 
• Tachycardia, defined as a mean heart rate >2 
standard deviations above normal for age, or 
for children <1 year of age, bradycardia 
defined as a mean heart rate <10th percentile 
for age 
• Mean respiratory rate >2 standard deviations 
above normal for age 
• Leukocyte count elevated or depressed for 
age, or >10 percent immature neutrophils 
(1) Goldstein B, Giroir B, Randolph A. 
International pediatric sepsis consensus 
conference: definitions for sepsis and organ 
dysfunction in pediatrics. Pediatr Crit Care 
Med. 2005:2–8 
 
(HT/10040054), (LT/10002714), (LT/10002715), 
(LT/10011213), (LT/10014824), (LT/10015296), 
(LT/10027268), (LT/10027280), (LT/10027281), 
(LT/10028912), (LT/10034110), (LT/10034111), 
(LT/10034511), (LT/10034690), (LT/10035650), 
(LT/10035651), (LT/10039444), (LT/10039445), 
(LT/10040047), (LT/10040048), (LT/10040049), 
(LT/10040050), (LT/10040051), (LT/10040053), 
(LT/10040070), (LT/10040070), (LT/10040072), 
(LT/10040073), (LT/10040078), (LT/10040079), 
(LT/10040081), (LT/10040082), (LT/10040083), 
(LT/10040084), (LT/10040085), (LT/10040086), 
(LT/10040087), (LT/10040088), (LT/10040089), 
(LT/10040092), (LT/10040095), (LT/10040096), 
(LT/10040097), (LT/10040580), (LT/10040580), 
(LT/10041930), (LT/10041931), (LT/10042184), 
(LT/10042185), (LT/10042197), (LT/10045470), 
(LT/10045471), (LT/10046161), (LT/10046231), 
(LT/10046237), (LT/10047431), (LT/10047434), 
(LT/10048960), (LT/10049151), (LT/10049253), 
(LT/10049665), (LT/10051017), (LT/10051018), 
(LT/10051080), (LT/10051379), (LT/10051379), 
(LT/10051739), (LT/10053022), (LT/10053166), 
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See references for further details 
 
(LT/10053588), (LT/10053596), (LT/10053597), 
(LT/10053598), (LT/10053599), (LT/10053600), 
(LT/10053840), (LT/10053879), (LT/10053879), 
(LT/10054047), (LT/10054137), (LT/10054160), 
(LT/10054162), (LT/10054167), (LT/10054168), 
(LT/10054169), (LT/10054170), (LT/10054177), 
(LT/10054188), (LT/10054189), (LT/10054210), 
(LT/10054213), (LT/10054219), (LT/10054221), 
(LT/10054249), (LT/10054250), (LT/10054252), 
(LT/10054253), (LT/10054254), (LT/10054255), 
(LT/10054256), (LT/10054257), (LT/10054264), 
(LT/10054284), (LT/10054608), (LT/10054611), 
(LT/10054612), (LT/10054613), (LT/10054615), 
(LT/10054616), (LT/10054617), (LT/10054618), 
(LT/10054619), (LT/10054620), (LT/10054637), 
(LT/10054641), (LT/10054642), (LT/10054688), 
(LT/10054691), (LT/10055078), (LT/10056430), 
(LT/10057767), (LT/10057847), (LT/10058040), 
(LT/10058041), (LT/10058867), (LT/10058872), 
(LT/10058873), (LT/10058874), (LT/10058875), 
(LT/10058876), (LT/10058877), (LT/10058878), 
(LT/10058879), (LT/10058888), (LT/10058889), 
(LT/10058973), (LT/10059070), (LT/10060410), 
(LT/10060411), (LT/10060413), (LT/10060437), 
(LT/10062357), (LT/10062357), (LT/10063085), 
(LT/10064952), (LT/10066745), (LT/10069141), 
(LT/10069141), (LT/10069684), (LT/10070681), 
(LT/10071362),(MTH_HT/10040054), 
(MTH_LT/10040078), (MTH_LT/10040082), 
(MTH_LT/10047431), (OL/10021867), 
(OL/10021901), (PT/10014824), (PT/10015296), 
(PT/10027280), (PT/10040047), (PT/10040049), 
(PT/10040051), (PT/10040070), (PT/10040070), 
(PT/10045470), (PT/10048960), (PT/10049151), 
(PT/10051017), (PT/10051018), (PT/10051379), 
(PT/10051379), (PT/10051739), (PT/10053166), 
(PT/10053588), (PT/10053840), (PT/10053879), 
(PT/10053879), (PT/10054047), (PT/10054137), 
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(PT/10054160), (PT/10054162), (PT/10054177), 
(PT/10054210), (PT/10054213), (PT/10054219), 
(PT/10054221), (PT/10054264), (PT/10056430), 
(PT/10057767), (PT/10057847), (PT/10058040), 
(PT/10058041), (PT/10058872), (PT/10058873), 
(PT/10058874), (PT/10058875), (PT/10058876), 
(PT/10058877), (PT/10058878), (PT/10058879), 
(PT/10058889), (PT/10058973), (PT/10059070), 
(PT/10063085), (PT/10064952), (PT/10069141), 
(PT/10069141), (PT/10069684), (PT/10070681), 
(PT/10071362), (SMQ/20000070) 
 
S/N Event Medical (case) definition References MedDRA codes 
16 sudden 
infant death 
syndrome 
(SIDS) 
‘sudden infant death syndrome (SIDS) is defined 
as the sudden death of an infant younger than 
one year of age, which remains unexplained after 
a thorough case investigation, including 
performance of a complete autopsy, examination 
of the death scene, and review of the clinical 
history’. 
 
‘This definition emphasizes the necessity of 
autopsy, death scene investigation, and review 
of the clinical history when making the diagnosis 
of SIDS, to exclude other explanations for the 
sudden unexpected infant death that can mimic 
SIDS’. 
 
See references for further details 
 
 
(1) CDC(1996) Sudden infant death syndrome—United States, 1983–
94. MMWR Morb Mortal Wkly Rep 45:859–863 
(2) Willinger M, James LS, Catz C. Defining the sudden infant death 
syndrome (SIDS): deliberations of an expert panel convened by 
the National Institute of Child Health and Human Development. 
Pediatr Pathol.1991;11 :677– 684 
  (LT/10011220), (LT/10011910), 
(LT/10040666),(LT/10040667), 
(LT/10042439), (LT/10042440), 
(LT/10055089), (LT/10055090), 
(LT/10055091), (LT/10055092), 
(LT/10069606), (OL/10011939), 
(OL/10021733), (PT/10042440) 
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Appendix 3: Evaluation of all positive drug-event associations. 
ATC Code Drug Name Adverse Event (AE) 
Type 
Labelled as AE in SPC [Yes/No] Type/No. of Supporting Literature Citations 
J01FA09 clarithromycin bullous eruption Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 7 
Cohort study = 2 
Case report = 5 
J01CF05 doxycycline bullous eruption Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): Adverse effects→serious 
Total number of supporting citations = 5 
Case report = 3 
Case series = 2 
J04AC01 isoniazid bullous eruption Yes 
#eMC (Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse Reactions 
Total number of supporting citations = 6 
Clinical Trial = 1 
Cohort study = 1  
Case report = 4 
P01BC01 Quinine bullous eruption Yes 
 Dailymed (Adverse reactions) 
Micromedex (Summary): 
Contraindications/Warnings→ precautions  
Total number of supporting citations = 2 
Case report = 1 
Case series = 1 
 
M01AE01 Ibuprofen bullous eruption Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 10 
Case report = 5 
Case series = 5 
P01BC01 Quinine aplastic anaemia Yes 
#eMC (Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Total number of supporting citations = 4 
Biological study = 1 
 Case report = 3 
P02CA01 mebendazole agranulocytosis Yes Total number of supporting citations = 1 
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#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Cohort study = 1  
P01BC01 Quinine agranulocytosis Yes 
#eMC ( Undesirable effects) 
Micromedex (Summary): Adverse effects→serious 
Total number of supporting citations = 4 
Review of biological mechanism = 2 
Case report = 2 
Note: this was considered a ‘positive 
control – grade 1’ despite the fact that they 
were only 2 case reports, because of the 
availability of biological evidence. 
J01FA09 Clarithromycin thrombocytopenia Yes 
#eMC (Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Total number of supporting citations = 1 
Case control= 1 
J01CF05 Doxycycline thrombocytopenia Yes 
#eMC (Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Total number of supporting citations = 1 
Systematic literature review = 1 
P01BC01 Quinine thrombocytopenia Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ contraindications); 
(Adverse effects→serious) 
Total number of supporting citations = 20 
Biological studies = 8 
Review of biological studies = 4 
Systematic literature review = 1 
 Review of spontaneous reports = 2 
Case report = 4 
Case series = 1 
M01AE01 Ibuprofen thrombocytopenia Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): Adverse effects→serious 
Total number of supporting citations = 3 
Clinical trial = 1 
Case control =1 
Case series = 1 
J01FA09 Clarithromycin psychosis Yes 
#eMC (Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Total number of supporting citations = 4 
Case report = 4 
 
J04AC01 Isoniazid psychosis Yes 
#eMC (Special warnings and precautions for use) 
Total number of supporting citations = 4 
Cohort study = 2 
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Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Case report = 2 
R03DC03 montelukast psychosis Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 1 
Case series = 1 
D10BA01 Isotretinoin psychosis Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 2 
Systematic literature review = 1 
Case report = 1 
N06BA04 methylphenidate psychosis Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); 
(Adverse effects→serious) 
Total number of supporting citations = 4 
Biological study = 2 
Cross over clinical trial = 1 
Case series = 1 
D10BA01 isotretinoin suicide Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 3 
Systematic literature review = 1 
Review of spontaneous reports = 1 
Review of spontaneous reports and case 
series = 1 
R03DC03 montelukast suicide Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); 
(Adverse effects→serious) 
Total number of supporting citations = 1 
Review of spontaneous reports = 1 
J01FA09 clarithromycin ventricular arrhythmia Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
Contraindications/Warnings→ Contraindications; 
precautions 
Total number of supporting citations = 1 
Review of spontaneous reports = 1 
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P01BC01 quinine ventricular arrhythmia Yes 
Dailymed (Contraindications; Warnings and 
Precautions; Adverse reactions) 
Micromedex (Summary): 
(Contraindications/Warnings→ contraindications; 
precautions); (Adverse effects→serious) 
Total number of supporting citations = 1 
Case series = 1 
A03FA03 domperidone ventricular arrhythmia Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); 
(Adverse effects→serious) 
Total number of supporting citations = 3 
Biological study = 1 
Cohort study = 1 
Case control = 1 
J01FA09 clarithromycin sudden death Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 4 
Clinical trial = 1 
Case-control = 2 
Case report = 1 
A03FA03 domperidone sudden death Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ precautions); 
(Adverse effects→serious) 
Total number of supporting citations = 7 
Experimental study = 1 
Nested case control = 1 
Case control = 5 
J01FA09 clarithromycin QT prolongation Yes 
#eMC (Contraindications; Special warnings and 
precautions for use; Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ contraindications); 
(Adverse effects→serious) 
Total number of supporting citations = 2 
Basic science = 1 
Review of spontaneous reports = 1 
P01BC01 quinine QT prolongation Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ contraindications; 
precautions); (Adverse effects→serious) 
Total number of supporting citations = 7 
Clinical trial = 1 
Systematic literature review = 4 
Review of spontaneous reports = 1 
Case report = 1 
M01AE01 ibuprofen anaphylaxis Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
Total number of supporting citations = 5 
Review of pharmacology = 1 
Review of spontaneous reports = 1 
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(Contraindications/Warnings→ precautions); 
(Adverse effects→serious) 
Case report = 2 
Case series = 1 
J04AC01 isoniazid seizure Yes 
#eMC (Special warnings and precautions for use) 
Micromedex (Summary): Adverse effects→serious 
Total number of supporting citations = 8 
Review of biological mechanism = 1 
Clinical trial = 1 
Case report = 5 
Case series = 1 
P01BC01 quinine acute kidney injury Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 5 
Case report with systematic literature 
review = 1 
Case report = 4 
M01AE01 ibuprofen acute kidney injury Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 10 
Review of clinical trials = 1 
Case control = 1 
Case report = 5 
Case series = 2 
Review of spontaneous reports = 1 
J01CF05 flucloxacillin acute liver injury Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Drugdex): Cautions → Adverse 
Reactions 
Total number of supporting citations = 11 
Cohort study = 2 
Literature review = 4 
Review of spontaneous reports = 1 
Case reports = 3 
Case series = 1 
J01FA09 clarithromycin acute liver injury Yes 
#eMC (Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→ contraindications; 
precautions); (Adverse effects→serious) 
Total number of supporting citations = 3 
Cohort study = 1 
Case report = 1 
Review of spontaneous reports = 1 
J05AE06 lopinavir acute liver injury Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 4 
Clinical trial = 2 
Cohort study = 1 
Case report = 1 
J04AC01 isoniazid acute liver injury Yes Total number of supporting citations = 7 
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#Electronic Medicines Compendium 
  
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Clinical trial = 1 
Case report = 4 
Case series = 2 
P02CA01 mebendazole acute liver injury Yes 
Dailymed (Warnings and precautions; Adverse 
Reactions) 
Micromedex (Summary): Adverse effects→serious 
Total number of supporting citations = 2 
Clinical trial = 1 
Case report = 1 
P01BC01 quinine acute liver injury Yes 
Dailymed (Adverse Reactions) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 3 
Case reports = 3 
M01AE01 ibuprofen acute liver injury Yes 
#eMC (Special warnings and precautions for use; 
Undesirable effects) 
Micromedex (Summary): 
(Contraindications/Warnings→precautions); (Adverse 
effects→serious) 
Total number of supporting citations = 5 
Review of spontaneous reports = 1 
Case report = 3 
Case series = 1 
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Appendix 4: Comparison of GRiP, EU-ADR  and OMOP  reference sets 
Abbreviations: m’dazole – mebendazole;  AKI – acute kidney injury; ALI – acute liver injury; SIDS – sudden infant death syndrome;  
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Chapter 3.2 Drug safety monitoring in children: Performance of signal 
detection algorithms and impact of age stratification  
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Abstract 
Introduction: Spontaneous reports of suspected adverse drug reactions (ADRs) can be 
analysed to yield additional drug safety evidence for the pediatric population. Signal detection 
algorithms (SDAs) are required however the performance of SDAs in the pediatric population 
specifically is unknown. We tested the performance of two SDAs on pediatric data from the US 
FDA Adverse Event Reporting System (FAERS) and investigated the impact of age stratification 
and age adjustment on SDAs’ performance. 
Methods: We tested the performance of two established SDAs: Proportional Reporting Ratio 
(PRR) and Empirical Bayes Geometric Mean (EBGM) on a pediatric dataset from FAERS (2004 to 
2012). We compared SDAs' performance to a published pediatric-specific reference set, by 
calculating diagnostic-test related statistics including the area under the Receiver Operating 
Characteristics curve (AUC). Impact of age stratification and age-adjustment SDAs’ performance 
was assessed. Age adjustment was performed by pooling (Mantel-Hanszel) stratum-specific 
estimates.   
Results: A total of 115,674 pediatric reports (patients aged 0-18 years) comprising 893,587 
drug-event combinations (DECs) were analysed. Crude values of the AUC were similar for both 
SDAs: 0.731 (PRR) and 0.745 (EBGM). Stratification unmasked four DECs, for example 
‘ibuprofen and thrombocytopenia’.  Age-adjustment did not improve performance.  
Conclusion: The performance of the two tested SDAs was similar in the pediatric population. 
Age adjustment does not improve performance and is therefore not recommended to be 
performed routinely. Stratification can reveal new associations, therefore is recommended when 
either drug use is age-specific or when an age-specific risk is suspected.  
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Introduction  
Spontaneous reports of suspected adverse drug reactions (ADRs) can yield important 
information regarding the safety of drugs 124. Usually, such reports are screened for emerging 
safety issues by applying statistical methods called signal detection algorithms (SDAs). Current 
SDAs compare the reporting rate of a drug-event combination (DEC) of interest with the 
expected count calculated from the overall reporting rate of that reaction in the entire database 
124,125. Although SDAs are routinely applied to reports pertaining to the general population, the 
performance of SDAs in the pediatric population specifically has not been investigated to date. 
Compared to adults, the pattern of drug use and occurrence of ADRs in pediatrics may differ 126-
128 since the latter population comprises a heterogeneous group of subjects at various stages of 
development with age-dependent organ maturation and hormonal changes 129. Several studies 
investigating ADR reporting in children identified different reporting patterns in this population 
compared to adults 126,128,130,131. Since ADRs may be age–specific, adjustment for age seems to 
be a logical step when investigating pediatric ADRs and has been advocated by some 
researchers 127. The major aim of stratification is verification of confounding and effect 
modification which otherwise may mask true signals 132. Confounding by age can be dealt with 
by stratifying for age categories and pooling stratum-specific estimates. However if age specific 
estimates differ (in case of effect modification) pooling/adjustment should not be done, but 
instead, a verification of each individual stratum. While stratification has been investigated by 
some researchers 133, adjustment is routinely implemented in some Bayesian but not in 
frequentist SDAs 134-136 Few studies have systematically addressed the impact of age 
stratification or adjustment and the results are contradictory 132,137,138.  
Within the context of the Global Research in Pediatrics (GRiP) – Network of excellence 139, we 
aimed to evaluate the performance of two well-established SDAs in the pediatric population and 
determine if age stratification or adjustment impacts signal detection in this population.   
 
Methods 
Data source 
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Data was retrieved from the publicly available version of the US FDA Adverse Event Reporting 
System (FAERS), which comprises spontaneous reports of suspected ADRs submitted by 
manufacturers, healthcare professionals and patients. FAERS is one of the largest repositories 
of spontaneous reports in the world 140,141. In this study, we analyzed reports received from the 
first quarter of 2004 through the third quarter of 2012.  
For performance analysis, only reports of ADRs occurring in children and adolescents (<18 
years of age) were retained. The ADRs in FAERS are coded according to the Medical Dictionary 
for Regulatory Activities (MedDRA®)142.  
To improve the quality of the dataset, we excluded reports with missing age, the main variable 
in our study. Also, reports with reported age equal to zero and with a MedDRA® preferred term 
indicating prenatal exposure were removed, as these imply in-utero drug exposure and were 
therefore not relevant for our study. We minimized the number of duplicates (i.e. the same 
report submitted by different reporters) by applying an algorithm based on case identifier, 
report identifier, drug and event names. For multiple reports (i.e. the same report is reported at 
a later time, with additional and updated information) 143, the most recent (and most updated) 
report was retained for analysis.  
As drug names included in FAERS are not standardized, a harmonization procedure was 
implemented. Briefly, this consisted of removing superfluous characters and applying a 
generalized edit distance matching algorithm 144 to map free text drug names to synonyms and 
finally to the corresponding active substance and World Health Organization-Anatomic 
Therapeutic Chemical (WHO-ATC) code.  
In this study, only those drugs reported as primary or secondary suspect in the FAERS database 
were retained for analysis. Analysis was performed at Drug-Event Combination (DEC) level, 
meaning that within each report, every suspect drug was combined with all reported ADRs. 
Thus, one report may comprise more than one DEC.  
Signal Detection Algorithms (SDAs) 
We tested two well established SDAs which are routinely used by various national and 
international regulatory and/or research institutions for signal detection: the proportional 
reporting ratio (PRR) 125  and the empirical Bayes geometric mean (EBGM) 136  (see Table 1). 
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We also tested count of reports, as a positive control. In order to define a signal of 
disproportionate reporting (SDR) 145,146, we selected thresholds that are currently applied in 
routine practice. We applied the SDAs at the end of the study period, when the maximum 
number of reports had accrued.  
Table 1: Signal detection algorithms and corresponding thresholds applied 
Signal Detection 
Algorithm   Applied Threshold
a 
Institution where the method and 
the respective threshold is 
currently used  
Number of  
reports  
n ≥5 NA 
   PRR PRR lower bound 95% CI ≥ 1 & n ≥ 5 
reports 
European Medicines Agency  
EBGM EB05 CI≥ 1.8 and n≥ 3 reports & EBGM 
≥2.5 
Medicines and Healthcare products 
Regulatory Agency (MHRA) 
PRR= Proportional reporting ratio; EBGM= Empirical Bayes Geometric Mean; CI=confidence interval; NA= Not 
available; EB05= Lower bound of the 95% confidence interval 
a Thresholds were obtained from Candore et al 146 
 
Performance assessment measures 
The performance of the SDAs was assessed by calculating diagnostic-test related statistics, 
namely specificity and sensitivity, positive predictive value (PPV), and negative predictive value 
(NPV) 147[25]. Sensitivity is the ability of the method to correctly identify true signals while 
specificity is the ability to correctly exclude false signals. PPV and NPV are posterior 
probabilities, describing how many of the signals classified as positive or negative are indeed 
correctly classified 147,148.  
Since diagnostic-test related statistics are dependent on the threshold choice, their individual 
comparison has only limited, albeit practical value. Therefore, we also estimated the area under 
the curve (AUC) of receiver operating characteristics (ROC) in order to compare the 
performance of the SDAs [32]; the AUC incorporates both sensitivity and specificity across all 
the possible values for a certain SDA.  Calculation of AUCs was conducted by varying only the 
point estimate of each SDA and did not take into account the other components of the SDA. 
For the purpose of performance evaluation, a previously constructed pediatric-specific GRIP 
reference set of positive and negative drug-event associations was used. It consists of 37 
positive and 90 negative DECs and includes drugs that are administered to children and events 
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that are regarded as important for this population. The positive DECs are those that were 
confirmed to occur based on evidence from Summary of Product Characteristics (SmPC) and 
the published literature, while the negative DECs are those that could not be confirmed at the 
time of literature review by neither the SmPC nor the published literature. For a full description 
of the reference set, see Osokogu et al 149. 
Stratification and adjustment for age 
The impact of age stratification and adjustment on the performance of the SDAs was 
investigated. First, we checked for possible effect modification across age strata, by stratifying 
the data according to age categories defined by the International Conference on Harmonization 
(ICH) 150 and calculating stratum-specific measures for each SDA.  
Secondly, we calculated age-adjusted estimates for PRR and EBGM by combining the stratum-
specific estimates in an overall measure 151. The performance of each SDA was reassessed after 
adjustment.  
Statistical analysis 
Differences in the performance (AUC) of each SDA, crude versus age-adjusted and crude versus  
count of reports (positive control) were tested using paired chi-squared tests. Stratum-specific  
contingency tables were tested for homogeneity using the Breslow Day Tarone test 152. The 
Mantel-Haenszel approach was used for pooling and calculating age-adjusted estimates [28]. 
The lower bound of the EBGM 95% confidence interval (EBGM05) was calculated using the 
EB05 for each stratum and then computing a Mantel-Haenszel average based upon Zeinoun 153. 
Statistical significance was defined by p value < 0.05.  
Analysis was performed using SAS software version 9.2. Graphs were made in SAS software 
version 9.2 and R version 3.1.3.  
Results 
Descriptive analysis 
For the study period (first quarter of 2004 through the third quarter of 2012), a total of 
4,285,088 reports were retrieved from FAERS. After eliminating duplicates (n=43,125), removal 
of adult reports (n=2,686,530) and reports with missing age (n=1,419,524) or age equal to 
zero with a MedDRA® preferred term indicating prenatal exposure (n=20,235), 115,674 reports 
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corresponding to 893,587 individual DECs were retained for analysis of pediatric spontaneous 
reports (see Table 2).     
Table 2 Description of pediatric reports by age categories 
Age group Number of reports, n (%) 
Neonates: 0-27 days 5,091 (4.40%) 
Infants: 28 days-23 months 12,566 (10.86%) 
Children: 2-11 years 49,982 (43.21%) 
Adolescents: 12-17 years 48,035 (41.53 %) 
Total  115,674 (100%) 
 
The total number of pediatric reports that included the investigated drugs and ADRs from the 
reference set can be observed in Fig. 1, which also shows data regarding adults (for 
comparison purposes). The number of children exposed to the drugs of interest, for whom any 
of the investigated ADRs was reported, varied from 26 patients (for praziquantel) to 7,535 
patients (for ibuprofen) with a median of 781 patients exposed across all drugs. The number of 
events of interest in FAERS ranged from 164 reports (ventricular arrhythmia) to 14,777 
(anaphylaxis), with a median of 1,004 reports across all events. For a more detailed description 
of reports counts please refer to Electronic Supplementary material Table 1.   
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Fig. 1 Count of reports in pediatric and adult population for the investigated ADRs 
and drugs, cumulatively for the period Q1 2004 -Q3 2012a   
 
a -Number of reports in children is represented by bars and plotted on the left axis, while the number of reports in 
adults is represented by the red line and plotted on the right axis; Reports with missing age or age=0 were excluded. 
Only reports mentioning any of the drugs or events in the reference set were considered.  
 
Overrall performance of SDAs 
Both SDAs showed high specificity and low sensitivity. They both had similar specificity values 
(PRR:83.8% and EBGM:91.9%), while sensitivity was lower for EBGM than for PRR (17.2% vs. 
37.9%). The NPV and PPV were similar for both SDAs. When we applied the threshold-
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independent (AUC-based) approach, the tested SDAs showed similar performance in the 
pediatric population although the AUC value for EBGM (0.745) was slightly higher than for PRR 
(0.731).  None of the SDAs performed better than the simple report count (AUC=0.634, p-
values: PRR=0.27 and EBGM=0.14) 
Stratification and adjustment for age and its impact on performance 
Upon calculating SDA values per age stratum and testing for heterogeneity across strata, we 
observed effect modification for some associations.  Some false negatives (positive DECs which 
failed to be highlighted as signals when analyzing data pertaining to the entire pediatric 
population) were unmasked in some strata. Four DECs were unmasked in total: ibuprofen-
thrombocytopenia and isoniazid-seizure (by PRR) and clarithromycin-erythema multiforme and 
ibuprofen-erythema multiforme (by EBGM). Conversely, ‘ibuprofen-acute liver injury’, also a 
positive DEC, was highlighted when we analyzed data pertaining to the entire pediatric 
population but after stratifying, it became clear that this DEC was highlighted  only in older 
children (adolescents), and  not highlighted in younger children (see Fig. 3). For an overview of 
SDA values across age strata and results of heterogeneity tests please refer to the Electronic 
Supplementary material figures 1A and 1B.  
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Fig. 2: Performance of signal detection algorithms within the entire pediatric 
population  
 
SDA Sensitivity Specificity PPV NPV AUC  p-valueb  
Number of 
reports   
58.62 67.57 58.62 67.57 0.634 reference 
PRR 37.93 83.78 64.71 63.27 0.731 0.266 
EBGM 17.24 91.89 62.50 58.62 0.745 0.144 
After age 
adjustment a   
     (reference-
crude 
PRR/EBGM) 
PRR  34.48 86.49 66.67 62.75 0.688 0.267 
EBGM  10.34 97.30 75.00 58.06 0.683 0.216 
 
 
We evaluated the performance of the methods within individual age strata (see Table 3). On 
average, performance of the SDAs was lower within age strata compared to the entire pediatric 
population and performance improved with increasing stratum size. For infants and neonates, 
the performance was very low, not better than chance (p-value > 0.5 for both SDAs). The 
adolescent group exhibited the best performance which was similar to the overall performance.   
Table 3 Performance of signal detection algorithms across age strata 
Age groups Signal Detection 
Algorithms 
Size of the age 
stratum 
(number of 
reports) 
AUC 
Neonates   5,091   
 
Number of Reports 
 
0.625 
 
EBGM 
 
0.600 
 
PRR 
 
0.65 
Infants   12,566  
 
Number of Reports 
 
0.667 
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EBGM 
 
0.548 
 
PRR 
 
0.554 
Children   49,982   
 
Number of Reports 
 
0.654 
 
EBGM 
 
0.698 
 
PRR 
 
0.649 
Adolescents   48,035   
 
Number of Reports 
 
0.698 
 
EBGM 
 
0.771 
 
PRR 
 
0.718 
Entire pediatric population  Number of Reports 115,674 0.634 
 EBGM  0.746 
 PRR  0.733 
PRR= Proportional reporting ratio; EBGM= Empirical Bayes Geometric Mean; AUC=area under the curve   
 
After adjusting for age by pooling the stratum-specific estimates, the performance of the SDAs 
decreased, although not significantly (see Fig. 2; crude vs. adjusted AUC for PRR 0.731 vs. 
0.688, p-value = 0.267; crude vs. adjusted AUC for EBGM 0.745 vs. 0.683, p-value = 0.216).  
 
 
Fig. 3: Variation of PRR and EBGM estimates across pediatric specific strata –
selected examples  
 
p-values were calculated with Breslow Day Tarone test for homogeneity 
 
Discussion 
In this study, we have demonstrated that age stratification for detection of drug safety signals 
in children may unmask some signals that do not appear in neither crude nor adjusted analysis. 
Adjustment for age does not improve performance of the PRR and EBGM.  
For the investigated events, similar reporting patterns were observed for children and adults 
while the investigated drugs appeared to have different reporting patterns (see Figure 1). 
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Different drug-related reporting patterns in children vs adults were previously reported 
128.Consequently, reported drug-event associations for children may differ from adults 126,128, 
underlining the need for pediatric-specific approaches to signal detection especially when we 
consider that even within the pediatric population, reported drugs may vary by age group 
126,154.   
Overall, the PRR and EBGM showed good performance although results were slightly lower than 
results reported on other (not pediatric-specific) reference sets 155,156. The similarity in 
performance between PRR and EBGM is in accordance with recent results from the PROTECT 
project 146.  The fact that the performance (based on AUC) of PRR and EBGM was not 
statistically significantly better than simple report count may be due to the lack of power. 
Within age strata, performance seemed to correlate with stratum size: the poorest results were 
observed for infants and neonates (the smaller groups), slightly improving for children while the 
best performance was observed for adolescents, the age stratum with the highest number of 
tested DECs. Decrease in power due to fewer reports and therefore DECs may account for this 
observation. The fact that we used lower bounds of confidence intervals for signaling instead of 
point estimates might have exacerbated the influence of sample size on the results, since 
smaller strata will have higher variability. In neonates and infants for whom expected counts 
were difficult to calculate because of few reports, we observed that simple report counts 
performed similar or even better than the SDAs and might be an alternative to commonly used 
SDAs. The fact that simple report count performed better than SDAs may have been because 
the reference set comprised known DECs (which in turn may have influenced reporting) rather 
than emerging safety issues, a hypothesis proposed by Noren et al 157.  
Inspection of SDA values across child specific strata (age-stratification) revealed some 
heterogeneity in estimates pointing to some effect modification. For example, ‘ibuprofen-
thrombocytopenia’, was found as a signal in the adolescents’ group but not detected in the 
entire pediatric population or the younger age categories. This suggests that age-specific SDA 
calculations are sometimes needed, rather than age-adjusted SDA estimates. The age-adjusted 
estimates did not improve performance; in fact even PPV unexpectedly decreased. Simulation 
studies have shown that when adjusted for strata, Bayesian methods such as EBGM tend to be 
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underestimated when there are sparse strata 138; this was also the case in our study. Previous 
studies in adults show contradictory results, with some showing a beneficial effect 132 while 
others did not 138. The reason for our finding is not entirely clear; a possible explanation is that 
age is not a strong confounder for the investigated DECs. Also, the method of weighting 
(Mantel-Haenszel approach) may have played a role since more weight was assigned to age 
groups with more reports (adolescents and children). This may have masked signals occurring 
in age groups with fewer reports. 
The limitations of data mining in FAERS include those inherent to spontaneous reporting 
databases: underreporting, lack of denominator data and control group, biases in reporting, as 
well as missing and poor quality data 158. Missing information regarding age substantially 
reduced the study sample size since we could not determine whether these reports described 
patients aged less than 18 years old. While these biases are well acknowledged and have a 
definite impact, they cannot be completely avoided. Compared to adults, there are fewer 
reports and different reporting patterns for children 126,159,160 which may complicate signal 
detection in the pediatric population.   
Evaluating performance of SDAs is a constant challenge due to lack of standard methodologies, 
imperfect reference standards and uncertainty regarding the best thresholds (See 
supplementary material for measures of performance using alternative thresholds). Some of the 
drugs and events in the reference set are specific to one age group within pediatrics and this is 
obvious in Fig. 1, even though the reference set was designed to be relevant for the entire 
pediatric population. We acknowledge that the reference set used, although specifically 
constructed for this purpose, does not include all the ADRs that are highly specific for 
pediatrics. This highlights the need for pediatric-specific approaches to signal detection; 
accounting for not just the entire pediatric population but also the different age strata within 
pediatrics. Still, the reference set captures various drug use and ADRs patterns 161  and is 
currently the only available pediatric-specific reference set. The thresholds applied to define a 
signal were obtained from previous publications and other cut-off points may generate better 
results; further research on pediatric-specific thresholds should be encouraged.  
Conclusion 
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Our study revealed that age adjustment did not improve performance of the SDAs. However, 
stratification revealed some variation in SDAs’ values across strata (effect modification) and 
inspection of stratum-specific estimates might sometimes yield useful information during routine 
surveillance. 
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Supplementary Material 
Supplementary Table 1 Counts of reports DECs from reference set in pediatrics 
True Positive Associations a 
Drug Event A B C Db 
 
Clarithromycin 
 
Erythema Multiforme 
 
11 
 
778 
 
540 
 
113446 
Clarithromycin Liver Injury 18 771 2216 111770 
Clarithromycin Psychosis 9 780 1323 112663 
Clarithromycin QT prolongation 6 783 511 113475 
Clarithromycin Sudden death 1 788 276 113710 
Clarithromycin Thrombocytopenia comb 11 778 1689 112297 
Clarithromycin Ventricular arrhythmia 3 786 243 113743 
Domperidone Sudden death 1 78 276 114420 
Doxycycline Erythema Multiforme 1 208 550 114016 
Doxycycline Thrombocytopenia comb 3 206 1697 112869 
Flucloxacillin Liver Injury 3 14 2231 112527 
Ibuprofen Acute Renal failure 247 3015 1262 110251 
Ibuprofen Anaphylaxis combined 547 2715 14296 97217 
Ibuprofen Erythema Multiforme 36 3226 515 110998 
Ibuprofen Liver Injury 86 3176 2148 109365 
Ibuprofen Thrombocytopenia comb 52 3210 1648 109865 
Isoniazid Liver Injury 13 344 2221 112197 
Isoniazid Psychosis 3 354 1329 113089 
Isoniazid Seizure combined 37 320 9198 105220 
Isotretinoin Psychosis 99 3130 1233 110313 
Isotretinoin Suicide 197 3032 2023 109523 
Lopinavir Liver Injury 5 202 2229 112339 
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Mebendazole Liver Injury 2 56 2232 112485 
Montelukast Psychosis 95 2316 1237 111127 
Montelukast Suicide 130 2281 2090 110274 
Quinine Agranulocytosis 1 96 528 114150 
Quinine Liver Injury 2 95 2232 112446 
Quinine Thrombocytopenia comb 1 96 1699 112979 
Quinine Ventricular arrhythmia 1 96 245 114433 
 
True Negative Associations a 
 
Drug Event A B C Db 
 
Clarithromycin 
 
Suicide 
 
3 
 
786 
 
2217 
 
111769 
Clarithromycin Thromboembolism 1 788 697 113289 
Cyproterone Anaphylaxis combined 2 17 14841 99915 
Domperidone Acute Renal failure 2 77 1507 113189 
Domperidone Agranulocytosis 2 77 527 114169 
Domperidone Anaphylaxis combined 5 74 14838 99858 
Domperidone Aplastic anaemia 1 78 994 113702 
Domperidone Liver Injury 2 77 2232 112464 
Domperidone Sepsis 2 77 2012 112684 
Domperidone Suicide 3 76 2217 112479 
Domperidone Thrombocytopenia comb 4 75 1696 113000 
Doxycycline QT prolongation 1 208 516 114050 
Doxycycline Suicide 5 204 2215 112351 
Doxycycline Thromboembolism 3 206 695 113871 
Fluticasone Acute Renal failure 2 1703 1507 111563 
Fluticasone Liver Injury 3 1702 2231 110839 
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Fluticasone QT prolongation 1 1704 516 112554 
Fluticasone Sepsis 3 1702 2011 111059 
Fluticasone Thrombocytopenia comb 6 1699 1694 111376 
Ibuprofen Sepsis 79 3183 1935 109578 
Isoniazid Sepsis 1 356 2013 112405 
Isoniazid Ventricular arrhythmi 6 351 240 114178 
Isotretinoin Anaphylaxis combined 230 2999 14613 96933 
Isotretinoin QT prolongation 2 3227 515 111031 
Isotretinoin Sepsis 28 3201 1986 109560 
Loperamide Acute Renal failure 2 166 1507 113100 
Loperamide Liver Injury 1 167 2233 112374 
Loperamide Sepsis 3 165 2011 112596 
Loperamide Suicide 21 147 2199 112408 
Loperamide Thrombocytopenia comb 11 157 1689 112918 
Mebendazole Anaphylaxis combined 13 45 14830 99887 
Montelukast Anaphylaxis combined 142 2269 14701 97663 
Montelukast Aplastic anaemia 4 2407 991 111373 
Montelukast QT prolongation 1 2410 516 111848 
Montelukast Sepsis 4 2407 2010 110354 
Montelukast Thrombocytopenia comb 15 2396 1685 110679 
Montelukast Thromboembolism 1 2410 697 111667 
a Reference set associations with no reports in pediatrics not presented 
b A, B, C, and D represent the following cell counts: 
A = Reports related to the drug of interest and the event of interest 
B = Reports of the exposure of interest associated with a different event 
C = Reports of the event of interest associated with a different exposure 
D = Reports related to exposures and events other than those of interest 
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Electronic Supplementary material figures 1A and 1B. 
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Chapter 4 Pharmacoepidemiological safety studies 
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Chapter 4.1 Pharmacoepidemiological safety studies in children: a systematic 
review  
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Abstract 
 
Purpose: In order to identify challenges in pediatric pharmacoepidemiological safety studies, 
we assessed the characteristics of such studies that included children. 
 
Methods: Relevant articles from inception to 2013 were retrieved from Embase and Medline. 
We sequentially screened titles, abstracts and full texts with independent validation. We 
systematically collected data regarding general information, study methods, and results. 
  
Results: Out of 4825 unique articles, 268 full texts (5.6%) were retained; 147 (54.9%) 
pertained to drugs rather than vaccines. Considering the 268 studies, 202 (75.4%) concerned 
children and adolescents (2 to 11 years) and 14 (5.3%) included preterm newborns. Most 
studies originated from North America (154 [57.5%]) or Europe (92 [34.3%]). Only 47 studies 
(17.5%) were privately funded. The majority (174 [64.9%]) were cohort studies. Out of 268 
studies, 196 (73.1%) collected data retrospectively; paper medical charts were the most 
common data source for the exposures (85 [31.7%]) and outcomes (122 [45.5%]). Only 3 
(2.0%) drug-only studies investigated rarely used drugs. Considering all 268 studies, only 27 
(10.1%) reported sample size or power calculation. Most (75 [51.0%]) drug-only studies 
corrected confounding by multivariate modelling unlike stratification in 66 (55.9%) vaccine-only 
studies. Considering 75 child-only studies without any statistically significant result, 41 (54.7%) 
did not discuss lack of power.  
 
Conclusions: Although the field of pediatric pharmacoepidemiology is steadily developing 
evaluation seldom includes neonates, is mainly focused on few drug classes and safety 
outcomes and concerns mainly drug use in developed countries. Small study size is a specific 
challenge in paediatrics.  Reporting should be improved.  
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Introduction 
Legislation has been introduced to stimulate the conduct of clinical trials in children 26,43,44, 
leading to more evidence on efficacy of new drugs or new formulations of existing drugs in 
children 162. This laudable action has greatly improved the evidence for new drugs but does not 
impact much on the available safety data since information on rare and potentially more serious 
safety issues cannot be obtained from randomized clinical trials (RCTs) 163,164.  
Safety data can be generated more efficiently from postmarketing observational studies 165,166, 
particularly relevant in children among whom the use of drugs is high and frequently off-label 
but recorded in routine care records 167. The availability of large scale healthcare and claims 
databases provides an outstanding opportunity to perform safety studies. However, since the 
studies are observational, their design requires extra attention to avoid misclassification and 
address potential confounding. Although the field of pharmacoepidemiology has grown 
substantially in the last 20 years, very few researchers focus on pediatrics.  
As part of the Global Research in Paediatrics - Network of Excellence (http://www.grip-
network.org/), we conducted a systematic review of the medical literature in order to assess 
the characteristics of pharmacoepidemiological studies evaluating the safety of drugs in 
children. 
Methods 
Search strategy 
We conducted this review according to PRISMA guidelines 168. We identified relevant articles by 
systematically searching EMBASE.COM and MEDLINE (via OvidSP) from inception to 29th 
November 2013. We used the following abbreviated search strategy: “children” AND 
“pharmacoepidemiology” AND “comparative studies”. Details of the full search strategy are 
included in Appendix 1. The computer-based searches were conducted by a biomedical 
information specialist (WB), and were limited to human research without language limitations. 
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One reviewer (OO) manually searched the bibliographies of relevant articles for additional 
relevant studies. 
Study selection 
All observational studies with the main objective to quantify the association between a drug 
exposure(s) and the occurrence of adverse drug reaction(s) in children and adolescents (≤18 
years of age) were eligible for inclusion in the review. Studies that included both children and 
adults were also retained. Drug exposures concerned all medicinal products including vaccines, 
applied either systemically or locally, and adverse drug reactions (ADRs) concerned all clinical 
events described as adverse outcomes to an individual (or combination of) drug(s) and/or 
vaccine(s).  
We excluded RCTs and observational studies that evaluated drug safety signal detection in 
spontaneous reporting systems, compliance rates to medicinal treatments, incidence or 
prevalence of ADRs or other diseases within a defined population, teratogenic effects of drug 
exposure in pregnancy or through breast milk, medication errors, accidental and intentional 
poisoning, drug abuse, management of ADRs or other diseases, pharmacogenomics, 
pharmacoeconomics, health services utilization, environmental exposures or herbal treatments. 
We excluded case series, case reports, abstracts, letters, duplicate studies, preliminary 
publications or reviews. Only studies published in English were retained for the analysis.  
All titles and abstracts were initially screened by one reviewer (OO) and full texts of potentially 
relevant articles were retrieved. A second reviewer (FK), blinded to the initial assessment, 
independently screened a sample of abstracts that comprised all abstracts retained plus a 
random selection of abstracts rejected by the first reviewer. Any disagreements between the 
two reviewers were examined by a third reviewer (Gt’J). Full texts retained through this process 
were independently screened by two reviewers (OO and JD), disagreements were examined by 
a third reviewer (CF).  
Data collection  
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We developed a standardized form that was tested on 10 randomly selected papers, and was 
modified accordingly.  
Data collected from each study pertained to journal impact factor (measured in 2013), study 
design, study period, type of data, study population, exposure, outcome, statistical analysis and 
results. We used country of corresponding author as a proxy for study setting. In the absence 
of information regarding study design, designs were classified based on data reviewers’ 
judgement. Case control studies included those studies that applied the nested case control 
design. Type of data implied primary versus secondary data (i.e. ‘large’ datasets like ‘primary 
care (prescription) data’, ‘outpatient (pharmacy) dispensing data’ and ‘claims data’). The age of 
the study population was categorized according to guidelines defined by the International 
Conference on Harmonization (ICH)150: newborns (0-27 days), infants and toddlers (28 days -
23 months), children (2-11 years) and adolescents (12-18 years). We used the term drug to 
refer to small molecules as opposed to vaccines. Exposures and outcomes were classified as 
rare based on authors’ definitions. For the sources of exposure data, inpatient dispensing data 
included electronic prescription data for hospitalized patients, medical charts at the clinic 
implied paper charts, outpatient dispensing data implied pharmacy dispensing records, and 
registry included those that recorded information on vaccination and drug use. To assess 
whether follow-up was long enough to observe the outcomes of interest in cohort studies, we 
applied the following minimum time intervals from drug exposure: fever – 1 day, other acute 
events – 2 weeks, cancer and other chronic (i.e. neurological and psychiatric) events – 5 years. 
The full data extraction form is given in Appendix 2. 
Both drugs and vaccines were mapped to the World Health Organization-Anatomical 
Therapeutic Chemical (WHO-ATC) classification (second or fifth level codes). The outcomes 
were mapped to the main divisions of the International Classification of Diseases (ICD), ninth 
edition.  
Two reviewers (OO and JD) independently collected data from all full text articles. 
Discrepancies were discussed with three senior reviewers (FK, DW and CF).  
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In order to check for the impact of the Best Pharmaceuticals for Children Act (BPCA) which was 
introduced in the US in 200226, we compared the number of pediatric studies published before 
and after its introduction. We compared pediatric studies to all the published studies (i.e. 
pertaining to the general population). 
Data analysis 
All continuous variables were described using medians (first [Q1] - third [Q3] quartiles) and 
categorical variables were summarized using counts and percentages. We performed hypothesis 
testing using the Mann-Whitney U test for continuous variables and Pearson chi-square, 
Fischer’s exact test or Z test for categorical variables. Analysis was performed by utilizing 
Statistical Package for the Social Sciences (SPSS) version 21. 
Results 
The search strategy yielded 4825 unique records after de-duplication (Figure 1). After screening 
titles and abstracts, we retained 301 articles (inter-reviewer concordance 90%) and after full 
text review, we retained 268 for analysis (inter-reviewer concordance 92%).  
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General characteristics of the studies  
The 268 retained studies were published from 1979 to 2013. In figure 2, we compare the 268 
studies to the total number (30,098) of studies (pertaining to the general population) published 
during the same period. After 2002, the number of pediatric studies steadily increased, more 
studies (196 [73.1%]) were published during the 10-year period from 2003 to 2013, compared 
to studies (72 [26.9%]) published during the preceding 24-year period. 
 
Figure 2: Number of pharmacoepidemiological safety studies in children 
Note: In order to retrieve all published pharmacoepidemiological safety studies that investigated the 
general population, we applied the same search algorithm that was utilized for studies in children except 
that for the former, we did not limit to the pediatric population; papers that were published in 2013 are 
those papers that were indexed in Embase and Medline as at 29th November 
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Most studies originated from North America (154 [57.5%]) or Europe (92 [34.3%]) and most 
studies (147 [54.9%]) assessed only drugs. Only 3 studies (1.1%) evaluated both drugs and 
vaccines, the studies investigated only children for the effect of the following drug classes 
(WHO-ATC second level): ‘corticosteroids for systemic use’, ‘ántibacterials for systemic use’, 
‘cough and cold preparations’, and ‘anti-inflammatory and anti-rheumatic products’. The 
investigated vaccines were ‘diphtheria-tetanus-pertussis’, ‘measles-mumps-rubella’, ‘hepatitis B 
virus’, ‘óral polio virus’ and ‘inactivated polio virus’. 
Considering 268 studies, 183 (68.3%) included only children, the remainder studied both 
children and adults. Studies on drug safety evaluation included most frequently children aged 2-
11 years while vaccine safety studies were most frequently conducted in infants and toddlers 
(Table 1). Only 14 studies (5.0%) included preterm newborns. 
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Table 1: General characteristics for 268 pharmacoepidemiological studies that 
evaluated the safety of drugs and vaccines in children (≤ 18 years) 
  
Total 
(268) 
Type of exposure investigated  
Only drugs  
(147) 
Only vaccines   
(118) 
 
number(%) 
or 
median(Q1-
Q3) 
number(%) 
or 
median(Q1-
Q3) 
number(%) 
or 
median(Q1-
Q3) 
p-
value 
Continent of the corresponding author    0.90 
  North America 154 (57.5) 83 (56.5) 70 (59.3)  
  Europe 92 (34.3) 52 (35.4) 39 (33.1)  
  Asia 12 (4.5) 7 (4.8) 4 (3.4)  
  Others 10 (3.7) 5 (3.4) 5 (4.2)  
     
Type of journal    0.07 
  Pediatric specialty 88 (32.8) 45 (30.6) 42 (35.6)  
  
Pharmacology/pharmacoepidemiology 
30 (11.2) 21 (14.3) 7 (5.9)  
  General medicala 39 (14.6) 17 (11.6) 22 (18.6)  
  Othersb 111 (41.4) 64 (43.5) 47 (39.8)  
     
2013 two-year journal impact factor 3.8 (3.1-5.3) 3.7 (2.6-5.5) 4.6 (3.6-5.6) 0.01 
  Missing data  18 (6.7) 14 (9.5) 4 (3.4)  
     
Funding sources    <0.01 
  Public 96 (35.8) 38 (25.9) 55 (46.6)  
  Private 47 (17.5) 25 (17.0) 22 (18.6)  
  Public and private 26 (9.7) 14 (9.5) 12 (10.2)  
  No funding  7 (2.6) 5 (3.4) 2 (1.7)  
  Funding not reported 92 (34.3) 65 (44.2) 27 (22.9)  
     
Study period, years  3.7 (1.7-8.9) 4.6 (1.7-9.0) 3.2 (1.7-7.0) 0.31 
 Missing data  14 (5.2) 11 (4.1) 3 (1.1)  
     
Study populationc     
  Age at inclusion     
    Minimum age, years  0.1 (0-2.0) 0.1 (0-3.0) 0.2 (0-1.0) 0.51 
    Maximum age, years  16.5 (2.0-
21.0) 
18.0 (13.5-
63.5) 
5.0 (1.5-17.0) <0.01 
  Preterm newborns    <0.01 
    Exclusively 9 (3.3) 9 (6.1) 0  
    Partially 5 (1.9) 4 (2.7) 1 (0.8)  
    No 254 (94.8) 134 (91.2) 117 (99.2)  
 Term newborns (0-27 days) 106 (39.5) 61 (41.5) 44 (37.3) 0.49 
 Infants/toddlers (28 days-23months)   168 (62.9) 80 (54.4) 86 (72.9) <0.01 
 Children (2-11 years) 202 (75.4) 117 (80.0) 82 (69.5) 0.05 
 Adolescents (12-18 years) 157 (58.9) 110 (74.8) 45 (38.1) <0.01 
 Mixed (adults and children) 85 (31.7) 67 (45.6) 18 (15.3) <0.01 
     
WHO-ATC level of investigated 
exposure (reported name)d 
   <0.01 
  Fifth level (specific compound) 203 (75.7) 87 (59.2) 116 (98.3)  
  Second,third or fourth level (class) 51 (19.0) 51 (34.7) 0   
  Both  14 (5.2) 9 (6.1) 2 (1.7)  
     
Number of specific compounds (WHO-
ATC fifth level) that were 
investigatede 
   0.14 
  1 137 (63.1) 54 (56.3) 81 (68.6)  
  2 35 (16.1) 20 (20.8) 15 (12.7)  
  ≥3 45 (20.7) 22 (22.9) 22 (18.6)  
     
Number of drug/vaccine classes 
(WHO-ATC second, third or fourth 
   0.27 
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level) that were investigatedf 
  1 48 (73.8) 45 (75.0) 1 (50.0)  
  2 8 (12.3) 7 (11.7) 1 (50.0)  
  ≥3 9 (13.8) 8 (13.3) 0  
Note: Missing data is presented for only instances where it constitutes greater than 5% 
NA=Not applicable 
Studies assessing drugs (147) or vaccines (118) exclusively, do not add up to the total number of studies (268) because 
3 studies that investigated both drugs and vaccines are not presented in the table. 
a Refers to journals that publish wide variety of medical topics (irrespective of specialty);  
b Journals that do not fit into any of the specified categories i.e. PLOS ONE; 
c For the age distributions, the proportions do not add up to 100% because some studies included multiple age 
categories; 
d World Health Organization-Anatomic Therapeutic Chemical; 
e  The proportions are based on only those studies that  investigated specific compounds either exclusively or in 
combination with drug/vaccine class; 
f  The proportions are based on only those studies that investigated drug/vaccine class either exclusively or in 
combination with specific compounds 
 
 
 
The median impact factor of the journals in which the studies were published was 3.8 (3.1-5.3). 
As seen in table 1, vaccine-only studies (4.6 [3.6-5.6]) were published in higher impact journals 
than drug-only studies (3.7 [2.6-5.5]) (Mann Whitney U p-value 0.01). Few studies were 
published in pediatric (88 [32.8%]) or pharmacoepidemiological specialty (30 [11.2%]) 
journals. Only 14 studies (17.5%) were privately funded, vaccine studies were more frequently 
publicly funded but for a large proportion the type of funding was unknown. Regardless of the 
type of exposure that was investigated, privately funded studies (journal impact factor=3.5; 
3.1-5.3) were of lower impact than studies receiving public funding (journal impact factor=5; 
3.5-7.8) (Mann Whitney U p-value<0.01). 
Methodology of the studies 
From the 268 studies, 202 (75.4%) reported the study design(s) and for the remaining study 
design was classified according to the reviewers’ judgment. Cohort studies were the most 
common (174 [64.9%]), and 23 studies (8.6%) applied more than one design. Case-only 
designs were seldom used: the self-controlled case series (SCCS) design was utilized in only 30 
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studies (11.2%), to evaluate vaccine-related outcomes exclusively. Similarly, case-crossover 
studies were few (4 [1.5%]).  
In most studies (196 [73.1%]), data collection was retrospective. Prospective studies (88 
[32.8%]) were usually cohort studies that used mainly primary data (56 [63.6%]) and were 
smaller than studies with retrospective data. Secondary data was utilized for both drugs and 
vaccines and concerned 183 studies (68.3%). Studies using secondary data had larger sample 
sizes than studies using primary data collection. Exposure and outcome data were collected 
from mainly medical charts ((85 [31.7%]) and (122 [45.5%]) respectively) followed by claims 
data and primary care medical or dispensing data (Table 2).  
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Table 2: Methodology of 268 pharmacoepidemiological studies that evaluated the 
safety of drugs and vaccines in children (≤ 18 years) 
  
Total 
(268) 
Type of exposure investigated  
Only drugs  
(147) 
Only vaccines  
(118) 
 
Number(%) 
or 
median(Q1-
Q3) 
Number(%) 
or 
median(Q1-
Q3) 
Number(%) 
or 
median(Q1-
Q3) 
p-
valu
e 
Designa     
  Cohort 174 (64.9) 114 (77.6) 60 (50.8) <0.01 
  Case control 73 (27.2) 31 (21.1) 39 (33.1) 0.03 
  Self-controlled case series 30 (11.2) 0  30 (25.4) NA 
  Case crossover 4 (1.5) 3 (2.0) 1 (0.8) 0.42 
  Othersb 14 (5.2) 6 (4.1) 8 (6.8) 0.33 
     
Mode of data collectionc     
  Retrospective 177 (66.0) 96 (65.3) 80 (67.8) 0.66 
  Prospective 69 (25.7) 41 (27.9) 26 (22.0)) 0.27 
  Both 19 (7.1) 10 (6.8) 9 (7.6) 0.80 
  Uncleard 3  (1.1) 0  3 (2.5) NA 
     
Type of data      0.11 
  Primary 58 (21.6) 38 (25.9) 18 (15.3)  
  Secondary 183 (68.3) 95 (64.6) 87 (73.7)  
  Mixed 27 (10.1) 14 (9.5) 13 (11.0)  
     
Source of (collection method for) 
exposure datae 
    
  Primary care (prescription) 
data 
27 (10.1) 14 (9.5) 12 (10.2) 0.85 
  Outpatient (pharmacy) 
dispensing data 
19 (7.1) 7 (4.8) 12 (10.2) 0.09 
  Inpatient dispensing data 21 (7.8) 18 (12.2) 2 (1.7) <0.01 
  Paper medical chart 85 (31.7) 54 (36.7) 29 (24.6) 0.03 
  Claims data 55 (20.5) 25 (17.0) 30 (25.4) 0.09 
  Registry 35 (13.1) 16 (10.9) 19 (16.1) 0.21 
  Self-report questionnaire 12 (4.5) 7 (4.8) 5 (4.2) 0.82 
  Telephone call 13 (4.9) 5 (3.4) 8 (6.8) 0.20 
  Face to face interview 17 (6.3) 6 (4.1) 10 (8.5) 0.14 
  Othersf 40 (14.9) 15 (10.2) 25 (21.2) 0.01 
  Unclearg 13 (4.9) 7 (4.8) 6 (5.1) 0.91 
     
Source of (collection method for) 
outcome datah 
    
  Primary care data 29 (10.8) 14 (9.5) 15 (12.7) 0.41 
  Paper medical charts 122 (45.5) 66 (44.9) 53 (44.9) 1.00 
  Institution, administrative or 
electronic  heath records 
60 (22.4) 23 (15.6) 37 (31.4) <0.01 
  Claims data 71 (26.5) 32 (21.8) 38 (32.2) 0.06 
  Registry  38 (14.2) 21 (14.3) 17 (14.4) 0.98 
  Self-report questionnaire 25 (9.3) 13 (8.8) 12 (10.2) 0.70 
  Telephone call 13 (4.9) 8 (5.4) 5 (4.2) 0.65 
   Face to face interview 12 (4.5) 6 (4.1) 6 (5.1) 0.70 
   Othersi 32 (11.9) 18 (12.2) 14 (11.9) 0.94 
   Unclearj 4 (1.5%) 3 (2.0) 1 (0.8) 0.42 
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Size of the study population per 
design 
       
  Fixed cohort        
    Exposed, number of 
participants  
2050 (103-
34544) 
283 (51-12432) 44001 (4009-278624) <0.01 
    Unexposed, number of 
participants  
1073 (74-
27417) 
372 (58-8533) 24175 (1215-227288) 0.67 
      Missing data 18 (32.2) 6 (6.2) 12 (30.8)  
  Dynamic cohort [person-
years(PY)] 
    
    Exposed PY  92835 (11931-
731043) 
62383 (3600-
416018) 
123287 (14708-
1220006) 
0.56 
    Unexposed PY  362142 (9235-
1315038) 
162622 (5485-
1728969) 
535375 (17496-
1298601) 
0.90 
  Case-control     
    Cases  189 (68-467) 79 (30-532) 252 (133-452) 0.03 
    Number of controls per case  2.2 (1.1-4.2) 2.1 (1.0-4.4) 2.8 (2.0-4.1) 0.24 
  SCCS and Case Crossover, 
number of participants  
402 (168-1380) NA 369 (173-1334) NA 
   Missing data 5 (14.7) 0 5 (16.1)  
 
Control of confounding k 
    
  Matching 98 (36.6) 43 (29.3) 53 (44.9) <0.01 
  Stratification 103 (38.4) 36 (24.5) 66 (55.9) <0.01 
  Multivariate modelling 
adjustment 
138 (51.5) 75 (51.0) 60 (50.8) 0.97 
Note: Missing data is presented for only instances where it constitutes greater than 5% 
NA = Not applicable 
Studies assessing drugs (147) or vaccines (118) exclusively, do not add up to the total number of studies (268) because 
3 studies that investigated both drugs and vaccines are not presented in the table. 
a The proportions do not add up to 100% because some studies applied multiple designs; 
b Includes study designs that are not listed i.e. case-time-control 
cThe proportions do not add up to 100% because some studies applied multiple data collection modes; 
d Implies that there was inadequate information to determine if data collection was done prospectively or 
retrospectively; 
e The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) 
exposure data; 
f Includes data sources (or collection methods) that are not specified e.g. maternal and child health handbook; 
g Implies that there was inadequate information to determine the source of (or collection mode for) the exposure data; 
h The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) 
outcome data; 
iIncludes data sources (or collection methods) that are not specified e.g. maternal and child health handbook; 
j Implies that there was inadequate information to determine the source of (or collection mode for) the outcome data; 
k The proportions do not add up to 100% because some studies applied methods to control confounding; 
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Out of 147 studies that evaluated drugs exclusively, 87 (59.2%) assessed only exposures to 
specific compounds (i.e. amoxicillin), 51 (34.7%) evaluated exposures to a specific drug class 
(i.e. ‘antibacterials for systemic use’), only 9 (6.1%) assessed both specific compound and drug 
class. Regarding the 96 studies that assessed specific compounds, 54 (56.3%) investigated only 
one compound, 20 (20.8%) assessed two compounds and 22 (22.9%) assessed three or more. 
Given the 60 studies that assessed drug class, 45 (75.0%) investigated only one class, 7 
(11.7%) assessed two classes and 8 (13.3%) investigated three or more. Fourteen studies 
(23.3%) evaluated ‘antibacterials for systemic use’, 10 (16.7%) assessed psychoanaleptics and 
7 (11.7%) assessed psycholeptics. Considering 14 drug safety studies that included preterm 
newborns, ‘antibacterials for systemic use’ were evaluated in 3 (21.4%) and ‘corticosteroids for 
systemic use’ in 2 (14.3%). For details of studied drug by age, see electronic supplementary 
material. 
Across the 150 studies that assessed drugs whether exclusively or with vaccines, a total of 291 
unique exposures representing 39 unique classes (WHO-ATC second level) were investigated. 
Psychoanaleptics (53 [18.2%]) were the commonest, followed by ‘antibacterials for systemic 
use’ (40 [13.7%]) and psycholeptics (38 [13.1%]). For further details, see table 3. 
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Table 3: Twenty most frequently investigated drug classes across the 150 studies that 
investigated drugs (whether exclusively or with vaccines) 
Drug class (WHO-ATC second level)a Code N (%)b 
Psychoanaleptics N06 53 (18.2) 
Antibacterials for systemic use J01 40 (13.7) 
Psycholeptics N05 38 (13.1) 
Antineoplastic agents L01 30 (10.3) 
Anti-inflammatory and Anti-rheumatic 
products 
M01 18 (6.2) 
Anti-epileptics N03 12 (4.1) 
Corticosteroids for systemic use H02 11 (3.8) 
Analgesics N02 10 (3.4) 
Contrast media V08 8 (2.7) 
Immunosuppresants L04 7 (2.4) 
Anesthetics N01 6 (2.1) 
Antihistamines for systemic use R06 6 (2.1) 
Antihemorrhagics B02 5 (1.7) 
Pituitary and hypothalamic hormones 
and analogues 
H01 5 (1.7) 
Antivirals for systemic use J05 5 (1.7) 
Drugs for obstructive airway diseases R03 4 (1.4) 
Cardiac therapy C01 3 (1.0) 
Cough and cold preparations R05 3 (1.0) 
Drugs for functional gastrointestinal 
disorders 
A03 2 (0.7) 
Agents acting on the renin-angiotensin 
system 
C09 2 (0.7) 
a World Health Organization-Anatomic Therapeutic Chemical classification; 
b Proportion is based on the total number (291) of unique drug exposures that were investigated  
 
 
Considering drug evaluations exclusively, only 3 studies (2.0%) assessed the effect of rarely 
used drugs (i.e. ciprofloxacin) and only 30 (20.0%) assessed dose-effects.  
Altogether, 588 outcomes were evaluated with a median of 1 (1-2) outcome per study, 36 
studies (13.4%) did not state the outcome definition. Most events (68 [39.5%]) were acute, 
and defined as symptoms, signs or ill-defined conditions (i.e. diarrhea) (Figure 3). Rare 
outcomes (i.e. Stevens-Johnson syndrome) were evaluated in only 17 studies (6.3%). Expert 
validation of the outcomes was frequent (172 [64.2%]) but only in 46 of those (26.7%) the 
experts were blinded to exposure.  
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Figure 3: Distribution of papers according to the main divisions of the  International Classification of diseases (ninth edition), and type of exposure 
Note: ‘Certain conditions originating in the perinatal period’ includes ‘Other conditions originating in the perinatal period’(764-779) which does not include  maternal causes i.e. Necrotizing 
enterocolitis (777.5); ‘Injury and poisoning’ includes ‘unspecified adverse effect of drug medicinal and biological substance not elsewhere classified’ (995.2)  
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Out of 174 cohort studies, the follow-up time was inadequate to observe the investigated 
outcomes in 76 (43.7%). 
Only 27 studies (10.1%) reported sample size or power calculations. Cohort studies were the 
largest unlike SCCS and case crossover studies which included few participants. Most studies 
(229 [85.4%]) adjusted for confounding either by stratification (mainly vaccine safety studies), 
matching or by multivariate modelling (mainly drug safety studies).  
Only 133 studies (49.6%) specified a primary objective and 129 studies (48.1%) reported at 
least one statistically significant result. This proportion increased to 59.0% when only 183 child-
specific studies were considered. Most studies with significant statistical results (97 [75.2%]) 
were published after 2002. Among the 75 child-specific studies that did not present any 
statistically significant result, 41 (54.7%) did not discuss lack of power. 
Discussion 
We have conducted a systematic review to assess the characteristics of pediatric 
pharmacoepidemiological safety studies that were published over 34 years, while aiming to 
identify areas for improvement of these much needed studies. The review also highlights 
differences in drug versus vaccine pediatric studies. Some previous reviews have summarized 
evidence regarding specific drug or vaccine safety issues that affect children 169-172 while others 
have focused on specific methodological aspects of pediatric pharmacoepidemiology 173,174 but 
to the best of our knowledge no review has attempted to provide a general overview of these 
studies.  
Our main findings are: the absolute number of pediatric pharmacoepidemiological safety studies 
is low; in 2012 only 33 studies concerned pediatrics compared to a total of 3197 published 
studies (data not presented but utilized in constructing figure 2). Such studies are almost 
exclusively conducted in developed countries and receive very little private funding. Evaluated 
exposures concern few pharmaceuticals while investigating mainly intermediate clinical 
outcomes (signs/symptoms). As areas of improvement we recommend better global spread, 
interaction between pharmacoepidemiologists evaluating drugs and vaccines to apply designs 
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more broadly, more focus and funding of such studies, and collaboration between investigators 
so that larger size studies can be conducted that may have enough power to study the rarer 
and potentially more serious safety issues.   
Although paper medical charts may be regarded as the gold standard source of patient 
information electronic health records and claims data comprise vast amounts of routine care 
information that can be readily utilized for pharmacoepidemiological safety studies, as 
demonstrated by several authors175-178. More extensive use of such data may be needed to 
overcome the problem of inadequate follow-up for many cohort studies as demonstrated in this 
review, especially if this is related to the high costs that is associated with long follow up time in 
some prospective studies utilizing primary data collection. Generally, the potential of secondary 
data has been recognized by FDA in Sentinel 179, by Health Canada in their CNODES project 180, 
and in Europe by the GRIP consortium and other projects 181. We should now focus the 
potential of these powerful resources on pediatric studies specifically in order to quickly fill the 
existing gap in knowledge of drug use. 
The number of pediatric safety studies started increasing steadily after 2002, following the 
introduction of the ‘Best Pharmaceuticals for children’s Act’ (BPCA) 26. Under the BPCA, the US 
National Institutes of Health sponsored several pharmacoepidemiological studies in children 182. 
The pediatric regulation was introduced in the European Union in 2007, perhaps explaining the 
even steeper increase in the number of pediatric studies that is observed after 2007 (figure 2). 
The predominance of US and EU studies may be explained partially by these legislations but 
also by the number of epidemiologists and data resources. Whatever the explanation may be, 
this review points to a large public health need for more human capacity building and studies in 
many children that live in other parts of the world, particularly lower and middle income 
countries. From a publication and academic perspective it should be noted that the studies were 
published mostly in more general journals and the impact factors were well above the median 
in the pharmacology field.  
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Where should funding for such studies come from? Generally, studies relying on secondary data 
are affordable. In this review we observed that few studies were privately funded. We 
recommend that the politicians who passed the BPCA and other legislations to stimulate 
generation of efficacy data in children see the potential of pharmacoepidemiology rather than 
clinical trials to generate safety data and oblige long-term postmarketing studies in children for 
newly marketed drugs specifically. Studies on off-patent drugs that are frequently used in 
children should be investigated through public funding in both developing and developed 
countries.   
Almost half of the evaluated drugs belong to only 3 classes (table 3): anti-infectives, 
psychoanaleptics and psycholeptics. Although anti-infectives are often prescribed in pediatrics 
across all age groups, psychoanaleptics and psycholeptics represent a minority of drug 
exposure in children 85. However, these drugs have been surrounded by specific safety issues 
183,184. Specifically, psychoanaleptics (i.e. atomoxetine and methylphenidate) were commonly 
mentioned in pediatric case reports submitted to FAERS between 2004 and 2011185, probably 
reflecting its increased use and high risk of toxicity, notably cardiovascular toxicity, as 
demonstrated by several authors in our review 183,184,186-188.  
Very few studies evaluated rare drug exposures possibly because such studies would not have 
been adequately powered to detect an association. Specifically, in preterm newborns, the 
investigated drugs (i.e. sildenafil and morphine) are possibly associated with serious safety 
issues 189-191 however these studies could not confirm safety associations possibly because of 
their limited sample size. Inadequate sample size may account for the lack of at least one 
statistically significant result in 41% of the child-specific studies, even if majority of these 
studies did not discuss lack of power. Size issues may be addressed by implementing case-only 
(i.e. SCCS) designs 192. In our review, few studies applied case-only analysis essentially to 
evaluate vaccine safety. However, case-only designs present strengths that are suited for the 
drug utilization patterns and characteristics of outcomes in children 193,194. Further, multi-site 
data pooling may be necessary to acquire adequate power to study rare events in children77,195. 
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International collaboration on a global scale may be required; this is the main aim of the Global 
Research in Pediatrics (GRIP) project.  
The strength of this review is the systematic assessment of pharmacoepidemiological safety 
studies in children, with broad inclusion criteria. Regarding limitations, we applied minimum 
follow-up periods (to cohort studies) according to the type of investigated outcome; this may 
not have been accurate for some specific outcomes. Yet, standardization was necessary 
because the outcomes were numerous and highly heterogeneous. Also, the findings we have 
presented are based on published data reported by authors of the studies therefore if such 
reporting was incomplete and/or inaccurate; this may have impacted our findings. For example, 
several irrelevant drug exposures were assessed in neonates (electronic supplementary 
material), like anti-obesity preparations or antineoplastic drugs merely because authors stated 
that included pediatric population started at 0 years of age. Such imprecisions inevitably lead to 
erroneous conclusions. Also, we used country of corresponding author as a proxy for the study 
setting; by doing this, study setting for multi-country database studies may not have been 
accurately captured. Further, we used the journal impact factor as a proxy for the quality of the 
studies that we reviewed; the limitations of this measure have been described in the literature.  
Based on the reviewed literature, we conclude that there is a need to build global collaborative 
capacity and funding opportunities for pediatric pharmacoepidemiology since this is one of the 
most powerful ways to provide evidence of drug safety in children.  
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Appendix 1: Full search strategy 
Search criteria for Embase.com 
1. 'pediatrics'/exp OR 'child'/exp OR 'childhood'/exp OR 'newborn'/exp OR 
('adolescent'/exp OR 'adolescence'/exp NOT ('adult'/exp OR adult*:ab,ti)) 
 
2. child*:ab,ti OR pediatric*:ab,ti OR paediatric*:ab,ti OR infant*:ab,ti OR infancy:ab,ti OR 
baby:ab,ti OR babies:ab,ti OR toddler*:ab,ti OR neonate*:ab,ti OR newborn*:ab,ti OR 
premature*:ab,ti OR adolescen*:ab,ti OR teenage*:ab,ti OR preschool:ab,ti OR 
school*:ab,ti OR neonat*:ab,ti 
 
3. 1 or 2 
 
4. 'risk'/de OR 'attributable risk'/de OR 'risk factor'/de OR 'risk benefit analysis'/de OR 'risk 
assessment'/de OR 'risk management'/de OR 'risk reduction'/de OR 'incidence'/de OR 
'hazard ratio'/exp OR 'logistic regression analysis'/exp  
 
5. odds:ab,ti OR 'logistic regression':ab,ti OR 'relative risk':ab,ti OR incidence:ab,ti OR 
prevalence:ab,ti OR (hazard* NEAR/3 ratio*):ab,ti OR 'safety assessment':ab,ti OR (risk 
NEAR/3 (ratio OR attribut* OR differen* OR assess* OR adjust* OR analy* OR relativ* 
OR factor* OR manag* OR reduc*)):ab,ti 
 
6. 4 or 5 
 
7. 'drug toxicity and intoxication'/exp OR 'adverse drug reaction'/exp OR 'drug'/exp/dd_ae 
OR ('side effect'/exp OR 'adverse outcome'/exp AND ('drug'/exp OR 'drug therapy'/exp 
OR 'vaccine'/exp OR 'adjuvant'/exp OR 'immunization'/exp)) OR 'drug safety'/de  
 
8. ((pharmacol* OR pharmaceut* OR medication* OR medicine* OR drug* OR 
pharmacotherap* OR medicament* OR 'medicinal product' OR vaccin* OR immunizat* 
OR immunisat* OR adjuvant* OR treatment* OR therap*) NEAR/6 (safet* OR toler* OR 
intoler* OR toxic* OR intoxic* OR react* OR aftereffect* OR fatal* OR 'side effect' OR 
'side effects' OR adverse)):ab,ti OR pharmacotox*:ab,ti OR (adverse NEAR/3 (event* 
OR reaction* OR effect* OR outcome)):ab,ti  
 
9. 7 or 8 
 
10. 'epidemiology'/de OR 'pharmacoepidemiology'/de OR 'cohort analysis'/de OR 
'observational study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 
'longitudinal study'/de  
 
11. epidemiol*:ab,ti OR pharmacoepidemiol*:ab,ti OR cohort*:ab,ti OR (follow NEXT/1 
up*):ab,ti OR observation*:ab,ti OR retrospectiv*:ab,ti OR prospectiv*:ab,ti  
 
12. 10 or 11 
 
13. 'comparative study'/de OR 'comparative toxicology'/de OR 'drug comparison'/exp OR 
'controlled study'/de OR 'case control study'/exp  
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14. control*:ab,ti OR compar*:ab,ti OR referen*:ab,ti OR match*:ab,ti OR nested:ab,ti OR 
('self controlled' NEXT/1 serie*):ab,ti OR 'case cross over':ab,ti OR 'case centered':ab,ti 
OR 'case coverage':ab,ti OR 'case cohort':ab,ti 
 
15. 13 or 14 
 
16. 12 and 15 
 
17. 3 and 6 and 9 and 16 
 
18. [article]/lim NOT ('pregnancy'/exp OR pregnan*:ab,ti OR fetus:ab,ti OR fetal:ab,ti OR 
foetus:ab,ti OR foetal:ab,ti) NOT ('clinical trial'/exp OR 'systematic review'/exp OR 
'randomized controlled trial'/de OR 'randomization'/de) NOT ([animals]/lim NOT 
[humans]/lim) 
 
19. 17 and 18 
 
Search criteria for Medline (via OvidSP) 
1. exp pediatrics/ or exp child/ or exp infant/ or (adolescent/ not (exp adult/ or 
adult*.ab,ti.)) 
 
2. (child* or pediatric* or paediatric* or infant* or infancy or baby or babies or toddler* or 
neonate* or newborn* or premature* or adolescen* or teenage* or preschool or 
school* or neonat*).ab,ti. 
3. 1 or 2 
 
4. exp risk/ or "Odds Ratio"/ or incidence/ 
 
5. (Odds or "logistic regression" or "relative risk" or incidence or prevalence or (hazard* 
adj3 ratio*) or "safety assessment" or (risk adj3 (ratio or attribut* or differen* or 
assess* or adjust* or analy* or relativ* or factor* or manag* or reduc*))).ab,ti. 
 
6. 4 or 5 
 
7. exp "drug toxicity"/ or exp Pharmaceutical Preparations/ae or exp drug therapy/ae or 
exp vaccines/ae or exp immunization/ae 
 
8. (((pharmacol* or pharmaceut* or medication* or medicine* or drug* or 
pharmacotherap* or medicament* or "medicinal product" or vaccin* or immunizat* or 
immunisat* or adjuvant* or treatment* or therap*) adj6 (safet* or toler* or intoler* or 
toxic* or intoxic* or react* or aftereffect* or fatal* or "side effect" or "side effects" or 
adverse)) or pharmacotox* or (adverse adj3 (event* or reaction* or effect* or 
outcome))).ab,ti. 
 
9. 7 or 8 
 
10. "epidemiology"/ or epidemiology.xs. or pharmacoepidemiology/ or exp "Epidemiologic 
Studies"/ or observation/ 
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11. (epidemiol* or pharmacoepidemiol* or Cohort* or ( FOLLOW adj up*) or observation* 
or retrospectiv* or prospectiv*).ab,ti. 
 
12. 10 or 11 
 
13. "comparative study".pt. or "drug comparison"/ or "controlled study"/ or "case control 
study"/ 
 
14. (control* or compar* or referen* or match* or nested or ("self controlled" adj serie*) 
or "case cross over" or "case centered" or "case coverage" or "case cohort").ab,ti. 
 
15. 13 or 14 
 
16. 12 and 15 
 
17. 3 and 6 and 9 and 16 
 
18. Limit 17 to Journal Article 
 
19. Limit 18 to humans 
 
20. 19 not (pregnancy/ or (pregnan* or fetus or fetal or foetus or foetal).ab,ti.) 
 
21. 20 not (clinical trial/ or systematic review/ or randomized controlled trial/ or 
randomization/) 
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Appendix 2: Data collection form  
1. General data 
a. Unique ID |__|__|__| 
b. First author (surname) …………………………………………………………. 
c. Year of publication |__|__|__|___| 
d. Country (corresponding author) ……………………………………………………... 
e. Journal (abbreviation)………………………………………………………………………………………. 
f. Funding sources: |__| Public |__| Private |__| Public and private |__| No funding 
|__|unclear 
2. Study design  
a. Was study design clearly reported? |__| Yes    |__| No  
Some studies do not report on study design. If the answer to this question is ‘no’, 
provide answer to only question ‘b’.  
b. Number of designs studying the same association and using the same data……….  
c. Cohort |__| Yes    |__| No  
d. Case-control |__| Yes  |__| No  (including nested case-control studies) 
e. Case-based  
i. self-controlled case series (SCCS) |__| Yes  |__| No 
ii. case cross-over |__| Yes  |__| No 
iii. others |__| Yes  |__| No  
f. Data collection mode  
i. prospective |__| Yes |__| No 
ii. retrospective |__| Yes |__| No 
iii. unclear |__| Yes |__| No 
3. Study period 
a. Date of Start of study period | _|__|__|___|DDMMYYYY 
b. Date of End of study period |__|__|__|___| DDMMYYYY 
4. Type of data 
a. Only primary |__| (data collected specifically for the study) 
b. Only secondary  |__| (data collected for other purposes) 
c. Mixed (combining primary and secondary)|__|  
5. Study population (age range as in inclusion criteria)  
a. Preterm newborns |__| Yes |__| No 
b. Minimum age |__| and unit of age: days |__| months |__| years |__| 
c. Maximum age|__| and unit of age: days |__| months |__| years |__| 
d. unclear |__|  
If ‘c’ then what is the minimum and maximum age given in the results (regardless 
of the study group)? 
a. Minimum age |__| and unit of age: days |__| months |__| years |__| 
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b. Maximum age|__| and unit of age: days |__| months |__| years |__| 
6. Exposure  
a. |__| Drug |__| Vaccine |__| Drug and Vaccine  
b. Was drug class studied|__| Yes |__| No  
c. Number of drug classes studied ………………….. 
d. Drug classes studied ………………….. 
e. Was specific drug/vaccine studied|__| Yes |__| No 
f. Number of drugs/vaccines studied………………….. 
g. Substance/vaccine name (WHO) ………………….. 
h. ATC code reported |__| Yes |__| No …………if yes reported ATC 
code:…………………. 
i. Characteristics of exposure in the paediatric indication (s): 
i. Rare |__| Yes |__| No |__| Unclear 
ii. Intermittent |__| Yes |__| No |__| Unclear 
iii. Chronic |__| Yes |__| No |__| Unclear 
iv. Exposure is changing medication (e.g. new dose, new formulation…) 
|__| Yes |__| No |__| Unclear 
j. Is the effect of dose studied? |__| Yes |__| No 
k. Data sources (or collection methods) of exposure data 
i. In patient dispensing data |__| Yes |__| No (electronic prescription 
data) 
ii. Medical charts at the clinic |__| Yes |__| No (paper prescription charts) 
iii. Primary healthcare data |__| Yes |__| No 
iv. Outpatient dispensing data (pharmacy) |__| Yes |__| No 
v. Claims data |__| Yes |__| No 
vi. Registry |__| Yes |__| No (including vaccination registry) 
vii. Self-report questionnaire or query |__| Yes |__| No 
viii. Telephone call |__| Yes |__| No 
ix. Web site |__| Yes |__| No 
x. Interview |__| Yes |__| No 
xi. Others |__| Yes |__| No 
7. Outcome 
a. Number of events studied…………….. 
b. Event term(s)………………….. 
c. Was the event(s) definition(s) clearly described or sourced by a stated reference? 
|__| Yes |__| No 
d. Was the event(s) validated by experts? |__| Yes |__| No 
e. Was the event(s) validation (s) done blinded to exposure? |__| Yes |__| No 
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f. Characteristics of the event (s): (more than 1 option is possible) 
a. Acute |__| Yes |__| No |__| Unclear 
b. Rare |__| Yes |__| No |__| Unclear 
c. Irreversible (e.g. mortality, handicap …) |__| Yes |__| No |__| Unclear 
d. Recurrent |__| Yes |__| No |__| Unclear 
g. Data sources (or collection methods) for data about the events 
i. Institution or administrative /electronic Hospital records |__| Yes |__| No 
ii. Paper medical charts/visits at the clinic |__| Yes |__| No 
iii. Primary healthcare data |__| Yes |__| No 
iv. Claims/reimbursement data |__| Yes |__| No 
v. Registry |__| Yes |__| No 
vi. Self-report questionnaire or query |__| Yes |__| No 
vii. Telephone call |__| Yes |__| No 
viii. Web site |__| Yes |__| No 
ix. Interview |__| Yes |__| No 
x. Others |__| Yes |__| No 
 
8. Statistical analysis and results 
a. Calculation of a sample size is reported |__| Yes |__| No 
If yes, required sample size calculated …….. 
 
b. Total size of the study population  
i. Number of cases………. / Number of controls……….  
ii. Size of exposed cohort ………. / Size of unexposed cohort ………. (absolute 
number for fixed cohorts and person-years (PY) for dynamic cohorts) 
iii. Number of cases……….  
c. Length of follow-up was summarized using: |__| mean |__|median |__|unclear (If 
the answer is ‘unclear’, ignore questions ‘i’ and ‘ii’ that follow). 
i. Exposed cohort ………. / unexposed cohort ………. (Cohort) 
ii. Cases………. (SCCS) 
d. Adjustment for confounding variables has been made |__| Yes |__| No 
if yes what has been performed? 
Restriction |__| 
Matching |__| 
Stratification|__| 
Multivariate modelling analysis |__| 
Adjusted by study design (case-only) |__| 
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e. Primary statistical analysis (these questions should be completed for primary 
analysis, if primary objective is not described or unclear then just complete the first 
question and not the remaining. 
 Was the primary objective clearly defined? |__| Yes |__| No |__| unclear 
 Were results on primary analysis presented for the paediatric population? 
Not presented|__|adjusted|__| unadjusted|__| unclear|__| 
f. There is at least one statistically significant result for the paediatric population |__| 
Yes |__| No 
If no, the authors discussed the problem of having a lack of power |__| Yes |__| No 
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Chapter 4.2 Quality of published pediatric pharmacoepidemiological safety 
studies: Implications for evidence-based drug prescribing in pediatrics 
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Abstract 
Background: Pharmacoepidemiological studies can yield important safety evidence for better 
drug use in children but such studies are prone to important challenges that may limit the 
credibility of evidence. Identifying important pediatric-specific study characteristics may improve 
the methodological evaluation of published studies. 
Objective: To assess the quality of published pharmacoepidemiological safety studies in 
children, and its association with characteristics related to the design and conduct of the 
studies. 
Methods: Relevant articles from inception to 2013 were retrieved from Embase.com and 
Medline. We sequentially screened titles, abstracts and full texts, with independent validation. 
We systematically evaluated the quality of retained studies with a modified Newcastle-Ottawa-
scale (maximum score=9.0) and derived a summary quality score (median [25th; 75th 
percentiles]) for each study. By applying Kruskal Wallis H (KWH) and Mann Whitney U (MWU) 
tests, we assessed the association between quality and several characteristics including year of 
publication, geographical setting, funding, design, type of data and exposure. 
Results: Out of 4,825 unique articles, 259 full texts were evaluated; 54.4% pertained to drugs, 
the remainder to vaccines. Generally, quality was high (median score=7.0; p25=6.0; p75=8.0). 
The characteristics that were significantly associated with quality include: year of publication 
(KWH p-value=0.01), geographical setting (KWH p-value=0.04), funding (KWH p-value<0.01), 
type of data (KWH p-value<0.01), design (KWH p-value<0.01) and exposure (MWU p-
value<0.01). Studies with the highest quality were self-controlled case series (median 
score=7.0; p25=7.0; p75=8.0) that assessed vaccines.   
Conclusion: Published pediatric pharmacoepidemiological safety studies show good quality, 
which has improved over time and is associated with geographical setting, design, and conduct 
of the studies. SCCS studies of vaccines scored the best. By applying our findings, study 
evaluators may find it easier to assess published studies thereby enhancing their impact on 
pediatric drug prescribing. 
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Introduction 
Evidence-based medicine (EBM) may be defined as the integration of best research evidence 
with clinical expertise and patient values196. Although widely applauded, evidence-based drug 
prescribing is limited by the time and ability to interpret evidence appropriately.  
Pharmacoepidemiological studies have become crucial for benefit-risk assessment of drugs but 
well-known methodological challenges still limit the validity of results and credibility of 
evidence197. Pediatric studies are prone to additional challenges. For example, inadequate 
sample size77,195 often limits age-specific safety studies, which is recommended in children 
because of organ maturation, hormonal imbalances and varying susceptibility to adverse drug 
reactions (ADRs)198. Although detailed information about a child’s age (especially for newborns 
and infants) and administered drug(s) is often needed when conducting 
pharmacoepidemiological safety studies in children, such data is often missing from many 
routinely utilized databases199,  but can be obtained if data is collected for research purposes 
specifically. Vaccines are frequently administered to children200,201, most vaccine exposures are 
transient and evaluating such exposures requires the application of specific (appropriate) study 
designs 202. The impact of various challenges on the methodological quality of 
pharmacoepidemiological safety studies in children specifically is not completely understood.  
Following the introduction of drug legislations26,43,203, more pediatric pharmacoepidemiological 
studies have been conducted204. However, the quality of these studies is not certain, has not 
been systematically evaluated yet is important for results’ uptake and implementation in clinical 
practice. The US Institute of Medicine emphasizes the importance of evaluating the quality of 
evidence generated from postmarketing drug safety studies 205. Although the quality of 
pharmacoepidemiological safety studies in the general population has been evaluated 206-210, 
little effort has been focused on children specifically.  
As part of the Global Research in Paediatrics (GRiP) (http://www.grip-network.org/), we 
systematically evaluated the quality of pharmacoepidemiological safety studies that included 
children. We tested the association between various characteristics pertaining to the design and 
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conduct of the studies, and the quality. The aim was to identify features that may indicate 
which studies are of high quality thereby improving the critical appraisal of published studies.  
 
Methods 
Literature retrieval 
Briefly, we systematically searched EMBASE.COM and MEDLINE (via OvidSP) from inception to 
29th November 2013 for observational comparative drug or vaccine safety studies that included 
children (0-18 years). We described the characteristics of 268 retained studies published from 
1979 to 2013, see appendix 1 for the full search strategy. The results have been published204. 
In the current report, we systematically evaluated the quality of 259 cohort, case control, self-
controlled case series (SCCS) and/or case cross over studies, we excluded 9 studies that applied 
other study designs. The study design(s) was (were) classified according to the reports of the 
authors, otherwise it (they) were assigned based on the judgement of the reviewers. Out of 
259 studies, 20 studies applied 2 designs (each) and 1 study applied 3 designs. 
See appendix 2 for the article selection process.  
Quality assessment tool 
Currently, there is no ’gold standard’ to assess the methodological quality of observational 
studies although several guidelines exist211-215. Some existing tools were not designed for 
pharmacoepidemiological safety studies specifically 216-219 or are meant for meta-analysis of a 
specific drug-event association 220,221. We aimed at evaluating all studies irrespective of drug or 
event; therefore no existing tool could be readily utilized.  
The Newcastle-Ottawa scale (NOS) was developed for assessing the quality of non-randomized 
studies that are included in systematic reviews 222,223. It is endorsed by the Cochrane 
collaboration and has been widely applied since 2004 224. Results from many validation studies 
have been published 225-227. It includes the cohort and case control versions. Each version 
comprises a set of questions, a manual, and an explanatory slide presentation, all freely 
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accessible via the website of the Ottawa Hospital Research Institute 223. Both versions consist of 
eight multiple-choice questions that address three domains: subject selection, groups’ 
comparability and the assessment of the exposure (case control) or the outcome (cohort). Each 
question has two to five possible answers. High-quality answers earn one ‘star’ and the 
maximum quality score for a study is ‘nine stars’ (the comparability question earns up to two 
‘stars’). All star-earning answers are categorised as ‘low risk of bias’ and all other responses as 
‘high risk of bias’.  
Study quality assessment 
As presented in appendix 3, both (case-control and cohort) versions of the NOS were tailored to 
assess the quality of studies that we reviewed. Regarding cohort studies, a star was assigned 
for the item ‘representativeness of the exposed cohort’ if the exposed cohort was identified 
from electronic medical records or claims data whether exclusion criteria were applied or not; 
‘was follow-up long enough for outcomes to occur’ assesses the appropriateness of the 
predefined risk windows, for the current study we defined the following risk periods i.e. fever - 
1 day, other acute events - 2 weeks, cancer and other chronic (including neurological and 
psychiatric) events - 5 years; ‘adequacy of follow-up of cohorts’ evaluates whether groups are 
comparable with respect to attrition or missing data, for this item studies were also assigned a 
star if the investigated population was dynamic.  
For the case control version, studies were assigned a star if the exposure was ascertained from 
prescription or dispensing database.  
For both versions, ‘Select the most important factor’ and ‘study controls for any additional 
factor’ require the researcher to select the appropriate factors for that systematic review. We 
selected age as the most important factor because it is a known confounder of many 
pharmacoepidemiological safety studies especially in children 228. We selected sex 229, medical 
indication 230 and calendar time 231 (only for case control studies) as additional factors to be 
assessed.  
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Since the self-controlled case series (SCCS) and case-crossover designs are modifications of the 
cohort 192 and case control designs 232 respectively, we applied the cohort version of the NOS to 
SCCS studies and the case-control version to case-crossover studies.  
The NOS was independently applied by two researchers (OO and JD). Disagreements were 
resolved by consensus. 
Results obtained by applying the NOS have been presented (in other systematic reviews) with 
varying levels of detail: from the answer to each question for each study (maximum detail) to a 
summary score equal to the number of stars earned by each study (minimum detail). We 
derived a score summarizing the number of stars earned by each study that we evaluated.  
We checked for association between the quality of studies and the year of publication, 
categorised into four periods (1979-1997, 2000-2002, 2005-2007, and 2010-2013) according to 
the introduction of the US FDA Modernization Act (1997), US Best Pharmaceuticals for children’s 
Act (2002) and EU Pediatric Regulation (2007) respectively. We assessed the influence of other 
characteristics that may impact study quality, 197,233,234, including geographical setting, type of 
journal i.e. pediatric specialty, pharmacology/pharmacoepidemiology, general medical or others, 
two-year journal impact factor (measured in 2013), funding status, mode of data collection 
(prospective, retrospective or both), type of data (primary, secondary or mixed), design, age of 
the studied population i.e. only children or ‘children and adults’, and type of exposure i.e. drug 
or vaccine.  
For studies applying multiple designs (one of which was the primary design), all the designs 
were considered in testing the association between design and quality. However for the 
association between quality and the other characteristics that we investigated, only the primary 
design was considered. Otherwise data regarding those characteristics may be unintentionally 
duplicated, leading to invalid results235. 
We stratified quality scores by design and type of exposure, and investigated the risk of bias 
that may result from each NOS domain. 
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Data analysis  
We described the quality scores using the range and median (with corresponding 25th percentile 
[p25] and 75th percentile [p75]) and counts (%).  
In order to test the association between study quality and two-year journal impact factor 
measured in 2013 (continuous variable), we applied Spearman’s rank correlation coefficient; for 
the association with other study characteristics (categorical variables), we applied Mann-
Whitney U test (variables with 2 categories) or Kruskal-Wallis H test (variables with  ≥ 3 
categories; with the Dunn’s test for pairwise comparisons). 
Data was analyzed using SPSS version 21. Statistical significance was set at alpha level 0.05. 
Results 
Inter-rater concordance was 90.0%. 
Considering 259 studies (only the primary design for studies applying multiple designs), the 
quality scores ranged from 1.0 to 9.0 (the range of possible scores goes from 0 through 9.0) 
with a median of 7.0 (p25=6.0; p75=8.0). 
Out of 259 studies, only 6 (2.3%) attained the highest possible quality (score=9.0), 5 (83.3%) 
of which investigated vaccines exclusively. Considering the 5 studies, 2 (40.0%) were self-
controlled case series (SCCS), were publicly funded, utilized retrospectively collected secondary 
data and originated from North America. One each was published in 2008 and 2011, both in 
pediatric specialty journals with 2013 two-year impact factor 5.3 and 4.2 respectively. In 
contrast, the 2 (0.8%) lowest-quality studies (score=1.0) assessed drugs exclusively.  The 
source of funding for both studies was unclear; one each was a cohort or case control study 
with 2013 two-year journal impact factor 0 and 0.9 respectively. However, the later study (like 
the highest scoring studies) utilized retrospectively collected secondary data and was published 
recently (2009) in North America, in a pediatric specialty journal.  
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As seen in figure 1, the quality of studies apparently improved over time; of note, studies 
published from 2010 (median score=6.8; p25=7.0; p75=8.0) seemed better than those 
published from 1979 to 1997, confirmed by a statistically significant test (Dunn’s p-value<0.01). 
Compared to previous years, summary quality scores for studies published between 2010 and 
2013 appeared to fall within a narrower range. 
 
Note: NOS=Newcastle-Ottawa scale; FDAMA=US FDA Modernization Act; BPCA=Best Pharmaceuticals for 
children’s act; EU=European Union 
 
Figure 1: Evolution of summary quality scores  
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North American and European studies (median score=7.0; p25=6.0; p75=8.0) were better than 
those from other continents although the difference in quality was statistically significant for 
only the former (Dunn’s p-value=0.03). Studies that received only public or private funding 
showed similar quality but each type of study was better than those benefitting from both 
funding sources simultaneously. See table 1 for further details. 
Table 1: Relationship between general characteristics and quality of 259 pediatric 
pharmacoepidemiological safety studies  
  
Characteristic 
 
Number of 
studies 
(%) 
Summary NOSa score  
p-
value
b 
25th percentile Median 75th percentile 
Calendar year of publicationc     0.01 
  1979-1997 35 (13.5) 5.0 6.0 7.0  
  2000-2002 26 (10.0) 5.0 6.5 8.0  
  2005-2007 90 (34.7) 6.0 7.0 8.0  
  2010-2013 35 (13.5) 6.8 7.0 8.0  
      
Continent of the corresponding 
author 
    0.04 
  North America 149 (57.5) 6.0 7.0 8.0  
  Europe 90 (34.3) 6.0 7.0 8.0  
  Asia 11 (4.2) 4.0 6.0 8.0  
  Others 9 (3.5) 5.0 6.0 7.0  
      
Type of journal     0.30 
  Pediatric specialty 84 (32.4) 6.0 7.0 8.0  
  
Pharmacology/pharmacoepidemiol
ogy 
30 (11.6) 6.0 7.0 8.0  
  General medicald 39 (15.1) 6.0 7.0 8.0  
  Otherse 106 (40.9) 6.0 7.0 8.0  
      
Funding sources     <0.01 
  Public 91 (35.1) 6.0 7.0 8.0  
  Private 47 (18.1) 6.0 7.0 8.0  
  Public and private 26 (10.0) 5.8 6.5 7.0  
  No funding  7 (2.7) 6.0 7.0 7.0  
  Funding not reported 88 (34.0) 5.0 6.0 7.0  
a Newcastle Ottawa scale; 
b Derived from either Kruskal Wallis H or Mann Whitney U test; 
c The proportions do not add up to 100% because we excluded studies that were published during the years 1998, 
1999, 2003, 2004, 2008 and 2009 in order to allow for possible impact of the drug legislations; 
d Refers to journals that publish wide variety of medical topics (irrespective of specialty);  
e Journals that do not fit into any of the specified categories i.e. PLOS ONE 
 
The mode of data collection significantly impacted study quality (Kruskal Wallis p-value<0.01), 
studies utilizing retrospectively collected data were the best. Interestingly, the 176 (68.0%) 
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studies utilizing only secondary data (median score=7.0; p25=6.0; p75=8.0), most (159 
[90.3%]) of which were published from 2000, were significantly better (Dunn’s p-value<0.01) 
than those based on primary data exclusively. Neither the 2013 two-year impact factor 
(Spearman rank correlation p-value=0.19) nor the type of journals in which studies were 
published (Kruskal Wallis H p-value=0.30) was significantly associated with quality.  
All the 4 case crossover studies attained ‘quality score=8’, 3 (75.0%) of the studies utilized 
retrospectively collected secondary data and were published from 2000. Considering all the 
designs (for studies with multiple designs), overall, SCCS studies (median score=7.0; p25=7.0; 
p75=8.0) were better than both cohort (Dunn’s p-value<0.01) and case control (Dunn’s p-
value=0.01) studies. Child-specific studies did not differ (Mann Whitney U p-value=0.21) from 
those that also included adults. Vaccine-specific studies (median score=7.0; p25=6.0; p75=8.0) 
were better (Mann-Whitney U p-value<0.01) than drug-specific studies. See table 2 for further 
details. 
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Table 2: Relationship between the methodology and quality of 259 pediatric 
pharmacoepidemiological safety studies  
  
Characteristic 
 
Number 
of studies 
(%) 
Summary NOSa score  
p-
valu
eb 
25th percentile Median 75th 
percentile 
Mode of data collectionc     <0.0
1 
  Prospective 67 (25.9) 5.0 6.0 7.0  
  Retrospective 171 (66.0) 6.0 7.0 8.0  
  Both 18 (6.9) 5.0 6.0 8.0  
        
Type of data     <0.0
1 
  Primary data exclusively 57 (22.0) 4.5 6.0 7.0  
  Secondary data exclusively 176 (68.0) 6.0 7.0 8.0  
  Mixed data 26 (10.0) 5.0 7.0 8.0  
      
Study design(s) that was  (were) 
utilizedd 
    <0.0
1 
  Cohort 174 (67.2) 5.0 7.0 8.0  
  Case control 73 (28.2) 6.0 7.0 8.0  
  Self-controlled case series 
(SCCS) 
30 (11.6) 7.0 7.0 8.0  
      
Study population      0.21 
  Children exclusively 175 (67.6) 6.0 7.0 8.0  
  Children and adults 84 (32.4) 6.0 7.0 8.0  
      
Type of exposuree     <0.0
1 
  Drug 141 (54.4) 5.0 7.0 7.0  
  Vaccine 115 (44.4) 6.0 7.0 8.0  
a  Newcastle Ottawa scale; 
b  Derived from either Kruskal Wallis H or Mann Whitney U test; 
c Does not include 3 studies (1.2%) for which the mode of data collection was unclear; 
d  The proportions do not add up to 100% because 4 studies that applied the case crossover design are not presented, 
some studies utilized multiple designs which were all considered; 
e Three studies (1.2%) that evaluated both drugs and vaccines are excluded  
 
As seen in figure 2, all the 174 cohort studies included exposed subjects that were 
representative of the source population but only 9 (7.9%) out of 114 drug studies and 9 
(15.0%) out of 60 vaccine studies followed subjects for enough time to observe the outcomes 
of interest. Also, only 52 (45.6%) drug studies and 22 (36.7%) vaccine assessments 
demonstrated absence of the investigated outcomes prior to start of the study. As many as 57 
(50.0%) drug and 19 (31.7%) vaccine studies indicated inadequate follow-up of subjects. For 2 
(66.7%) out of the 3 described NOS items that suggested high risk of bias, drug (rather than 
vaccine) studies were more commonly implicated.  
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All the SCCS studies showed low risk of bias for all the NOS items except adequacy of follow-up 
for which only 7 (23.3%) studies demonstrated low risk of bias. Also, only 12 (40.0%) studies 
demonstrated absence of the investigated outcome prior to start of the study.  
 
 
Fig 2: Risk of bias by question in 174 cohort (above) and 30 SCCS (below) studies, 
assessed using a modified cohort version of the Newcastle-Ottawa Scale (numbers 
within the green bar represent the number of studies with low risk of bias and the 
corresponding percentage) 
 
Figure 3 shows that all the case control studies assessing vaccines showed low risk of bias 
relating to age differences between the cases and controls.  However regarding the rate of non-
response (exposure ascertainment) between cases and controls, only 11 (35.5%) drug and 18 
(46.2%) vaccine assessments showed low risk of bias. Also, only 14 (35.9%) vaccine studies 
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defined controls as not experiencing the outcome of interest. Of note, none of the items 
comprising the NOS was favorably addressed by all the case control studies.  
 
Fig 3: Risk of bias by question in 70 case control studies, assessed using a modified 
case-control version of the Newcastle-Ottawa Scale (numbers within the green bar 
represent the number of studies with low risk of bias and the corresponding 
percentage) 
Note: Three case control studies that investigated both drugs and vaccines are not presented in the figure 
 
Further details (per NOS question) of the quality scores (per design) derived for all the studies 
that we evaluated are presented in the electronic supplementary material tables 1 to 4. 
Discussion 
We present the quality of pediatric pharmacoepidemiological safety studies spanning 34 years. 
Generally the studies showed good quality. The ‘best’ studies  were published from 2010 
onwards, originated from North America and Europe, reported funding source to be public or 
private but not both and utilized retrospectively collected secondary data. The studies assessed 
vaccines, using the SCCS design. Cohort studies were most likely to be biased because 
prevalent cases of the investigated outcomes were not identified before the study started and 
because the subjects were not followed for enough time to observe occurrence of the 
outcome(s). Case control studies were most likely to be biased because controls were not 
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defined as not experiencing the outcome and because of differences in non-response rate 
(regarding ascertainment of the exposure) between the cases and controls. 
The quality of studies may have been generally high, especially from 2010, because of the 
pediatric drug legislations that were introduced including the US Best Pharmaceuticals for 
Children Act (BPCA) (2002), and EU pediatric regulation (2007). Although the legislations were 
primarily aimed at stimulating clinical trials, pediatric pharmacoepidemiological studies were 
conducted as part of the BPCA. The increased focus on such studies may have resulted in the 
utilization of better methods particularly in Europe and North America. Specifically, SCCS studies 
were the best. The SCCS studies investigated only vaccines, perhaps accounting for the better 
quality of vaccine-specific studies compared to those that assessed only drugs. We recommend 
that where feasible, the SCCS design should be applied to more studies, also of drug 
assessments. That neither the journal impact factor nor type of journal in which the studies 
were published significantly impacted the quality is not surprising. Impact factor may not 
accurately indicate the quality of a journal or studies that are published by that journal 236. Also, 
we utilized two-year impact factor measured in 2013, even though some studies were published 
as far back as 1979, possibly influencing our findings. Whether a study was conducted in only 
children or included both children and adults did not impact its quality, possibly because the 
same methods were applied to adult and pediatric studies. The need for researchers that are 
trained in pediatric pharmacoepidemiology specifically has been emphasized199, providing such 
training is an aim of the Global Research in Pediatrics (GRIP).  
The majority of retrospective studies utilizing only secondary data showed good quality possibly 
because most of them were published from the year 2000, a period during which  extensive 
research effort has been focused on improving the quality and utilization of such data 237-240. 
Detailed patient information is now recorded in many healthcare databases especially electronic 
health records (EHR), thereby improving the utility of secondary data when compared to 
primary data collection. When utilizing EHR data for cohort studies, it should be possible to 
exclude prevalent cases of the outcome before commencing the studies. However this was not 
our finding. This may have occurred because in some studies that we evaluated, the 
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researchers aimed to investigate new episodes of the outcomes of interest in subjects that 
previously experienced that outcome. For such assessments, stratified analysis may be 
performed, comparing measures of association between subjects with a history of the outcome 
and those without a history. It is possible that prevalent cases were indeed excluded but this 
was not reported by the authors. Regarding the case control studies, incomplete reporting may 
also account for the lack of definition of controls. The impact of reporting on quality 
(assessment) of research has been emphasized197,241,242. Recently the RECORD statement was 
introduced, aimed at encouraging better reporting of studies based on EHR specifically 233.  
Documents have been published, designed to improve the design, conduct and reporting of 
pharmacoepidemiological studies243,244, by shedding light on important aspects of such studies 
required for proper evaluation of their quality. Still, pediatric-specific aspects were not 
emphasized. For adequate assessment of pediatric studies specifically, detailed information 
about various characteristics is required including specific date of birth (rather than just birth 
year), gestational age at birth, birthweight/length, small for gestational age status, school 
performance, and mental health status199. Also, detailed information about drug doses, 
concomitant medication, indication for treatment and reasons for changes to dose or therapy is 
required. We recommend complete reporting of the aforementioned information in pediatric 
studies specifically.  
Our findings show that the following factors were significantly associated with the quality of the 
studies that we evaluated: recently published studies, studies conducted in Europe and North 
America, utilization of retrospectively collected secondary data, and the application of the SCCS 
design. We propose that when appraising pediatric pharmacoepidemiological safety studies, 
clinicians (or other evaluators) with limited knowledge of pediatric pharmacoepidemiology may 
check if any of the aforementioned characteristics and/or design choices were applied. This may 
indicate that a study is of good quality. When there are many studies to be appraised, focusing 
on studies with these characteristics and/or design choices may make the evaluation more 
efficient. Also, appraising a study may be more efficient if the most likely sources of bias are 
known. Our findings show that for cohort studies, selection bias arising from non-ascertainment 
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of the outcome prior to study start occurs commonly. For case-control studies, unclear 
definition of controls and differential non-response rate (regarding ascertainment of exposure) 
between cases and controls are probable sources of bias. 
The use of an appropriate tool is crucial for an adequate assessment of study quality. Yet, many 
available quality assessment tools do not include critical assessment elements (i.e. confounding 
by indication) that are relevant to pharmacoepidemiological safety studies specifically. 
Moreover, no existing tool was developed for pediatric studies specifically. Margulis et al. 
compared the NOS and RTI item bank, concluding that the latter allows a more complete 
quality assessment than the former but is more burdensome. Similarly, the ‘Risk of Bias In Non-
randomized Studies - of Interventions’ (ROBINS-I) tool allows a more detailed and transparent 
assessment of study quality245 but the NOS is easier to use. Also, the ROBINS-I tool is most 
relevant for cohort studies; although it can be modified for case-control studies, this may not be 
easy. Meanwhile the NOS has a separate version for case control studies specifically, its face 
and content validity is based on critical review of its items by many experts in the field, and it 
has been refined based on experience of its use in several projects. We recommend further 
research to develop a tool that can easily be utilized to evaluate pediatric studies specifically.  
To our knowledge, this is the first study that evaluated the quality of pharmacoepidemiological 
safety studies in children specifically. We sought to evaluate vaccine studies separately, which is 
particularly important in children since they are frequently exposed to vaccines. Although the 
advantages of the SCCS design are known, to our knowledge no study previously quantified its 
impact on the quality of published studies.  
Although the NOS is useful, it is not completely suited for assessing the quality of 
pharmacoepidemiological safety studies specifically. We modified the NOS to make it more 
applicable for the current assessment. Given the heterogeneity of outcomes that were 
investigated in the cohort studies that we evaluated, we defined minimum time intervals in 
order to assess whether follow-up was long enough to observe the outcomes in such (cohort) 
studies. However, such time intervals may not have been accurate for specific safety outcomes. 
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Conclusion 
Published pediatric pharmacoepidemiological safety studies show good quality which has 
improved over time and is associated with geographical setting, design and conduct of the 
studies. Specifically, SCCS studies of vaccines are the best. By applying our findings, study 
evaluators may find it easier to assess published studies thereby enhancing their 
implementation in pediatric drug prescribing.   
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Appendix 1: Full search strategy 
Search criteria for Embase.com 
20. 'pediatrics'/exp OR 'child'/exp OR 'childhood'/exp OR 'newborn'/exp OR 
('adolescent'/exp OR 'adolescence'/exp NOT ('adult'/exp OR adult*:ab,ti)) 
 
21. child*:ab,ti OR pediatric*:ab,ti OR paediatric*:ab,ti OR infant*:ab,ti OR infancy:ab,ti OR 
baby:ab,ti OR babies:ab,ti OR toddler*:ab,ti OR neonate*:ab,ti OR newborn*:ab,ti OR 
premature*:ab,ti OR adolescen*:ab,ti OR teenage*:ab,ti OR preschool:ab,ti OR 
school*:ab,ti OR neonat*:ab,ti 
 
22. 1 or 2 
 
23. 'risk'/de OR 'attributable risk'/de OR 'risk factor'/de OR 'risk benefit analysis'/de OR 'risk 
assessment'/de OR 'risk management'/de OR 'risk reduction'/de OR 'incidence'/de OR 
'hazard ratio'/exp OR 'logistic regression analysis'/exp  
 
24. odds:ab,ti OR 'logistic regression':ab,ti OR 'relative risk':ab,ti OR incidence:ab,ti OR 
prevalence:ab,ti OR (hazard* NEAR/3 ratio*):ab,ti OR 'safety assessment':ab,ti OR (risk 
NEAR/3 (ratio OR attribut* OR differen* OR assess* OR adjust* OR analy* OR relativ* 
OR factor* OR manag* OR reduc*)):ab,ti 
 
25. 4 or 5 
 
26. 'drug toxicity and intoxication'/exp OR 'adverse drug reaction'/exp OR 'drug'/exp/dd_ae 
OR ('side effect'/exp OR 'adverse outcome'/exp AND ('drug'/exp OR 'drug therapy'/exp 
OR 'vaccine'/exp OR 'adjuvant'/exp OR 'immunization'/exp)) OR 'drug safety'/de  
 
27. ((pharmacol* OR pharmaceut* OR medication* OR medicine* OR drug* OR 
pharmacotherap* OR medicament* OR 'medicinal product' OR vaccin* OR immunizat* 
OR immunisat* OR adjuvant* OR treatment* OR therap*) NEAR/6 (safet* OR toler* OR 
intoler* OR toxic* OR intoxic* OR react* OR aftereffect* OR fatal* OR 'side effect' OR 
'side effects' OR adverse)):ab,ti OR pharmacotox*:ab,ti OR (adverse NEAR/3 (event* 
OR reaction* OR effect* OR outcome)):ab,ti  
 
28. 7 or 8 
 
29. 'epidemiology'/de OR 'pharmacoepidemiology'/de OR 'cohort analysis'/de OR 
'observational study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 
'longitudinal study'/de  
 
30. epidemiol*:ab,ti OR pharmacoepidemiol*:ab,ti OR cohort*:ab,ti OR (follow NEXT/1 
up*):ab,ti OR observation*:ab,ti OR retrospectiv*:ab,ti OR prospectiv*:ab,ti  
 
31. 10 or 11 
 
32. 'comparative study'/de OR 'comparative toxicology'/de OR 'drug comparison'/exp OR 
'controlled study'/de OR 'case control study'/exp  
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33. control*:ab,ti OR compar*:ab,ti OR referen*:ab,ti OR match*:ab,ti OR nested:ab,ti OR 
('self controlled' NEXT/1 serie*):ab,ti OR 'case cross over':ab,ti OR 'case centered':ab,ti 
OR 'case coverage':ab,ti OR 'case cohort':ab,ti 
 
34. 13 or 14 
 
35. 12 and 15 
 
36. 3 and 6 and 9 and 16 
 
37. [article]/lim NOT ('pregnancy'/exp OR pregnan*:ab,ti OR fetus:ab,ti OR fetal:ab,ti OR 
foetus:ab,ti OR foetal:ab,ti) NOT ('clinical trial'/exp OR 'systematic review'/exp OR 
'randomized controlled trial'/de OR 'randomization'/de) NOT ([animals]/lim NOT 
[humans]/lim) 
 
38. 17 and 18 
 
Search criteria for Medline (via OvidSP) 
22. exp pediatrics/ or exp child/ or exp infant/ or (adolescent/ not (exp adult/ or 
adult*.ab,ti.)) 
 
23. (child* or pediatric* or paediatric* or infant* or infancy or baby or babies or toddler* or 
neonate* or newborn* or premature* or adolescen* or teenage* or preschool or 
school* or neonat*).ab,ti. 
24. 1 or 2 
 
25. exp risk/ or "Odds Ratio"/ or incidence/ 
 
26. (Odds or "logistic regression" or "relative risk" or incidence or prevalence or (hazard* 
adj3 ratio*) or "safety assessment" or (risk adj3 (ratio or attribut* or differen* or 
assess* or adjust* or analy* or relativ* or factor* or manag* or reduc*))).ab,ti. 
 
27. 4 or 5 
 
28. exp "drug toxicity"/ or exp Pharmaceutical Preparations/ae or exp drug therapy/ae or 
exp vaccines/ae or exp immunization/ae 
 
29. (((pharmacol* or pharmaceut* or medication* or medicine* or drug* or 
pharmacotherap* or medicament* or "medicinal product" or vaccin* or immunizat* or 
immunisat* or adjuvant* or treatment* or therap*) adj6 (safet* or toler* or intoler* or 
toxic* or intoxic* or react* or aftereffect* or fatal* or "side effect" or "side effects" or 
adverse)) or pharmacotox* or (adverse adj3 (event* or reaction* or effect* or 
outcome))).ab,ti. 
 
30. 7 or 8 
 
31. "epidemiology"/ or epidemiology.xs. or pharmacoepidemiology/ or exp "Epidemiologic 
Studies"/ or observation/ 
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32. (epidemiol* or pharmacoepidemiol* or Cohort* or ( FOLLOW adj up*) or observation* 
or retrospectiv* or prospectiv*).ab,ti. 
 
33. 10 or 11 
 
34. "comparative study".pt. or "drug comparison"/ or "controlled study"/ or "case control 
study"/ 
 
35. (control* or compar* or referen* or match* or nested or ("self controlled" adj serie*) 
or "case cross over" or "case centered" or "case coverage" or "case cohort").ab,ti. 
 
36. 13 or 14 
 
37. 12 and 15 
 
38. 3 and 6 and 9 and 16 
 
39. Limit 17 to Journal Article 
 
40. Limit 18 to humans 
 
41. 19 not (pregnancy/ or (pregnan* or fetus or fetal or foetus or foetal).ab,ti.) 
 
42. 20 not (clinical trial/ or systematic review/ or randomized controlled trial/ or 
randomization/) 
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Appendix 2: Flow chart depicting the selection of relevant papers 
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Appendix 3: Modified Newcastle-Ottawa Scale 
 
A. COHORT STUDIES (Scale) 
Note: A study can be awarded a maximum of one star for each numbered item 
within the Selection and Outcome categories. A maximum of two stars can be 
awarded for comparability 
Selection 
1. Representativeness of the exposed cohort 
a. truly representative of the average _______________ (describe) in the community* (if 
in general population with claims/medical records and no exclusion criteria)  
b. somewhat representative of the average ______________ in the community* (if in 
general population with claims/medical records and exclusion criteria) 
c.  selected group of users e.g. nurses, volunteers (e.g. from setting, if only in hospital 
whereas drug is also used outpatient) 
d. no description of the derivation of the cohort 
 
2. Selection of the non-exposed cohort 
a. drawn from the same community as the exposed cohort* 
b. drawn from a different source 
c. no description of the derivation of the non-exposed cohort 
 
3. Ascertainment of exposure 
a. secure record (e.g. surgical records) * 
b. structured interview * 
c. written self-report 
d. no description 
 
4. Demonstration that outcome of interest was not present at start of study 
a. yes * 
b. no 
 
 Comparability 
5. Comparability of cohorts on the basis of the design or analysis 
a. study controls for  age (select the most important factor) * 
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b. study controls for any additional factor * (This criteria could be modified to indicate 
specific control for a second important factor.) (sex and medical indication) 
 
Exposed and non-exposed individuals must be matched in the design and/or confounders must 
be adjusted for in the analysis. If the relative risk for the exposure of interest is adjusted for the 
confounders listed, then the groups will be considered to be comparable on each variable used 
in the adjustment. 
Statements of no differences between groups or that differences were not statistically 
significant are not sufficient for establishing comparability.  
 Outcome 
6. Assessment of outcome 
a. independent blind assessment * 
b. record linkage * 
c. self-report 
d. no description 
 
7. Was follow-up long enough for outcomes to occur  
a. yes (select an adequate follow up period for outcome of interest) * 
b. no 
 
 
8. Adequacy of follow up of cohorts (please assess whether fixed (reporting 
cumulative incidence with persons as denominator) or dynamic cohort (person-
time as denominator) ) 
a. complete follow up in fixed cohort- all subjects accounted for * 
b. subjects lost to follow up in fixed cohort unlikely to introduce bias - small number lost - 
> __80%__ % (select an adequate %) follow up, or description provided of those lost) 
* 
c. dynamic cohort study * 
d. follow up rate < ____% (select an adequate %) and no description of those lost in 
fixed cohort 
e. no statement in fixed cohort 
 
B. CASE-CONTROL 
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Note: A study can be awarded a maximum of one star for each numbered item 
within the Selection and Exposure categories. A maximum of two stars can be given 
for Comparability. 
Selection 
1. Is the case definition adequate? 
a. yes, with independent validation * 
b. yes, e.g. record linkage or based on self-reports 
c. no description 
 
2. Representativeness of the cases 
a. consecutive or obviously representative series of cases  * 
b. potential for selection biases or not stated 
 
3. Selection of Controls 
a. community controls *  
b. hospital controls 
c. no description 
 
4. Definition of Controls 
a. no history of disease (endpoint) * 
b. no description of source 
 
Comparability 
5. Comparability of cases and controls on the basis of the design or analysis 
a. study controls for age  (Select the most important factor.) * 
b. study controls for any additional factor  * (This criteria could be modified to 
indicate specific control for a second important factor.)  time, sex, indication 
 
Cases and controls must be matched in the design and/or confounders must be 
adjusted for in the analysis. If the relative risk for the exposure of interest is adjusted 
for the confounders listed, then the groups will be considered to be comparable on 
each variable used in the adjustment. 
Statements of no differences between groups or that differences were not statistically 
significant are not sufficient for establishing comparability.  
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Exposure 
6. Ascertainment of exposure 
a. secure record (e.g. surgical records, medical charts) * 
b. structured interview where blind to case/control status * or dispensing 
databases or prescription data or medical records * 
c. interview not blinded to case/control status 
d. written self-report  
e. no description 
 
7. Same method of ascertainment for cases and controls 
a. yes  * 
b. no 
 
8. Non-Response rate 
a. Similar response rate for both cases and controls  * 
b. non respondents described 
c. rate different and no designation 
d. non-response rate not reported
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Electronic Supplementary Material 
Table 1: Quality scores derived for 174 cohort studies, assessed using a modified cohort version of the Newcastle Ottawa scale (NOS) 
S/N First author Year Title Investigated 
exposure 
NOS Questions Total NOS 
score Q1  Q2 Q3 Q4 Q5a  Q5b Q6 Q7 Q 8 
1 Zangwill K.M. 2008 A Population-Based, Postlicensure 
Evaluation of the Safety of a 
Combination Diphtheria, Tetanus, 
Acellular Pertussis, Hepatitis B, and 
Inactivated Poliovirus Vaccine in a 
Large Managed Care Organization 
vaccine yes no yes no yes yes yes no no 5 
2 Young H. A.  2008 Thimerosal exposure in infants and 
neurodevelopmental disorders: 
An assessment of computerized 
medical records in the 
Vaccine Safety Datalink 
vaccine yes yes yes no yes no yes no yes 6 
3 Winterstein A. G.  2012 Cardiovascular safety of central 
nervous system stimulants in children 
and adolescents: population based 
cohort study 
drug yes yes yes yes yes yes yes no yes 8 
4 Winterstein A. G.  2009 Cardiac Safety of Methylphenidate 
Versus Amphetamine Salts in the 
Treatment of ADHD 
drug yes yes yes yes yes yes yes no yes 8 
5 Winterstein A. G.  2007 Cardiac Safety of Central Nervous 
System Stimulants in Children and 
Adolescents With Attention-
Deficit/Hyperactivity Disorder 
drug yes yes yes yes yes yes yes no yes 8 
6 The Victorian 
Infant 
Collaborative study 
group 
2000 Postnatal corticosteroids and 
sensorineural outcome at 5 years of 
age 
drug yes no yes no no no yes no no 3 
7 Verstraeten T.  2003 Safety of Thimerosal-Containing 
Vaccines: A Two-Phased Study of 
Computerized Health Maintenance 
Organization Databases 
vaccine yes yes yes yes yes yes yes no no 7 
8 Velentgas P.  2012 Risk of Guillain–Barré syndrome after 
meningococcal conjugate vaccination 
vaccine yes yes yes no no no yes no yes 5 
9 Van Staa T. P.  2004 Are inhaled corticosteroids associated 
with an increased risk of fracture in 
children? 
drug yes yes yes no yes yes yes no no 6 
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10 Van Dijken T. D.  2011 Development of inflammatory bowel 
disease in patients with juvenile 
idiopathic arthritis treated with 
etanercept 
drug yes no yes yes no no yes no yes 5 
11 Van Der Linden P. 
D.  
1998 Skin Reactions to Antibacterial Agents 
in General Practice 
drug yes yes yes no yes yes yes no yes 7 
12 Vainionpaa L.  1995 Vincristine Therapy for Children With 
Acute Lymphoblastic Leukemia 
Impairs Conduction in the Entire 
Peripheral Nerve 
drug yes no no no yes yes no no no 3 
13 Tyczynski J. E.  2012 Safety assessment of an anti-obesity 
drug (sibutramine): a retrospective 
cohort study. 
drug yes yes yes no yes yes yes no yes 7 
14 Tutar H. E.  1999 Effects of cisapride on ventricular 
repolarization in children 
drug yes no no no no no no no no 1 
15 Tucker M. A.  1987 Leukemia After Therapy With 
Alkylating Agents for Childhood Cancer 
drug yes no no no no no yes no yes 3 
16 Tseng H. F.  2013 Postlicensure surveillance for pre-
specified adverse events following the 
13-valent pneumococcal conjugate 
vaccine in children 
vaccine yes yes yes no no no yes no yes 5 
17 Tse A.  2012 Signal identification and evaluation for 
risk of febrile seizures in children 
following trivalent inactivated 
influenza vaccine in the Vaccine Safety 
Datalink Project, 2010–2011 
vaccine yes yes yes no yes yes yes no yes 7 
18 Toback S. L.  2013 A postlicensure evaluation of the 
safety of Ann Arbor strain live 
attenuated influenza vaccine in 
children 24–59 months of age 
vaccine yes yes yes no yes yes yes no yes 7 
19 Thorp A. W.  2009 Ketamine-Associated Vomiting. Is it 
Dose-Related? 
drug yes yes yes no yes no yes no no 5 
20 Terrin G.  2012 Ranitidine is Associated With 
Infections, Necrotizing Enterocolitis, 
and Fatal Outcome in Newborns 
drug yes yes yes yes yes yes yes no no 7 
21 Ter Wolbeek M.  2013 Early life intervention with 
glucocorticoids has negative effects on 
motor development and 
neuropsychological function in 14—17 
year-old adolescents 
drug yes yes yes yes yes yes yes no yes 8 
22 Tahara T.  2013 Safety of oseltamivir in infants less 
than one year old: Prospective 
surveillance during the 2004–2005 
drug yes yes yes no no no yes no no 4 
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influenza season in Japan 
23 Szer I. S.  1991 Paucity of renal complications 
associated with nonsteroidal 
antiinflammatory drugs in children 
with chronic arthritis 
drug yes yes yes yes no no yes no no 5 
24 Szekely A.  2008 Aprotinin and renal dysfunction after 
pediatric cardiac surgery 
drug yes yes yes no yes yes yes no no 6 
25 Sun Y.  2012 Risk of Febrile Seizures and Epilepsy 
After Vaccination With Diphtheria, 
Tetanus, Acellular Pertussis, 
Inactivated Poliovirus, and 
Haemophilus Influenzae Type b 
vaccine yes yes yes yes yes yes yes no yes 8 
26 Sugawara T.  2009 Diarrhea as a Minor Adverse Effect 
Due to Oral Polio Vaccine 
vaccine yes yes no no yes yes no no no 4 
27 Stohr W.  2006 Comparison of epirubicin and 
doxorubicin cardiotoxicity in children 
and adolescents treated within the 
German Cooperative Soft Tissue 
Sarcoma Study (CWS) 
drug yes yes yes yes yes yes yes no yes 8 
28 Staffa J. A.  1995 Risk of Selected Serious Cardiac 
Events Among New Users of 
Antihistamines 
drug yes yes yes yes no no yes no no 5 
29 Spycher B. D.  2009 Routine Vaccination Against Pertussis 
and the Risk of Childhood Asthma: A 
Population-Based Cohort Study 
vaccine yes yes yes yes yes yes yes no yes 8 
30 Spitzer T. R.  1994 Etoposide in combination with 
cyclophosphamide and total body 
irradiation or busulfan as conditioning 
for marrow transplantation in adults 
and children 
drug yes yes yes no no no yes no yes 5 
31 Shui I. M.  2012 Risk of Intussusception Following 
Administration of a Pentavalent 
Rotavirus Vaccine in US Infants 
vaccine yes yes yes yes yes no yes no yes 7 
32 Seagroatt V.  2003 Crohn’s disease, ulcerative colitis, and 
measles vaccine in an English 
population, 1979–1998 
vaccine yes yes yes yes yes yes yes no no 7 
33 Schneeweiss S.  2009 Topical Treatments with Pimecrolimus, 
Tacrolimus and Medium- to High-
Potency Corticosteroids, and Risk of 
Lymphoma 
drug yes yes yes yes yes yes yes no yes 8 
34 Schneeweiss S.  2010 Comparative Safety of Antidepressant 
Agents for Children and Adolescents 
drug yes yes yes no yes yes yes no yes 7 
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Regarding Suicidal Acts 
35 Schechter T.  2012 Safety of anticoagulants in children 
with arterial ischemic stroke 
drug yes yes yes no no no yes no no 4 
36 Roze J. C.  2008 Prolonged Sedation and/or Analgesia 
and 5-Year Neurodevelopment 
Outcome in Very Preterm Infants 
drug yes yes yes no yes yes yes no no 6 
37 Roke Y.  2012 Risk of Hyperprolactinemia and Sexual 
Side Effects in Males 10–20 Years Old 
Diagnosed with Autism Spectrum 
Disorders or Disruptive Behavior 
Disorder and Treated with Risperidone 
drug yes yes yes yes yes yes yes no no 7 
38 Roelofzen J. H. J.  2010 No Increased Risk of Cancer after Coal 
Tar Treatment in Patients with 
Psoriasis or Eczema 
drug yes yes yes no yes yes yes no no 6 
39 Ritwik P.  2013 Post-sedation Events in Children 
Sedated for Dental Care 
drug yes yes yes no no no no no yes 4 
40 Risnes K. R.  2011 Antibiotic Exposure by 6 Months and 
Asthma and Allergy at 6 Years: 
Findings in a Cohort of 1,401 US 
Children 
drug yes yes no yes no no no no no 3 
41 Quinn C. T.  1997 Elevation of Homocysteine and 
Excitatory Amino Acid 
Neurotransmitters in the CSF of 
Children Who Receive Methotrexate 
for the Treatment of Cancer 
drug yes yes no no no no yes no yes 4 
42 Pratt C. M.  1994 Risk of Developing Life-Threatening 
Ventricular Arrhythmia Associated with 
Terfenadhe in Comparison with Over-
the-Counter Antihistamines, Mwprofen 
and CIemastine 
drug yes yes yes no yes yes yes no yes 7 
43 Petousis-Harris H.  2012 Febrile events including convulsions 
following the administration of four 
brands of 2010 and 2011 inactivated 
seasonal influenza vaccine in NZ 
infants and children: The importance 
of routine active safety surveillance 
vaccine yes yes yes no yes yes yes no yes 7 
44 Pallavicini F. B.  2010 Tumour necrosis factor antagonist 
therapy and cancer development: 
Analysis of the LORHEN registry 
drug yes yes yes no yes yes yes no yes 7 
45 Olfson M.  2012 Tumour recurrence and enlargement 
in patients with craniopharyngioma 
with and without GH replacement 
therapy during more than 10 years of 
drug yes yes yes yes yes yes yes no yes 8 
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follow-up 
46 Nohynek H.  2012 AS03 Adjuvanted AH1N1 Vaccine 
Associated with an Abrupt Increase in 
the Incidence of Childhood Narcolepsy 
in Finland 
vaccine yes yes yes no no no yes no yes 5 
47 Niu M. T.  1998 Comparative Safety of Two 
Recombinant Hepatitis B Vaccines in 
Children: Data from the Vaccine 
Adverse Event Reporting System 
(VAERS) and Vaccine Safety Datalink 
(VSD) 
vaccine yes yes yes no yes no yes no yes 6 
48 Neudorfer M.  2012 Ocular Adverse Effects of Systemic 
Treatment With Isotretinoin 
drug yes yes yes yes yes yes yes no yes 8 
49 Nelson J. C.  2013 Adapting Group Sequential Methods to 
Observational Postlicensure Vaccine 
Safety Surveillance: Results of a 
Pentavalent Combination DTaP-IPV-
Hib Vaccine Safety Study 
vaccine yes yes yes yes yes yes yes no yes 8 
50 Needelman H.  2008 Effects of Postnatal Dexamethasone 
Exposure on the Developmental 
Outcome of Premature Infants 
drug yes yes yes no yes yes yes no yes 7 
51 Myleus A.  2012 Early Vaccinations Are Not Risk 
Factors for Celiac Disease 
vaccine yes yes yes yes no no yes no yes 6 
52 Mustieles C.  1995 Male Gonadal Function After 
Chemotherapy in Survivors of Child 
hood Malignancy 
drug yes no yes yes no no yes no yes 5 
53 Mulheran M.  2001 Occurrence and Risk of Cochleotoxicity 
in Cystic Fibrosis Patients Receiving 
Repeated High-Dose Aminoglycoside 
Therapy 
drug yes yes yes yes yes yes yes no yes 8 
54 Mrozek-Budzyn D.  2013 Measles, mumps and rubella (MMR) 
vaccination has no effect on cognitive 
development in children – The results 
of the Polish prospective cohort study 
vaccine yes yes yes yes yes yes yes no yes 8 
55 Morris D. L.  2000 Measles Vaccination and Inflammatory 
Bowel Disease: A National British 
Cohort Study 
vaccine yes yes yes yes yes yes yes no yes 8 
56 Mikaeloff Y.  2007 Hepatitis B vaccine and risk of relapse 
after a first childhood episode of CNS 
inflammatory demyelination 
vaccine yes yes yes yes yes yes yes yes no 8 
57 McKee M. R.  2008 Oral Analgesia Before Pediatric 
Ketamine Sedation is not Associated 
with an Increased Risk of Emesis and 
drug yes yes yes no no yes yes no yes 6 
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Other Adverse Events 
58 McIntyre R. S.  2008 Metabolic and Cardiovascular Adverse 
Events Associated With Antipsychotic 
Treatment in Children and Adolescents 
drug yes yes yes yes yes yes yes no yes 8 
59 McCarthy N. L.  2013 Evaluating the safety of influenza 
vaccine using a claims-basedhealth 
system 
vaccine yes yes yes yes yes yes yes no yes 8 
60 McAlvin B.  2007 Routine Immunizations and Adverse 
Events in Infants With Single-Ventricle 
Physiology 
vaccine yes yes yes no yes yes yes no yes 7 
61 Martin A.  2000 Risperidone-Associated Weight Gain in 
Children and Adolescents: A 
Retrospective Chart Review 
drug yes yes yes no yes yes yes no no 6 
62 Maraqa N. F.  2002 Higher Occurrence of Hepatotoxicity 
and Rash in Patients Treated with 
Oxacillin, Compared with Those 
Treated with Nafcillin and Other 
Commonly Used Antimicrobials 
drug yes yes yes no no no yes no no 4 
63 Main M. L.  2008 Acute Mortality in Hospitalized Patients 
Undergoing Echocardiography With 
and Without an Ultrasound Contrast 
Agent (Multicenter Registry Results in 
4,300,966 
Consecutive Patients) 
drug yes yes yes no yes yes yes no yes 7 
64 Madsen K. M.  2002 A Population-Based Study of Measles, 
Mumps, and Rubella Vaccination and 
Autism 
vaccine yes yes yes no yes yes yes no yes 7 
65 Loughlin J.  2012 Postmarketing Evaluation of the Short-
term Safety of the Pentavalent 
Rotavirus Vaccine 
vaccine yes yes yes yes yes yes yes no yes 8 
66 Loughlin J.  2010 Tegaserod and the Risk of 
Cardiovascular Ischemic Events: An 
Observational Cohort Study 
drug yes yes yes yes yes yes yes no yes 8 
67 Lindqvist H.  2013 Folinic Acid Supplementation in Higher 
Doses is Associated with Graft 
Rejection in Pediatric Hematopoietic 
Stem Cell Transplantation 
drug yes yes yes no no yes yes no no 5 
68 Leyvi G.  2011 A Comparison of the Effect of 
Aprotinin and  -Aminocaproic Acid on 
Renal Function in Children Undergoing 
Cardiac Surgery 
drug yes yes yes no yes yes yes no no 6 
69 Leonard C. E.  2011 Antidepressants and the risk of 
sudden cardiac death and ventricular 
drug yes yes yes no yes yes yes no yes 7 
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arrhythmia 
70 Lee J.  2006 Frequency of apnea, bradycardia, and 
desaturations following first 
diphtheria-tetanus-pertussis-
inactivated polio-Haemophilus 
influenzae type B immunization in 
hospitalized preterm infants 
vaccine yes yes yes no yes yes yes no no 6 
71 Lee J. S. 2008 Comparison of Methohexital and 
Propofol Use in Ambulatory 
Procedures in Oral and Maxillofacial 
Surgery 
drug yes yes yes no yes yes yes no no 6 
72 Lawrence R.  1988 The Risk of Zoster after Varicella 
Vaccination in Children with Leukemia 
vaccine yes yes yes yes yes yes yes no yes 8 
73 Lackmann G. M.  2004 Comparative investigation of the 
safety of hexavalent vaccines for 
primary scheduled infant 
immunizations in Germany over a time 
period of 2 years 
vaccine yes yes yes no no no no no no 3 
74 Kuppala V. S.  2011 Prolonged Initial Empirical Antibiotic 
Treatment is Associated with Adverse 
Outcomes in Premature Infants 
drug yes yes yes yes yes yes yes no no 7 
75 Krawczynska H.  1979 Goitre and hypothyroidism in children 
and adolescents during long-term 
anticonvulsive therapy 
drug yes no yes no no no yes no no 3 
76 Kramarz P.  2000 Does Influenza Vaccination Exacerbate 
Asthma? Analysis of a Large Cohort of 
Children With Asthma 
vaccine yes yes yes no yes yes yes yes yes 8 
77 Klein N. P.  2010 Measles-Mumps-Rubella-Varicella 
Combination Vaccine and the Risk of 
Febrile Seizures 
vaccine yes yes yes no yes yes yes no yes 7 
78 Klein N. P.  2010 Post-Marketing Safety Evaluation of a 
Tetanus Toxoid, Reduced Diphtheria 
Toxoid and 3-Component Acellular 
Pertussis Vaccine Administered to a 
Cohort of Adolescents in a United 
States Health Maintenance 
Organization 
vaccine yes yes yes yes yes yes yes no no 7 
79 Klein N. P.  2012 Safety of Quadrivalent Human 
Papillomavirus Vaccine Administered 
Routinely to Females 
vaccine yes yes yes yes yes yes yes no yes 8 
80 Kim J. Y.  2009 Effects of highly active antiretroviral 
therapy (HAART) on cholesterol in 
HIV-1 infected children: a 
drug yes yes yes no yes yes yes no yes 7 
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retrospective cohort study 
81 Khan R. A.  2009 Effects of Olanzapine and Risperidone 
on Metabolic Factors in Children and 
Adolescents: A Retrospective 
Evaluation 
drug yes yes yes yes yes yes yes no yes 8 
82 Kemp T.  1997 Is infant immunization a risk factor for 
childhood asthma or allergy? 
vaccine yes yes yes no yes yes yes no no 6 
83 Katayama H.  1990 Adverse reactions to ionic and 
nonionic contrast media. A report from 
the Japanese Committee on the Safety 
of Contrast Media. 
drug yes yes yes no no no yes no yes 5 
84 Karvonen M.  1999 Association between type 1 diabetes 
and Haemophilus influenzae type b 
vaccination: birth cohort study 
vaccine yes yes no no no no yes no yes 4 
85 Karsies T. J.  2010 Thrombotic Risk of Recombinant 
Factor Seven in Pediatric Cardiac 
Surgery: A Single Institution 
Experience 
drug yes yes yes yes yes yes yes no no 7 
86 Karikas G. A.  2006 Lipids, Lipoproteins, Apolipoproteins, 
Selected Trace Elements and Minerals 
in the Serum of Children on Valproic 
Acid Monotherapy 
drug yes no yes no yes no yes no no 4 
87 Karavitaki N.  2006 GH replacement does not increase the 
risk of recurrence in patients with 
craniopharyngioma 
drug yes yes yes no yes yes yes yes no 7 
88 Judkins J.H.  1996 Intraoperative Ketorolac and 
Posttonsillectomy Bleeding 
drug yes yes yes no yes yes yes yes yes 8 
89 Johnson C. C.  2005 Antibiotic exposure in early infancy 
and risk for childhood atopy 
drug yes yes yes no yes yes yes no no 6 
90 Jerrell J. M.  2010 Neurological and Cardiovascular 
Adverse Events Associated with 
Antimanic Treatment in Children and 
Adolescents 
drug yes yes yes yes yes yes yes no no 7 
91 Jerrell J. M.  2010 Adverse events associated with 
psychotropic treatment in African 
American children and adolescents. 
drug yes yes yes yes yes yes yes yes no 8 
92 Jerrell J. M.  2010 Neuroendocrine-Related Adverse 
Events Associated with Antidepressant 
Treatment in Children and Adolescents 
drug yes yes yes yes yes yes yes yes no 8 
93 Jerrell J. M.  2010 Metabolic, Digestive, and Reproductive 
Adverse Events Associated With 
Antimanic Treatment in Children and 
Adolescents: A Retrospective Cohort 
drug yes yes yes yes yes yes yes no no 7 
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Study 
94 Jerrell J. M.  2009 Cardiovascular and neurological 
adverse events associated with 
antidepressant treatment in children 
and adolescents 
drug yes yes yes yes yes yes yes no no 7 
95 Jerrell J. M.  2008 Neurological Adverse Events 
Associated with Antipsychotic 
Treatment in Children and Adolescents 
drug yes yes yes yes yes yes yes yes no 8 
96 Jerrell J. M.  2009 Hyperprolactinemia-related adverse 
events associated with antipsychotic 
treatment in children and adolescents 
drug yes yes yes yes yes yes yes yes no 8 
97 Jerrell J. M.  2008 Adverse events in children and 
adolescents treated with antipsychotic 
medications. 
drug yes yes yes yes yes yes yes no no 7 
98 Jacobsen S. J. 2009 Observational safety study of febrile 
convulsion following first dose MMRV 
vaccination in a managed care setting 
vaccine yes no yes yes yes yes yes yes yes 8 
99 Jackson L. A.  2013 Vaccination Site and Risk of Local 
Reactions in Children 1 Through 6 
Years of Age 
vaccine yes yes yes yes yes yes yes no no 7 
100 Iftikhar U.  2013 Risk of hearing loss in children 
exposed to gentamicin for the 
treatment of sepsis in young infancy: 
A community based cohort study in 
Pakistan 
drug yes yes yes yes yes yes yes no no 7 
101 Hviid A.  2003 Association Between Thimerosal-
Containing Vaccine and Autism 
vaccine yes yes yes no yes yes yes yes yes 8 
102 Hviid A.  2009 Antibiotic use and intussusception in 
early childhood 
drug yes yes yes no yes yes yes yes yes 8 
103 Huerta C.  2002 Risk of clinical blood dyscrasia in a 
cohort of antibiotic users 
drug yes yes yes yes no no yes yes yes 7 
104 Huang W. T.  2010 Lack of Association Between Acellular 
Pertussis Vaccine and Seizures in Early 
Childhood 
vaccine yes yes yes no yes yes yes yes yes 8 
105 Hornik C. P.  2013 Adverse Events Associated With 
Meropenem Versus 
Imipenem/Cilastatin Therapy in a 
Large Retrospective Cohort of 
Hospitalized Infants 
drug yes yes yes yes yes yes yes no yes 8 
106 Horen B.  2002 Adverse drug reactions and off-label 
drug use in paediatric outpatients 
drug yes yes yes no yes yes yes no no 6 
107 Henderson J.  1999 Pertussis vaccination and wheezing 
illnesses in young children: 
vaccine yes yes yes no yes yes no no no 5 
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prospective cohort study 
108 Harrison C. N.  1999 High-dose BEAM chemotherapy with 
autologous haemopoietic stem cell 
transplantation for HodgkinÕs disease 
is unlikely to be associated with a 
major 
increased risk of secondary MDS/AML 
drug yes yes yes no yes yes yes no yes 7 
109 Hamed S. A.  2009 The risk of asymptomatic 
hyperammonemia in children with 
idiopathic epilepsy treated with 
valproate: Relationship to blood 
carnitine status 
drug yes no yes yes yes yes yes no no 6 
110 Hall G. C.  2004 Triptans in migraine: the risks of 
stroke, cardiovascular disease, and 
death in practice. 
drug yes yes yes yes yes yes yes no yes 8 
111 Hall A. S.  2003 The effects of corticosteroids on 
behavior in children with nephrotic 
syndrome 
drug yes yes yes yes no no no no yes 5 
112 Guthrie S. O.  2004 Initial Dosing of Inhaled Nitric Oxide in 
Infants with Hypoxic Respiratory 
Failure 
drug yes yes yes no yes yes yes no no 6 
113 Greene S. K. 2013 Risk of adverse events following 
oseltamivir treatment in influenza 
outpatients, Vaccine Safety Datalink 
Project, 2007–2010 
drug yes yes yes yes yes yes yes no no 7 
114 Greene S. K. 2010 Near Real-Time Surveillance for 
Influenza Vaccine Safety: Proof-of-
Concept in the Vaccine Safety Datalink 
Project 
vaccine yes yes yes no yes yes yes no yes 7 
115 Geier D. A.  2010 Thimerosal exposure & increasing 
trends of premature puberty in 
the vaccine safety datalink 
vaccine yes yes yes no yes yes yes no no 6 
116 Geier D. A.  2005 A two-phased population 
epidemiological study of the safety of 
thimerosal-containing vaccines: a 
follow-up analysis 
vaccine yes yes yes no yes yes yes no no 6 
117 Gee J.  2011 Monitoring the safety of quadrivalent 
human papillomavirus vaccine: 
Findings 
from the Vaccine Safety Datalink 
vaccine yes yes yes no yes yes yes no yes 7 
118 Gasse C.  2009 Preadmission use of SSRIs alone or in 
combination with NSAIDs and 30-day 
mortality after peptic ulcer bleeding 
drug yes yes yes yes yes yes yes no yes 8 
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119 Garcia Rodriguez L. 
A.  
1996 Risk of Acute Liver Injury Associated 
With the Combination of Amoxicillin 
and Clavulanic Acid 
drug yes yes yes yes yes yes yes no yes 8 
120 France E. K.  2008 Risk of Immune Thrombocytopenic 
Purpura After Measles-Mumps-Rubella 
Immunization in Children 
vaccine yes yes yes yes yes yes yes yes yes 9 
121 Fosbol E. L.  2010 Cause-Specific Cardiovascular Risk 
Associated With Nonsteroidal 
Antiinflammatory Drugs Among 
Healthy Individuals 
drug yes yes yes no yes yes yes no yes 7 
122 Fosbol E. L.  2009 Risk of Myocardial Infarction and 
Death Associated With the Use of 
Nonsteroidal 
Anti-Inflammatory Drugs (NSAIDs) 
Among Healthy Individuals: A 
Nationwide Cohort Study 
drug yes yes yes yes yes yes yes no yes 8 
123 Fleischhaker C.  2007 Weight gain associated with clozapine, 
olanzapine and risperidone in children 
and adolescents 
drug yes yes yes yes no no yes yes yes 7 
124 Finer N. N.  1984 Vitamin E and Necrotizing Enterocolitis drug yes yes yes no yes yes yes no yes 7 
125 Fine R.N.  2003 Adverse events with rhGH treatment 
of patients with chronic renal 
insufficiency and end-stage renal 
disease 
drug yes yes yes no no no yes no yes 5 
126 Filippi L.  2010 Oral Topiramate in Neonates with 
Hypoxic Ischemic Encephalopathy 
Treated with Hypothermia: A Safety 
Study 
drug yes yes yes yes no no yes no no 5 
127 Fang A. Y. W.  2013 The effect of sildenafil on retinopathy 
of prematurity in very preterm infants 
drug yes yes yes yes yes yes yes no no 7 
128 Eriksen E. M.  2004 Lack of Association Between Hepatitis 
B Birth Immunization and Neonatal 
Death. A Population-Based Study 
From the Vaccine Safety Datalink 
Project 
vaccine yes yes yes yes yes yes yes yes no 8 
129 Enders J.  2006 Morphine-related apnoea in CPAP-
treated preterm neonates 
drug yes yes yes no yes yes yes no yes 7 
130 Drossou-Agakidou 
V.  
2004 Use of ciprofloxacin in neonatal sepsis: 
lack of adverse effects up to one year 
drug yes yes yes no yes yes yes no no 6 
131 Donahue J. G.  2009 Varicella Vaccination and Ischemic 
Stroke in Children: Is There an 
Association? 
vaccine yes yes yes yes yes yes yes no yes 8 
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132 Dieleman J.  2011 Guillain-Barré syndrome and 
adjuvanted pandemic influenza A 
(H1N1) 2009 vaccine: multinational 
case-control study in Europe 
vaccine yes yes yes no yes yes yes no no 6 
133 Delbe-Bertin L.  2013 Does rituximab induce 
hypogammaglobulinemia in patients 
with pediatric idiopathic nephrotic 
syndrome? 
drug yes yes yes yes yes yes yes no no 7 
134 De Wals P.  2012 Risk of Guillain-Barre´ Syndrome 
Following H1N1 Influenza Vaccination 
in Quebec 
vaccine yes yes yes no yes yes yes yes yes 8 
135 De Wals P.  2008 Risk of Guillain-Barre´ Syndrome 
following Serogroup C Meningococcal 
Conjugate Vaccine in Quebec, Canada 
vaccine yes yes yes no yes no yes yes yes 7 
136 De Oliveira L. H.  2000 Vaccine-associated paralytic 
poliomyelitis: a retrospective cohort 
study of acute flaccid paralyses in 
Brazil. 
vaccine yes yes no no yes yes yes no no 5 
137 De Bruin M. L.  2008 Treatment-related risk factors for 
premature menopause following 
Hodgkin lymphoma 
drug yes yes yes no yes yes yes no no 6 
138 Dayton J. D.  2011 Role of immunosuppression regimen 
in post-transplant lymphoproliferative 
disorder in pediatric heart transplant 
patients 
drug yes yes yes no no no yes no no 4 
139 Davis R. L.  2004 Post-marketing evaluation of the short 
term safety of COMVAX 
vaccine yes yes yes no yes yes yes no yes 7 
140 Davenport M. S.  2013 Effect of Abrupt Substitution of 
Gadobenate Dimeglumine for 
Gadopentetate Dimeglumine on Rate 
of Allergic-like Reactions 
drug yes yes yes no yes yes yes no no 6 
141 Dahllof G.  1997 Impact of conditioning regimens on 
salivary function, caries-associated 
microorganisms and dental caries in 
children after bone marrow 
transplantation. A 4-year longitudinal 
study 
drug yes no yes yes yes yes yes no no 6 
142 Czaja A. S.  2013 Comparative safety of selective 
serotonin reuptake inhibitors among 
pediatric users with respect to adverse 
cardiac events 
drug yes yes yes no yes yes yes no yes 7 
143 Cullinan P.  2004 Early prescriptions of antibiotics and 
the risk of allergic disease in adults: a 
drug yes yes yes no yes no yes no no 5 
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cohort study 
144 Correll C. U.  2009 Cardiometabolic Risk of Second-
Generation Antipsychotics During 
First-Time Use in Children and 
Adolescents 
drug yes yes yes yes no no yes no no 5 
145 Cooper W. O.  2011 ADHD Drugs and Serious 
Cardiovascular Events in Children and 
Young Adults 
drug yes yes yes yes yes yes yes no yes 8 
146 Connor D. F.  2001 Neuroleptic-related dyskinesias in 
children and adolescents. 
drug yes yes yes no no no yes no no 4 
147 Clark R. H.  2006 Empiric Use of Ampicillin and 
Cefotaxime, Compared With Ampicillin 
and Gentamicin, for Neonates at Risk 
for Sepsis Is Associated With an 
Increased Risk of Neonatal Death 
drug yes yes yes no yes yes yes no no 6 
148 Center K. J.  2009 Lack of association of Kawasaki 
disease after immunization in a cohort 
of infants followed for multiple 
autoimmune diagnoses in a large, 
phase-4 observational database safety 
study of 7-valent pneumococcal 
conjugate vaccine: lack of association 
between Kawasaki disease and seven-
valent pneumococcal conjugate 
vaccine. 
vaccine yes yes yes no yes yes yes no yes 7 
149 Celedon J. C.  2002 Lack of Association between Antibiotic 
Use in the First Year of Life and 
Asthma, Allergic Rhinitis, or Eczema at 
Age 5 Years 
drug yes yes yes no yes no no no no 4 
150 Casscells S. W.  2009 The association between oseltamivir 
use and adverse neuropsychiatric 
outcomes among TRICARE 
beneficiaries, ages 1 through 21 years 
diagnosed with influenza 
drug yes yes yes yes yes yes yes no yes 8 
151 Brehler R.  2000 Safety of a two-day ultrarush insect 
venom immunotherapy protocol in 
comparison with protocols of longer 
duration and involving a larger 
number of injections 
drug yes yes no no no no no no yes 3 
152 Borgna-Pignatti C.  2006 Cardiac morbidity and mortality in 
deferoxamine- or deferiprone-treated 
patients with thalassemia major 
drug yes yes yes yes yes yes yes no yes 8 
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153 Blumentals W. A.  2007 The Safety of Oseltamivir in Patients 
with Influenza: Analysis of Healthcare 
Claims Data from Six Influenza 
Seasons 
drug yes yes yes yes yes yes yes no yes 8 
154 Bloomgren G.  2012 Assessment of malignancy risk in 
patients with multiple sclerosis treated 
with intramuscular interferon beta-1a: 
retrospective evaluation using a health 
insurance claims database and 
postmarketing surveillance data 
drug yes yes yes no yes yes yes no no 6 
155 Black S.  1999 Postmarketing evaluation of the safety 
and effectiveness of varicella vaccine 
vaccine yes yes yes no yes yes yes no yes 7 
156 Bertolini P.  2004 Platinum Compound-Related 
Ototoxicity in Children. Long-Term 
Follow-Up Reveals Continuous 
Worsening of Hearing Loss 
drug yes yes yes yes no no yes no no 5 
157 Belongia E. A.  2010 Real-Time Surveillance to Assess Risk 
of Intussusception and Other Adverse 
Events After Pentavalent, Bovine-
Derived Rotavirus Vaccine 
vaccine yes yes yes no yes yes yes no yes 7 
158 Bell J.  2010 Long-Term Safety of Recombinant 
Human Growth Hormone in Children 
drug yes no yes no no no yes no yes 4 
159 Baxter R.  2012 A postmarketing evaluation of the 
safety of Ann Arbor strain live 
attenuated influenza vaccine in 
children 5 through 17 years of age 
vaccine yes yes yes no yes yes yes no yes 7 
160 Barlow W. E.  2001 The Risk of Seizures after Receipt of 
Whole-Cell Pertussis or Measles, 
Mumps, and Rubella Vaccine 
vaccine yes yes yes no yes yes yes no yes 7 
161 Baird E. A.  1992 Effect of maintenance chemotherapy 
in childhood on numbers of 
melanocytic naevi 
drug yes no no no yes no yes no yes 4 
162 Backer C. L.  2007 Aprotinin is safe in pediatric patients 
undergoing cardiac surgery 
drug yes no yes no yes yes no no yes 5 
163 Ayuk F.  2008 Comparison of Two Doses of 
Antithymocyte Globulin in Patients 
Undergoing Matched Unrelated Donor 
Allogeneic Stem Cell Transplantation 
drug yes yes no no yes yes no no no 4 
164 August K. J.  2013 Comparison of Hypersensitivity 
Reactions to PEG-Asparaginase in 
Children After Intravenous and 
Intramuscular Administration 
drug yes yes yes no no no yes no no 4 
165 Ashraf E.  1999 Safety profile of ibuprofen suspension drug yes yes no no no no no no no 2 
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Note: Q1 to Q8 correspond to the eight questions of the Newcastle Ottawa scale (cohort version); Q5a and Q5b correspond to the two questions that assess whether a study controlled for selected 
confounding factors; for the current study, Q5a assessed control of confounding by age and Q5b assessed control of confounding by sex or medical indication; 
For each study, the total NOS score is derived by adding up all the ‘yes’ responses; yes=implies that the study earned a star for that NOS question; no= implies that the study did not earn a star for 
that NOS question 
in young children 
166 Arnheim-Dahlstrom 
L.  
2013 Autoimmune, neurological, and 
venous thromboembolic adverse 
events after immunisation of 
adolescent girls with quadrivalent 
human papillomavirus vaccine in 
Denmark and Sweden: cohort study 
vaccine yes yes yes yes yes yes yes no yes 8 
167 Armstrong P. K.  2011 Epidemiological study of severe febrile 
reactions in young children in Western 
Australia caused by a 2010 trivalent 
inactivated influenza vaccine 
vaccine yes yes yes no yes no yes no no 5 
168 Archambault P.  2012 Adrenal inhibition following a single 
dose of etomidate in intubated 
traumatic brain injury victims 
drug yes yes yes yes yes yes yes no yes 8 
169 Apter A. J.  2006 Is There Cross-Reactivity Between 
Penicillins and Cephalosporins? 
drug yes yes yes no yes yes yes no yes 7 
170 Andrews N.  2004 Thimerosal Exposure in Infants and 
Developmental Disorders: A 
Retrospective Cohort Study in the 
United Kingdom Does Not Support a 
Causal Association 
vaccine yes yes yes yes yes yes yes no yes 8 
171 Anderson H. D.  2012 Rates of 5 Common Antidepressant 
Side Effects Among New 
Adult and Adolescent Cases of 
Depression: A Retrospective 
US Claims Study 
drug yes yes yes yes yes yes yes no yes 8 
172 Aljadhey H.  2012 The safety of H1N1 vaccine in children 
in Saudi Arabia: a cohort study using 
modern technology in a developing 
country. 
vaccine yes yes yes no yes yes no no no 5 
173 Schelleman H.  2011 Cardiovascular Events and Death in 
Children Exposed 
and Unexposed to ADHD Agents 
drug yes yes yes no yes yes yes no yes 7 
174 Heron J.  
 
2004 
 
Thimerosal Exposure in Infants and 
Developmental Disorders: A 
Prospective Cohort Study in the United 
Kingdom Does Not Support a Causal 
Association 
vaccine 
 
yes yes yes no no no no no no 3 
    
177 | P a g e  
 
 
Table 2: Quality scores derived for 30 studies that applied the self-controlled case series (SCCS) design, assessed using a modified cohort 
version of the Newcastle Ottawa scale (NOS) 
S/N First author Year Title NOS Questions Total NOS 
score Q1  Q2 Q3 Q4 Q5a  Q5b Q6 Q7 Q 8 
1 Yih W. K.  2012 Surveillance for Adverse Events Following 
Receipt of Pandemic 2009 H1N1 Vaccine in 
the Post-Licensure Rapid Immunization 
Safety Monitoring (PRISM) System, 2009–
2010 
yes yes yes no yes yes yes no yes 7 
2 Wilson K.  2011 Adverse Events following 12 and 18 Month 
Vaccinations: a Population-Based, Self 
Controlled Case Series Analysis 
yes yes yes yes yes yes yes no yes 8 
3 Ward K. N.  2007 Risk of Serious Neurologic Disease After 
Immunization of Young Children in Britain 
and Ireland 
yes yes yes no yes no yes no yes 6 
4 Velazquez F. R.  2012 Postmarketing Surveillance of 
Intussusception Following Mass 
Introduction of the Attenuated Human 
Rotavirus Vaccine in Mexico 
yes yes yes no yes yes yes no yes 7 
5 Tse A.  2012 Signal identification and evaluation for risk 
of febrile seizures in children following 
trivalent inactivated influenza vaccine in 
the Vaccine Safety Datalink Project, 2010–
2011 
yes yes yes no yes yes yes no yes 7 
6 Taylor B.  2007 No increased risk of relapse after 
meningococcal C conjugate vaccine in 
nephrotic syndrome 
yes yes yes no yes yes yes no yes 7 
7 Sun Y.  2012 Risk of Febrile Seizures and Epilepsy After 
Vaccination With Diphtheria, Tetanus, 
Acellular Pertussis, Inactivated Poliovirus, 
and Haemophilus Influenzae Type b 
yes yes yes yes yes yes yes no yes 8 
8 Stehr-Green P.  2007 The risk of bronchiolitis hospitalisation 
following administration of a group B 
meningococcal vaccine in New Zealand 
yes yes yes no yes yes yes no yes 7 
9 Stehr-Green P.  2008 The risk of simple febrile seizures after 
immunisation with a new group B 
meningococcal vaccine, New Zealand 
yes yes yes yes yes yes yes no yes 8 
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10 Patel M. M.  2011 Intussusception Risk and Health Benefits of 
Rotavirus Vaccination in Mexico and Brazil 
yes yes yes no yes yes yes no yes 7 
11 O'Leary S. T.  2012 The Risk of Immune Thrombocytopenic 
Purpura After Vaccination in Children and 
Adolescents 
yes yes yes yes yes yes yes no yes 8 
12 Naleway A. L.  2009 Risk of immune hemolytic anemia in 
children following immunization 
yes yes yes yes yes yes yes no yes 8 
13 Murphy T. V.  2001 Intussusception among Infants Given an 
Oral Rotavirus Vaccine 
yes yes yes yes yes yes yes no yes 8 
14 Mullooly J.P.  2002 Wheezing lower respiratory disease and 
vaccination of full-term infants 
yes yes yes yes yes yes yes no yes 8 
15 Morgan T. M.  2011 Vaccines Are Not Associated With Metabolic 
Events in Children With Urea Cycle 
Disorders 
yes yes yes yes yes yes yes no yes 8 
16 Miller E.  2013 Risk of narcolepsy in children and young 
people 
receiving AS03 adjuvanted pandemic 
A/H1N1 2009 influenza vaccine: 
retrospective analysis 
yes yes yes yes yes yes yes no yes 8 
17 Miller E.  2001 Idiopathic thrombocytopenic purpura and 
MMR 
vaccine 
yes yes yes no yes yes yes no yes 7 
18 Kramarz P.  2000 Does Influenza Vaccination Exacerbate 
Asthma? Analysis of a Large Cohort of 
Children With Asthma 
yes yes yes no yes yes yes yes yes 8 
19 Huang W. T.  2010 Lack of Association Between Acellular 
Pertussis 
Vaccine and Seizures in Early Childhood 
yes yes yes no yes yes yes yes yes 8 
20 Hanf M.  2013 Validation of the French national health 
insurance information systemas a tool in 
vaccine safety assessment: Application to 
febrileconvulsions after pediatric 
measles/mumps/rubella immunization 
yes yes yes no yes yes yes no yes 7 
21 Hambidge S. J.  2012 Trivalent Inactivated Influenza Vaccine Is 
Not Associated With Sickle Cell Crises in 
Children 
yes yes yes no yes yes yes yes yes 8 
22 Hambidge S. J.  2006 Safety of Trivalent Inactivated Influenza 
Vaccine in Children 6 to 23 Months Old 
yes yes yes no yes yes yes yes yes 8 
23 Greene S. K.  2010 Near Real-Time Surveillance for Influenza 
Vaccine Safety: Proof-of-Concept in the 
Vaccine Safety Datalink Project 
yes yes yes no yes yes yes no yes 7 
24 Glanz J. M.  2011 Safety of Trivalent Inactivated Influenza 
Vaccine in Children Aged 24 to 59 Months 
yes yes yes yes yes yes yes yes yes 9 
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Note: Q1 to Q8 correspond to the eight questions of the Newcastle Ottawa scale (cohort version); Q5a and Q5b correspond to the two questions that assess whether a study controlled for selected 
confounding factors; for the current study, Q5a assessed control of confounding by age and Q5b assessed control of confounding by sex or medical indication; 
For each study, the total NOS score is derived by adding up all the ‘yes’ responses;  
yes=implies that the study earned a star for that NOS question; no= implies that the study did not earn a star for that NOS question 
  
in the Vaccine Safety Datalink 
25 France E. K.  2008 Risk of Immune Thrombocytopenic Purpura 
After Measles-Mumps-Rubella 
Immunization in Children 
yes yes yes yes yes yes yes yes yes 9 
26 Donegan K.  2013 Bivalent human papillomavirus vaccine and 
the risk of fatigue syndromes in girls in the 
UK 
yes yes yes no yes yes yes no yes 7 
27 De Wals P.  2012 Risk of Guillain-Barre´ Syndrome Following 
H1N1 Influenza Vaccination in Quebec 
yes yes yes no yes yes yes yes yes 8 
28 Benchimol E. I.  2013 Safety and Utilization of Influenza 
Immunization in Children With 
Inflammatory Bowel Disease 
yes no yes yes yes yes yes no yes 7 
29 Asturias E. J.  2013 Post-authorization safety surveillance of a 
liquid pentavalentvaccine in Guatemalan 
children 
yes yes yes no yes yes yes no yes 7 
30 Andrews N.  2007 Post-Licensure Safety of the Meningococcal 
Group C Conjugate Vaccine 
yes yes yes no yes yes yes no yes 7 
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Table 3: Quality scores derived for 73 case-control studies, assessed using a modified case control version of the Newcastle Ottawa scale 
(NOS) 
S/N First author Year Title Investigated 
exposure 
NOS Questions Total NOS 
score 
Q1  Q2 Q3 Q4 Q5a  Q5b Q6 Q7 Q 8 
1 White J. R.  2003 Discontinuation of levetiracetam 
because of behavioral side effects.  A 
case-control study 
drug yes yes yes yes no no yes yes no 6 
2 Walker A. M.  1988 Neurologic Events Following 
Diphtheria-Tetanus-Pertussis 
Immunization 
vaccine no yes yes yes yes yes yes yes no 7 
3 The Victorian 
Infant Collaborative 
study group 
2000 Postnatal corticosteroids and 
sensorineural outcome at 5 years of 
age 
drug yes yes no no yes yes yes no no 5 
4 Van Staa T. P.  2004 Are inhaled corticosteroids associated 
with an increased risk of fracture in 
children? 
drug yes yes yes no yes yes yes yes no 7 
5 Uno Y.  2012 The combined measles, mumps, and 
rubella vaccines and the total number 
of vaccines are not associated with 
development of autism spectrum 
disorder: The first case–control study 
in Asia 
vaccine yes yes yes yes yes yes yes yes no 8 
6 Tucker M. A.  1987 Leukemia After Therapy With 
Alkylating Agents 
for Childhood Cancer 
drug yes yes yes yes yes yes yes yes no 8 
7 Tanihara S.  2002 A Case-control Study of Asthma Death 
and Life-threatening Attack:Their 
Possible Relationship with Prescribed 
Drug Therapy in Japan 
drug no yes yes yes yes yes yes yes no 7 
8 Takahashi H.  2003 An epidemiological study on Japanese 
autism concerning routine childhood 
immunization history. 
vaccine yes yes yes yes yes yes yes yes no 8 
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9 Sutter R. W.  1992 Attributable risk of DTP (diphtheria and 
tetanus toxoids and pertussis vaccine) 
injection in provoking paralytic 
poliomyelitis during a large outbreak in 
Oman 
vaccine yes yes yes no yes no yes yes no 6 
10 Stehr-Green P.  2007 The risk of bronchiolitis hospitalisation 
following administration of a group B 
meningococcal vaccine in New Zealand 
vaccine no yes yes yes yes yes yes yes yes 8 
11 Spiro D. M.  2003 Association Between Antibiotic Use and 
Primary Idiopathic Intussusception 
drug yes yes yes yes yes yes yes yes no 8 
12 Smeeth L.  2004 MMR vaccination and pervasive 
developmental disorders: a 
case-control study 
vaccine no yes yes yes yes yes yes yes yes 8 
13 Schumock G. T.  2012 Risk of suicide attempt in asthmatic 
children and young 
adults prescribed leukotriene-
modifying agents: A nested 
case-control study 
drug no yes yes yes yes yes yes yes yes 8 
14 Schneeweiss S.  2009 Topical Treatments with Pimecrolimus, 
Tacrolimus and Medium- to High-
Potency Corticosteroids, and Risk of 
Lymphoma 
drug no yes yes yes no no yes yes yes 6 
15 Rzany B.  1999 Risk of S tevens-Johnson syndrome 
and toxic epider m a l 
necrolysis during first weeks of 
antiepileptic therapy: a casecontrol 
study 
drug yes yes no yes yes yes yes yes no 7 
16 Ray P.  2006 Encephalopathy After Whole-Cell 
Pertussis or Measles Vaccination Lack 
of Evidence for a Causal Association in 
a Retrospective Case–Control Study 
vaccine yes yes yes no yes yes yes yes no 7 
17 Rawson N. S.  1998 Hospitalizations for Aplastic Anemia 
and Agranulocytosis in 
Saskatchewan: Incidence and 
Associations with Antecedent 
Prescription Drug Use 
drug yes yes yes yes yes yes yes yes yes 9 
18 Plumb J.  2001 Exposures and Outcomes of Children 
With Urticaria Seen in a Pediatric 
Practice-Based Research NetworkA 
Case-Control Study 
drug yes yes yes no yes yes no yes no 6 
19 M. M. Patel 2011 Intussusception Risk and Health 
Benefits of Rotavirus 
Vaccination in Mexico and Brazil 
vaccine yes yes yes no yes yes yes yes no 7 
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20 Olsson D. S.  2012 Tumour recurrence and enlargement in 
patients with 
craniopharyngioma with and without 
GH replacement therapy 
during more than 10 years of follow-up 
drug yes yes yes no yes yes yes yes no 7 
21 Myleus A.  2012 Early Vaccinations Are Not Risk Factors 
for 
Celiac Disease 
vaccine yes yes yes no yes yes yes yes no 7 
22 Murphy T. V.  2001 Intussusception among Infants Given 
an Oral Rotavirus Vaccine 
vaccine yes yes yes yes yes yes yes yes no 8 
23 Mullooly J. P. 2007 Vaccines, antibiotics, and atopy drug and 
vaccine 
yes no yes yes yes yes yes yes yes 8 
24 Mullooly J. P. 2002 Wheezing lower respiratory disease 
and vaccination 
of full-term infants 
vaccine yes yes yes yes yes yes yes yes yes 9 
25 Miller D.  1993 Pertussis immunisation and serious 
acute neurological illnesses in children 
vaccine yes yes yes no yes yes yes yes yes 8 
26 Miller D. L. 1981 Pertussis immunisation and serious 
acute neurological 
illness in children 
vaccine yes yes yes no yes yes yes no no 6 
27 Mikaeloff Y.  2009 Hepatitis B vaccine and the risk of CNS 
inflammatory demyelination in 
childhood 
vaccine no yes yes no yes yes yes yes no 6 
28 Mikaeloff Y.  2007 Hepatitis B Vaccination and the Risk of 
Childhood-Onset Multiple Sclerosis 
vaccine yes no yes no yes yes yes yes no 6 
29 Menniti-Ippolito F.  2001 Niflumic acid and cutaneous reactions 
in children 
drug yes yes no yes no no yes yes no 5 
30 Melendez E.  2009 Serious Adverse Events During 
Procedural Sedation 
With Ketamine 
drug yes yes no yes no yes yes yes yes 7 
31 Martinez C.  2005 Antidepressant treatment and the risk 
of fatal and non-fatal self 
harm in first episode depression: 
nested case-control study 
drug yes yes yes no yes yes yes no yes 7 
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32 Mallol-Mesnard N.  2007 Vaccination and the risk of childhood 
acute leukaemia: the ESCALE study 
(SFCEy) 
vaccine yes no yes no yes yes yes yes no 6 
33 Maher J. E.  2004 Infant vaccinations and childhood 
asthma among full-term 
infants 
vaccine no no yes no yes yes yes yes yes 6 
34 Magnus P.  2009 Vaccination as teenagers against 
meningococcal disease and the risk of 
the chronic fatigue syndrome 
vaccine no no yes no yes yes no yes no 5 
35 Li S. T. T.  2004 Intussusception and Oral Poliovirus 
Vaccination: Is There an Association? 
vaccine no no yes no yes yes yes yes yes 6 
36 Kahn A.  1982 Phenothiazines and Sudden Infant 
Death Syndrome 
drug yes no yes yes no no yes yes no 5 
37 Kaatsch P.  2009 Case–control study on the therapy of 
childhood cancer 
and the occurrence of second 
malignant neoplasms in Germany 
drug no no yes no yes yes yes yes yes 6 
38 Jonville-Bera A. P.  2001 Sudden unexpected death in infants 
under 3 months of age and 
vaccination status ± a case-control 
study 
vaccine yes yes yes no yes yes yes no no 6 
39 Joffe L. S. 1992  Diphtheria-tetanus toxoids-pertussis 
vaccination does not increase the risk 
of hospitalization with an infectious 
illness 
vaccine yes no yes no yes yes yes yes no 6 
40 Jick H.  2004 Antidepressants and the Risk of 
Suicidal Behaviors 
drug no no yes yes yes yes yes yes yes 7 
41 Jick H.  2001 Live attenuated polio vaccine and the 
risk of intussusception 
vaccine yes no yes no yes yes yes yes yes 7 
42 Hurwitz E. S.  1985 Public Health Service Study on Reye's 
Syndrome and Medications. Report of 
the Pilot Phase 
drug yes no yes yes yes yes no yes no 6 
43 Hurwitz E. S.  1987 Public Health Service Study of Reye's 
Syndrome and Medications. Report of 
the Main Study 
drug yes no yes no yes yes no yes no 5 
44 Huerta C.  2002 Risk of clinical blood dyscrasia in a 
cohort of antibiotic users. 
drug yes yes yes no yes yes yes yes no 7 
45 Hoffman H. J. 1987 Diphtheria-Tetanus-Pertussis 
Immunization and Sudden Infant 
vaccine yes no yes no yes yes yes yes no 6 
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Death: Results of the National Institute 
of Child Health and Human 
Development Cooperative 
Epidemiological Study of Sudden Infant 
Death Syndrome Risk Factors 
46 Hamilton R. A. 1998 Frequency of hospitalization after 
exposure to known drug-drug 
interactions in a Medicaid population. 
drug no yes yes yes no no yes yes yes 6 
47 Hambidge S. J.  2012 Trivalent Inactivated Influenza Vaccine 
Is Not Associated With Sickle Cell 
Crises in Children 
vaccine yes yes yes yes yes yes yes yes yes 9 
48 Hambidge S. J.  2006 Safety of Trivalent Inactivated 
Influenza Vaccine in Children 6 to 23 
Months Old 
vaccine yes yes yes yes yes yes yes yes yes 9 
49 Grimaldi-Bensouda 
L.  
2011 Guillain-Barre´ Syndrome, 
Influenzalike Illnesses, and Influenza 
Vaccination During Seasons With and 
Without Circulating A/H1N1 Viruses 
vaccine yes yes yes no yes yes yes yes no 7 
50 Greco D.  1985 Case-control study on encephalopathy 
associated with 
diphtheria-tetanus immunization in 
Campania, Italy 
vaccine yes yes yes yes yes yes yes yes no 8 
51 Goodman M. J.  2006 The Safety of Trivalent Influenza 
Vaccine Among Healthy Children 6 to 
24 Months of Age 
vaccine yes yes no yes yes yes yes yes yes 8 
52 Gale J. L.  1994 Risk of Serious Acute Neurological 
Illness After Immunization With 
Diphtheria-Tetanus-Pertussis Vaccine A 
Population-Based Case-Control Study 
vaccine yes yes yes no yes yes yes yes no 7 
53 Gabb G. M.  1996 Epidemiological study of angioedema 
and ACE inhibitors 
drug no yes no yes yes yes yes yes no 6 
54 Feeney M.  1997 A case-control study of measles 
vaccination and inflammatory 
bowel disease 
vaccine yes yes yes no yes yes yes yes no 7 
55 Ernst P.  1993 Is the Association between Inhaled 
Beta-Agonist Use and Life-threatening 
Asthma because of Confounding by 
Severity? 
drug yes yes yes no yes yes yes yes yes 8 
56 Dieleman J.  2011 Guillain-Barré syndrome and 
adjuvanted pandemic influenza A 
(H1N1) 2009 vaccine: multinational 
case-control study in Europe 
vaccine yes yes no no yes yes yes yes yes 7 
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57 DeStefano F.  2001 Childhood Vaccinations, Vaccination 
Timing, and Risk of Type 1 
Diabetes Mellitus 
vaccine yes yes yes no yes yes yes yes yes 8 
58 Deivanayagam N.  1993 Intramuscular injection as a provoking 
factor for paralysis in acute 
poliomyelitis. A case control study.  
drug and 
vaccine 
yes yes no no yes yes yes yes no 6 
59 Dawkins T. N.  2009 Safety of intravenous use of ketorolac 
in infants following 
cardiothoracic surgery 
drug no no no no no no yes no no 1 
60 Davis R. L.  2001 Measles-mumps-rubella and other 
measles-containing vaccines do not 
increase the risk for inflammatory 
bowel disease: a case-control study 
from the Vaccine Safety Datalink 
project. 
vaccine yes yes yes no yes yes yes yes yes 8 
61 Dauvilliers Y.  2013 Increased risk of narcolepsy in children 
and adults 
after pandemic H1N1 vaccination in 
France 
vaccine yes no yes yes yes yes no yes no 6 
62 Campbell J. R.  2000 Systemic Candidiasis in Extremely Low 
Birth Weight Infants Receiving Topical 
Petrolatum Ointment for Skin Care: A 
Case–Control Study 
drug no yes no no yes yes yes no yes 5 
63 Bremner S. A.  2005 Timing of routine immunisations and 
subsequent hay 
fever risk 
vaccine no no yes yes yes yes yes yes yes 7 
64 Bremner S. A.  2003 Early-life exposure to antibacterials 
and the subsequent development of 
hayfever in childhood in the UK: case–
control studies using the General 
Practice Research Database and the 
Doctors’ Independent Network 
drug no no yes no yes yes yes yes yes 6 
65 Boyce T. G.  2004 Pertussis Vaccination and the Risk of 
Respiratory Syncytial 
Virus-Associated Hospitalization 
vaccine no no yes no yes yes yes yes yes 6 
66 Black S.  1997 Risk of hospitalization because of 
aseptic meningitis after measles-
mumps-rubella vaccination in one- to 
two-year-old children: an analysis of 
the Vaccine  
vaccine yes yes yes yes yes yes yes yes yes 9 
67 Black C. 2003 MMR vaccine and idiopathic 
thrombocytopaenic purpura 
vaccine yes yes no no yes yes yes yes yes 7 
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Note: Q1 to Q8 correspond to the eight questions of the Newcastle Ottawa scale (case-control version); Q5a and Q5b correspond to the two questions that assess whether a study controlled for 
selected confounding factors; for the current study, Q5a assessed control of confounding by age and Q5b assessed control of confounding by sex, medical indication or calendar time; 
For each study, the total NOS score is derived by adding up all the ‘yes’ responses;  
yes=implies that the study earned a star for that NOS question; no= implies that the study did not earn a star for that NOS question 
  
68 Bertuola F.  2010 Association between drug and vaccine 
use and acute immune 
thrombocytopenia in childhood: a 
case-control study in Italy. 
drug and 
vaccine 
yes no no yes no no yes yes no 4 
69 Bellis J.R.  2013 Adverse drug reactions and off-label 
and unlicensed medicines in children: a 
nested case–control study of inpatients 
in a pediatric hospital 
drug yes yes no yes yes yes yes yes no 7 
70 Anderson H. R.  2005 Bronchodilator treatment and deaths 
from asthma: case-control 
study 
drug yes yes no no yes yes yes yes no 6 
71 Ahlgren C.  2009 A population-based case–control study 
on viral infections 
and vaccinations and subsequent 
multiple sclerosis risk 
vaccine yes no yes no yes yes yes yes yes 7 
72 Centers of Disease 
Control and 
Prevention 
1993 Ceftriaxone-Associated Biliary 
Complications of Treatment of 
Suspected Disseminated Lyme 
Disease\p=m-\NewJersey, 1990-1992 
drug yes yes yes no no no yes yes no 5 
73 Gould M.S.  2009 Sudden Death and Use of Stimulant 
Medications in Youths 
drug yes no yes yes yes yes yes yes no 7 
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Table 4: Quality scores derived for 4 case crossover studies, assessed using a modified case control version of the Newcastle Ottawa scale 
(NOS) 
Note: Q1 to Q8 correspond to the eight questions of the Newcastle Ottawa scale (case-control version); Q5a and Q5b correspond to the two questions that assess whether a study controlled for 
selected confounding factors; for the current study, Q5a assessed control of confounding by age and Q5b assessed control of confounding by sex, medical indication or calendar time; 
For each study, the total NOS score is derived by adding up all the ‘yes’ responses;  
yes=implies that the study earned a star for that NOS question; no= implies that the study did not earn a star for that NOS question 
  
S/N First author Year Title Investigated 
exposure 
NOS Questions Total NOS 
score Q1  Q2 Q3 Q4 Q5a  Q5b Q6 Q7 Q 8 
1 France E. K.  2004 Safety of the Trivalent Inactivated 
Influenza Vaccine Among Children 
vaccine no yes yes yes yes yes yes yes yes 8 
2 Fosbol E. L.  2010 Cause-specific cardiovascular risk 
associated with nonsteroidal 
antiinflammatory drugs among 
healthy individuals. 
drug no yes yes yes yes yes yes yes yes 8 
3 Fosbol E. L.  2009 Risk of Myocardial Infarction and 
Death Associated With the Use of 
Nonsteroidal Anti-Inflammatory Drugs 
(NSAIDs) Among Healthy Individuals: 
A Nationwide Cohort Study 
drug no yes yes yes yes yes yes yes yes 8 
4 Biskupiak J. E.  2006 Gastrointestinal complications of over-
the-counter nonsteroidal 
antiinflammatory drugs. 
drug no yes yes yes yes yes yes yes yes 8 
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Chapter 5 Comparative (pharmacoepidemiological) effectiveness studies 
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Chapter 5.1 Comparing drug effectiveness in children: a systematic review 
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Abstract  
Context: In order to overcome the lack of knowledge about effects of drugs in children, data 
on drug effectiveness that can be generated using routine health care data might be useful. 
Objective: We conducted a systematic review of published pharmacoepidemiological studies 
that evaluated drug effectiveness in children to assess the current state of the art and potential 
gaps and areas of improvement. 
Data Sources: Relevant articles from inception to February 2015 were retrieved from Embase 
and Medline.  
Study Selection: We sequentially screened titles, abstracts and full texts, with independent 
validation.  
Data Extraction: Data regarding general information and study methods including statistical 
analysis were extracted systematically. Study quality was assessed with a modified Newcastle-
Ottawa-scale (NOS) Investigated drugs were ranked and compared with data on prevalence of 
pediatric drug use. 
Results: Out of 4926 unique articles, 164 full texts were retained. Most studies were from 
North America (46.7%). Only 78 studies (47.6%) reported the design: 90.9% were cohort 
studies. Neonates were least investigated. The drugs that were most often studied included 
systemic antibacterials (11.4%), psycholeptics (7.9%) and antiepileptics (7.6%). Adjustment for 
confounding was made using propensity scores in 8.5% of the studies. Studies that did not 
report the design were of lower quality. Many effectiveness studies were done on antineoplastic 
agents, which are not frequently used and few studies on analgesics and drugs for obstructive 
airway diseases which are frequently prescribed.  
Limitations:  
Conclusions:  There is ample opportunity to improve the comparative effectiveness research 
for drugs used in pediatrics; routinely prescribed drugswere seldom investigated. Modern 
methods for confounding adjustment, such as propensity scores, were rarely used.   
  
    
191 | P a g e  
 
Introduction  
Randomized Controlled Trials (RCTs) generate important drug efficacy evidence246,247 but such 
evidence may not be generalizable to routine clinical practice. Children were seldom included in 
RCTs prior to the pediatric regulation247 and therefore evidence on the effects of older (and 
most frequently used) drugs is often lacking, which leads to high frequencies of unlicensed or 
“off label” drug use22,248,249 Prescribing is then based on physician’s extrapolation from adults, 
but organ maturation and hormonal changes may impact drug pharmacokinetics and 
pharmacodynamics as children are not small adults, nor are the formulations always adequate 
or resulting in similar pharmacokinetics198,250. To address the lack of knowledge on the 
effectiveness of drugs in children, we should produce better evidence to guide routine drug 
prescribing in pediatrics. Comparative effectiveness research, that is based on routine health 
care data may therefore be especially important for this population251.  
We conducted a systematic review of the medical literature to assess the characteristics, quality 
and potential gaps of observational comparative studies that evaluated the effectiveness of 
drugs in children. 
 
Methods 
Search strategy 
This systematic review was conducted in accordance with PRISMA guidelines252. We identified 
relevant studies by searching Embase.com and Medline (via OvidSP) from inception to 24th 
February 2015. We applied the following abbreviated search strategy: “children” AND 
“pharmacoepidemiology” AND “comparative studies”. Details of the search strategy are included 
in Appendix 1.The search was limited to human research.  
 
Study selection 
We included all observational studies which have as objective to quantify and compare the 
effectiveness of a drug exposure(s) within the pediatric population (age 0-18 years). Drug 
exposures concerned all medicinal products, applied either systemically or locally. We excluded 
experimental studies and observational studies pertaining to case reports/series, compliance 
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rates to medicinal treatments, herbal treatment, non-pharmacological treatments, 
pharmacoeconomics, health services utilization, adults exclusively, vaccine exposures, abstracts, 
letters, duplicate studies, preliminary publications or reviews, and other languages (besides 
English). 
Validity assessment 
All retrieved titles and abstracts were initially screened by one reviewer (JD) and full texts of 
potentially relevant articles were obtained. A second reviewer (OO) who was blinded to the 
initial assessment independently screened a sample of abstracts that comprised all abstracts for 
which the first reviewer obtained full text, plus a random selection of abstracts rejected at the 
initial screening. Any disagreements between the two reviewers were examined by a third 
reviewer (CF). Full texts retained through this process were independently screened by two 
reviewers (JD and KP), while disagreements were examined by a third reviewer (OO). In order 
to validate the final set of selected articles, a random sample of all the articles retained by 
agreement between JD and KP was assessed by OO. Further disagreements were resolved by 
discussion. 
Data extraction  
For data extraction from the papers, we developed a standardized form that was pre-tested in 
10% (random selection) of the retained articles. The extracted data pertained to: general 
information (first author, year of publication, country of corresponding author and journal), 
funding source, study period, type of data, study population, study design, outcome, exposure, 
and statistical analysis (details in Appendix 2). Age categories were based on guidelines 
recommended by the international Conference on Harmonization (0-27days, 28days-23 months, 
2-11years, and 12-18 years)150. Two researchers (JD and KP) independently extracted data 
from the final set of included articles. Differences were resolved by discussion between the 
authors. 
All exposures were mapped to World Health Organization-Anatomical Therapeutic Chemical 
(WHO-ATC). When individual drugs were investigated, they were cross checked against the 
labels, using Micromedex Solutions for studies conducted in the USA and Health Canada Drug 
Product database for studies conducted in Canada. 
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Quality assessment 
.We applied a slightly modified form of the Newcastle-Ottawa-scale (NOS) 223. The NOS has 
been widely used and endorsed by The Cochrane Collaboration in its 2011 handbook 206. There 
are two versions, a cohort and case control version which both consist of eight multiple-choice 
questions that address subject selection, comparability (of cases and controls in case-control 
studies and of cohorts in cohort studies) and the assessment of the exposure (case control) or 
the outcome (cohort). The number of possible answers per question ranges from two to five 
and high quality responses earn one star totalling up to 9 stars (the comparability question 
earns up to 2 stars). The modified version of the NOS can be found in Appendix 3. Two 
researchers (JD and KP) independently assessed the quality of included articles using the NOS, 
disagreements were resolved through discussion between the authors.  
Data analysis 
Categorical variables are described using counts (proportions) and continuous variables with the 
median value and the interquartile (IOR) range. Ranks were assigned to the frequency of drug 
class in the review (1-20) and from outpatient drug utilization rates (1-51) based on a recent 
study in the BMJ248.  Drug classes with the same frequency of investigation were assigned the 
same rank. In the same way, drug classes with the same utilization rate were assigned the 
same rank. To investigate the association between funding source on one hand and BPCA, and 
reporting of study design and BPCA on the other hand, Pearson’s chi-square test was applied.All 
analyses were performed using Microsoft Excel 2010 and Statistical Package for the Social 
Sciences (SPSS) version 21. 
Results 
The literature search yielded 4926 unique records after de-duplication. Following title and 
abstract screening, 275 articles were retained and evaluated for inclusion (agreement between 
the researches was 87.6 %). After the full text review, 164 articles were retained (agreement 
between the researchers was 95.0%).The list of retained articles is available in the 
supplementary material (table 1). Details of the study selection process are presented in Figure 
1.  
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Figure 1: Flow chart depicting the selection of relevant articles 
 
Compared to the total number of published epidemiological studies that were indexed in 
Embase.com, the number of published pediatric comparative effectiveness studies increased 
more rapidly over time (figure 2).  
 
 
5542 papers identified via 
database search 
 
• Embase.com - 2830 
• Medline - 2712 
3926 articles screened after 
removal of duplicates 
• 3656 articles excluded 
• 1 article not retrieved 
269 full-text articles screened 
164 articles included in 
qualitative synthesis 
105 full texts excluded 
 
Experimental: 69 
Studies investigating adults exclusively: 12 
Case series: 12 
Drug utilization: 1 
Health services research: 1 
In Vitro: 1 
Other exposure: 1 
Other objective: 1 
Prenatal: 2 
Review: 1 
Letter: 3 
Studies investigating safety only: 1 
Studies investigating safety only:1 
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Figure 2: Distribution of retained articles by year of publication 
 
Most of the included studies were from North America (46.7%), Europe (29.7%) and Asia 
(15.2%). In 53.0 % of the studies the funding source was not reported. Public and private 
funding was reported in 17.1% and 15.9% respectively; while 7.3 percent of the studies 
reported that they didn’t receive any funding (private or public).  The number of studies with 
unclear funding source decreased from 63.6 % to 51.5% after the introduction of the Best 
Pharmaceuticals for Children’s Act (BPCA) in 2002, more studies reported public funding in the 
period after the introduction of the BPCA 
The study design was reported in 47.6% of the studies. Before the BPCA only 18.2% of the 
studies reported study design, while in the time period after the adoption study design was 
reported in 54.5% of the studies Cohort studies were the most common designs (90.8%) while 
case-control, self-controlled case series and case crossover designs accounted for 4.0%, 1.0% 
and 1.0% of the studies respectively. More than half of the studies (65.8%) investigated the 
pediatric population exclusively, the remainder pertained to adults and children. The most 
frequently investigated pediatric age groups were children (74.4%) and adolescents (72%). 
Less represented age groups were infants (45.1%) and neonates (31.1%).  
Antibacterials for systemic use (WHO-ATC 2nd level J01) were the most frequently investigated 
drug class (11.4%), followed by antiepileptics (WHO-ATC 2nd level N03) and psycholeptics 
(WHO-ATC 2nd level N05) (table 1).  
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Table 1: Twenty most frequently investigated therapeutic drug classes with median number of 
stars for all the studies investigating that drug class, assessed using the Newcastle Ottawa 
Scale 
a Proportion is based on the total number (394) of drugs investigated. 
 
Therapeutic Drug Class WHO-
ATC 
   N(%)a Median NOS 
(IQR) 
Antibacterials For Systemic Use J01 45(11.4) 6.0 (5.0-7.0) 
Psycholeptics N05 31(7.9) 5.0 (3.75-7.0) 
Antiepileptics N03 30 (7.6) 5.0 (4.0-6.0) 
Antineoplastic Agents L01 25 (6.3) 5.0 (5.0-8.0) 
Immunosuppressants L04 20 (5.1) 4.0 (4.0-5.0) 
Corticosteroids For Systemic Use H02 19 (4.8) 5.0 (4.0-6.0) 
Antivirals For Systemic Use J05 16 (4.1) 6.0 (5.0-9.0) 
Analgesics N02 15 (3.8) 4.0 (4.0-6.0) 
Antimycotics For Systemic Use J02 14 (3.7) 6.0 (5.0-7.0) 
Drugs For Obstructive Airway Diseases R03 14 (3.6) 7.0 (6.0-8.0) 
Nasal Preparations R01 12 (3.0) 7.0 (7.0-7.0) 
Psychoanaleptics N06 11 (2.8) 5.0 (5.0-5.0) 
Antiinflammatory And Antirheumatic 
Products 
M01 10 (2.6) 4.5 (4.0-6.0) 
Antimycobacterials J04 9 (2.4) 6.0 (5.5-8.0) 
Anesthetics N01 8 (2.1) 4.5 (3.0-5.0) 
Immune Sera And Immunoglobulins J06 8 (2.1) 8.0 (6.0-8.0) 
Antithrombotic Agents B01 8 (2.1) 6.0 (6.0-7.0) 
Beta Blocking Agents C07 7 (1.8) 5.0 (4.0-8.0) 
Cardiac Therapy C01 7 (1.8) 8.0 (5.0-8.0) 
Antidiarrheals,Intestinal, 
Antiinflammatory/Antiinfective Agents 
A07 5 (1.3) 5.0 (3.0- 5.5) 
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When the analysis was performed per age subgroup, a difference was observed only in 
neonates (table 2).  
Table 2: Most frequently investigated drug classes in specific age subgroups 
Age group  ATC-WHO  (N %)a 
Neonates N03 
(10.0) 
J01 
(9.2) 
J02 
(8.3) 
J05 
(6.7) 
L01 
(6.7) 
M01 
(5.8) 
N05 
(5.8) 
C01 
(4.2) 
J06 
(4.2) 
J04 
(3.3) 
Infants J01 
(21.2) 
N03 
(11.6) 
N05 
(7.9) 
J05 
(6.3) 
L01 
(6.3) 
J02 
(5.3) 
H02  
(3.7) 
J06 
(3.2) 
N02 
(3.2) 
C01 
(2.6) 
Children J01 
(13.6) 
N03 
(9.5) 
L01 
(7.9) 
N05 
(7.6) 
H02 
(4.7) 
L04 
(4.4) 
R03  
(4.4) 
J05 
(3.8) 
J02 
(3.2) 
J04 
(2.8) 
Adolescents J01 
(11.7) 
L01 
(8.1) 
N03 
(7.8) 
L04 
(5.8) 
H02 
(5.2) 
N05 
(5.2) 
J02 
(4.5) 
R01 
(3.9) 
R03 
(3.9) 
NO2 
(3.6) 
a Proportions are presented from left to right in a descending order 
 
The most frequently investigated drug classes in this subgroup were antiepileptics (WHO-ATC 
2nd level N03), followed by antibacterials for systemic use (WHO-ATC 2nd level J01) and 
antimycotics for systemic use (WHO-ATC 2nd level J02). Half of the drugs investigated in North 
American studies were based on off-label use. Dose response relationships were investigated in 
only 12.2 % of the studies, which included antihelmintics, antibacterials for systemic use and 
psycholeptics.  Figure 3 shows the ranking of drug classes by prevalence of use as reported in 
the literature and the frequency of publications on effectiveness.  
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Figure 3: Ranking of drug classes in published studies on effectiveness and prevalence of drug 
use for the fifteen most frequently investigated therapeutic drug classes 
 
The biggest gap can be observed for analgesics (WHO-ATC NO2) and drugs for obstructive 
airway diseases (WHO-ATC R03), anti-inflammatory and Antirheumatic (WHO-ATC M01) as well 
as the nasal preparations (WHO-ATC R01) which are all frequently utilized drug classes in the 
peediatric population but infrequently studied in comparative effectiveness research. On the 
other hand, for drug classes like Antineoplastic agents (WHO-ATC L01) and 
Immunosuppressants (WHO-ATC L04) for which the prevalence of use is low, comparative 
effectiveness studies were conducted frequently. 
More than half of the studies (60.4%) investigated only intermediate outcomes. Clinical 
outcomes were investigated in 27.4% of the studies, while 12.2% of the studies investigated 
both clinical and intermediate outcomes. Multiple outcomes were studied in 56.1% of the 
studies. Median number of outcomes investigated was 2 (IQR: 1-3).  
Most of the studies were based on retrospective re-use of data collected for other purposes 
(79.3%). The exact data-source for exposure and outcome was not clearly stated in 22.5% and 
14.0% of the studies, respectively. For the studies reporting the data source, medical charts 
were the most frequently used data source for both exposure (48.8%) and outcome (57.9%). 
Claims data were used in 10.0% of the studies and medical records from general practitioners 
in only 3.7 % of articles for exposure and 3.0 % for the outcome.   
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Adjustment for confounding was applied in 52.4% of studies, through restriction, matching and 
propensity scores adjustment in 12.8%, 14.0% and 8.5% of the studies respectively. 
Adjustment on instrumental variables was not applied in any study.  
The results of the quality assessment are reported in figure 4, 5 and 6.  
 
 
 
Figure 4: Risk of bias in Cohort studies where design was reported (evaluated using NOS) 
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Figure 5: Risk of bias in studies not reporting study design, where design was assessed as 
Cohort (evaluated using NOS) 
 
 
Figure 6: Risk of bias in case control studies (evaluated using NOS) 
 
All cohort studies earned a star for the representativeness of the exposed cohort, while only 8 
studies earned a star for the adequacy of follow up question (low follow up rate or follow up 
not reported). Median number of stars was 7.0 (IQR: 5.0 – 8.0). For the articles in which the 
study design was not reported, we classified the study design and evaluated the quality using 
Newcastle Ottawa Scale. Median number of stars was 5.0 (IQR: 4.5-5.0). 
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In total, five studies used a case-control design. Median number of stars was 4.0 (IQR: 2.5 – 
6.5). The quality of studies that investigated dose-response is provided in figure 7. 
 
 
Figure 7: Risk of bias in studies investigating dose effect relationship (evaluated using NOS) 
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This paper provides a systematic overview of observational comparative studies evaluating drug 
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opportunities. The number of pharmacoepidemiological studies that focus on comparative 
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effectiveness research in children, we compared our findings with the prevalence of drug use in 
three European countries4 (figure 3). Although commonly utilized, analgesics (WHO-ATC NO2), 
drugs for obstructive airway diseases (WHO-ATC R03), anti-inflammatory and Antirheumatic 
(WHO-ATC M01) drugs and nasal preparations (WHO-ATC R01) were seldom studied, possibly 
because effects can be investigated in clinical trials. Although seldom utilized, Antineoplastic 
agents (WHO-ATC L01) and Immunosuppressants (WHO-ATC L04) were frequently studied, 
The reason for this may be the well-known adverse effects, for which their benefit-risk profile 
needs to be continuously evaluated. In addition, studying the beneficial effects of these drugs 
will require long-term studies that are only feasible in observational research. The same pattern 
existed in the different pediatric age groups. Detailed information on dose was often absent and 
only few studies investigated dose-effect relationship. We recommend closer collaboration 
between pediatricians, clinical pharmacologists and pharmacoepidemiolgists in conducting dose-
effect studies, which represents a missed opportunity to not investigate dose effects250.  
Only few studies used Electronic Healthcare Records databases, even though their great 
potential for pediatric research has been demonstrated253. It shows that the full potential of 
available data sources is not being exploited for comparative effectiveness research in children. 
Confounding by indication is a serious problem in comparative effectiveness research and needs 
to be dealt with properly. The studies that we reviewed applied mostly traditional methods such 
as multivariate modelling analysis, matching and restriction. The more modern methods were 
applied in only few studies. Propensity scores were not used frequently although these are 
particularly suited for comparative effectiveness studies247,254.  
Based on quality assessment with the Newcastle-Ottawa scale, cohort studies had higher scores 
than case control studies. Unfortunately there is no established threshold to label studies as 
having low or high risk of bias206. Metwally et al used a cut-off of five255, while Chowdhury et al 
used a cut-off of seven for medium risk of bias and nine for low risk of bias256. Studies on 
analgesics and immunosuppressants had the lowest median scores. The low number of stars for 
analgesics, a frequently utilized drug class, may be explained by the specific challenges in pain 
studies. Firstly, it is difficult to define pain as an outcome, which can lead to misclassification of 
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the outcome and secondly, it is difficult to assess the use of over-the-counter medications and 
medications that are used as needed in various doses257. 
Since this review didn’t focus on any specific exposure or outcome, we introduced the most 
important restrictions (such as “Randomized Controlled Trial” as keywords) in the search 
algorithms in order to retrieve the most relevant articles and make the review process more 
feasible. This means that some relevant studies may have been missed. However, considering 
the size and the objectives of this review, we believe that this would not significantly influence 
our conclusions. Also, our review was limited to studies published in English language. 
Based on the systematic review and the reported results we conclude that comparative 
effectiveness research in pediatric pharmacoepidemiology is heavily underdeveloped underlining 
the big potential that is available to improve our knowledge on the effects of drugs in children. 
State of the art methods should be applied to control for confounding, and many frequently 
drugs lack proper effectiveness studies and do not properly use the wealth of big data that is 
available. Collaboration between pharmacoepidemiologists, pediatricians and pediatric clinical 
pharmacologists should be boosted to improve the quantity and quality of the studies.  With 
improvements in recognized areas, comparative effectiveness research might considerably 
contribute to better drug use in children. 
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Appendix 1: Full search strategy 
 
Search criteria for Embase.com 
((('drug therapy'/exp OR drug/exp OR 'drug therapy':lnk OR ((medication* OR medicine* OR 
drug* OR pharmac* OR medicament* OR 'medicinal product' OR 'medicinal products' ) NEAR/3 
(therap* OR treatment* OR effect*)):ab,ti) AND ('comparative effectiveness'/de OR ((compar* 
NEAR/3 effect*)):ab,ti)) OR ('drug comparison'/exp OR ((medication* OR medicine* OR drug* 
OR pharmac* OR medicament* OR 'medicinal product' OR 'medicinal products' ) NEAR/3 
(effectiv* OR efficien* OR compar*)):ab,ti)) AND ('epidemiology'/de OR 
pharmacoepidemiology/de OR 'cohort analysis'/de OR 'observational study'/de OR 'retrospective 
study'/de OR 'prospective study'/de OR 'longitudinal study'/de OR 'case control study'/exp OR 
'Cross-sectional study'/exp OR (epidemiol* OR pharmacoepidemiol* OR (Cross NEXT/1 
section*) OR (population NEXT/1 bas*) OR Cohort* OR (follow NEXT/1 up*) OR observation* 
OR Longitudinal OR retrospectiv* OR prospectiv* OR (case NEAR/3 (referen* OR match* OR 
nested OR  'cross over' OR  centered OR  coverage OR control*)) OR ('self controlled' NEXT/1 
serie*)):ab,ti)  AND (pediatrics/exp OR child/exp OR childhood/exp OR newborn/exp OR 
((adolescent/exp OR adolescence/exp) NOT (adult/exp)) OR (child* OR pediatric* OR 
paediatric* OR infant* OR infancy OR baby OR babies OR toddler* OR neonate* OR newborn* 
OR premature* OR adolescen* OR teenage* OR preschool OR school* OR neonat*):ab,ti)  NOT 
(vaccine/exp OR vaccination/exp OR 'randomized controlled trial'/exp OR 'traditional 
medicine'/exp OR homeopathy/exp OR 'alternative medicine'/exp OR (vaccin*):ti OR 
'randomized controlled trial':ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Conference Paper]/lim OR [Editorial]/lim) NOT ([animals]/lim NOT [humans]/lim) 
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Search criteria for Medline (via OvidSP) 
(((exp drug therapy/ OR drug therapy.xs. OR ((medication* OR medicine* OR drug* OR 
pharmac* OR medicament* OR medicinal product OR medicinal products ) ADJ3 (therap* OR 
treatment* OR effect*)).ab,ti.) AND (exp Comparative Effectiveness Research/ OR ((compar* 
ADJ3 effect*)).ab,ti.)) OR (((medication* OR medicine* OR drug* OR pharmac* OR 
medicament* OR medicinal product OR medicinal products ) ADJ3 (effectiv* OR efficien* OR 
compar*)).ab,ti.)) AND (epidemiology/ OR epidemiology.xs. OR Epidemiologic Studies/  ORexp 
Cohort Studies/ OR observational study.pt. OR Case-Control Studies/ OR Cross-Sectional 
Studies/ OR (epidemiol* OR pharmacoepidemiol* OR (Cross ADJ section*) OR (population ADJ 
bas*) OR Cohort* OR (follow ADJ up*) OR observation* OR Longitudinal OR retrospectiv* OR 
prospectiv* OR (case ADJ3 (referen* OR match* OR nested OR  cross over OR  centered OR  
coverage OR control*)) OR (self controlled ADJ serie*)).ab,ti.)  AND (exppediatrics/ OR exp 
child/ OR exp infant/ OR ((adolescent/) NOT (exp adult/)) OR (child* OR pediatric* OR 
paediatric* OR infant* OR infancy OR baby OR babies OR toddler* OR neonate* OR newborn* 
OR premature* OR adolescen* OR teenage* OR preschool OR school* OR neonat*).ab,ti.)  
NOT (exp vaccines/ OR exp vaccination/ OR exp Medicine, Traditional/ OR homeopathy/ OR exp 
Complementary Therapies/ OR randomized controlled trials.pt. OR (vaccin*).ti. OR randomized 
controlled trial.ti.) NOT (letter OR news OR comment OR editorial OR congresses OR 
abstracts).pt. NOT (exp animals/ NOT humans/) 
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Appendix 2: Data extraction form 
General data 
 
a. Unique ID |__|__|__| 
b. First author (surname) …………………………………………………………. 
c. Year of publication |__|__|__|___| 
d. Country (corresponding author) ……………………………………………………... 
e. Journal (abbreviation)………………………………………………………………………………………. 
f. Funding sources: |__| Public |__| Private |__| Public and private|__| No funding 
|__|unclear 
 
Study design 
 
a. Was study design clearly reported? |__| Yes        |__| No   
Some studies do not report on study design. If the answer to this question is ‘no’, provide 
answer to only question ‘b’. In addition, answer the questions for quality assessment.  
b. Number of designs studying the same association and using the same data……….  
c. Cohort |__| Yes        |__| No   
d. Case-control |__| Yes   |__| No   (including nested case-control studies) 
e. Case-based  
i. self-controlled case series (SCCS) |__| Yes   |__| No 
ii. case cross-over |__| Yes   |__| No 
iii. case-time-control |__| Yes   |__| No 
iv. others |__| Yes   |__| No   
f. Data collection mode  
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i. prospective |__| Yes  |__| No 
ii. retrospective |__| Yes  |__| No 
iii. unclear |__| Yes  |__| No 
 
Study period 
 
a. Date of Start of study period  | _|__|__|___|DDMMYYYY 
b. Date of End of study period  |__|__|__|___| DDMMYYYY 
 
Type of data 
 
a. Only primary |__| (data collected specifically for the study) 
b. Only secondary   |__| (data collected for other purposes) 
c. Mixed (combining primary and secondary)|__|  
 
Study population (age range as in inclusion criteria) 
 
a. Minimum age |__| and unit of age: days|__| months|__| years|__| 
b. Maximum age|__|  and unit of age: days|__| months|__| years|__| 
c. unclear |__|  
If ‘c’ then what is the minimum and maximum age given in the results (regardless of the study 
group)? 
a. Minimum age |__| and unit of age: days|__| months|__| years|__| 
b. Maximum age|__| and unit of age: days|__| months|__| years|__| 
Outcome 
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a. Number of events studied…………….. 
b. Event term(s)………………….. 
c. Intermediate outcome  |__| Yes  |__| No 
d. Clinical outcome |__| Yes  |__| No 
e. Was the event(s) definition(s) clearly described or sourced by a stated reference? |__| 
Yes  |__| No 
f. Was the event(s) validated by experts? |__| Yes  |__| No 
g. Was the event(s) validation (s) done blinded to exposure?  |__| Yes  |__| No 
h. Characteristics of the event (s): (more than 1 option is possible) 
a. Acute |__| Yes  |__| No  |__| Unclear 
b. Rare |__| Yes  |__| No  |__| Unclear 
c. Irreversible (e.g. mortality, handicap …) |__| Yes  |__| No |__| Unclear 
d. Recurrent |__| Yes  |__| No |__| Unclear 
e. Sudden onset |__| Yes  |__| No |__| Unclear 
i. Data sources from which data about the events were extracted 
i. Institution or administrative /electronic Hospital records |__| Yes  |__| No 
ii. Paper medical charts/visits at the clinic |__| Yes  |__| No 
iii. Primary healthcare database |__| Yes  |__| No 
iv. Claims/reimbursement database |__| Yes  |__| No 
v. Registry |__| Yes  |__| No 
vi. Self-report questionnaire or query |__| Yes  |__| No 
vii. Telephone call |__| Yes  |__| No 
viii. Web site |__| Yes  |__| No 
ix. Interview |__| Yes  |__| No 
    
209 | P a g e  
 
x. Others |__| Yes  |__| No 
 
Exposure  
 
a. Was drug class studied|__| Yes  |__| No  
b. Number of drug classes studied ………………….. 
c. Drug classes studied ………………….. 
d. Was specific drug studied|__| Yes  |__| No 
e. Number of drugs studied………………….. 
f. Substance name (WHO) ………………….. 
g. ATC code reported |__| Yes |__| No …………if yes reported ATC code:…………………. 
h. Characteristics of exposure in the paediatric  indication (s): 
i. Rare |__| Yes  |__| No |__| Unclear 
ii. Intermittent |__| Yes  |__| No |__| Unclear 
iii. Chronic |__| Yes  |__| No |__| Unclear 
iv. Exposure is changing medication (e.g. new dose, new formulation…) |__| Yes  |__| No 
|__| Unclear 
i. Is the effect of dose studied? |__| Yes  |__| No 
j. Data sources of exposure data 
i. In patient dispensing data  |__| Yes  |__| No  (electronic prescription data) 
ii. Medical charts at the clinic |__| Yes  |__| No  (paper prescription charts) 
iii. Primary healthcare database |__| Yes  |__| No 
iv. Outpatient dispensing data (pharmacy/claims) |__| Yes  |__| No 
v. Registry |__| Yes  |__| No  (including vaccination registry) 
vi. Self-report questionnaire or query |__| Yes  |__| No 
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vii. Telephone call |__| Yes  |__| No 
viii. Web site |__| Yes  |__| No 
ix. Interview |__| Yes  |__| No 
x. Others |__| Yes  |__| No 
 
Statistical analysis and Results 
 
a. Calculation of a sample size is reported |__| Yes  |__| No 
If yes, required sample size calculated …….. 
b. Total size of the study population  
i. Number of cases………. / Number of controls……….  
ii. Size of exposed cohort ………. / Size of non-exposed cohort ………. (absolute number for 
fixed cohorts and PY for dynamic cohorts) 
iii. Number of cases……….   
c. Length of follow-up was summarized using: |__| mean |__|median |__|unclear (If the 
answer is ‘unclear’, ignore questions ‘i’ and ‘ii’ that follow). 
i. Exposed cohort ………. / Non-exposed cohort ………. (Cohort) 
ii. Cases……….  (SCCS) 
d. Adjustment for confounding variables has been made |__| Yes  |__| No 
If yes what has been performed? 
Restriction |__| 
Matching |__| 
Stratification|__| 
Propensity score matching/adjusting/stratifying|__| 
Instrumental variable |__| 
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Multivariate modelling analysis |__| 
Adjusted by study design (case-only) |__| 
 
e. Primary statistical analysis (these questions should be completed for primary analysis, if 
primary objective is not described or unclear then just complete the first question and not the 
remaining. 
 Was the primary objective clearly defined? |__| Yes  |__| No |__| unclear 
 Were results on primary analysis presented for the paediatric population?  Not 
presented|__| adjusted|__|  unadjusted|__| unclear|__| 
f. There is at least one statistically significant result for the paediatric population |__| Yes  
|__| No 
If no, the authors discussed the problem of having a lack of power |__| Yes |__| No 
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Appendix 3: Quality assessment (Modified Newcastle-Ottawa Scale) 
 
A. COHORT STUDIES (Scale) 
 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be awarded for comparability 
 
Selection 
 
1. Representativeness of the exposed cohort 
a. truly representative of the average _______________ (describe) in the community* (if 
in general population with claims/medical records and no exclusion criteria)  
b. somewhat representative of the average ______________ in the community* (if in 
general population with claims/medical records and exclusion criteria) 
c.  selected group of users e.g. nurses, volunteers (e.g. from setting, if only in hospital 
whereas drug is also used outpatient) 
d. no description of the derivation of the cohort 
 
2. Selection of the non-exposed cohort 
a. drawn from the same community as the exposed cohort* 
b. drawn from a different source 
c. no description of the derivation of the non-exposed cohort 
 
3. Ascertainment of exposure 
a. secure record (e.g. surgical records) * 
b. structured interview * 
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c. written self-report 
d. no description 
 
4. Demonstration that outcome of interest was not present at start of study 
a. yes * 
b. no 
 
Comparability 
 
5. Comparability of cohorts on the basis of the design or analysis 
a. study controls for  age * 
b. study controls for any additional factor *(sex or medical indication) 
 
Exposed and non-exposed individuals must be matched in the design and/or confounders must 
be adjusted for in the analysis. If the relative risk for the exposure of interest is adjusted for the 
confounders listed, then the groups will be considered to be comparable on each variable used 
in the adjustment. 
Statements of no differences between groups or that differences were not statistically 
significant are not sufficient for establishing comparability.  
 
 Outcome 
 
6. Assessment of outcome 
a. independent blind assessment * 
b. record linkage * 
c. self-report 
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d. no description 
 
7. Was follow-up long enough for outcomes to occur  
a. yes (select an adequate follow up period for outcome of interest) * 
b. no 
 
8. Adequacy of follow up of cohorts (please assess whether fixed (reporting cumulative 
incidence with persons as denominator or dynamic cohort (person-time as denominator) ) 
a. complete follow up in fixed cohort- all subjects accounted for * 
b. subjects lost to follow up in fixed cohort unlikely to introduce bias - small number lost - 
> __80%__ % (select an adequate %) follow up, or description provided of those lost) * 
c. dynamic cohort study * 
d. follow up rate < ____% (select an adequate %) and no description of those lost in 
fixed cohort 
e. no statement in fixed cohort 
 
B. CASE-CONTROL 
 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for Comparability. 
 
Selection 
 
9. Is the case definition adequate? 
a. yes, with independent validation * 
b. yes, e.g. record linkage or based on self-reports 
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c. no description 
 
10. Representativeness of the cases 
a. consecutive or obviously representative series of cases  * 
b. potential for selection biases or not stated 
 
11. Selection of Controls 
a. community controls *  
b. hospital controls 
c. no description 
 
12. Definition of Controls 
a. no history of disease (endpoint) * 
b. no description of source 
 
Comparability 
13. Comparability of cases and controls on the basis of the design or analysis 
a. study controls for age  * 
b. study controls for any additional factor  *( sex or indication) 
 
Cases and controls must be matched in the design and/or confounders must be adjusted for in 
the analysis. If the relative risk for the exposure of interest is adjusted for the confounders 
listed, then the groups will be considered to be comparable on each variable used in the 
adjustment. 
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Statements of no differences between groups or that differences were not statistically 
significant are not sufficient for establishing comparability.  
 
Exposure 
 
14. Ascertainment of exposure 
a. secure record (e.g. surgical records, medical charts) * 
b. structured interview where blind to case/control status * or dispensing databases or 
prescription data or medical records * 
c. interview not blinded to case/control status 
d. written self-report  
e. no description 
 
15. Same method of ascertainment for cases and controls 
a. yes  * 
b. no 
 
16. Non-Response rate 
a. Similar response rate for both cases and controls  * 
b. non respondents described 
c. rate different and no designation 
d. non-response rate not reported 
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Chapter 5.2 Comparing drug effectiveness in children using propensity scores 
based on different durations of patient history: a retrospective cohort study 
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Abstract 
Purpose: In order to control for confounding by indication in comparative (drug) effectiveness 
studies, propensity scores (PS) methods may be utilized. Since childhood disease or outcomes 
are often acute we compared the impact of using different look back periods in electronic 
health care data, for the construct of the PSs. This was applied to a comparison of asthma 
exacerbations in combinations of corticosteroids/long-acting beta-2-agonists (ICS+LABA), either 
as fixed combination or used as loose combination (2 separate inhaler devices). 
Methods: We created a cohort of children (5-17 years) diagnosed with asthma from the Dutch 
Integrated Primary Care information (IPCI) database. This cohort was subdivided in  new users 
of inhaled corticosteroids/long-acting beta-2-agonists (ICS+LABA), either as fixed combination 
or used as loose combination (2 separate inhaler devices). The outcome of interest was 
moderate to severe asthma exacerbations. Propensity scores  for type of treatment were fitted 
using co-morbidity and drug use history in different time windows namely 1 week, 1 month, 3 
months, 1 year and full history prior to the start of treatment. Time to first asthma exacerbation 
was analysed with a Cox Proportional Hazard regression. PSs were used for matching, for 
inverse probability treatment weighting and as adjustment variable. We compared our results to 
published clinical trials on the efficacy of ICS+LABA in the prevention of asthma exacerbations.  
Results: Out of 39,682 asthmatic children, 3,500 (8.8%) were new users of either ICS+LABA 
fixed (3,324 [95.0%]) or loose (176 [5.0%]). The crude HR for an asthma exacerbation, 
comparing ICS+LABA fixed to loose was 0.366 (95% confidence interval [CI]: 0.202; 0.664).  
PS-matched HR (1-week, 1-month and 3-month) were 0.480 (95% CI: 0.222; 1.036); 0.601 
(95% CI: 0.262; 1.376) and 0.699 (95% CI: 0.311; 1.571) respectively. 
Conclusions: PS models can be used to control for confounding in pediatric comparative 
(drug) effectiveness studies, the impact of different look back periods and the choice of the way 
to implement the PS is important. The results are comparable to clinical trial data on the 
comparison between fixed and loose ICS+LABA combinations in preventing worsening of 
asthma in children. 
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Introduction 
Historically, children have been underrepresented in randomized clinical trials (RCTs) because 
of ethical, scientific and technical issues as well as commercial priorities258. Yet doctors 
prescribe approved drugs for children based on mainly evidence extrapolated from adults. 
Appropriate pediatric doses and formulations are often lacking. To evaluate the ‘real-world’ 
effectiveness of drug therapies in pediatrics, comparative effectiveness studies can be 
conducted. In such studies, drug exposure is dependent on prescribers’ decisions taking into 
account the clinical (including disease severity), functional and/or behavioral characteristics of 
patients. In addition, the prescribers’ preferences may vary over time. Selective prescribing can 
result in confounding by indication259, which should be adequately controlled to obtain valid 
study results.  
Asthma is a common and chronic condition in children. Inadequate treatment can result in poor 
quality of life. The Global Initiative for Asthma (GINA) recommends a step-wise approach to 
treating  asthma, depending on the severity21. Step 3 and step 4 of asthma treatment consist of 
use of inhaled corticosteroids (ICS) in combination with long-acting beta-2-agonists (LABA)260. 
Both drugs can be combined in a single device (ICS+LABA fixed) thereby improving adherence 
to treatment with  better outcomes, especially in children in whom treatment adherence may be 
worse261. Clinical trials already investigated the efficacy and safety of fixed combination of 
ICS+LABA compared to ICS in children with asthma. Clinical guidelines promote the use of 
ICS+LABA as fixed compared to loose combination as observational studies have shown that 
treatment adherence is higher for the fixed combination. In young children (<6 years), few 
studies, and to our knowledge none in children only, investigated the effectiveness of 
ICS+LABA as fixed combination vs loose combination in the prevention of asthma 
exacerbations. To obtain valid results, confounding by indication resulting from varying levels of 
asthma severity or from other patient characteristics should be adequately controlled.  
Methods for confounding control depend on the type of design and treatment 
pattern(intermittent or chronic), but one of the most recommended strategies for controlling 
confounding by indication in cohort studies is the propensity score, especially when the number 
of events are small and the set of measurable risk factors high262. The PS is an estimated 
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probability of receiving a specific treatment rather than another, given a set of baseline 
characteristics263. It can be used to adjust for imbalances between treatment groups.  
The factors that exacerbate asthma and result in treatment step-up are likely to occur shortly 
before such step-up but the relevant period over which confounding occurs is not clear. Since 
there is no clear guidance on the impact of, or use of different look-back periods to build the 
propensity score model we investigated this using a real life example of a comparison of the 
effectiveness of loose and fixed combinations of ICS + LABA  on the prevention of asthma 
exacerbations as a prototype.  
Methods 
Study design and data source 
We conducted a retrospective cohort study utilizing data from the Dutch Integrated Primary 
Care Information database (IPCI), a population-based general practice database. IPCI is a 
longitudinal observational dynamic database containing the complete electronic medical records 
of approximately 1,500,000 patients from about 450 general practitioners in the Netherlands. 
Regarding the Dutch healthcare system, patients register with a single General Practitioner (GP) 
who acts as a gatekeeper for secondary care. Patients’ records comprise anonymized data 
pertaining to demographics, symptoms and diagnoses, referrals, laboratory tests and results, 
drug prescriptions, hospitalizations and discharge letters. Details of the data source have been 
published elsewhere 47. Diagnoses are coded according to the International Classification for 
Primary Care (ICPC) 48, and drug names are coded following the World Health Organization-
Anatomic Therapeutic Chemical (WHO-ATC) classification system. The study and access to the 
database were approved by the IPCI Governance Board (reference number 3/2012). 
 
Study population  
We created a cohort of all children (5-17 years) with asthma who were registered in the 
database for at least one year during the period January 1 2008 to December 31 2013. In order 
to enter the asthma cohort, the children had to be enrolled in IPCI for at least one year and 
have at least one asthma-specific disease code (ICPC=‘R96’) together with prescription of 
asthma drugs within 3 months before or after an asthma code. The asthma drugs comprised 
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the following: inhaled corticosteroids (ICS), short-acting beta-2-agonists (SABA), long-acting 
beta-2-agonists (LABA), ICS+LABA fixed, leukotriene receptor antagonist (LTRA), short-acting 
muscarinic antagonist (SAMA), fixed combination of SABA+SAMA, xanthenes and anti-IgE 
treatment. Information on drug use was retrieved from prescription records by searching on the 
corresponding ATC codes. The codes are presented in appendix 1. 
From the cohort of children with asthma, children entered the study cohort upon the ‘first’ 
prescription of ICS+LABA - either fixed (primary exposure) or loose (figure 1). For both 
treatment groups, use of the treatment (ICS+LABA fixed and ICS and LABA loose respectively) 
in the year before cohort entry was an exclusion criterium. All the children in the study cohorts 
were allowed to use other drugs for asthma. Start of follow-up was from cohort entry and end 
of follow-up was defined as the first of the following dates: leaving the GP practice, becoming 
18 years old, switching from ICS+LABA fixed to the loose combination or vice versa, first 
occurrence of the study outcome or end of the study period.  
 
 
 
Figure 1: Entry of children with asthma into the ‘ICS+LABA’ (loose) group 
 
Outcome 
The study outcome was a first episode of moderate to severe asthma exacerbation. A moderate 
asthma exacerbation was defined as the need for systemic corticosteroids for treatment of 
asthma. Severe asthma exacerbation was defined as visit to the emergency department or 
hospitalization because of asthma exacerbation264.  
Covariates included in the propensity score models 
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Usually when calculating PS, all potential confounders (i.e. baseline characteristics related to 
either the outcome and/or exposure) are included in the PS model 265,266. For the current study, 
the following characteristics were included in the PS models based on clinical knowledge and 
evidence from literature: 264,267-275: Age (years), sex, calendar year of treatment start, season of 
treatment start (winter, spring, summer, and autumn), severity of asthma (medical history of 
exacerbations or use of high-dose ICS), history (or concomitant use) of SABA, SAMA and LTRA, 
comorbidity (obesity) and history of  use (or concomitant use) of antacids, hypnotics, 
anxiolytics, antidepressants, anti-histamines, antibiotics, nasal preparations and aspirin. 
Previous history or current episodes of the following comorbidities were initially considered but 
since the drugs for treating the comorbidities were also included in the PS model, the 
comorbidities were excluded so that the model could converge: gastrointestinal reflux disease, 
anxiety, psychosis and lower respiratory tract infection.  In order to investigate the impact of 
the different look back periods the aforementioned characteristics were extracted in the 
following periods prior to cohort entry (figure 2): 1 week, 1 month, 3 months, 1 year and the 
full history (within IPCI) of each study subject. It should be noted that the covariate information 
included for each successively longer period was incremental when compared to the previous 
period. Therefore the previous period was not nested within the longer period. 
 
 
Figure 2: The different periods (before study entry) in which covariates were 
assessed, which were included in the calculation of propensity scores 
 
Statistical analyses 
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Comparison of baseline characteristics prior to calculation of the propensity score was done 
using Chi-square test for categorical variables and analysis of variance for continuous variables. 
Cox proportional hazards regression models were applied to compare the time to first episode 
of exacerbation for children receiving incident prescription of ICS+LABA fixed versus loose. We 
calculated hazard ratios (HR) and corresponding 95% confidence intervals (CIs).  
We used binary logistic regression to estimate the propensity score and compared the PS 
distribution between the exposure groups graphically. 
We compared the crude HRs with the HRs from conventional multivariate modelling and from 
analyses using different PS methods: matching (PS-matching), inverse probability of treatment 
weighting (PS-IPTW), and adjustment (PS-adjustment) 276. For matching, we applied caliper 
matching without replacement 276,277. Compared to ICS+LABA fixed, fewer children received the 
loose combination and therefore, each subject receiving the loose combination was matched 
with a maximum of five subjects receiving ICS+LABA fixed. As recommended by Austin 2011, 
the matched subjects (from the group receiving ICS+LABA fixed) had to be within the caliper 
width of 0.2 of the standard deviation of the logit of the PS278. Both conventional multivariate 
modelling and the PS methods were repeated for each investigated period (figure 2). Analyses 
were conducted using SAS software, version 9.3 (SAS Institute).  
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Results 
Study population 
Out of 39,682 asthmatic children (5-17 years) that were identified during the study period, 
3,500 (8.8%) received incident prescriptions of either ICS+LABA fixed (3324 [95.0%]) or loose 
(176 [5.0%]).  Age, sex, season and year of cohort entry did not differ between the treatment 
groups, mean age was around 12 years (12.7 [fixed cohort] vs 11.6 [loose cohort]) and the 
majority was male (56%[fixed cohort] vs 54.5% [loose cohort]).  Baseline characteristics of the 
varying co-variates during the different look back periods are provided in table 1.  
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Table 1: Baseline characteristics of the study population before propensity scores matching, according to the investigated periods 
Look back-period 
Characteristics 
1 week 1 month 3 months 1 year Full history 
Fixeda 
(3,324) 
Looseb 
(176) 
p-val. Fixed 
(3,324) 
Loose 
(176) 
p-val. Fixed 
(3,324) 
Loose 
(176) 
p-val. Fixed 
(3,324) 
Loose 
(176) 
p-val. Fixed 
(3,324) 
Loose 
(176) 
p-val. 
History of 
moderate to 
severe asthma 
exacerbations 
(Yes; n [%]) 
34 (1.0) 11 
(6.3) 
<0.01 65 (2.0) 18(10.2) <0.01 113(3.4) 25 
(14.2) 
<0.01 242 (7.3) 42 (23.9) <0.01 1031 
(31.0) 
94 
(53.4) 
<0.01 
                
History of use (or 
concomitant use) 
of specific anti-
asthma drugs 
(Yes; n [%]) 
               
  SABA 620 
(18.7) 
63 
(35.8) 
<0.01 684 
(20.6) 
69 
(39.2) 
<0.01 836 
(25.2) 
77 
(43.8) 
<0.01 1,489(44.8) 105(59.7) <0.01 2,559 
(77.0) 
151 
(85.8) 
<0.01 
  SAMA 2 (0.1) 1 (0.6) 0.02 5 (0.2) 1 (0.6) 0.20 9 (0.3) 1 
(0.6) 
0.47 21(0.6) 2 (1.1) 0.42 285(8.6) 21 
(11.9) 
0.12 
  LTRA 100 
(3.0) 
11 
(6.3) 
0.02 130 
(3.9) 
11 (6.3) 0.12 166(5.0) 13 
(7.4) 
0.16 235(7.1) 23 (13.1) <0.01 428 
(12.9) 
32 
(11.2) 
0.04 
                
  Systemic   
corticosteroid 
19 (0.6) 3 (1.7) 0.06 36 (1.1) 7 (4.0) <0.01 64 (1.9) 11 
(6.3) 
<0.01 162 (4.9) 18 (10.2) <0.01 674 
(20.3) 
40 
(22.7) 
0.43 
                
History of (or 
current) 
comorbidities 
(Yes; n[%]) 
               
  Obesity 0 (0) 0 (0) 0.93 2 (0.1) 1 (0.6) 0.92 7 (0.2) 1 
(0.6) 
0.54 32 (1.0) 2 (1.1) 0.82 95 (2.9) 4 
(2.3) 
0.65 
  Gastrointestinal 
reflux disease 
1 (0) 0 (0) 0.82 1 (0) 0 (0) 0.82 2 (0.1) 0 (0) 0.74 10 (0.3) 0 (0) 0.47 58 (1.7) 3 
(1.7) 
0.97 
                
  Anxiety 0 (0) 0 (0 ) 0.82 5 (0.2) 0 (0) 0.61 9 (0.3) 0 (0) 0.49 18 (0.5) 0 (0) 0.33 52 (1.6) 4 
(2.3) 
0.47 
                
  Lower 
respiratory tract 
disease 
0 (0) 0 (0 ) 0.82 0 (0) 0 (0) 0.02 0 (0) 0 (0) 0.40 0 (0) 0 (0) 0.96 0 (0) 0 (0) 0.35 
                
History ( or                
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concommitant 
use)  of other 
drugs (Yes; n 
[%]) 
  Antacids 0 (0) 0 (0) 0.93 1 (0) 0 (0) 0.82 6 (0.2) 1 
(0.6) 
0.26 7 (0.2) 0(0) 0.54 33 (1.0) 0 (0) 0.18 
  Hypnotics 14 (0.4) 2 (1.1) 0.17 23 (0.7) 2 (1.1) 0.50 36 (1.1) 3 
(1.7) 
0.44 67 (2.0) 3 (1.7) 0.77 115 
(3.5) 
8 
(4.6) 
0.45 
  Anxiolytics 8 (0.2) 0 (0) 0.51 14 (0.4) 0 (0) 0.39 14 (0.4) 0 (0) 0.39 28 (0.8) 2 (1.1) 0.68 125 
(3.8) 
6 
(3.4) 
0.81 
  Antidepressants 7 (0.2) 0 (0) 0.54 8 (0.2) 0 (0) 0.51 10 (0.3) 0 (0) 0.47 16 (0.5) 2 (1.1) 0.24 26 (0.8) 3 
(1.7) 
0.19 
  Antihistamines 304 
(9.2) 
24 
(13.6) 
0.05 400 
(12.0) 
32 
(18.2) 
0.02 489 
(14.7) 
31 
(17.6) 
0.29 943 (28.4) 58 (33.0) 0.19 2,015 
(60.6) 
117 
(66.5) 
0.12 
  Antibiotics 94 (2.8) 4 (2.3) 0.66 149(4.5) 13 (7.4) 0.07 250(7.5) 16 
(9.1) 
0.44 734 (22.1) 50 (28.4) 0.05 2,764 
(83.2) 
147 
(83.5) 
0.90 
  Nasal 
preparations 
284 
(8.5) 
25 
(14.2) 
<0.01 328 
(9.9) 
27 
(15.3) 
0.02 453 
(13.6) 
37 
(21.0) 
<0.01 847 (25.5) 61 (34.7) <0.01 1,816 
(54.6) 
110 
(62.5) 
0..04 
  Aspirin 0 (0) 0 (0) 0.66 0 (0) 0 (0) 0.07 0 (0) 0 (0) 0.44 1 (0) 0 (0) 0.82 0 (0) 0 (0) 0.89 
a Inhalational corticosteroids + Long-acting beta-adrenoceptor agonists (fixed combination); b Inhalational corticosteroids + Long-acting beta-adrenoceptor agonists (loose combination) 
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As could be expected; using longer look back periods increased the prevalence of the risk 
factors substantially. Compared to children receiving ICS+LABA fixed, significantly more (p-
value < 0.01) of those receiving the loose combination had severe asthma; and this was 
observed across all the investigated periods. Significantly more (p-value < 0.01) of the children 
receiving the loose combination had received SABA. In contrast, few children were prescribed 
SAMA or LTRA.  Of note, children in both exposure groups were similar in the comorbidities 
they experienced, including obesity, gastrointestinal reflux disease, anxiety and lower 
respiratory treat disease. Also, children in both exposure groups were similar in their use of 
drugs (whether in the past or together with the studied drugs), except for nasal preparations. 
Figure 3 shows that for all the investigated periods, the PS distribution for children receiving 
ICS+LABA fixed versus loose, overlapped considerably.  
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Figure 3: Distribution of propensity scores and overlap between the exposure groups, according to the investigated periods 
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After matching on propensity scores (for each period), the initially observed differences 
between the exposure groups were no longer present (table 2). 
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Table 2: Characteristics of the study populations after propensity scores matching, according to the investigated periods 
 
 Matched sets based on propensity model using different history periods 
Look back-
period 
Characteristics 
1 week 1 month 3 months 1 year Full history 
Fixeda 
(838) 
Looseb 
(175) 
p-
valc 
Fixed 
(824) 
Loose 
(173) 
p-
val. 
Fixed 
(828) 
Loose 
(172) 
p-
val. 
Fixed 
(819) 
Loose 
(172) 
p-
val. 
Fixed 
(811) 
Loose 
(171) 
p-
val. 
Number of 
events 
(incidence [per 
100 
personyears]) 
30 (9.3) 13 (15.2) 0.14 25 (8) 11 
(13.5) 
0.14 31 (9.9) 13 
(15.3) 
0.19 31 (10) 12 
(14.7) 
0.26 26 (8.2) 11 
(13.5) 
0.16 
                
History of 
severe asthma 
(Yes; n [%]) 
33(3.9) 11 (6.3) 0.17 58 
(7.0) 
17 (9.8) 0.21 93 
(11.2) 
23 
(13.4) 
0.43 158 
(19.3) 
40 
(23.3) 
0.24 423 (52.2) 90 
(52.6) 
0.91 
                
History of use 
of specific anti-
asthma drugs 
(Yes; n [%]) 
               
  SABA 257 
(30.7) 
62 (35.4  0.22 293 
(35.6) 
66 
(38.2) 
0.52 344 
(41.6) 
74 
(43.0) 
0.72 464 
(56.7) 
102 
(59.3) 
0.52 687 (84.7) 146 
(85.4) 
0.82 
  SAMA 2 (0.2) 0 (0) 0.52 1 
(0.1) 
0 (0) 0.65 1 (0.1) 0 (0) 0.65 7 (0.9) 1 (0.6) 0.72 93 (11.5) 20 
(11.7) 
0.93 
  LTRA 47 (5.6) 10 (5.7) 0.96 47 
(5.7) 
10 (5.8) 0.97 55 (6.6) 12 
(7.0) 
0.87 92 (11.2) 22 
(12.8) 
0.56 144 (17.8) 31 
(18.1) 
0.91 
                
                
Prescence of 
comorbidities 
(Yes; n[%]) 
               
  Obesity 0 (0) 0 (0) 0.92 2 
(0.2) 
1 (0.6) 046 0 (0) 0 (0) 0.24 23 (2.8) 3 (1.7) 0.43 18 (2.2) 4 (2.3) 0.92 
                
Concommitant 
drug use (Yes; 
n [%]) 
               
  Antacids 0 (0) 0 (0) 0.92 0 (0) 0 (0) 0.46 5 (0.6) 1 (0.6) 0.97 0 (0) 0 (0) 0.72 0 (0) 0 (0) 0.92 
  Hypnotics 9 (1.1) 2 (1.1) 0.94 8 
(1.0) 
1 (0.6) 0.62 13 (1.6) 3 (1.7) 0.87 12 (1.5) 3 (1.7) 0.79 35 (4.3) 7 (4.1) 0.90 
  Anxiolytics 0 (0) 0 (0) 0.91 0 (0) 0 (0) 0.41 0 (0) 0 (0) 0.72 8 (1.0) 2 (1.2) 0.82 32 (4) 6 (3.5) 0.79 
  
Antidepressants 
0 (0) 0 (0) 0.94 0 (0) 0 (0) 0.62 0 (0) 0 (0) 0.87 7 (0.9) 1 (0.6) 0.72 6 (0.7) 2 (1.2) 0.57 
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Antihistaminies 
93 
(11.1) 
24 (13.7) 0.32 107 
(13.0) 
27 
(15.6) 
0.36 148 
(17.9) 
31 
(18.0) 
0.96 278 
(33.9) 
57 
(33.1) 
0.84 547 (67.5) 114 
(66.7) 
0.84 
  Antibiotics 18 (2.2) 4 (2.3) 0.91 44 
(5.3) 
12 (6.9) 0.41 70 (8.5) 16 
(7.3) 
0.72 221 (27) 48 
(27.9) 
0.80 677 (83.5) 142 
(83) 
0.89 
  Nasal 
preparations 
87 
(10.4) 
25 (14.3) 0.13 112 
(13.6) 
26 
(15.0) 
0.62 175 
(21.1) 
36 
(20.9) 
0.95 267 
(32.6) 
59 
(34.3) 
0.67 258 (31.8) 57 
(33.3) 
0.70 
  Aspirin 0 (0) 0 (0) 0.91 0 (0) 0 (0) 0.41 0 (0) 0 (0) 0.72 0 (0) 0 (0) 0.80 0 (0) 0 (0) 0.68 
a Inhalational corticosteroids + Long-acting beta-adrenoceptor agonists (fixed combination); b Inhalational corticosteroids + Long-acting beta-adrenoceptor agonists (loose combination) 
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Within the fixed cohort, 73 children experienced a moderate to severe asthma exacerbation resulting in 
an incidence of 6.3/100 person years. In the loose cohort, the incidence rate of moderate to severe 
asthma exacerbations was 15.1/100 person years (13 children with exacerbations). Crude and adjusted 
HRs (comparing the effect of ICS+LABA fixed versus loose) are provided in figure 4 for different ways of 
adjustment.   
The crude HR on the risk of asthma exacerbations following use of  ICS+LABA as fixed combination vs. 
ICS+LABA as loose combination was  0.366 (95% CI: 0.202; 0.664). With regard to the effect of PS on 
the change in estimate, PS-matching had the most pronounced impact on the change in estimate – in the 
3 month look back period, the HR changed from 0.366 to 0.699 and was no longer statistically significant. 
See figures 4 and 5 for further details.  
 
 
Figure 4: Forest plot showing crude and adjusted hazard ratios (HRs) for the average effect of ICS+LABA fixed 
versus loose, according to the different look back periods
Time Analysis HazardRatio 95 % Hazard Ratio Confidence Limits
0.366 (0.202 ; 0.664)
Multivariate 0.406 (0.221 ; 0.745)
PS-matching 0.480 (0.222 ; 1.306)
PS-IPTW 0.381 (0.196 ; 0.742)
PS-adjustment 0.433 (0.231 ; 0.811)
Multivariate 0.468 (0.250 ; 0.877)
PS-matching 0.601 (0.262 ; 1.375)
PS-IPTW 0.408 (0.207 ; 0.806)
PS-adjustment 0.565 (0.287 ; 1.112)
Multivariate 0.533 (0.282 ; 1.008)
PS-matching 0.699 (0.311 ; 1.571)
PS-IPTW 0.428 (0.209 ; 0.878)
PS-adjustment 0.564 (0.290 ; 1.097)
Multivariate 0.552 (0.296 ; 1.030)
PS-matching 0.561 (0.253 ; 1.244)
PS-IPTW 0.452 (0.207 ; 0.988)
PS-adjustment 0.608 (0.315 ; 1.174)
Multivariate 0.477 (0.259 ; 0.880)
PS-matching 0.575 (0.242 ; 1.364)
PS-IPTW 0.384 (0.166 ; 0.887)
PS-adjustment 0.525 (0.282 ; 0.978)
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Figure 5: Hazard ratios comparing ICS+LABA fixed versus ICS+LABA loose, according to method used 
to control confounding and the investigated period  
(Multivariate=conventional multivariate modelling; PS=propensity scores; IPTW=Inverse probability of treatment 
weighting)
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Discussion 
This study aimed to explore the impact of different look back periods on the estimation of the 
propensity score to deal with confounding by indication in pediatric comparative effectiveness 
studies. Based on a case study on the effects of fixed and loose ICS+LABA combinations we 
learned that the time period over which the PS is estimated makes quite some difference, as 
well as how the PS is used. Compared to other PS methods, matching on PS resulted in the 
largest changes in the point estimate. Regarding the investigated periods, controlling for 
characteristics that occurred during the 3 months before study entry resulted in the largest 
adjustment of the crude HR. The study demonstrated that children receiving the loose 
combination had more severe asthma but matching on the propensity score balanced the 
covariates in the different groups, as expected. Using a fixed combination reduced the risk of 
exacerbation in comparison to loose combination in most models, however not in the PS-
matched analysis, in which a non-significant reduction was observed.  
The usefulness of PS for controlling confounding in comparative effectiveness studies has been 
demonstrated multiple times 279,280. To ensure that the PS is efficient, covariates related to the 
outcome (irrespective of the exposure) should always be included 265,266,281. Crucial to achieving 
this is to know the most relevant period (before drug exposure) for identifying such covariates. 
In asthma, it is plausible that the factors predisposing to exacerbation and resulting in 
treatment step-up will occur just before such step-up 282. Our results show that including 
covariates that occurred during the few months before treatment start resulted in the biggest 
change of estimate. This is not surprising; in asthmatic children specifically, respiratory tract 
infections can quickly trigger exacerbations274,283. Meanwhile a physician will most likely step-up 
treatment based on the current situation and not necessarily considering events that occurred 
further off in the past. The beneficial effects of the fixed combination of ICS+LABA compared to 
the loose combination has been confirmed in RCTs where the fixed combination had a larger 
effect on peak flow284. A recent observational study using data from the CPRD and the 
Optimum Patient Care Research Database also reported that fixed combinations of ICS+LABA 
are more effective in the prevention of asthma exacerbations285. Fixed combinations guarantee 
    
235 | P a g e  
 
use of ICS, which are crucial for asthma control. In addition, it is suggested that treatment 
adherence is higher in fixed combinations vs loose combinations.   
Before implementing PS, the distributions of the PS should be checked to ensure there is 
sufficient overlap. We demonstrated reasonable overlap leading to little loss of matched pairs 
with increasing look back periods. There are various approaches to implementing PSs 276,281. 
Among these, matching is the most common and has been extensively investigated 263,281,286,287. 
Ali et al. 2015 stated that the choice of PS method should be dictated by the objective of the 
research. Since our primary objective was not to estimate treatment effect we decided to 
explore all methods and applied PS matching in addition to other methods. Austin 2014 
concluded that calliper matching tended to yield estimates of treatment effect with less bias 
compared with optimal and nearest neighbor matching even though the latter two methods 
resulted in treatment estimates with negligibly less variability. Moreover, matching with 
replacement offered no advantage over matching without replacement. Perhaps these explain 
two of our findings. First, matching yielded effect estimates that are similar to results from 
RCTs although the investigated outcome in the RCTs was peak flow284. Secondly, the 
confidence interval for PS-matched HRs were wider (reflecting greater variability around the 
point estimates) when compared to the other PS methods that we applied. For matching, we 
applied a calliper (maximum distance) width of 0.2 of the standard deviation of the logit of the 
PS, recommended by Austin 2011 based on simulation studies278. Consequently, both exposure 
groups had similar characteristics irrespective of the look-back period. Of note, the proportions 
of patients that had experienced severe asthma in both groups was the same. Nearest 
neighbour matching without specifying a calliper can result in bad matches since the nearest 
neighbour can be very far away 288. Therefore calliper matching helps to minimize bias in 
treatment effect 277. The benefits of regression adjustment for the PS (PS-adjustment) are less 
clear because it involves modelling the outcome in addition to the PS 289. Although the use and 
interest of PS-IPTW has increased in recent years,  Austin and Stuart 2015 observed that most 
researchers did not check whether weighting balanced measured covariates between the 
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exposure groups 290. The authors attributed this to lack of suitable methods.  We recommend 
further research into these alternative methods. 
Conclusion 
PS models should be used to control for confounding in pediatric comparative (drug) 
effectiveness studies. The impact of different look back periods and the choice of the way to 
implement the PS are important.  The results on a matched analysis are comparable to clinical 
trial data on the comparison between fixed and loose ICS+LABA combinations in preventing 
worsening of asthma. 
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Appendix 1: World Health Organization-Anatomic Therapeutic Chemical (WHO-ATC) codes used to identify anti-asthma drugs 
• Inhaled corticosteroids (ICS): R03BA  
• Short acting β2 agonists (SABA): R03AC02, R03AC03,R03AC04, R03AC05, R03AC06, R03AC07, R03AC08, R03AC09, R03AC10, R03AC15, R03AC16, R03AC17  
• Long acting β2 agonists (LABA): R03AC11, R03AC12, R03AC13, R03AC14, R03AC18, R03AC19  
• Fixed combination of ICS and LABA: R03AK06, R03AK07, R03AK08, R03AK09, R03AK10, R03AK11 
• Leukotriene modifier (LTRA): R03DC01, R03DC02, R03DC03, R03DC04 
• Short acting muscarinic antagonist (SAMA): R03BB01, R03BB02 
• Fixed combination of SABA and SAMA: R03AL01, R03AL02, R03AK03, R03AK04 
• Theophyllines: R03DA, R03DB 
• Systemic glucocorticosteroids for the treatment of asthma: H02AB 
• Anti-IgE treatment: R03DX05 
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Chapter 6 Other considerations 
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Chapter 6.1 Reference set for performance testing of pediatric vaccine safety 
signal detection methods and systems  
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Abstract 
Background: Safety signal detection in spontaneous reporting system databases and 
electronic health-care records is key to detection of previously unknown adverse events 
following immunization. Various statistical methods for signal detection in these different 
datasources have been developed, however none are geared to the pediatric population and 
none specifically to vaccines. A reference set comprising pediatric vaccine-adverse event pairs is 
required for reliable performance testing of statistical methods within and across data sources. 
Methods: The study was conducted within the context of the Global Research in Paediatrics 
(GRiP) project, as part of the seventh framework programme (FP7) of the European 
Commission. Criteria for the selection of vaccines considered in the reference set were routine 
and global use in the pediatric population. Adverse events were  primarily selected based on 
importance. Outcome based systematic literature searches were performed for all identified 
vaccine-adverse event pairs and complemented by expert committee reports, evidence based 
decision support systems (e.g. Micromedex), and summaries of product characteristics. 
Classification into positive (PC) and negative control (NC) pairs was performed by two 
independent reviewers according to a pre-defined algorithm and discussed for consensus in 
case of disagreement. 
Results: We selected 13 vaccines and 14 adverse events to be included in the reference set. 
From a total  of 182 vaccine-adverse event pairs, we classified 18 as PC, 113 as NC and 51 as 
unclassifiable. Most classifications (91) were based on literature review, 45 were based on 
expert committee reports, and for 46 vaccine-adverse event pairs, an underlying 
pathomechanism was not plausible classifying the association as NC. 
Conclusion: A reference set of vaccine-adverse event pairs was developed. We propose its use 
for com-paring signal detection methods and systems in the pediatric population.   
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Introduction 
Every year, more infants, children, and adolescents are protected from illness, disability and 
death by virtue of global immunization programs 291. Robust systems for monitoring benefits 
and risks of these programs and the vaccines administered are pivotal for program 
sustainability, the safety of the mostly healthy vaccine recipients and for maintaining public 
confidence in the vaccine292. This requires the ability to reliably detect safety signals in the 
pediatric population in a globally harmonized approach. 
Today, various definitions of what constitutes a signal exist including definitions by WHO and 
CIOMS. The latter defined safety signal as follows: ‘Information that arises from one or multiple 
sources (including observations and experiments) which suggests a new potentially causal 
association, or a new aspect of a known association, between an intervention and an event or 
set of related events, either adverse or beneficial, that is judged to be of suffi-cient likelihood to 
justify verificatory action’ 293,294. Further, various methods for signal detection in spontaneous 
reporting system (SRS) databases and electronic healthcare records (EHR) have been devel-
oped for drugs295. Approaches to test their performance within systems and to compare 
systems are based on reference sets com-prising drug/vaccine-adverse event pairs with a high 
likelihood for a strong association (positive controls [PC]) and an absence of any association 
(negative controls [NC]). A reference set allows assessing if statistical methods can detect 
expected positive or no associations between events and vaccines. Previous approaches to 
develop such standards for drugs included consulting reference books such as the Physicians 
Drug Reference or Martindale296, considering label changes297, combining information from sum-
mary of product characteristics (SPC) and the literature as in two recent initiatives, the 
‘Observational Medical Outcomes Partner-ship (OMOP)’ and the ‘EU-ADR project’ 298,299. Work 
on validating approaches for the pediatric population is in progress 149. 
However, to the best of our knowledge no such reference sets are available for vaccines. The 
aim of the current study was to develop such a reference set applicable in SRS databases and 
EHR around the globe to test performance of statistical methods for signal detection and the 
systems in general. 
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Methods 
The study was conducted within the context of the Global Research in Paediatrics (GRiP) 
project, funded under the seventh framework programme (FP7) of the European Commission. 
FP7 is a funding program of the European Union for Research and Innovation. The main goal of 
GRiP is to establish a network of excellence to improve the development and safe use of 
medicines in children ( www.grip- network.org). 
 
Selection of vaccines 
As the GRiP project focuses on the performance testing of sta-tistical methods for signal 
detection of pediatric vaccines, we only considered vaccines which are used in children for the 
construc-tion of the reference set. Vaccines also had to be routinely used for several years to 
ascertain adequate exposure and to allow detec-tion of associations with potentially rare 
adverse events of interest. As GRiP is an international project, most of the included vaccines 
should also have global utility and applicability. These criteria resulted in the inclusion of 13 
commonly used vaccines: Bacil-lus Calmette–Guérin (BCG), diphtheria-tetanus-acellular 
pertussis (DTaP), diphtheria-tetanus-whole cell pertussis (DTPw), hepatitis A (HAV), hepatitis B 
(HBV), haemophilus influenzae type B (Hib), influenza (any type), pneumococcal (PV), 
meningococcal (MV), measles-mumps-rubella (MMR), oral polio (OPV), rotavirus (RV) and 
varicella zoster virus (VZV) vaccine. 
 
Selection of adverse events 
Given the expectation that few PCs might be found, adverse events were first selected based 
on their likelihood of being PCs for at least one vaccine based on literature review or their 
previous formal evaluation in an official report. The list was then narrowed down based on the 
specificity and importance of the event 300. Thus, we selected clearly defined clinical entities to 
increase the likelihood of comprehensive literature searches and comparable data sets for 
performance testing. Adverse events generally considered to be “important” in the European 
and North American routine immunization programs were prioritized, because their reporting is 
generally required in most member states of these regions regardless of the available 
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knowledge on their causal association with specific vaccines. A total of 14 adverse events were 
included: anaphylaxis, arthritis, Bell’s palsy, convulsions, insulin-dependent diabetes mellitus 
(IDDM), disseminated BCG-itis, encephalitis, disseminated Oka VZV, Guillain-Barré Syndrome 
(GBS), hypotonic hyporesponsive episode (HHE), intussuscep-tion, thrombocytopenia, vaccine-
associated paralytic poliomyelitis (VAPP), and wheezing (reactive airway disease). This resulted 
in a total of 182 vaccine-adverse event pairs which needed to be clas-sified into PC or NC, or 
unclassifiable [UC]. 
 
Literature search and included studies 
We performed literature searches until end of 2012 in MedLine through OvidSP (from 1946), 
Embase (all years) and the Cochrane Library and extracted the references to EndnoteX7. Table 
1 exemplifies a search algorithm in Medline. All other search strategies are available from the 
authors on request. To maximize the number of potentially relevant studies, we performed the 
searches by outcome instead of specific searches by vaccine-event pair. An exception was 
made for anaphylaxis, where we performed a specific vaccine-event pair search for unknown 
associations (i.e. associations between anaphylaxis and OPV, RV, Hib, BCG and PV) to reduce 
the size of the highly sensitive search result. We focused on English literature with no age 
restrictions and reviewed the search result of vaccine-event pairs that were not previously 
reviewed and classified by the Institute of Medicine (IOM, 2011 report on ‘Adverse effects of 
vaccines – Evidence and Causality’, 2004 report on ‘Influenza Vaccines and neurological 
complications’) 300, or included in WHO information sheets or in the Vaccine Injury Table (VIT) 
[16] (91 in total). For each vaccine-event pair of inter-st, we included all relevant studies by 
title or abstract in the first instance, and by full text, if the title or abstract did not provide 
sufficient information. As in the IOM report, review papers, letters and editorials were not 
included. However, we checked these publications for any additional relevant references of 
original data. 
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Table 1: Search algorithm for Bell’s palsy as an adverse event following 
immunization – an example  
 
Medline #1  exp Vaccines/ (Mesh) 
#2  exp Vaccination/ (Mesh) 
#3  exp Immunization/ (Mesh) 
#4  (vaccin$ OR immuni$ OR inoculat$).tw. 
#5  or/1-4 
#6  exp Bell Palsy/ (Mesh) 
#7  exp Facial Paralysis/ (Mesh) 
#8  (bell$ palsy OR facial$ paralys$ OR facial diplegia OR facial nerve 
paralys$ OR facial nerve palsy OR facial nerve paresis OR facial palsy 
OR facial paresis OR prosopoplegia OR facioplegia OR facial weakness 
OR facial synkinesis OR facial neuropath$).tw. 
#9  ((seventh cranial nerve OR 7th cranial nerve) adj (palsy OR paralys$ 
OR paresis OR neuropath$)).tw. 
#10  ((seventh nerve OR 7th nerve) adj (palsy OR paralys$ OR paresis OR 
neuropath$)).tw.  
#11  (face adj (paralys$ OR palsy OR paresis OR neuropath$)).tw.  
#12  or/6-11  
#13  5 and 12 
#14  limit 13 to (english language and humans) 
 
We extracted study identifiers (author, title, publication year), details on type of study, vaccine 
of interest, sample size, age category of the study population, number of cases with the 
adverse event of interest and risk measure(s) by using a standard data extraction form 
(available from the authors upon request). A first extraction of relevant articles was performed 
individually by CN, MP and YB. Subsequent classification of vaccine-adverse event pairs based 
on the extracted literature (described below) was done by two reviewers (from the list of 
authors) in parallel and then dis-cussed for consensus with a third arbitrator (JB or TV) in case 
of uncertainties. The quality of the extraction process of relevant arti-cles was randomly double-
checked. 
 
Classification of vaccine-adverse event pairs 
If a vaccine-adverse event pair had been evaluated by the IOM, WHO or VIT sources, we 
accepted this classification. Vaccine-adverse event associations, which were 
pathophysiologically unlikely (e.g. disseminated Oka VZV following HBV vaccine) were classified 
as NC. For all other vaccine-adverse event pairs, a lit-erature review was performed and the 
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algorithm as shown in Table 2 was applied. “Evidence” was defined as at least one ran-domized 
controlled trial or meta-analysis (level I) OR at least one controlled observational study 
(cohort/case–control/case-cross over/self-controlled case series) (level II). Surveillance studies 
counting events observed in spontaneous reporting (e.g. evaluation of number of reports to the 
US Vaccine Adverse Event Reporting System [VAERS]) and clinical trials reporting only the rates 
of the events of interest were not considered for classification. Fig. 1 displays our classification 
method graphically. 
 
Table 2: Definitions of positive and negative control exposure-outcome pairs for 
performance testing of signal detection methods and systems 
Positive control (PC) Negative control (NC) Unclassifiable (UC) 
Evidence* in favour  
AND 
Any additional information 
in favour  
AND 
Not enough evidence not in 
favour 
Absence of any evidence in our 
Pubmed searches and 
Micromedex  
AND  
No listing in SPC 
OR 
Evidence against an association  
AND 
No evidence in favour of the 
association 
Neither fits the 
definitions of negative 
nor positive control 
 
   
Explanations 
Enough evidence: at least 
one evidence of the same 
weight of evidence in 
favour 
For case reports evidence is in 
favour if at least three 
independent case reports from 
different sources and concerning 
different patients OR  
less than three case reports but 
at least one with proven 
mechanism 
 
 
a Evidence: at least one properly designed randomized controlled trial or meta-analysis (level I) OR at least one 
controlled observational study (cohort/case-control/case-cross over/self-controlled case series) (level II);SPC – 
summary of product characteristics 
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Fig. 1. Classification algorithm for development of the reference set for performance testing 
of signal detection methods and systems (considers pathophysiologically possiblevaccine-adverse event 
associations only) VIT, vaccine injury table; IOM, reports of the Institute of Medicine; MDX, micromedex; SPC, summary 
of product characteristics;UC, unclassifiable; PC, positive control; NC, negative control. 
 
 
 
We have classified the exposure event pairs based on target dis-ease rather than on specific 
products. Thus, one exposure type may comprise different products immunizing against the 
same target disease. Therefore, this simplification will not allow for product level signal 
detection. 
For the purpose of developing a reference set for performance testing of signal detection 
methods, the NC category was designed to comprise the following three subsets of evidence for 
the vaccine-adverse event pairs that have been classified by literature review: vaccine-adverse 
event pairs with evidence of absence of an association, those with absence of evidence and 
those with an unlikely pathomechanism for an association. 
To identify any associations that may not be published in the scientific literature, but known to 
the industry or the regulators, we also checked the product labeling for vaccine-adverse event 
pairs classified as NC based on literature and Micromedex review. We could not check the labels 
for all vaccine brands and from all countries as there is a lack of a central resource for such 
information. Hence, we decided to focus on the Summary of Product Character-istics (SPC) of 
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European centrally authorized products based on a table created in the frame of the IMI project 
PROTECT 301. If not available, then the UK SPC was used as it is in English or the WHO 
information leaflets. 
 
Results 
Literature search and included studies 
The literature search resulted in a total of 42803 publications including 2871 for anaphylaxis, 
8975 for arthritis, 340 for Bell’s palsy, 3097 for convulsions, 6369 for diabetes mellitus, 6265 for 
encephalitis, 2578 for GBS, 3804 for HHE, 532 for intussusception, 4932 for thrombocytopenia 
and 3040 for wheezing. Of these pub-lications, 119 references of case reports, controlled 
observational studies, and meta-analyses were retained for classification of the 91 
pathophysiologically possible vaccine-adverse event associations that had not been classified by 
other sources, i.e. IOM, WHO or VIT. For more than half of the associations, we did not find 
any relevant literature. Table 3 exemplifies the classification table for the event 
thrombocytopenia. A table referencing all studies considered for classification of each vaccine-
adverse event pair is available from the authors upon request. Although we did not specifically 
focus on case reports or studies in children, the majority of the publications focused on children 
or on children and adults. Only for the outcome arthritis, most of the considered studies 
included only adults. 
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Table 3:Classification table for the event thrombocytopenia – an example 
Type of 
publication 
Case report/Case series Meta-analysis Clinical trial Controlled 
epidemiological study 
Events in 
clinical 
trials or 
from sur-
veillance 
studies* 
In 
MDX? 
In 
SPC? 
Classi- 
fication 
Evidence in 
favour? 
Yes / possible no / 
unknown 
Yes / 
possible 
no / 
unknown 
Yes / 
possible 
no / 
unknown 
Yes / 
possible 
no / 
unknown 
N/A    
Vaccine             
BCG          no no NC 
DTaP 1[C]**      1[C] 
 
 5 (A/C) 
 
yes yes PC 
DTPw 2[C], 1 [C]       1[A] 
 
 no yes UC 
HAV       1[C] 
 
  yes no UC 
HBV 1[A], 2[A/C] , 1 
[C], 3 [C], 5 [C], 12 
[C], 7 [C], 3 [C] 
 
     1 [A/C], 1 
[A/C] 
 
 263 [A/C] 
 
yes yes PC 
PV 1 [A], 1 [A], 1[C] 
 
     1[A], not 
controlled 
 
 6[A/C] 
 
yes no UC 
Influenza 1[A], 1[A], 1[C] 
 
1[A] 
 
    1[A] 
 
1[A] 
 
8[A/C] 
 
yes yes UC 
MV        1 [C] 
 
 no no NC 
MMR            PC based 
on VIT 
VZV            UC based 
on IOM 
OPV 1[A] 
 
        no no NC 
RV         1[A/C] 
 
yes (PI) no NC 
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Hib          yes (1 
report 
to FDA) 
no NC 
[C], children; [A], adults; [A/C], children and adults; MDX, micromedex; PI, product information: if reference in Micromedex refers to product information, this was not considered as listed in 
SPC; 
PC, positive control; NC, negative control; UC, unclassifiable; * not considered for classification; ** one entry refers to one publication 
BCG, Bacillus Calmette–Guérin; DTaP, Diphteria-Tetanus-acellular Pertussis; DTPw, Diphteria-Tetanus-whole cell Pertussis; HAV, Hepatitis A Virus; HBV, Hepatitis B Virus; PV, Pneumococcal 
Virus; MV, Meningococcal Virus; MMR, Measles-Mumps-Rubella; VZV, Varicella Zoster Virus; OPV, Oral Polio Virus; RV, Rotavirus; Hib, Haemophilus Influenza Virus 
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Classification of vaccine-adverse event pairs 
The reference table resulting from the vaccine-adverse event pair classifications is shown in 
Table 4. Forty-five vaccine-adverse event pairs were previously classified by the IOM, WHO and 
VIT, of which 14 were considered PC, 4 NC and 27 UC. The events of disseminated BCG-itis, 
VAPP and disseminated Oka strain VZV are specific to the respective vaccines and cannot be 
related to any other vaccination. Of the 91 vaccine-adverse event pairs, for which we did a 
literature review, only 4 could be classified as PC, 63 as NC, and 24 were UC. Overall, we 
identified 18 PC and 113 NC, respectively. Review of the literature showed that the number of 
controlled epidemiological studies on vaccine-adverse event pairs not already classified by 
expert committee reports was limited. Furthermore, we found only few published clinical trials 
specifically investigating any of the included vaccine-adverse event pairs and only three meta-
analyses302-304. While the NC category comprises three quite different types of evidence, Table 5 
specifies these sub-categories for transparency. 
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Table 4: Reference table of positive and negative controls for vaccine-adverse event pairs. 
Vaccines Anaphylaxis 
Thrombo- 
cytopenia 
Convu
lsions 
Disseminate
d BCG-itis HHE 
Enceph
alitis 
Intussus-  
ception VAPP 
Disseminate
d Oka VZV 
Art
hriti
s 
GBS 
Wheezing / 
Reactive Airway 
disease 
IDDM Bell's Palsy 
BCG UC (1) NC (1) NC (1) WHO NC (1) NC (1) NM NM NM NC (1) 
UC 
(2) NC (2) NC (2) NC (2) 
DTaP IOM (1) PC IOM (1) NM MG 
IOM (1), 
VIT NM NM NM 
IOM 
(1) 
IOM 
(1) NC (2) 
IOM 
(1) IOM (1) 
DTPw VIT UC (1) UC (1) NM MG VIT NM NM NM IOM (1) 
NC 
(2) NC (2) NC (2) NC (1) 
HAV IOM (1) UC (3) NC (1) NM NC (1) NC (1) NM NM NM NC (2) 
IOM 
(1) UC (2) NC (1) IOM (1) 
HBV IOM (1) PC IOM (1) NM NC (1) IOM (1) NM NM NM 
IOM 
(1) 
IOM 
(1) UC (2) NC (2) UC (2) 
PV UC (2) UC (3) UC (2) NM UC (2) NC (1) NM NM NM NC (2) 
NC 
(1) WHO 
NC (1) NC (1) 
Influenza 
(any) IOM (1) UC (1) 
IOM 
(1) NM NC (1) IOM (1) NM NM NM 
IOM 
(1) 
IOM 
(2) IOM (1)** NC (1) IOM (1) 
MV IOM (1) NC (2) UC (2) NM UC (2) IOM (1) NM NM NM NC (2) 
IOM 
(1) NC (2) NC (1) NC (1) 
MMR IOM (1) VIT IOM (1)* NM NC (1) IOM (1) NM NM NM 
IOM 
(1) 
IOM 
(1) UC (1) 
IOM 
(1) NC (1) 
VZV IOM (1) IOM (1) IOM (1) NM NC (1) IOM (1) NM NM IOM (1) 
IOM 
(1) 
IOM 
(1) UC (2) NC (2) UC (2) 
OPV NC (1) NC (1) NC (1) NM NC (1) NC (1) NC (2) VIT NM NC (1) 
UC 
(1) NC (2) NC (2) NC (1) 
RV NC (1) NC (1) NC (2) NM NC (1) NC (2) UC (1) NM NM NC (1) 
NC 
(1) NC (2) NC (1) NC (1) 
Hib UC (2) NC (1) UC (2) NM UC (2) NC (1) NC (1) NM NM NC (1) 
UC 
(2) NC (2) NC (2) NC (1) 
              
Detailed information about basis for classification; association classified by: 
1) Literature review: 
• PC = positive control 
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• NC (1) = negative control - absence of evidence, NC (2) = negative control - evidence against 
• UC (1) conflicting evidence, UC (2) absence of evidence or evidence of absence and ≥3 independent case reports/case series or proven pathomechanism or in SPC, UC (3) some 
evidence but not enough for positive control 
• NM = pathomechanism not possible 
• MG = review: Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf. 2002;25(2):85-90. Review.305 
 
2) Official report:  
IOM (1) = Reports of the Institute of Medicine, Adverse Effects of Vaccines: Evidence and Causality (2011)306  
IOM (2) = Reports of the Institute of Medicine, Influenza Vaccines and neurological complications (2004)307  
VIT = Vaccine Injury Table (July 2011)308 
WHO = WHO, World Health Organisation, vaccine reaction rates information sheets309 
 
BCG, Bacillus Calmette–Guérin; DTaP, Diphteria-Tetanus-acellular Pertussis; DTPw, Diphteria-Tetanus-whole cell Pertussis; HAV, Hepatitis A Virus; HBV, Hepatitis B Virus; PV, Pneumococcal 
Virus; MV, Meningococcal Virus; MMR, Measles-Mumps-Rubella; VZV, Varicella Zoster Virus; OPV, Oral Polio Virus; RV, Rotavirus; Hib, Haemophilus Influenza Virus;  
HHE, Hypotonic-Hyporesponsive Episode; VAPP, Vaccine-associated paralytic poliomyelitis; GBS, Guillain-Barré Syndrome; IDDM, type I Diabetes Mellitus 
 
*  = for febrile seizure 
** = unclassifiable for children <5 years   Positive control  Negative control  Unclassifiable 
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Table 5: Subcategories of negative control category 
Evidence of absence Absence of evidence Pathomechanism unlikely 
Thrombocytopenia 
MV 
Convulsion 
RV 
Encephalitis 
RV 
Intussuception 
OPV 
Arthritis 
HAV, PV, MV 
Guillain-Barré Syndrome 
DTPw, 
Wheezing, reactive airway disease 
BCG, DTaP, DTPw, MV, OPV, RV, Hib, Influenza* 
Type 1 diabetes mellitus 
BCG, DTPw, HBV, VZV, OPV, Hib, DTaP*, MMR* 
Bell’s palsy 
BCG, Influenza* 
 
Anaphylaxis 
OPV, RV 
Thrombocytopenia 
BCG, OPV, RV, Hib 
Convulsions 
BCG, HAV, OPV 
HHE 
BCG, HAV, HBV, Influenza, MMR, VZV, OPV, RV 
Encephalitis 
BCG, HAV, PV, OPV, Hib 
Intussusception 
Hib 
Arthritis 
BCG, OPV, RV, Hib 
Guillain-Barré Syndrome 
PV, RV 
Type 1 diabetes mellitus 
HAV, PV, Influenza, MV, RV 
Bell’s palsy 
DTPw, PV, MV, MMR, RV, Hib 
Disseminated BCG-it is 
DTaP, DTPw, HAV, HBV, PV, Influenza, MV, MMR, VZV, 
OPV, RV, Hib 
Intussusception 
BCG, DTaP, DTPw, HAV, HBV, PV, Influenza, MV, MMR, 
VZV 
Vaccine-associated paralytic poliomyelitis 
BCG, DTaP, DTPw, HAV, HBV, PV, Influenza, MV, MMR, 
VZV, RV, Hib 
Disseminated Oka VZV 
BCG, DTaP, DTPw, HAV, HBV, PV, Influenza, MV, MMR, 
OPV, RV, Hib 
 
*associations evaluated by IOM report 
 
BCG, Bacillus Calmette–Guérin; DTaP, Diphteria-Tetanus-acellular Pertussis; DTPw, Diphteria-Tetanus-whole cell Pertussis; HAV, Hepatitis A Virus; HBV, Hepatitis B Virus; PV, Pneumococcal 
Virus; MV, Meningococcal Virus; MMR, Measles-Mumps-Rubella; VZV, Varicella Zoster Virus; OPV, Oral Polio Virus; RV, Rotavirus; Hib, Haemophilus Influenza Virus 
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Discussion 
In this study, we presented our approach to create a reference set for performance testing of 
signal detection methods for vaccines in SRS databases and EHR and for functional 
performance testing across signal detection systems. To our knowledge, this is the first 
structured approach in this direction. We decided to apply an outcome driven approach to 
search the published literature due to the variability of antigen composition in the various 
products for the same target disease and the various combination vaccines addressing different 
selections of target disease. This resulted in a high number of references identified in the 
literature, but a relatively low number of articles used in the end for classification of vaccine-
event pairs. In addition, only controlled studies and case reports were used for classification. 
From 182 vaccine-adverse event pairs, we classified 18 as PC, 113 as NC and 51 as 
unclassifiable. 
In a study on performance testing of vaccine safety signal detection algorithms, van Holle L et 
al. have used information in the product label of vaccines as a proxy for true safety signals 310. 
However, as vaccine coverage is usually high in the healthy and non-healthy population, the 
probability for case reports to emerge is high, and lists of adverse events in product labels tend 
to be long for multiple medical and legal reasons. Hence, we considered the listing of an 
adverse event in the SPC of vaccines not as evidence of an association but only as evidence 
against a negative association. 
Our reference set of 18 (10%) positive, and 113 (62%) negative controls was similar with 
regards to the frequency of PC and NC in the reference set developed by OMOP with 17% PC 
and 83% NC for performance testing of eight analytic methods in ten observational healthcare 
databases 298. The official sources (mainly the IOM report 300) classified the majority of the 
vaccine-adverse event pairs as UC (‘Evidence is inadequate to accept or reject a causal 
relationship’) and only very few pairs as NC. In contrast, in our review, we classified more than 
two thirds of the pairs as NC and less than one third as UC. This difference may be explained 
by the different aim of the IOM committee evaluating causality. Therefore, the IOM committee 
did not consider absence of evidence to reject a causal association. The IOM Committee only 
rejected a causal relationship in presence of strong and convincing evidence against a causal 
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relationship. Furthermore, evidence they found had to be strong and the studies of good 
methodological quality for favoring acceptance or rejection of a causal association. Our 
classification system is established for a different purpose. We did not set out to verify a causal 
association but to establish a reference set for signal detection methods. Thus, the findings of 
the IOM report inform our purpose, while our findings may not be interpreted as an extension 
of the IOM table. Our reference table classifies absence of evidence and evidence of absence as 
NC. This is because most of the vaccines in our reference set have been on the market for quite 
some time, and we assumed that at least some case reports could have been expected. 
However, the influence of the unequal distribution of few PC in our reference set as compared 
with NC needs to be evaluated in the frame of the performance measurement of statistical 
methods and if necessary, additional PC need to be identified. 
As mentioned in the methodology section, we focused on clearly defined adverse events. The 
example of arthritis showed us that this is particularly important. Initially, we had chosen 
arthralgia as event of interest. Upon review of the literature, we noticed that there were no 
studies investigating an association between vaccines and arthralgia. Furthermore, arthralgia is 
not a disease entity, but a symptom with various underlying causes, and it is a frequently 
observed event in clinical trials. We hence decided to focus on various forms of arthritis as clear 
disease entities. 
The authors acknowledge that the published evidence for classification as positive or negative 
control pair includes data obtained in adults. As all selected vaccines are given in the pediatric 
population, and all events can be observed in the pediatric population, we do not consider this 
a weakness of the method applied. If we assess unexpected results though when testing the 
performance of signal detection methods using events rather seen in adults (e.g. arthritis), we 
will evaluate the findings. 
We limited our literature search to English literature only. Furthermore, for non-Mesh terms 
used in the search algorithms, we only searched in title, abstract, and keywords. With these 
limitations, we may have missed some articles. However, we do not think that availability of 
such articles would have changed the final classification as our search was already quite broad. 
For a recent systematic review on the safety of vaccines used for routine immunization of US 
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children 311, the authors updated the search in the IOM report from 2011 and included 
additional vaccines. No additional studies relevant for our work were identified in this review 
article which could have influenced our reference set. 
As in the IOM report, we did not differentiate by age, vaccine antigen or time of publication 
when classifying the vaccine-adverse event pairs based on the literature. While we collected 
this information for each reference in our literature review, we do not have this information 
extracted consistently from the publications referenced in the IOM report and may have to go 
back to the original literature should the evaluation of the performance of statistical methods 
for signal detection in databases make this necessary. 
Independent of the reference set, another important issue that needs to be evaluated in 
performance evaluation of statistical methods for signal detection is the influence of the 
database characteristics on the methods. The amount of reports to a SRS is dependent on 
various factors, such as the time since market introduction of a new product, seriousness of the 
report, media attention and availability of compensation programs. EHR are less influenced by 
those factors, however, completeness of the data may have an influence in this case. Since we 
used events that are likely to be reported, we may introduce a bias in the comparison for 
methods between SRS and EHR. 
We wish to highlight that the proposed reference set is based on knowledge accumulated up to 
the point of the literature review, i.e. until end of 2012. If we had closed the search of evidence 
at any different point in time, the reference set may be different, e.g. vaccine-adverse event 
pairs classified as NC or UC may become PC over time because of potential accumulation of 
evidence. This time-dependency is shown in Fig. 2 and needs to be considered and evaluated in 
the performance testing of the signal detection methods and highlights the need for cyclical 
revision. Furthermore, it precludes the reference set to be used outside the purpose of 
evaluating signal detection methods. 
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Fig. 2. Time-dependency of reference set validity. 
 
Well-tested statistical methods for safety signal detection of pediatric vaccines and well-tested 
signal detection systems are a precondition for optimization of methods and systems as well as 
meaningful interpretation of results. A reference set is a necessary condition for such 
improvements. For example, performance testing of pediatric vaccine signal detection methods 
and systems with the help of this reference set will be done as a next step. Thus, we trust that 
our work contributes to the improvement of vaccine pharmacovigilance in children. 
 
Conclusion 
Following a systematic approach, we have developed a reference set for performance testing of 
pediatric vaccine safety signal detection methods and systems. The method and established 
database allow for regular update of this reference set pending new evidence and field testing. 
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Chapter 6.2 Current needs in pediatric pharmacoepidemiology  
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Abstract  
Purpose: We report on a needs assessment conducted by the International Society of 
Pharmacoepidemiology (ISPE) Pediatric Special Interest Group (SIG) to identify critical needs in 
pediatric pharmacoepidemiology and directions for future activities. 
Methods: A mixed methods survey using a structured interview was conducted in the SIG and 
ISPE membership to elicit information about current activities in pediatric 
pharmacoepidemiology and identify critical methodologic issues. The interviews were conducted 
in two phases over 2013 and 2014, beginning with interviews of SIG members, and expanding 
to the wider ISPE membership. Members of the SIG conducted the interviews and summarized 
the responses. 
Results: Twenty-nine ISPE members participated in the needs assessment The respondents 
reported working with a total of 59 distinct databases, with only 8 databases used by more than 
one respondent.. Seventeen respondents (57%) reported issues of limited sample sizes, noting 
that the problem intensifies when studying age sub-groups or specific genetic populations. 
Missing data elements were a problem in three main areas: lack of detailed medication 
information, inability to link to parental data, and lack of detailed information about age. 
Respondents reported the need for data elements not typically required in studies of adults, 
such as birthweight and current height and weight, as well as school performance and mental 
health status. 
Conclusions: Our needs assessment describes a preliminary picture of the emerging sub-
specialty of pediatric pharmacoepidemiology encompassing a range of age sub-groups, disease 
areas and medical specialties. The assessment also documents a body of methodologic 
challenges unique to pharmacoepidemiologic research in children.  
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Background 
This report summarizes the results of a needs assessment conducted by the International 
Society for Pharmacoepidemiology (ISPE) Pediatric Special Interest Group (SIG) to identify key 
issues in the emerging sub-specialty of pediatric pharmacoepidemiology. Pediatric 
pharmacoepidemiology has grown out of the historic exclusion of children from clinical trials, a 
practice that was meant to protect children from the risks inherent in participating in clinical 
trials 312  313,314.  As a result of decades of this policy, and despite efforts to reverse the policy, 
clinical trial data about efficacy and safety of medications in children are not available for many 
widely used medications. This has led, in turn, to a general lack of pediatric labeling for many 
drugs and the widespread off-label use of medications in children 315-318.  Other factors include 
limitations in extrapolating data from studies conducted in adults to children because of the 
many differences between adults and children with regard to organ development, metabolism, 
absorption, pharmacokinetics and pharmacodynamics 319,320, and the increase in the numbers of 
medications used by children, as well as the numbers of children using medications on a regular 
basis. 
Pediatric pharmacoepidemiology relies on general methods developed to study all age groups. 
However, challenges unique to pediatric populations have led to the emergence of a separate 
sub-specialty within pharmacoepidemiology. ISPE, as the sole professional organization 
dedicated to pharmacoepidemiology, has a unique role in fostering the development of methods 
and best practices in pediatric pharmacoepidemiology. The ISPE Pediatric SIG undertook the 
needs assessment reported below to identify the critical scientific and educational issues in the 
emergence of pediatric pharmacoepidemiology as a sub-specialty. 
 
Methods  
A mixed methods approach was used with a two-phased series of qualitative interviews 
conducted in 2013 to identify critical needs in pediatric pharmacoepidemiology and directions 
for future activities of the ISPE Pediatric SIG, followed by quantitative descriptive analysis. An 
interview form was developed by a subgroup of SIG members and covered four domains: 
Research and Scientific Needs, Educational Needs, SIG Communications/Organizational Needs, 
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and participant Demographics.  The expected time to provide verbal answers to all questions by 
each interviewee was approximately 15 minutes.  No compensation for the interviewee’s time 
was provided.  The instrument was piloted with two interviews, and the pilot data were 
included along with data collected from subsequent interviews. The first phase of interviews 
targeted Pediatric SIG members and was conducted in June and July of 2013. Volunteers from 
the SIG with survey expertise conducted interviews, and all members of the SIG were invited to 
participate. The survey was conducted by telephone interview, and when telephone interview 
was not possible respondents were offered the opportunity to respond by email. We also 
allowed the interviewer to send the instrument to the respondent to allow time for the 
respondent to consider the questions. For telephone interviews, we agreed that the interviewer 
need not follow the survey wording verbatim, but should consider the script as a guide. 
Interviewers were encouraged to use judgment with probes and comments. When asking about 
additional comments interviewers encouraged open-ended responses (more information) rather 
than placing narrow restrictions on responses to ensure the needs assessment encompassed 
concepts we might not have anticipated. 
A second phase was conducted in December 2013 - January 2014 targeting the wider ISPE 
membership. Respondents for Phase II were identified by soliciting suggestions from other SIG 
chairs and from Phase I respondents. The identical interview instrument was used except 
questions about internal SIG communications/operations were eliminated. For both phases, 
responses were collated manually, and synthesized in a narrative form, as well as simple coding 
and categorization for descriptive summaries.  Responses from the two phases were 
summarized separately and then combined after reviewing the characteristics of respondents in 
each phase of the needs assessment.  Descriptive analysis was then performed to generate 
summary data. 
 
Results 
Twenty-nine ISPE members participated in the needs assessment with sixteen in Phase I and 
thirteen in Phase II (see Table 1). This constituted approximately 50% of SIG members, and 
2.2% of ISPE membership. The majority of respondents were at a higher level of seniority with 
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19 (66%) having 10 or years experience after receipt of their terminal degree. The largest 
number reported working in academia (11/29 or 38%) followed by industry (7/29 or 24%). The 
countries of respondents reflected the diversity of ISPE membership, and the largest number of 
respondents were from the United States (19/29, 66%), followed by two each from Canada, 
the Netherlands and Taiwan. 
 
Table 1: Research, scientific and educational needs. 
Survey Question Response n (%) 
Total: 29 respondents 
Research and Scientific Needs 
 
Which databases do you use most frequently ? 28 (96%) provided 59 distinct databases, with almost no 
overlap between respondents 
What types of databases do you use†?  
National or government sponsored 16 (55%) 
Insurance claims 14 (48%) 
Registry 11 (38%) 
Outpatient 10 (34%) 
Inpatient  4 (14%) 
Adverse Event 2 (7%) 
Pediatric Network 2 (7%) 
Have there been times in your research when 
the ability to answer questions in pediatric 
pharmacoepidemiology was limited because of 
an absence of data sources or adequate sample 
sizes, a problem especially likely to occur in 
pediatric research? What kind of data elements 
have you found to be missing or problematic? If 
data or adequate sample sizes weren’t available, 
how did you address the study questions? 
 
Sample size challenges encountered 17 (57%) 
Sample size not an issue 3 (10%) 
No comment on sample size 9 (31%) 
Other issues/themes identified: Inadequate medication information -  lack of : dose, 
defined daily dose for pediatrics,  time of administration, 
indication for treatment, reasons for changes to dose or 
therapy 
Inadequate clinical information - lack of current 
height or weight, laboratory results, access to relevant 
parental clinical or behavioral information such as smoking, 
achievement of developmental milestones 
Inadequate demographic or other information - lack 
of: gestational age at birth, birthweight/length, small for 
gestational age status, specific date of birth (rather than 
just birth year), school performance, mental health status 
How small sample size addressed: 
Multiples approach: combine databases or studies; 
triangulate results 
How missing data addressed: 
Imputation; limit analysis to subset with available data; 
bridging strategy for common elements of a comparative 
analysis 
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What do you think are the most pressing clinical 
questions that need to be addressed by pediatric 
pharmacoepidemiology*?” 
 
Disease Area Psychiatry/Mental Health (n=9) 
Infectious Disease (n=7) 
Asthma (n=4) 
Oncology (n=4) 
Sedation/Pain (n=4) 
Diabetes (n=3) 
Rheumatology (n=3) 
Other: Critical care, dermatology, ophthalmology, rare 
disease (n=1 each) 
Drug Category Vaccines (n=4) 
Antiretrovirals (n=3) 
Antibiotics (n=3) 
Other: Analgesics, anti-depressants, anti-convulsives, 
growth hormone, over-the-counter medications (n=1 each) 
Pediatric Subpopulations Preterm babies; neonates; genetic variations; global 
variations in pediatric diseases and health; socioeconomic 
groups such as foster children 
Methodologic Pediatric treatment effectiveness measures; defining 
pediatric laboratory test norms; long term effects on 
growth or development; changing type and/or 
susceptibility to adverse drug reactions during growth and 
maturation 
Educational Needs  
Are you aware of training programs specifically 
dedicated to pediatric pharmacoepidemiology?  
What are they?  
10 programs identified: 
• 3 specific to Pediatric Pharmacoepidemiology: 2 
medical school fellowships, 1 graduate level at 
college of pharmacy 
• 6 with Pediatric Pharmacoepdemiology content: 
Schools of public health, medical school 
department of pharmacology, colleges of 
pharmacy 
 
What other resources are most needed to 
further educate people about pediatric 
pharmacoepidemiology†? 
  
ISPE Course 18 (62%) 
Online Webinar 15 (52%) 
Continuing Education for pediatricians 14 (48%) 
Other (please provide) 10 (34%) 
Suggestions: Presentations at scientific congresses; whitepaper/peer 
reviewed journal article (n=3); add to 
pharmacoepidemiology curricula; add to ISPE or other 
relevant scientific organizations’ learning resources 
†Respondents could provide multiple categories and thus results are >100% 
 
* Respondents varied in their interpretation of the question, often including a focus on what issues or themes on which 
they were currently working. 
 
 
The survey assessed research, scientific and educational needs; the results are shown in Table 
1.  The vast majority (28 of 29) of respondents reported working with secondary databases 
such as insurance claims, primary care, pharmacy, or hospital databases. There was almost no 
overlap in the databases used by respondents with only eight databases mentioned by more 
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than one respondent. Seventeen respondents (57%) reported an issue of limited sample sizes, 
noting that the problem intensifies when studying age sub-groups or specific genetic 
populations. The question about missing data elements elicited discussion in three main areas: 
lack of detailed medication information, inability to link to parental data, and lack of detailed 
information about age, especially for newborns and infants.  
 
Discussion 
To our knowledge, this needs assessment is the first to address the emerging discipline of 
pediatric pharmacoepidemiology. It drew on expertise from the leading professional 
organization committed to pharmacoepidemiology, and solicited feedback from members with 
an interest in pediatric pharmacoepidemiology. It serves as a starting point for a thoughtful 
discussion of the current needs in pediatric pharmacoepidemiology. 
A striking finding was that respondents reported working with a total of 59 distinct databases of 
various types, and that only eight databases were mentioned by more than one respondent. 
This expands the information obtained from an earlier survey which identified 25 datasources 
from 12 European countries as suitable for pediatric pharmacoepidemiology 321. Our 
methodology went beyond a survey of databases by asking professionals to indicate the 
databases they were using, and we did not restrict our search to Europe. Both methods 
resulted in a large number of databases that can be used for pediatric pharmacoepidemiology, 
and it seems likely that our combined lists do not cover all the potential databases. It is also not 
clear how the pattern seen in our sample (many databases with few being used by more than 
one investigator) compares to the use of databases in other branches of 
pharmacoepidemiology. The pattern we observed seems to suggest diverse activities perhaps 
reflecting the wide range of disease areas investigated, or the large number (16) of 
respondents using national databases. If researchers in different countries rely on their national 
databases to conduct pediatric pharmacoepidemiology, it follows that an international group of 
researchers will not be using the same databases. The implications for developing an 
international body of knowledge about medications in children is unclear, as is the validity of 
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extrapolating from a national database to a global context. It may suggest that pediatric studies 
are less likely to be conducted across international boundaries than are adult studies. 
With regard to methodologic issues, 57% of respondents expressed concern about sample 
sizes, but the remainder did not. Respondents raised the issue of a lack of information about 
medication dosing, noting its particular importance because dosing guidelines are often 
unavailable for children, and dosing variation can have a big impact on efficacy and safety in 
children. A third area of methodologic concern were the problems in linking children’s records to 
the mother’s record, family information or school performance, although recent efforts have 
demonstrated some success in creating mother-baby linkages 322.  Finally, respondents noted 
the need for gestational age and more detailed age information especially in younger age 
groups where age in days or weeks is of importance, but extending up to older age groups 
where age in months or even years may be missing. 
Psychiatry and mental health were the areas mentioned most frequently by respondents, 
followed by infectious disease, and a range of conditions including asthma, oncology, and 
sedation. It is not clear whether this distribution reflects the priorities of pediatric 
pharmacoepidemiology outside of ISPE respondents, or some other factors. The increasing use 
of psychotropic medications in children has been well documented and the cluster of survey 
respondents working in this disease area may reflect the growing use of these medications 323-
326.  
A preliminary picture of the emerging sub-specialty of pediatric pharmacoepidemiology 
encompasses a range of age sub-groups, disease areas and medical specialties. This diversity of 
activities may pose a challenge as the field begins to coalesce. We also identified distinct 
methodologic issues that are of critical importance in pediatric pharmacoepidemiology and merit 
further discussion. These center around sample sizes, data availability, and data linkage. Finally, 
we identified the need for greater educational efforts in a range of venues including graduate 
and professional training. The ISPE Pediatric SIG has incorporated the information in planning 
its future activities, and offered the first pre-conference course in Pediatric 
Pharmacoepidemiology at the annual ICPE conference in 2015. The SIG will continue to serve 
as a platform for ongoing development of the sub-specialty of pediatric pharmacoepidemiology.   
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Chapter 7 Summary and general discussion 
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Chapter 7.1 Summary and general discussion 
 
Disease occurrence and the effects of drug use in children: the need for valid 
evidence 
Licensed drugs have limited or no direct evidence of safety and effectiveness in children and 
have resulted in high levels of unlicensed and off-label drug use18-22. To address this unfairness, 
evidence on safety and effectiveness should be generated  using  ‘real-world’ data in children. 
Methods need to be made ‘child-proof’. In this thesis, we study and develop methods for 
assessing the occurrence of disease, and drug safety and effectiveness in children. Based on 
our findings, we make appropriate recommendations.  
 
Accurately estimating the occurrence of diseases in children: a necessity  
In order to license drugs,  valid estimates of disease occurrence are required but often lacking. 
Such estimates can be easily obtained from population-based healthcare data like electronic 
health records (EHRs), but specific attention should be paid to the peculiarities of the databases 
themselves and those of childhood diseases.   
Electronic health care databases usually contain only ‘snapshots’ of a person’s life time. Entry 
may depend on healthcare system, age, insurance, residency, employment status, and exit may 
depend on the same factors as well as death. Following a new-born from birth till death is not 
possible, also because computerization of health care is relatively novel. In spite of these 
limitations, we can regard information in health care databases as dynamic populations 
applying a person-time denominator rather than fixed person cohort, however we will always 
need to account for the fact that we have right and left censoring. Another challenge of real 
world data is that it reflects real world patient behaviour, which means that we cannot estimate 
the duration of disease (patients typically visit the physician when they have complaints and not 
when such complaints are cured). Therefore assumptions need to be made on the duration of 
disease episodes for non-chronic conditions, and this may have impact on the disease 
occurrence measures.    
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In this thesis we tried to demonstrate that disease occurrence can be estimated from electronic 
health care databases,  using the Integrated Primary Care Information database, a longitudinal 
electronic medical record database. Also, we demonstrated that there is an impact of  left 
censoring and the choice of episode duration assumptions. We showed that for the common 
and recurrent diseases like acute otitis media (AOM), increasing the assumed length of an 
episode decreases the incidence but increases the prevalence estimates of disease in children. 
We recommend that researchers measuring the incidence of common recurrent childhood 
diseases explore the impact of applying different assumptions regarding episode duration. To 
determine the correct episode duration for different common recurrent diseases, we 
recommend that a a ‘new’ (relative to start of the study) birth cohort of children can be 
followed to determine (from electronic health care databases) their first contact with the 
general practitioner for such diseases; then surveys may be conducted to determine (from their 
caregivers) when disease symptoms resolve. For chronic childhood diseases, increasing the 
length of the run-in period prior to start of follow-up decreases the incidence rate with 
negligible effect on the prevalence. Of note, the length of the run-in period impacts both 
common and rare diseases. We recommend that when estimating the incidence of chronic 
diseases, researchers should apply the longest feasible run-in. Linkage across systems, which 
would allow a patient to be followed over life should be recommended.  
 
Detecting drug safety signals from pediatric spontaneous reporting data: crucial for 
routine safety surveillance 
Following the marketing of approved drugs, adverse events that were not identified during 
randomized clinical trials (RCTs) will be detected since more patients, and patients in unstudied 
populations (such as children/pregnant women, elderly) will use the drugs76. Healthcare 
professionals and patients (in some drug regulatory jurisdictions) should/can report suspected 
adverse drug reactions to the marketing authorization holders or national (i.e. US Federal Drug 
Administration - FDA) or international (European Medicines Agency - EMA, and WHO 
collaborating center for international drug monitoring) pharmacovigilance centers. Databases 
containing such spontaneous reports (i.e. FAERS (FDA), EUDRAVIGILANCE (EMA), and 
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VIGIBASE (WHO)) need to be screened to detect new signals, this is often done using statistical 
signal detection algorithms (SDAs) such as Proportional Reporting Ratio (PRR), Reporting Odds 
Ratio (ROR), Information Component (IC) and Empirical Bayes Geometric Mean (EBGM)327-330. 
For a long time, child-specific SDAs were lacking and children were analysed together with 
adults. Recently this has changed and WHO and EMA recommend that children be analysed 
separately331-333. Even if children are now separated from adults, children are still not a 
homogeneous group. Organ development and maturation may predispose certain age 
categories to different susceptibilities of adverse events334,335. In this thesis336 we verified 
whether further age stratification amongst children would have an impact on signal detection 
and whether this differed for different SDAs. In order to compare the performance of different 
SDAs on pediatric data specifically, a pediatric-specific reference set of drug-event combinations 
(DEC) was required as a first step.  
 
Creating a pediatric-specific drug-adverse event reference set 
We created a reference set comprising 37 known (positive controls - PC) and 90 ‘unknown’ 
(negative controls - NC) DECs. The reference set was based on drugs that are routinely used in 
pediatrics, in both outpatient and inpatient settings. In order to test (and develop SDAs that 
can be applied to) databases that exist in low and middle-income countries (LMIC), we included 
drugs that are used in such countries. Adverse events were selected considering both 
outpatient (i.e. frequent events) versus inpatient (i.e. rare and potentially life-threatening 
events) settings. Therefore, the reference set can be applied to databases existing in various 
contexts. As proof that a pediatric-specific reference set is welcome we would like to point out 
that there is limited overlap between our reference set and the ones created within the context 
of other projects like OMOP,  EU-ADR and PROTECT 83,95-97. Drugs were not selected 
independently of adverse events in OMOP and EU-ADR 83,84. Since our (GRIP) reference set was 
intended for testing both spontaneous reporting system (SRS) and EHR databases, selecting 
drugs independently of adverse events was necessary to avoid any bias. To ensure validity of 
the positive and negative controls, we conducted extensive literature reviews. To confirm the 
positive controls, we applied a specific literature search algorithm and therefore retrieved 
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publications that reported on the event and drug in the context of drug safety in children or 
adults, an approach similar to that adopted by the EU-ADR project83. Positive controls with 
evidence from only adults were not considered for testing signal detection algorithms. The 
downside of applying a specific literature search algorithm  may be that there was no or 
inadequate evidence to confirm some well-known associations in children (just because 
papers/studies were not available, or reported through means other than the peer-reviewed 
literature). We recommend that for creating a reference set, other drug regulatory documents 
should be consulted in addition to SPCs and peer-reviewed literature. With regard to 
confirmation of positive controls, we searched for evidence in children specifically and in 
addition searched for pharmacological (in addition to epidemiological) evidence to further 
strengthen the association. However we were able to find pharmacological evidence for only 13 
out of the 37 PCs. The limited pharmacological evidence for most of the PCs may reflect the 
current gap of knowledge and understanding of adverse drug reactions.  
Confirming a negative control required absolute certainty that the drug cannot cause the 
adverse event and both adult as well as pediatric data was used. The status of negative 
controls may change over time (if new evidence emerges), therefore we recommend regular 
update of their status. For the positive controls it is important to know at which point in time 
the association was in the public domain as this may lead to changes in reporting behaviour to 
spontaneous reporting databases and to changes in clinical care. Those changes may have an 
impact on the ability to detect associations (i.e. in spontaneous reporting databases it may 
increase the association whereas it may decrease such association in electronic health record 
databases) 121-123.  
Assessing the performance of SDAs when applied to pediatric data specifically 
Using the reference set that we created, we tested two routinely applied SDAs - the 
proportional reporting ratio (PRR) and Empirical Bayes Geometric Mean (EBGM) - on the 
pediatric dataset of FAERS (the FDA database on spontaneous reports in the USA comprising 
non-vaccine products only), and we stratified by age categories to investigate the impact of 
effect modification by age. We showed that the type of SDAs did not matter a lot. As reported 
in the PROTECT project146, the PRR and EBGM showed good performance overall, although the 
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results were slightly lower than results reported on other (not pediatric-specific) reference sets 
155,156. Age-stratified analysis in children revealed some drug-event combinations that were 
masked when data on the entire pediatric population was analysed. Conversely, some drug-
event combinations that were initially observed for the entire pediatric population were 
observed only in some but not all pediatric age groups. Such effect modification may result 
from differences in drug use126,154, susceptibility to adverse events across pediatric age groups 
and power issues. We recommend that when conducting drug safety surveillance in the 
pediatric population, age-stratified analysis should be performed to avoid masking. We also 
strongly recommend complete and detailed recording of age information in pediatric 
spontaneous adverse drug event reports, many subjects had empty/ zero age, and it was not 
clear whether age was missing or truly zero.  
 
Pediatric pharmacoepidemiological safety studies: current status and 
recommendations for improvement 
When drug safety signals are detected, further evaluation is required to quantify risk336.  This is 
often achieved by conducting pharmacoepidemiological studies. While such studies are  
conducted frequently in adults with progressively better methods, the same cannot be said of 
children. In order to assess the state of the art and potentially make recommendations, we 
conducted a systematic review to assess the characteristics of pediatric 
pharmacoepidemiological safety studies that were published over 34 years.  
As main findings, we discovered that the absolute number of pediatric pharmacoepidemiological 
safety studies is low and the studies are almost exclusively conducted in high income countries 
and receive limited funding from pharmaceutical companies and other private sources. Designs 
differed a lot between drug and vaccine studies. Focus in these studies was only on a small 
fraction of registered drugs and mainly intermediate outcomes (signs/symptoms) were studied. 
We recommend the conduct of more and better studies in LMICs, interaction between the drug 
safety and vaccine safety world to improve methodology and apply designs more broadly, 
better funding, particularly for under prioritized safety issues i.e. long term effects of drugs, and 
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collaboration across institutes. Sharing existing databases will enlarge sample size to study the 
rarer and potentially more serious safety issues.   
Although the pediatric legislations that have been introduced globally were primarily aimed at 
stimulating clinical trials, this also affected the conduct of pharmacoepidemiological studies. For 
example under the ‘Best Pharmaceuticals for children’s Act’ (BPCA)26, the US National Institutes 
of Health sponsored several pharmacoepidemiological studies in children182. These legislations 
may explain why most studies were conducted in the US and EU. Yet many children live in 
LIMCs. According to the United Nations Children’s Emergency Fund (UNICEF), between 2010 
and 2025, the child population of sub-Saharan Africa will rise by 130 million. From around 2030, 
sub-Saharan Africa will be the single region with the greatest number of children under 18 
years. By 2050, almost 1 in every 3 children under 18 years will be African. Also according to 
UNICEF, half of the world's 6.6 million under-five deaths occur in Africa with pneumonia, 
malaria and diarrhea accounting for 40% of the deaths. These diseases are mostly treated with 
drugs. It is important to further build on a worldwide pharmacoepidemiological capacity with 
regard to knowledge and information technology (IT) infrastructure to monitor the safety of 
these drugs. More effort should be focused on applying personal smart phone based methods 
(for collecting data on drug use and health outcomes) that may be more suitable for  for LIMCs.  
Even if the right data and methods are available for pediatric studies, there may be a need to 
prioritize the drug classes to be studied based on their frequency of use in children. In our 
review, we found that almost half of the evaluated drugs belonged to only 3 classes namely 
anti-infectives, psychoanaleptics and psycholeptics. Unlike anti-infectives, psychoanaleptics and 
psycholeptics represent a minority of drug exposure in children85. We recommend that pediatric 
pharmacoepidemiological safety studies should be focused on drugs that are commonly used in 
pediatrics and where required evidence is still missing. In LMICs, effort should be focused on 
studying the effects of drugs that are used in treating the aforementioned infectious diseases. 
There were few studies of rare drug exposures in our review. The effects of such exposures 
may better be studied using case-only designs i.e. self-controlled case series192. Case-only 
designs are particularly suited for the drug utilization patterns and characteristics of outcomes 
in children193,194. Case-only designs are particularly useful for studies in children since such 
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designs are much more efficient in terms of costs and data collection.  Multi-site data pooling 
should  be promoted to acquire adequate power to study rarer events in children77,195. 
International collaboration on a global scale may be required; which is one of the main aims of 
the Global Research in Pediatrics (GRIP) project.  
 
Quality of pediatric pharmacoepidemiological safety studies: implications for 
evidence based pediatrics 
Knowledge about the safety and efficacy (effectiveness in real life) of drugs allows clinicians to 
make better treatment decisions, a process termed evidence-based medicine (EBM)196. 
Successful practice of EBM is largely dependent on the ability to critically appraise and interpret 
research evidence. The US National Cancer Institute initiated a programme to address the use 
of epidemiology in knowledge integration which itself was defined as ‘the methodological 
process of selecting, storing, collating, analyzing, integrating, and disseminating information 
within and across disciplines for the benefit of population health’337. Central to this programme 
is the ability to know which information is valid. Many clinicians do not yet have the knowledge 
on research methodology to properly appraise study results338. Meanwhile, the peculiar 
challenges of pediatric pharmacoepidemiological studies make the appraisal of such studies 
particularly difficult. For adequate assessment of pediatric studies specifically, detailed 
information about various characteristics is required including specific date of birth (rather than 
just birth year), gestational age at birth, birthweight/length, small for gestational age status, 
school performance, and mental health status 199. Also, detailed information about drug doses, 
concomitant medication, indication for treatment and reasons for changes to dose or therapy is 
required. Finally, defining the optimal risk window to observe outcomes resulting from chronic 
drug exposures and the investigation of transient versus recurrent outcomes, which frequently 
occur in children, might be a burden in pediatric pharmacoepidemiology.   
We systematically assessed the quality of published pediatric pharmacoepidemiological safety 
studies. Our aim was to identify the likely sources of bias and other pediatric-specific study 
characteristics. As main findings, studies which scored the highest on quality were: published 
from 2010, SCCS studies of vaccines, and studies conducted in North America and Europe 
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based on retrospectively collected secondary data. Vaccine-only studies, which were better than 
drug-only studies, applied only SCCS design perhaps accounting for their higher quality because 
of better control of potential confounding factors. We recommend that where feasible, the SCCS 
and other case-only designs should be applied to more studies, and not only for vaccine 
studies. 
Cohort studies were most likely to be biased because historical time prior to study start was not 
considered for the identification of prevalent cases of the outcome of interest and because 
follow-up time after study start was not long enough to observe occurrence of the outcome(s). 
Case control studies were most likely to be of poor quality because of differences in non-
response rate (regarding ascertainment of the exposure) between the cases and controls, and 
because the authors did not specifically report that the controls did not experience the outcome 
of interest. The majority of studies utilizing retrospectively collected secondary data showed 
good quality possibly because most of them were published from the year 2000, a period 
during which  extensive research effort has been focused on improving the quality and 
utilization of such data 237-240. Detailed patient information is now recorded in many healthcare 
databases especially EHRs, thereby improving the utility of secondary data. Inadequate 
reporting may explain why despite this improvement, the quality of many pediatric 
pharmacoepidemiological studies still scored low. The impact of reporting on quality 
(assessment) of research has been emphasized197,241,242. Recently the RECORD statement was 
introduced, aimed at encouraging better reporting of studies based on EHR specifically 233.  
The use of an appropriate tool is crucial for an adequate assessment of study quality. Many 
available tools do not include critical assessment elements (i.e. confounding by indication) that 
are relevant to pharmacoepidemiological safety studies generally and pediatric studies 
specifically197. We recommend further research to develop a tool that can easily be utilized to 
evaluate pediatric studies specifically.  
 
Comparative drug effectiveness studies in children: recommendations for 
improvement  
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Efficacy evidence, upon which drug approval is based, may not translate into drug effectiveness 
following approval and routine clinical use. Comparative effectiveness research (CER) can yield 
‘real-world’ evidence about the benefits of a drug and therefore improve its prescribing 
339.  Especially for effectiveness research, the validity of such evidence is dependent on the 
ability to correct for bias and confounding in particular confounding by (contra)indication. In 
recent years, a lot of research has been focused on refining methods for CER research in adults 
however with no focus on children specifically.  
We conducted a systematic review to identify the weaknesses of published drug effectiveness 
studies in children and to make recommendations for improvement. We found that studies were 
few, mainly conducted in North America and Europe and mainly based on public funding. 
Comparative effectiveness studies in newborns were rare. With regard to study design, the 
cohort design was the most commonly applied, probably also because it allows to study 
multiple outcomes. With regard to outcome, intermediate outcomes were often used. Use of 
intermediate outcomes is frequently observed in RCTs because of short trial duration. In CER 
however, where duration of follow-up should not necessarily be an issue, we recommend the 
use of clinical outcomes. The investigated drugs did not always reflect routine drug utilization in 
paediatrics. Although commonly utilized, analgesics (WHO-ATC NO2), drugs for obstructive 
airway diseases (WHO-ATC R03), and anti-inflammatory and antirheumatic drugs (WHO-ATC 
M01) and nasal preparations (WHO-ATC R01) were seldom studied. In contrast, although 
seldom utilized, antineoplastic agents (WHO-ATC L01) and immunosuppressants (WHO-ATC 
L04) were frequently studied. 
Most studies that we reviewed applied traditional methods to control for confounding by 
indication; including multivariate modelling analysis, matching and restriction. Propensity scores 
adjustment was seldom applied even though it is particularly suited for controlling confounding 
by indication247,254.  
In addition, dose-effect studies were seldom conducted, representing a missed opportunity250. 
Few studies used EHRs, even though their great potential for pediatric research has been 
demonstrated253.  
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Based on quality assessment with the NOS, cohort studies had higher scores than case control 
studies and therefore may be viewed as better even though there is no established threshold to 
label studies as having low or high risk of bias206. Studies on analgesics and 
immunosuppressants had the lowest median scores. The low scores  for studies investigating 
analgesics, a frequently utilized drug class, may be explained by the specific challenges in pain 
studies. First, it is difficult to define pain as an outcome, resulting in misclassification. Secondly, 
it is difficult to assess the use of over-the-counter medications and medications that are used as 
needed in various doses257. As recommendation, we propose the development of tools to better 
quantify pain and other outcomes that are difficult to measure. 
 
Comparing drug effectiveness in children using propensity scores  
Propensity scores (PS) adjustment is one of the methods to better control for confounding by 
indication in comparative effectiveness studies. In this thesis we applied this in pediatrics, and 
we looked at the most optimal period (prior to drug exposure) during which potential 
confounders should be assessed for the calculation of PS using a case study in children with 
asthma. We compared the effectiveness of new users of ICS+LABA (fixed dose combination 
versus administration via 2 different inhalers) for the prevention of moderate to severe asthma 
exacerbations. We derived the PSs by modelling (logistic regression) confounding patient 
characteristics that were identified during six distinct periods before incident prescription of the 
fixed combination of ICS+LABA: 1 week, 1 month, 3 months, 6 months, 1 year and full history.  
Compared to the loose combination, ICS+LABA fixed protected against exacerbation. Calliper 
matching without replacement resulted in the largest adjustments of the crude hazard ratio 
(HR) especially in the 1 month prior to treatment start. The results of different ways to deal 
with propensity scores made a big impact. We recommend further research into use of PS 
methods in comparative effectiveness research in childhood. Since PSs can only be applied to 
control for measured confounders, other methods that can account for unmeasured 
confounders (i.e.. instrumental variable analysis) should be investigated. 
 
Current needs in pediatric pharmacoepidemiology: added value of a survey  
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The needs assessment drew on the expertise of the leading professional organization 
committed to pharmacoepidemiology – ISPE (International Society of Pharmacoepidemiology. 
We solicited feedback - through phone or face-to-face interviews - from ISPE members with an 
interest in pediatric pharmacoepidemiology, with regard to current needs in pediatric pharmaco-
epidemiology. 
Of note, respondents reported working with 59 distinct databases of various types, and only 8 
databases were mentioned by more than one respondent. This complements an earlier survey 
that identified 25 data sources from 12 European countries321; more so because we did not 
restrict our search to Europe. 
Our finding that few databases are used by more than one researcher may reflect the wide 
range of disease areas investigated or the large number (16) of respondents using national 
databases. If researchers in different countries rely on their national databases to conduct 
pediatric pharmacoepidemiological studies, the implications for developing an international body 
of knowledge about medications in children is unclear, as is the validity of extrapolating from a 
national database to a global context. This highlights the need for global efforts aimed at 
identifying all existing databases that can be used for pediatric pharmacoepidemiological 
studies. 
Regarding the disease areas covered by the databases, psychiatry and mental health were the 
areas mentioned most frequently by respondents, followed by infectious disease, and a range 
of conditions including asthma, oncology, and sedation. It is not clear whether this distribution 
reflects the priorities of pediatric pharmacoepidemiology outside of ISPE respondents. The 
increasing use of psychotropic medications in children has been well documented and the 
cluster of survey respondents working in this disease area may reflect the growing use of these 
medications323-326.  
 
Conclusions and future perspectives 
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This thesis was focused on disease occurrence, safety signal detection and methods for 
comparative outcome studies. Across all of these areas, it is evident that  methods  are required 
that are better suited for children.  
From the perspective of disease occurrence estimation, our methods should be verified in a 
wider realm of databases, in this thesis we focused on medical records from GPs, but the 
impact of different run in periods and disease episode durations should be systematically 
verified also in claims databases and systems with high turnover (short follow-up).  
Regarding signal detection  continuous refinement of signal detection algorithms is required. 
Where age-specific drug use is known or suspected, age-stratified safety monitoring should be 
conducted. Since the number of reports in newborns cannot be estimated well, since age may 
be put at 0 because of missingness, we would recommend complete recording of age in 
spontaneous reporting databases. In addition we would recommend that systems be developed 
where data from various international databases can be pooled since the power to detect in 
small age strata, remains low. We built a common data model for spontaneous reporting data 
which captured FAERS, EUDRAVIGILANCE and VAERS and the usefulness of that pooling should 
be verified.  To maintain the usefulness of the drug-adverse event reference set  for 
performance testing of signal detection algorithms, the status of the associations especially the 
negative controls should be quickly updated based on new evidence. This process can be 
facilitated if screening of the following data sources/types is automated: pharmacokinetic and 
pharmacodynamics data, summary of product characteristics and other regulatory documents, 
as well as published literature. Such automated approaches should be developed. Since 
screening of electronic health records can yield important complementary evidence to support 
drug safety monitoring in children, different methods should be tested to determine their 
suitability for such screening. Social media represents a potential source of information for 
suspected adverse drug reactions in children. In LMICs, the widespread use of mobile phones 
represents an opportunity to improve reporting of suspected adverse drug reactions; this should 
be further explored. In many LMICs, many people are religious. The leaders of religious groups 
usually exert enormous influence over their members. Researchers may liaise with such leaders 
and healthcare practitioners that are members of such groups to improve reporting of 
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suspected adverse drug reactions. In neonatal intensive care units (ICUs), there is often co-
adiministration of drugs which increases the possibility of occurrence of adverse drug reactions 
(ADRs) but which may however not be adequately reported. Methods for stimulating reporting 
of such suspected ADRs should be investigated; compared to other neonates and children, the 
number of neonates admitted in ICUs is usually much fewer and therefore it may be possible to 
evaluate every medical occurrence as a possible ADR. Also there should be more focus on 
methods dealing with drug drug interactions. 
From the quantity of studies, pediatric pharmacoepidemiology is an underdeveloped field. More 
researchers with specific training in this field are required. Also, more funding of studies is 
needed; although there has been a time when  the European Commission focused on children 
the shift now seems to be to healthy ageing, we recommend that children stay in the picture. 
Similarly, it is relevant to develop methods and systems that would allow to monitor long term 
effects of drugs in children.  More and better data is required to conduct studies that can 
provide answers to the most pressing clinical questions. Better methods for controlling 
confounding and bias are required.  
In this thesis we found  that the limited pediatric pharmacoepidemiological studies that are 
conducted, do not include  low-and-middle-income countries (LMICs). However the largest 
number of children live in those regions and the impact of adequate drug treatments on child 
health is highest there. Knowledge and/or competence in pharmacoepidemiological methods 
should be developed by providing scholarship for e-learning such as done in EU2P and GRIP. 
There are reputable health-related non governmental organizations (NGOs) that can serve as a 
platform for collaboration between researchers in LMICs and their colleagues in high-income 
countries; such collaboration should be encouraged and explored. In LMICs where collection 
and/or recording of medical records is still inadequate, the added benefit of surveys in 
collecting information on drug use and health outcomes should be explored to increase the 
internal validity of pharmacoepidemiological safety and effectiveness studies. Generally, more 
effort should be focused on the effects of prenatal drug exposures and maternal immunizations. 
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To overcome the limitations of clinical trials and to fill the knowledge gaps on the effects of 
drugs in children, we should increase secondary use of health care databases. However, there 
are challenges such as the ability to account for measured and unmeasured confounders. This 
is crucial to obtain valid results from pharmacoepidemiological studies. In addition to propensity 
scores, the utility of other modern methods like marginal structural models for controlling 
measured confounders should be investigated. Generally, more and better effort through global 
collaboration is required to identify and develop suitable methods that can be applied to 
adequately answer the most pressing and clinically relevant questions regarding the use and 
effects of drug in children worldwide. 
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Chapter 8 Summary/Samenvatting  
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Chapter 8.1 Netherlands Samenvatting 
 
Geneesmiddelen worden bij kinderen vaak gebruikt ondanks het feit dat de veiligheid en 
werkzaamheid bij kinderen niet getest werd aan de hand van klinische studies. Om die reden is 
het van belang  de veiligheid en effectiviteit te onderzoeken aan de hand van gegevens uit de 
dagelijkse praktijk, die er in overvloed zijn.  
In dit proefschrift bestudeerden methoden om het vóórkomen van ziekten en bestuderen van 
de effecten van geneesmiddelen in kinderen te schatten, gebruikmakend van routine zorg data 
uit de dagelijkse praktijk, dit maakte deel uit van het GRIP netwerk dat werd gefinancierd door 
de Europese Commissie en het EVIPED project dat werd gefinancierd door ZONMW.   
Geldige schattingen van het vóórkomen van ziekten in kinderen zijn een noodzakelijk onderdeel 
van het verlenen van een licentie, maar gegevens ontbreken vaak. Dergelijke schattingen 
zouden relatief  gemakkelijk verkregen kunnen worden door gebruik te maken van 
gezondheidszorg gegevens op bevolkingsniveau maar deze bestanden hebben beperkingen 
omdat ze niet voor onderzoek worden vastgelegd maar voor routine zorg, en vaak een beperkte 
periode van het ‘leven’ van een persoon beslaan, omdat personen veranderen van 
zorgverleners. In hoofdstuk 2.1 onderzochten we het effect van een aanname over de duur van 
ziekte-episodes op de nauwkeurigheid van de incidentie- en prevalentiemeting.  
Bij veelvoorkomende en terugkerende ziektes, zoals middenoorontsteking zorgde het verlengen 
van de aangenomen duur van een ziekte-episode voor een verlaagde incidentie, maar een 
verhoogde prevalentie. Om de effecten te schatten van het feit dat we niet de hele 
voorgeschiedenis hebben werd gekeken naar het effect van een verlenging van de 
inloopperiode (minimale follow-up periode die nodig is vooraleer de gegevens van de patiënt 
kunnen gebruikt worden). Bij een langere inloopperiode daalde de incidentie, maar was er 
slechts een verwaarloosbaar effect op de prevalentie.  
In de routine farmacovigilantie staat het rapporteren van bijwerkingen centraal. Hierdoor 
kunnen na het op de markt brengen van nieuwe geneesmiddelen nieuwe bijwerkingen aan het 
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licht komen. Databases met spontane meldingen van zorgverleners en patiënten worden 
regelmatig geanalyseerd met statistische detectie algoritmes (SDA’s), zoals de Proportional 
Reporting Ratio (PRR) en de Empirical Bayes Geometric Mean (EBGM) on ongekende 
bijwerkingen zo snel mogelijk op te pikken. Helaas wordt er vaak niet specifiek naar signalen in 
kinderen gekeken. In het kader van GRIP wilden we onderzoeken hoe we signaaldetectie bij 
kinderen kunnen verbeteren. Om dit te doen was in eerste instantie een   geneesmiddel-
bijwerking referentieset nodig. In hoofdstuk 3.1 beschrijven we een dergelijke referentieset 
bestaande uit 37 bekende (positieve controles - PC) en 90 ‘onbekende’ (negatieve controles - 
NC) geneesmiddel-bijwerking combinaties (GBC`s). Deze referentieset bevat geneesmiddelen 
die vaak gebruikt worden bij kinderen en bijwerkingen die optreden in de ambulante zorg of 
tijdens hospitalisatie. Om de validiteit van de PC`s en de NC`s te waarborgen werd een 
uitgebreide literatuurstudie gedaan. In hoofdstuk 3.2 hebben we dit referentieset gebruikt om 
de prestatie van de PRR en de EGBM te testen in de FDA spontane rapportage database 
(FAERS). Dit onderzoek liet zien dat het type SDA niet veel uitmaakte voor signaaldetectie maar 
dat het belangrijk is om te stratificeren omdat sommige signalen anders verborgen blijven.  
Als er nieuwe signalen van mogelijke bijwerkingen gedetecteerd worden, dan is verdere 
evaluatie nodig om de associatie te kwantificeren. Dit wordt vaak gerealiseerd aan de hand van 
hypothese toetsende farmaco-epidemiologische studies. In hoofdstuk 4.1 beschrijven we een 
systematische literatuurstudie naar de kenmerken van farmaco-epidemiologische “safety 
studies” die gepubliceerd werden in de afgelopen 34 jaar. De voornaamste bevindingen waren 
dat we ontdekten dat het aantal studies laag is, dat studies bijna uitsluitend in ontwikkelde 
landen werden uitgevoerd zijn en dat financiering beperkt was. Er waren grote verschillen in 
studieopzet tussen geneesmiddelen- en vaccinatiestudies. In de geneesmiddelenstudies lag de 
focus op een klein deel van de geregistreerde geneesmiddelen, en werden voornamelijk 
intermediaire uitkomsten (tekenen en symptomen) bestudeerd. Wij pleiten voor meer en betere 
studies in de toekomst waarbij  ook gegevens gebruikt worden  van lagere en 
middeninkomenlanden. Extra financiering is noodzakelijk zodat ook onderzoek kan gebeuren 
naar de langetermijneffecten van geneesmiddelen en geneesmiddelen die minder vaak worden 
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gebruikt. Tevens dient onderzoek gedaante worden naar optimalisatie van study designs zoals 
bijvoorbeeld self-controlled case series (SCCS). In hoofdstuk 4.2 keken we naar de kwaliteit van 
de studies. De voornaamste bevindingen waren als volgt: de studies met de hoogste 
kwaliteitscore waren recentelijk gepubliceerd (2010 en later), waren vaak vaccin-studies met 
SCCS als studieopzet, en gebruikten voornamelijk gegevens uit Europa en Noord-Amerika.  Bij 
cohort studies merkten we op dat de tijd vóór het begin van de studie vaak niet in overweging 
was genomen. Dit kan tot misclassificatie van prevalente gevallen leiden. Daarnaast was de 
duur van de follow-up tijd in cohort studies vaak onvoldoende lang om de beoogde 
uitkomst(en) te meten. Case-control studies waren veelal van slechte kwaliteit door de 
verschillen in non-respons (met betrekking tot het vaststellen van de bloostelling) tussen 
patiënten en controlepersonen, en omdat de auteurs niet specifiek rapporteerden dat de 
controlepersonen de beoogde uitkomst niet ontwikkelden. 
Werkzaamheid van een geneesmiddel vertaalt zich na goedkeuring en bij “real-life” gebruik niet 
altijd in effectiviteit. Vergelijkend effectiviteitsonderzoek kan bewijs geven van de voordelen van 
een geneesmiddel in “real life”. In hoofdstuk 5.1 beschreven we, aan de hand van een 
systematisch literatuuronderzoek de methoden die toegepast worden om studies naar de 
effectiviteit van geneesmiddelen uit te voeren bij kinderen. Het aantal studies was klein, met 
name met publieke gelden gefinancierd en voornamelijk uitgevoerd in Europa en Noord-
Amerika. Effectiviteitsonderzoek bij  pasgeborenen was zeldzaam. Wat betreft de gebruikte 
methodes, werd voornamelijk gebruik gemaakt van cohort studies, waarschijnlijk omdat 
daarmee meerdere uitkomsten onderzocht kunnen worden. Er werden vaak intermediaire 
uitkomsten gebruikt. Het gebruik van intermediaire uitkomsten ziet men vaak bij 
gerandomiseerde klinische studies vanwege de korte duur van het onderzoek. Daarentegen 
raden wij aan klinische uitkomsten te gebruiken voor effectiviteitsonderzoek, gezien de duur 
van de follow-up geen probleem hoeft te zijn. De onderzochte geneesmiddelen waren niet altijd 
representatief voor het geneesmiddelen gebruik bij kinderen. Traditionele methodes werden 
toegepast om te adjusteren voor confounding zoals matchen, restrictie en multivariaat analyse. 
Adjusteren of matchen op propensity scores werd nauwelijks toegepast. Het effect van dosering 
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werd zelden onderzocht, wat een gemiste kans is. Slechts een klein aantal onderzoeken maakte 
gebruik van elektronische patiëntendossiers.  
In hoofdstuk 5.2 onderzochten we het gebruik van propensity scores om te adjusteren voor 
confounding.  We vergeleken de effectiviteit van geïnhaleerde corticosteroiden (ICS’s) en 
langwerkende beta-2 agonisten (LABA’s), hetzij als vaste combinatie hetzij als twee losse 
inhalers, in de preventie van matige tot ernstige astma-exacerbaties. Wij kozen voor astma 
omdat het een veelvoorkomende en chronische aandoening in kinderen is. De propensity scores 
werden berekend aan de hand van een logistische regressie.  Propensity scores werden 
berekend aan de hand van patiënten karakteristieken,  vastgesteld in zes specifieke periodes 
voorafgaande aan het eerste (incident) voorschrijven van de vaste combinatie van ICS’s met 
LABA’s. De specifieke periodes waren één week, één maand, drie maanden, zes maanden, één 
jaar en de volledige geschiedenis voorafgaand aan het eerste voorschrift van een ICS+LABA. In 
de ongeadjusteerde analyse zagen we een verlaagd risico op matige tot ernstige astma 
exacerbaties bij het gebruik van een vaste combinatie van ICS’s met LABA’s . “Caliper matchen” 
op de propensity scores, zonder vervanging, resulteerde in  de grootste aanpassing van de 
hazard ratio (HR), met name in de eerste maand vóór het begin van de behandeling. Verder 
onderzoek is nodig naar het gebruik van propensity scores in vergelijkend 
doelmatigheidsonderzoek bij kinderen.  
Overige onderzoeken die van belang zijn om farmacoepidemiologisch onderzoek bij kinderen te 
verbeteren zijn opgenomen in hoofdstuk 6.  
In hoofdstuk 6.1 ontwikkelden we een vaccinatie-bijwerking referentieset. Dit referentieset kan 
gebruikt  worden om de prestaties van verschillende SDA’ s te testen voor het monitoren van 
de vaccinveiligheid. In hoofdstuk 6.2 presenteren we de resultaten van een enquête 
(telefonische of face-to-face interviews) onder leden (experts) van dé toonaangevende 
professionele organisatie gericht op farmaco-epidemiologie: ISPE (International Society of 
Pharmacoepidemiology). Dit om nader inzicht te krijgen in de behoeften van de kinder farmaco-
epidemiologie. Opvallend was dat 59 aparte databases werden vermeld, en dat maar acht 
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databases meer dan eens genoemd werden. Onze bevinding dat een gering aantal databases 
door meer dan één onderzoeker gebruikt wordt, kan een afspiegeling zijn van de grote 
verscheidenheid aan deelgebieden van ziektes die onderzocht wordt, of van het grote aantal 
(16) onderzoekers die nationale databases gebruiken. Dit accentueert de noodzaak tot het 
inventariseren van alle bestaande databases die gebruikt kunnen worden voor  farmaco-
epidemiologische studies bij kinderen.  
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